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Recent research suggests that adding protein (PRO) to a carbohydrate (CHO) 
supplement can have substantial benefits for endurance exercise performance and 
recovery beyond that of CHO alone. CHO+PRO supplements are often commercially 
available formulations consisting of carbohydrates (dextrose, maltodextrin) and whey 
protein. The effects of a supplement containing moderate protein and a low-CHO mixture 
on endurance performance has not been investigated. Also, the effects of CHO+PRO 
supplementation in the form of a natural food, flavored milk, on measures of recovery 
from acute endurance exercise, as well as on chronic aerobic exercise training 
adaptations, have not been characterized. Therefore, in this series of four studies, the 
effects of CHO+PRO supplementation on the following areas of endurance exercise 
performance, recovery, and adaptation are investigated: acute endurance exercise 
performance, inflammatory and muscle damage markers, muscle glycogen resynthesis, 
activation of signaling proteins involved in the initiation of protein synthesis and 
degradation, subsequent endurance exercise performance, and chronic aerobic training 
adaptations (maximal oxygen consumption, oxidative enzyme activity, body 
composition, immune cell levels, and inflammatory markers). Study 1 demonstrated that 
 vii 
a supplement containing a low-CHO mixture plus moderate protein significantly 
improved aerobic endurance when cycling at or below the ventilatory threshold, despite 
containing 50% less CHO and 30% fewer calories relative to a higher CHO beverage. 
Study 2 demonstrated that CHO+PRO supplementation in the form of chocolate milk 
(CM) is an effective post-exercise supplement that can improve subsequent performance 
and provide a greater intracellular signaling stimulus for protein synthesis compared to 
CHO and placebo. Study 3 found that post-exercise CM supplementation during 4.5 wks 
of aerobic exercise training improves the magnitude of cardiovascular adaptations more 
effectively than isocaloric CHO or placebo, while the fourth study demonstrated that 
post-exercise CM supplementation during 4.5 wks of aerobic training improves body 
composition more effectively than isocaloric CHO or placebo. The fourth study also 
demonstrated that 4.5 wks of training does not appear to perturb resting immune cell 
concentrations or markers of inflammation and muscle damage. Taken together, the 
results of this research series suggest that CHO+PRO supplementation extends endurance 
performance, improves recovery, and increases training adaptations more effectively than 
CHO or placebo.  
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Chapter I: General Introduction 
 
Proper nutritional supplementation during endurance exercise is essential for 
delaying fatigue and maintaining optimal performance. Providing the right nutrients 
following intense exercise is also critical, as adequately recovering from exhaustive 
endurance exercise is central to the ability to perform at one’s best day after day in 
training sessions and competitive events. Recovery is also essential for achieving positive 
training adaptations that occur in response to such exercise. It is well known that 
immediately after prolonged, intense endurance exercise, a catabolic physiological state 
prevails: catecholamines and cytokines are elevated, blood glucose and insulin levels are 
low, muscle and liver glycogen stores are depleted and immune function is suppressed. 
As such, the body’s ability to perform such exercise again in a matter of hours or even 
days is compromised, as is the ability to adapt to the training stimuli for long-term 
endurance performance improvements. 
In order to shift from a catabolic to an anabolic physiological state post-exercise, 
optimal nutrients must be provided. Replenishing depleted glycogen stores is of primary 
emphasis, as prolonged, intense exercise simply cannot be performed without adequate 
glycogen stores. Despite its great importance, glycogen is not the only variable central to 
recovery that is modulated by optimal post-exercise nutrition. Endurance exercise 
recovery is a highly complex process that involves the integration of multiple systems 
and many components, including immune system function, tissue damage repair, and 
protein synthesis pathways. All of these are positively affected by proper post-exercise 
nutrition. 
Eating or drinking something simply containing calories following endurance 
exercise is not enough, however, to shift into an optimally anabolic state. It is important 
to consume the appropriate amounts and types of nutrients post-exercise, and with 
appropriate timing.  When nutrient supplementation is performed properly and 
strategically, recovery from exercise is significantly enhanced, immune function is 
protected, subsequent endurance exercise performance is improved, and training 
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adaptations are increased.  
It is well known that carbohydrate is essential for recovery from prolonged, 
strenuous endurance exercise. However, recent research suggests that the addition of 
protein (PRO) to a carbohydrate (CHO) supplement can have substantial benefits beyond 
that of providing CHO alone. Several investigators have found that post-exercise 
CHO+PRO supplementation will speed the recovery process and improve subsequent 
exercise performance (2, 6-7, 9-10). 
Therefore, this series of studies aimed to investigate the effects of CHO+PRO 
supplementation on the following key areas of endurance exercise performance, recovery 
and adaptation: acute endurance exercise performance to exhaustion, muscle glycogen 
resynthesis, markers of inflammation, muscle damage and protein degradation, activation 
of signaling proteins involved in the initiation of protein synthesis, subsequent endurance 
exercise performance, and training adaptations (specifically, maximal oxygen 
consumption, muscle oxidative enzyme activity, body composition, and immune cell 
levels). 
OBJECTIVES 
 Study 1: to determine if a low-CHO + moderate PRO supplement given during 
endurance exercise can increase time to fatigue and reduce muscle damage that occurs 
during strenuous endurance exercise, despite containing 50% less carbohydrate and fewer 
calories than a CHO supplement. 
 Study 2: to determine if muscle glycogen resynthesis following  intense endurance 
exercise is increased with a CHO+PRO beverage in the form of chocolate milk (CM) 
given post-exercise, as compared to a CHO-only beverage or placebo, and to then 
determine if subsequent endurance exercise performance is improved after the recovery 
period. In addition, we purposed to determine if indicators of post-exercise inflammation, 
muscle damage and degradation is reduced in the CM treatment compared to the CHO or 
placebo treatments, and also determine the effects of the experimental treatments on the 
activation states of signaling proteins that control translation initiation for protein 
synthesis. 
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 Study 3: to determine if supplementing with a CHO+PRO beverage post-exercise 
compared to CHO only or placebo over a 4.5-week period of intense endurance exercise 
training results in a greater increase in maximal oxygen uptake, muscle oxidative enzyme 
activity, and indicators of mitochondrial biogenesis. 
 Study 4: to determine if supplementing with a CHO+PRO beverage post-exercise 
compared to CHO only or placebo over a 4.5-week period of intense endurance exercise 
training results in a greater improvements in body composition in the CHO+PRO group 
compared to the CHO or placebo groups. We also aimed to determine if immune cell 
levels are less perturbed, and markers of inflammation and muscle damage better 
attenuated, in the CHO+PRO group compared to the CHO or placebo groups. 
HYPOTHESES 
Study 1 
1. In comparison with a CHO-only supplement, a CHO+PRO supplement containing 
a lower amount of carbohydrate and a moderate amount of protein (MCP) taken 
during exercise will extend time to fatigue during strenuous cycling endurance 
exercise despite containing 50% less carbohydrate and 30% fewer calories than 
the CHO beverge. 
Study 2 
1.  In comparison with a CHO supplement and placebo, a dairy CHO+PRO 
supplement (chocolate milk, CM) will: (a) increase muscle glycogen resynthesis 
after a prolonged aerobic exercise bout that depletes the muscle glycogen stores, 
and (b) will enhance subsequent exercise performance, measured in the amount of 
time taken to complete a 40-km time trial. 
2. In comparison with an isocaloric CHO supplement and a placebo treatment, a 
CHO+PRO supplement will demonstrate greater activation states of cellular 
signaling proteins that control mRNA translation initiation (mTOR, rpS6, and 
eIF2B), and less protein degradation as assessed by FOXO3A phosphorylation 
and total ubiquitination of muscle tissue samples.  
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3. In comparison with an isocaloric CHO supplement and Placebo, a CHO+PRO 
supplement will better promote exercise recovery by: (a) reducing protracted 
exercise muscle damage as assessed by myoglobin and CPK levels, and (b) will 
reduce inflammation as measured by pro- and anti-inflammatory cytokine levels 
during recovery.  
Study 3 
1. In comparison with an isocaloric CHO supplement and placebo, a CM supplement 
given post-exercise will (a) increase the rate of training adaptations, defined as 
increased VO2max,  increased muscle oxidative enzyme activity, and increase in 
an indicator of mitochondrial biogenesis, that occur over 4.5 weeks of endurance 
training (cycling). 
Study 4 
1. In comparison with an isocaloric CHO supplement and placebo, a CM supplement 
will demonstrate improved body composition (maintenance of, or increase in, lean 
muscle mass and reduction in fat mass) during periods of chronic intense 
endurance training. 
2. In comparison with an isocaloric CHO supplement and placebo, a CM supplement 
will demonstrate less perturbations in circulating immune cell levels during 
periods of chronic intense endurance training. 
SIGNIFICANCE 
In the first study, we aimed to demonstrate the effectiveness of a low CHO + 
moderate PRO beverage in improving endurance performance and extending time to 
fatigue. A during-exercise supplement containing fewer total calories, yet an optimal 
blend of carbohydrate plus protein would fill a need for exercisers and athletes who 
desire a lower calorie but effective supplement and serve as an alternative to many of the 
traditional supplements. 
 Recent research suggests that a CHO+PRO supplement can have substantial 
benefits over CHO alone after exercise such that recovery is hastened and subsequent 
exercise performance is improved (2, 6-10). The recovery study described here is the first 
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to investigate all of these parameters in response to CHO+PRO supplementation in the 
form of flavored milk. Likewise, the training studies (Studies 3 and 4) will be the first to 
investigate the adaptive response to aerobic training with post-exercise CHO+PRO/CM 
supplementation compared to CHO and placebo.  If we were able to show a significant 
improvement in recovery measures as well as training adaptation with CM 
supplementation, this could yield a viable, natural low-cost recovery supplement for the 
endurance athlete and exerciser. 
Studies three and four examined the training adaptations that occur over a 4.5-
week endurance exercise training period in untrained individuals. If we demonstrate an 
increased rate of adaptation and increased fitness gain (as evidenced by improved 
maximal oxygen consumption and muscle oxidative enzyme activity) in the group 
supplementing with CM, then this would provide powerful evidence upon which sports 
nutritionists and coaches can base recommendations for proper recovery supplementation 
to exercisers and athletes in order to maximize the adaptive response to the training 
stimulus. Demonstrating improvements in body composition would be a novel and 
important finding for those seeking to decrease fat mass while gaining lean tissue during 
aerobic exercise training.  
CHO supplementation alone during prolonged exercise attenuates the typical 
increase in plasma stress hormones, such as cortisol, and potent pro-inflammatory 
cytokines such as IL-6 and TNF, while lowering blood neutrophil and monocyte counts 
(3-5). Surprisingly, the potential for added benefits to be gained from adding protein to an 
exercise or recovery drink has not yet been investigated. Therefore, given that CHO 
supplementation alone significantly reduces some aspects of the decline in immune 
function in response to intense exercise stress, and given that CHO+PRO has many 
demonstrated beneficial effects on performance and recovery that supersede the effects of 
CHO alone, including reductions in muscle damage (1, 7), we also hypothesized in Study 
4 that CM supplementation would attenuate immune cell and inflammatory marker 
perturbations in response to exercise training to a greater extent than CHO alone or 
placebo. This would be a significant finding, as reducing risk of infection and illness is 
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beneficial to the elite athlete, as well as to the avid exerciser who seeks to improve fitness 
without the risk of avoidable minor illnesses. 
Taken together, the goals of these studies was to demonstrate more effective ways 
to improve endurance exercise performance as well as recovery from strenuous exercise, 
and to increase the magnitude of adaptation to exercise training, while also reducing 
muscle damage and maintaining immune function. Ideally, this would translate to 
improved fitness, reduced illness and infection risk, and improved overall health for the 
endurance athlete and exerciser. 
LIMITATIONS AND DELIMITATIONS 
Although every attempt is made to recruit subjects with similar fitness levels, it is 
possible that there was variation in those levels and in individual training plans that could 
contribute to differing responses to the experimental trials in the first two studies. Since 
variations in normal dietary status or physical activity levels could affect substrate 
metabolism, subjects in all studies were asked to consume the same diet for the two days 
preceding each trial during which blood or muscle tissue was taken, and keep their 
activity levels consistent for the 3 days prior as well, so that starting muscle glycogen and 
glucose levels were not influenced by dietary and/or physical activity variation. However, 
standardizing the diet and training across the entire study period would likely yield better 
consistency and eliminate the possibility for performance differences between subjects 
due to these possible variations. 
Other possible limitations in these studies lie in techniques and measurement 
methods. When taking muscle biopsies, it is possible to not extract enough usable tissue 
to be able to accurately assess the signaling protein activation states or amounts of the 
oxidative enzymes. In addition, we use the standard technique for muscle glycogen 
determination where biopsies are taken from the vastus lateralis and the glycogen 
concentration is determined after its complete enzymatic degradation to glucose with 
amyloglucosidase. Liberated glucose is then measured using a spectophotometric Trinder 
reaction. While this method is used extensively in such studies, a newer, yet very 
expensive technique – NMR – is available that would allow for less invasiveness, more 
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frequent measurement time points, and greater accuracy. Due to funding limitations, this 
technique was beyond the scope of these studies. 
The use of chocolate milk as the CHO+PRO supplement of choice in the recovery 
and training studies has limitations. It is likely that chocolate milk is digested quite 
differently from typical carbohydrate-protein supplements that simply contain 1-3 
carbohydrates and whey protein isolate. Therefore, it would be useful in future studies to 
include a standard CHO+PRO treatment group in addition to the CM, CHO only, and 
placebo treatments to tease out the effects of the milk-based supplement. Although 
difficult to achieve, it would also be preferable to better disguise the non-CM treatments 
by either using chocolate flavored carbohydrate gels in solution, or using a cocoa+sugar 
power that lacks protein. This would reduce the subjects’ perception of what treatment 
they are receiving and help to eliminate confounding psychological responses to the 
treatments.  
The subjects in these studies were all in the age range of 18 – 39. Therefore, our 
results may not be generalizable to younger or older athletes. Also, given that the mode 
of exercise we studied is cycling, it is possible that the results, particularly concerning 
markers of muscle damage, may differ from what could be found in a more eccentric 
contraction-based mode, such as running or in resistance training. Therefore, the results 
may not be generalizable to other types of endurance athletes. In addition, the measures 
of body composition and plasma metabolic hormones in the training study are done in 
healthy untrained subjects, and the results may not be generalizable to populations such 
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Chapter II: Review of the Literature 
It is well known that carbohydrate is essential for recovery from prolonged, 
strenuous endurance exercise. However, recent research suggests that the addition of 
protein (PRO) to a carbohydrate (CHO) supplement can have substantial benefits beyond 
that of providing CHO alone. Several investigations have found that post-exercise 
CHO+PRO supplementation will in fact speed the recovery process and improve 
subsequent exercise performance (94, 173, 217, 257, 266). Therefore, in this review I will 
discuss the relevant literature regarding the effects of CHO+PRO supplementation on the 
following key areas of endurance exercise recovery and adaptation: glycogen resynthesis, 
immune system function and muscle tissue damage, initiation of protein synthesis, 
subsequent endurance exercise performance, and training adaptations (specifically, 
maximal oxidative capacity and maximal oxygen consumption). 
ACUTE ENDURANCE EXERCISE PERFORMANCE 
As mentioned previously, it is well established that endurance exercise 
performance is significantly improved when carbohydrate is ingested during exercise 
compared to water only or placebo beverages (37, 38, 99, 263, 264), yet recent 
investigations have reported significant improvements in endurance exercise performance 
when a carbohydrate-protein (CHO+PRO) beverage is ingested during exercise compared 
to a carbohydrate-only (CHO) beverage (100, 217, 219).  
Ivy et al. (100) compared the effects of a placebo, CHO (7.75%) and CHO+PRO 
(7.75% CHO, 1.94% PRO) supplement on aerobic endurance performance. Nine trained 
cyclists exercised on 3 separate occasions at intensities that alternated between 45% and 
75% of maximal aerobic consumption (VO2max) for 3 hours, and then at 74% - 85% 
VO2max until exhausted. Two hundred milliliters of randomly-assigned supplement was 
provided every 20 min during exercise. While CHO supplementation significantly 
increased time to exhaustion, the CHO+PRO supplementation extended time to 
exhaustion (TTE) by 36.5% (26.9 +/- 4.5 min vs 19.7 +/- 4.6 min, p<.05). Saunders et al. 
(217) reported similar TTE improvements with CHO+PRO compared to CHO 
 10 
supplementation during exercise, and also found significantly reduced muscle damage in 
the CHO+PRO condition compared to CHO. Improving TTE is important to elite 
athletes, especially those undertaking prolonged events such as road cycling races or 
triathlons, but it is also attractive to recreational exercisers as well who seek to exercise 
longer and increase endurance capacity.  
In addition to the need for exercise beverages to help improve endurance time, 
many athletes or recreational exercisers desire a lower caloric content alternative when 
maintaining or reducing body weight is a concern or goal. Since the addition of PRO to a 
CHO beverage has been demonstrated to improve the performance characteristics of a 6-
8% CHO sports drink (100, 173, 217), it is likely that the CHO content of a sports drink 
could be substantially reduced yet benefit performance with the addition of a smaller 
amount of protein. In this manner, the total energy content of the beverage could be 
reduced up to 50%. Martinez-Lagunas et al. (140) recently compared the effects of a 
4.5% CHO plus 1.15% PRO, and a 3% CHO plus 0.75% PRO beverage, to a traditional 
6% CHO beverage and found that there was no difference in the times to exhaustion 
between the treatments. This suggests that the efficacy of the supplements was 
maintained despite the reduction in total CHO and total energy content with the 
substitution of a small amount of protein (140).  
It is also known that the maximal rate of exogenous carbohydrate utilization is 
about 1.0-1.1 g/min when a single carbohydrate source (e.g., dextrose) is ingested (107-
109, 251), but when multiple carbohydrate types (e. g., dextrose, fructose and 
maltodextrin) are ingested, this rate can be increased significantly (102, 104, 106, 107). 
Currell and colleagues (46) demonstrated an 8% improvement in time to complete a 
subsequent time trial when a mixture of glucose and fructose was ingested during a 
previous bout of prolonged exercise compared to glucose only. The use of different 
intestinal carbohydrate transporters for glucose and fructose is most likely the reason for 
the improved exogenous carbohydrate oxidation and thus, improved performance. Thus, 
it is possible that a lower-carbohydrate, moderate-protein and lower calorie beverage that 
utilizes different carbohydrates for maximal intestinal absorption could extend endurance 
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as well as, or better than, the traditional higher calorie alternatives. 
While many investigations have demonstrated improved time to exhaustion with 
the addition of protein to a carbohydrate supplement ingested during exercise (100, 173, 
217, 219), the mechanisms by which this improved TTE occurred has still not been 
clearly elucidated. One possible mechanism through which CHO+PRO supplementation 
improves performance is that CHO+PRO spares endogenous fuel supplies by decreasing 
muscle glycogen use and/or reducing the depletion of Krebs cycle intermediates. Cermak 
and colleagues (31) provided 6% CHO or 6% + 2% PRO to trained male subjects such 
that they received 60 g/h CHO +/- 20 g/h PRO during 90 min of cycling at ~69% 
VO2peak. CHO+PRO ingestion increased the plasma branched chain and essential amino 
acids compared to CHO, but net muscle glycogen use and Kreb’s cycle intermediate 
expansion was not significantly different between trials (31). The investigators concluded 
that when CHO is ingested at the higher end of the generally recommended exercise 
ingestion amount (60g/h), the addition of PRO does not improve substrate availability via 
Kreb’s cycle imtermediates or spare muscle glycogen stores (31). However, key 
limitations in this study could have affected the results. For example, the only Kreb’s 
cycle intermediates measured were citrate and malate, which are not rate-limiting 
intermediates. Also, the duration of the exercise bout was only 90 min and at a moderate 
intensity; this is not a difficult effort for trained subjects, and muscle glycogen would 
likely not be adequately depleted after this bout. Therefore, the findings of the study by 
Cermak and colleagues may be hindered by the study design. 
Another proposed mechanism emerged from an investigation by Saunders and 
colleagues (217), in which 15 cyclists rode a cycle ergometer at 75% VO2max to 
exhaustion, followed 12-15 hours later by a second ride to exhaustion at 85% VO2max. 
Participants consumed 1.8 ml/kg body wt of a CHO or CHO+PRO beverage every 15 
min of exercise and 10 ml/kg body wt immediately post-exercise.  As occurred in the Ivy 
et al. (100) investigation, the cycling TTE was significantly increased in the CHO+PRO 
treatment. The cyclists rode 29% longer in the first and 40% longer in the second ride 
when consuming CHO+PRO compared to the CHO beverage. However, peak post-
 12 
exercise plasma creatine phosphokinase (CPK), an indirect measure of muscle damage, 
was also measured and was found to be 83% lower after the CHO+PRO trial compared 
the CHO trial (217). These findings suggest that the addition of protein to a carbohydrate 
supplement both increases aerobic endurance performance and reduces muscle damage 
caused by prolonged, intense exercise. In a follow-up investigation, Saunders and 
colleagues again examined the effects of CHO+PRO supplement on TTE and muscle 
damage as assessed by levels of creatine phosphokinase (CPK). TTE was extended by 
13% with CHO+PRO, and CPK levels were significantly elevated in the post-exercise 
period in the CHO treatment, they did not rise in the CHO+PRO treatment, suggesting a 
significant reduction in muscle damage (219). It is possible that reducing muscle damage 
may be a mechanism through which the extended time to exhaustion occurs, although a 
few recent investigations demonstrated significant reductions in muscle damage without 
differences in TTE (210, 246). 
Other recent investigations have substantiated the findings of improved TTE. 
Pratt et al. (199) had 10 non-elite triathletes perform two simulated duathlon trials 
consisting of an 8km run at 80% VO2max, followed by a 50km ride at 70% VO2max, and 
then a second run at 80% VO2max (with no rest in between modes) to exhaustion. 
Subjects were provided either CHO or CHO+PRO during the cycling portion of the 
protocol. The team found that TTE was significantly improved in CHO+PRO versus 
CHO (mean = 4.5±7.1min; p<.05) (199). Likewise, Saunders et al. (219) reported 
increased TTE and decreased post-exercise muscle damage (CPK levels) when athletes 
consumed CHO+PRO gels versus gels containing CHO alone during cycling exercise. 
Despite several reports of improved endurance performance with CHO+PRO, 
there are other investigations that have not corroborated this finding. Recent 
investigations using isocaloric CHO and CHO+PRO treatments found no difference in 
TTE (176, 210, 246). In addition, Van Essen and Gibala (247) found no difference in 
cycling time between isocarbohydrate CHO and CHO+PRO treatments when using a 
cycling time trial as the measure of performance.  
It is likely that some of the discrepancies in the literature regarding the benefits or 
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lack thereof of adding PRO to a CHO supplement stem from differences in methodology. 
The method of defining and assessing endurance performance could be one such 
difference. Van Essen and Gibala (247) used time to complete and 80-km time trial as the 
measure of performance, finding no difference between a 6% CHO and a 6% CHO-2% 
PRO beverage. Studies by Ivy et al. (100) and Saunders et al. (217, 219) utilized TTE as 
the performance measure. Perhaps the benefit of PRO added to a CHO supplement is 
extending endurance time and delaying onset of exhaustion, which is important in ultra-
distance events, triathlons, cycling stage races, and long cycling single-day events such as 
centuries (100 mi events).  
The difference in ingestion rates used in the various investigations could also be a 
reason for conflicting findings. In the investigations by Ivy et al. (100) and Saunders et al. 
(217, 219), CHO ingestion rates averaged about 47 g.h-1, 37 g.h-1, and 41 g.h-1, 
respectively, whereas Van Essen and Gibala (247) used a rate of 60 g.h-1. Van Essen and 
Gibala (247) suggested that when CHO ingestion rates closely match the optimal rate of 
CHO oxidation, the addition of PRO to a CHO supplement coffers no additional 
performance benefits. While the maximal rate of exogenous carbohydrate utilization 
during prolonged exercise is about 1.0-1.1 g.min-1 (or about 60-70 g.h-1) when a single 
CHO source is provided (107, 108, 251), the combination of multiple carbohydrates 
ingested at a high rate (2.4 g.min-1), during exercise, the oxidation rate can increase to 
1.75 g.min-1 (102, 103). It should be noted, however, that this is a large amount of CHO 
to ingest during exercise and may not be well tolerated by many exercisers. A more 
practical approach is to ingest a smaller caloric amount that maximizes both exogenous 
CHO oxidation and endogenous fat oxidation, and extends time to exhaustion. 
Given that many of the studies examining the effects of CHO+PRO on endurance 
performance use relatively small sample sizes, Saunders et al. (218) examined data across 
multiple studies to determine if performance was in fact related to changes in 
physiological measures during exercise. To accomplish this, thirty eight subjects were 
combined from three studies in which cyclists performed rides to exhaustion at 75% 
VO2peak. In each study analyzed, cyclists received CHO (7.3%) or CHO+PRO 
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(7.3+1.8%) every 15 min during exercise, using a random, counterbalanced and double-
blind design. VO2, heart rate, blood glucose, blood lactate, RER and RPE were compared 
between the treatments at the 30-min time point during exercise. This time point was 
chosen because it was a common measurement time for all subjects in all of the studies 
examined. Despite finding no differences in VO2 (2.89±0.58; 2.86±0.61 L/min), blood 
glucose (83.1±14.5; 82.4±17.8 mg/dL), and RER (.95±.03; .95±.03) between CHO and 
CHO+PRO treatments, TTE was 19% longer (p<.05) in CHO+PRO (116.5±33.9 min) 
than CHO (97.8±32.4 min). Heart rate (163.3±14.0; 159.3±14.1 bt/min), RPE (14.6±2.0; 
14.1±2.0) and lactate (3.4±1.3; 2.9±1.5 mmol/L) were significantly lower (p<.05) during 
the CHO+PRO trials.  The TTE differences were significantly correlated with treatment 
differences in exercise responses for heart rate (r=.410) and RPE (r=.306) but not lactate 
(r=.065) (218). Thus, the authors concluded that the combined data showed significant 
improvements in endurance performance with CHO+PRO versus CHO supplementation. 
While the decreases in HR and RPE were associated with improvements in performance, 
the magnitude of those differences did not appear large enough to explain the large 
improvements in performance with CHO+PRO treatments. The authors suggest that the 
underlying mechanism(s) underlying performance improvements with CHO+PRO 
beverages may also produce the physiological alterations in HR and RPE that were 
observed in this study (218). 
In summary, it is reasonable to hypothesize that a lower-carbohydrate, moderate-
protein supplement containing fewer calories relative to a higher carbohydrate and 
protein beverage can extend time to exhaustion during prolonged endurance exercise, and 
potentially reduce muscle damage as well.  
MUSCLE GLYCOGEN RESYNTHESIS 
The Importance of Muscle Glycogen in Recovery from Endurance Exercise 
The importance of muscle glycogen as a fuel source during prolonged strenuous 
exercise is well established. It has been demonstrated that aerobic endurance is directly 
related to the initial muscle glycogen stores (14, 15). Once these stores are depleted, 
strenuous exercise cannot continue, and even the perception of fatigue rises as muscle 
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glycogen levels fall (1, 14, 15, 78). Thus, the replenishment of muscle glycogen is of 
great importance for adequate recovery after intense training or competition and has a 
substantial impact on physiological readiness for subsequent exercise bouts. 
It is important to note that how investigators define moderate exercise or intense 
exercise can vary from study to study. Generally, and for purposes of this review, 
moderate endurance exercise is defined as <60 min and <65% VO2max, while prolonged, 
strenuous exercise is defined as >90 min and >65% VO2max. 
 
Amount and Timing of Post-Exercise Carbohydrate Supplementation and Glycogen 
Synthesis 
With sufficient CHO intake post-exercise, restoration of muscle glycogen to 
baseline levels can occur in 24 h (15, 28). However, for athletes who must train or 
compete again without the luxury of adequate restorative time, a more strategic approach 
must be employed in order to optimize glycogen replenishment to fuel the next exercise 
bout. Much research has been performed to elucidate the optimal amount and timing of 
post-exercise CHO supplementation for muscle glycogen resynthesis. Essentially, at least 
0.7g CHO/kg body weight/h is needed immediately and 2-hrs post-exercise to achieve a 
muscle glycogen restoration rate of approximately 7 mmol/kg/wet wt/h (19, 96, 98). 
However, this rate of resynthesis is apparently not the maximum that can be achieved, as 
has been demonstrated by investigations using greater supplementation frequencies (e.g., 
every 15 or 30 min) (48, 196, 248). In these instances, the CHO provided was at a rate of 
~1.0 to 1.2 g CHO/kg/hr, and suggests that muscle glycogen storage can be up to 30% 
more under these conditions than when CHO is provided at 2 h intervals. However, on a 
practical level, consuming this much CHO at 15 to 30 min intervals post-intense exercise 
is often unrealistic and undesirable, as this is a large amount to consume for most 
athletes. Therefore, a more practical and beneficial approach for maximizing muscle 
glycogen replenishment is preferred, and it appears that this can be achieved by adding 
protein to a CHO supplement.  
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Effects of Carbohydrate plus Protein on Post-Exercise Muscle Glycogen Resynthesis 
It is known that muscle is more sensitive to insulin following exercise (95) and 
that providing a CHO supplement immediately post-exercise results in a rate of glycogen 
synthesis twice as fast as providing the same supplement 2-hrs post-exercise (96). 
Investigations have shown that CHO intake greater than 0.75 g/kg/h body wt will 
maximize muscle glycogen storage when provided at 2-h intervals (98) and that the rate 
limiting step in muscle glycogen resynthesis is evidently not glucose delivery to the 
muscle (206). Combining PRO with CHO supplementation was found to significantly 
increase the post-exercise insulin response to CHO and accelerate the rate of muscle 
glycogen resynthesis beyond that of an isocarbohydrate (266) and isocaloric CHO 
supplement (94). Taken together, these findings suggest that the addition of PRO to a 
CHO supplement appears to increase the rate and efficiency of muscle glycogen 
synthesis.  
The study performed by Zawadski et al. (266) was the first to investigate the 
combined effect of CHO+PRO on post-exercise muscle glycogen synthesis. Nine 
subjects performed 2 h of glycogen-depleting cycling exercise and then were provided 
one of three treatments immediately and 2 h post-exercise: 112 g CHO, 112 g CHO + 
40.7 g PRO (total of 152.7 g), or 40.7 g PRO. Biopsies were taken immediately after 
exercise and 4 h later. Relative to the CHO treatment, the CHO+PRO treatment resulted 
in a 38% greater rate of muscle glycogen resynthesis across the 4 hours of recovery. 
Little glycogen storage occurred with the PRO treatment. Insulin levels were significantly 
greater with CHO+PRO, and the investigators attributed the faster rate of glycogen 
synthesis (35 versus 25 mol/g muscle protein) to the increased insulin response (266). 
However, the findings met with much controversy given that the treatments were not 
isocaloric (difference of 162.8 kcals per dose), despite previous studies that demonstrate 
that the addition of calories when the total caloric content is adequate does not achieve a 
greater rate of glycogen resynthesis and storage (98). 
Investigations by other laboratories (26, 105, 236, 248, 250) failed to confirm the 
findings of Zawadski et al. (266). However, rather than finding a negative effect of 
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CHO+PRO versus CHO alone, these studies simply found no significance difference 
between the two in terms of glycogen resynthesis. But it is important to note that there 
are obvious differences in the methodologies of these studies that may account for the 
difference in conclusions. Differences in both the timing/frequency of supplementation, 
as well as in the amount of macronutrients and total energy provided during the recovery 
period likely account for much of the differing reports.  
For example, Tarnopolsky et al. (236) used a very small amount of protein – 0.1 
g/kg --  in addition to 0.75 g CHO/kg body wt to compare against 1 g/kg CHO or placebo 
and found no significant differences between the CHO and the CHO+PRO supplements, 
although both increased glycogen resynthesis significantly above placebo. However, 
given the small amount of protein added to the supplement, and given that the 
CHO+PRO combination resulted in less total kcals than the 1 g/kg CHO supplement, it is 
not difficult to understand why this would fail to demonstrate an advantage. Other 
investigators provided a greater amount of CHO (1.2 g/kg/h divided into doses every 30 
min for 3 h) along with CHO+PRO and found that while the CHO+PRO did increase 
insulin levels, there was no significant difference in muscle glycogen synthesis, 
suggesting that as long as the amount of CHO provided is high enough, there is no 
benefit to be gained from the addition of protein (105). Compared to the studies described 
above, Van Hall et al. (248) provided more CHO (1.67 g/kg body wt and 1.67 g CHO 
plus 0.5 g/kg protein) at a greater frequency (every 15 min for 4 h). They found that the 
addition of PRO did not increase leg glucose uptake or glycogen resynthesis, and 
concluded that high amounts of CHO alone is enough to maximize resynthesis. However, 
these amounts of CHO should be considered excessive, and is not practical as a post-
training and competition strategy. 
Carrithers et al. (26) also used less PRO (only 0.2 g/kg/h PRO with 0.7 g/kg/h 
CHO) and more frequent supplementation intervals (every 30 min for 4 h), and likewise 
failed to find a significant difference in muscle glycogen resynthesis. However, the 
differences as described above from the Zawadski et al. (266) protocol could certainly 
account for what seems to be a null hypothesis--that adding PRO to CHO does not 
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improve muscle glycogen resynthesis beyond that achievable by adequate CHO alone. 
Recently, Howarth and colleagues (89) assessed muscle glycogen resynthesis when 
subjects were provided CHO and CHO+PRO treatments following 2 h of cycling 
exercise. The three randomly-ordered treatments provided either 1.2 g/kg/h CHO, 1.2 
g/kg/h CHO + 0.4 g PRO, or 1.6 g/kg/h CHO. Muscle biopsies were taken from the 
vastus lateralis to determine the muscle glycogen resynthesis that occurred over a 4-h 
recovery period. The glycogen resynthesis rate was not significantly different between 
the 3 treatments, nor were the plasma glucose and insulin response. These results 
suggests that a 1.2 g/kg/h CHO ingestion rate is sufficient to optimize muscle glycogen 
storage, and that adding 0.4 g/kg/h of either protein or additional carbohydrate does not 
further increase this process (89).  
Of these inter-study differences in supplementation frequency, CHO+PRO 
amounts and total energy content, a few important points should be addressed. Ivy et al. 
(98) showed that merely adding calories (adding more CHO to a CHO supplement) is not 
sufficient to continue increasing the rate of muscle glycogen resynthesis. Providing 3g 
CHO/kg/h versus 1.5 g CHO/kg/h had the same effect on muscle glycogen resynthesis. 
Therefore, simply adding energy when the energy amount in the supplement is already 
sufficient for muscle glycogen restoration is not an issue. Increasing the feeding 
frequency may not show a clear benefit from the addition of PRO to the CHO 
supplement, but are large boluses every 15 or 30 min really practical in real-world 
settings? More often than not, athletes consume a recovery supplement immediately after 
exercise, and then 1-2 h later. A strategy that addresses the practicality of daily training 
or competitive events, and that maximizes muscle glycogen restoration, is much more 
attractive and useful. 
Finally, another key difference in study design can also account for varied 
findings: different methods of assessing muscle glycogen levels. The gold standard has 
long been the needle biopsy, and it is performed successfully and reliably in laboratories 
all over the world. However, with the emergence of NMR (nuclear magnetic resonance) 
technology, assessments can be made non-invasively and at much more frequent intervals 
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than with the traditional biopsy method. Thus, more measurements are able to show a 
more detailed timecourse and sample a greater area of the thigh for more accurate 
measurements. Two studies that did in fact show significantly greater muscle glycogen 
resynthesis in response to CHO+PRO versus CHO alone used this method (13, 94). Ivy et 
al. (94) found a significant increase in glycogen resynthesis during recovery at 40 min 
and at 4 h (88 mmol/L with CHO+PRO versus 75.5 mmol/L with an isocaloric CHO 
supplement, versus 70 mmol/L with an isocarbohydrate supplement). While there was not 
a significant difference in insulin responses between the three treatments, blood glucose 
was lower in recovery with CHO+PRO, suggesting that more glucose was being 
converted to glycogen and stored. Interestingly, at the end of the 4 h recovery, 46% of the 
glycogen used was restored in the CHO+PRO treatment, versus 31% and 28% restored in 
the other 2 treatments (isocaloric and isocarbohydrate, respectively) (94). Berardi et al. 
(13) reported similar results using isocaloric treatments (CHO+PRO contained 0.8 g/kg 
CHO and 0.4 g/kg PRO and CHO contained 1.2 g/kg CHO) given immediately and at 1 
and 2 h post-exercise. Greater glycogen resynthesis was found after a 6 h recovery period 
in response to the CHO+PRO treatments (13).  
Recently, our laboratory investigated the effects of cereal with nonfat milk 
(Cereal) versus a traditional sports drink (Drink) immediately following prolonged 
aerobic exercise on muscle glycogen synthesis and the activity of enzymes controlling 
glycogen storage and mRNA translation (i.e., glycogen synthase, Akt, mTOR, rpS6K and 
eIF4E) (110). While both treatments raised plasma glucose and insulin levels during 
recovery, interestingly, Cereal raised plasma insulin significantly higher and blunted the 
rise in blood lactate relative to Drink. Although muscle glycogen storage was similar 
between the two treatments, mTOR phosphorylation was greater following recovery with 
Cereal verses Drink. As will be discussed later, mTOR is a key protein regulating not 
only glycogen synthesis, but importantly, for regulation of protein synthesis. In addition, 
only Cereal significantly altered the phosphorylation status of glycogen synthase and Akt 
during recovery indicating greater activation. Thus, Cereal had significant effects on the 
enzymes that are essential to the pathways for glycogen and protein synthesis, increased 
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insulin levels that appeared to facilitate muscle glucose uptake and glycogen storage, and 
blunted lactate formation during recovery, which suggests that more intracellular glucose 
was indeed converted to glycogen. Glycogen synthase also appeared to remain more 
active after Cereal compared to Drink despite higher glycogen levels (110).  
The findings of the many studies discussed above indicate that combined 
ingestion of CHO+PRO as a recovery supplement can indeed increase the rate and 
amount of muscle glycogen resynthesis when taken immediately post-exercise and at 
frequencies of 1-2 h. CHO+PRO supplementation may be especially beneficial when the 
amount of CHO that would otherwise be ingested is less than optimal (i.e., less than 0.8 
g/kg body wt). This is particularly important when an athlete has only a few hours 
between training sessions or competitive events. 
As will be discussed in detail below, there are many other benefits to the athlete 
of adding PRO to recovery supplements that extend well beyond simply optimizing 
glycogen stores, which is a worthy goal in and of itself. These benefits include protecting 
immune system function, reducing muscle damage, optimizing mRNA translation 
initiation for increased protein synthesis, improving performance in subsequent exercise 
bouts, and increasing the rate of training adaptations. 
IMMUNE CELLS, INFLAMMATORY MARKERS, AND MUSCLE DAMAGE 
The immune response to prolonged, intense endurance exercise has received 
much attention in recent years, and the specialized area of exercise immunology has 
become a relatively new and exciting niche field of research. Exercise immunology is a 
very broad area and encompasses all aspects of the immune system, as well as 
interactions with multiple systems such as the endocrine and nervous systems and their 
dynamic interplay with prolonged and strenuous exercise. Therefore, in order to fully 
understand the effects of training and supplementation down to the cellular level, the 
immune response to intense exercise must be more clearly elucidated. 
Over the past 25 years, many studies have shown that exercise induces changes in 
immune system function. These changes differ, however, based on the intensity and 
duration of the exercise. It is well accepted that regular moderate exercise is associated 
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with reduced incidence of bacterial infection compared with a completely sedentary state 
(69). In contrast, prolonged, strenuous bouts cause a temporary suppression of the 
immune system that lasts for several hours after exercise, and this immune dysfunction is 
most pronounced when the exercise is continuous, prolonged (>1.5 h), of moderate to 
high intensity (55 - >75% VO2max), and performed without food intake (69).  
 It is well established that intense exercise can negatively impact the immune 
system, resulting in decreased immune function and higher rates of illnesses such as 
upper respiratory tract infections (70, 154, 156, 158, 167). Many nutritional 
countermeasures have been investigated for potential impact on immune variables in 
response to endurance exercise, including CHO beverages, glutamine, bovine colostrum, 
phytonutrients such as quercetin, and antioxidants such as vitamins C and E (159, 162, 
164, 165, 224). Of these, carbohydrate ingestion has been demonstrated to be by far the 
most effective against many immune and inflammatory outcome measures (154, 158, 
159). The effects of CHO+PRO on immune response to exercise in such a model as this 
have never before been investigated, and thus much of the background for this review 
will draw from investigations using CHO supplements post-exercise. The effects of 
strenuous and prolonged endurance exercise alone will be reviewed in brief in order to 
demonstrate the potential importance of providing CHO+PRO after exercise to fully 
protect immune function. 
For the purposes of this review, I will focus on a few key immune parameters in 
relation to CHO+PRO supplementation post-endurance exercise: (1) two subpopulations 
of leukocytes -- monocytes and neutrophils; and (2) five key cytokines known to be 
impacted by strenuous exercise – IL-1Ra, IL-6, IL-8, IL-10, and TNF. Additionally, it is 
impossible to discuss the effects of exercise on the immune system without concurrently 
discussing muscle damage, as the two are intimately linked. Therefore, this discussion 
will also include two blood markers of muscle damage: creatine kinase (CK; also known 
as CPK, creatine phosphokinase) and myoglobin. 
 
Lymphocytes, Monocytes, and Neutrophils 
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The link between prolonged, strenuous endurance exercise and decreased immune 
function, as well as the immune-bolstering effect of moderate exercise, has been 
established and well reviewed (154, 189). For several hours after prolonged, intense 
endurance exercise, the number of circulating lymphocytes in the blood remains 
decreased, and immunity is impaired (154, 186). This period of immunosupression and 
increased risk of pathogenic attack is often called the “open window,” and may last from 
3 to 72 hours (172, 187). However, not all leukocytes respond in the same fashion. 
Prolonged, intense endurance exercise is associated with a biphasic perturbation of 
circulating leukocytes (66, 74, 168). Total leukocytes increase as much as 100% 
immediately post-exercise, with this increase evenly distributed by lymphocytes and 
neutrophils (NPs), and a smaller contribution made by monocytes (153). After longer 
events such as marathons, the increase has been shown to be much larger (200 – 300%) 
(157). However, within 30 minutes after exercise, total lymphocyte levels actually fall to 
30% - 50% below pre-exercise levels and remain low for 3 – 6 h (168).  The increase in 
lymphocyte concentration in the circulation immediately post-exercise is likely due to the 
release of all subpopulations into the blood during exercise (185), when heart rate and 
stroke volume - and thus, cardiac output - is increased to the active skeletal muscles and 
the cardiopulmonary system.   
Contrary to the initial rise and then fall in lymphocyte concentrations post-
exercise, however, NPs have been found to continually increase (neutrophilia) post-
exercise (142, 168, 185).  An elevation in circulating NPs was also found after only 30 
min of brisk walking exercise (161). In response to 45 min of running at 80% of 
VO2max, NP numbers were found to be increased from pre-exercise levels for ~8 h post-
exercise (168). This increase could translate to a heightened immunosurveillance against 
any possible invaders such as upper respiratory tract infection (URTI) causing pathogens. 
However, the increase may not necessarily mean a heightened immune effectiveness but 
rather an increased presence of immature, less battle-ready NPs. Following intense or 
prolonged endurance exercise, there is an increased release of younger, less mature NPs 
called band neutrophils into the circulation (234). This is often called the leftward shift. 
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Mature NPs are normally the most abundant leukocyte in the blood and are the first 
leukocytes to respond to bacterial infection. They are powerful pathogen killers due to 
their ability to engulf pathogens and destroy them via oxidative burst. NPs are non-
dividing cells, and have only a 1–4 day lifespan. If more immature NPs are circulating 
during the open window period, this could mean a less powerful response to a pathogen.  
The decrease in total lymphocytes and the increased neutrophilia post-exercise is 
likely due to the increase in stress hormones that are released in response to prolonged 
exercise. Cortisol, the catecholamines epinephrine and norepinephrine, and growth 
hormone have been shown to modulate NP function (82, 231, 233). These three types of 
stress hormones are reported to exert differing effects, as detailed in a review by Pedersen 
et al. (184). The catecholamines, especially epinephrine, appear to be responsible for the 
immediate effects of exercise on lymphocyte subpopulations and cytotoxic activities, and 
catecholamines and growth hormone mediate acute effects of exercise on NPs, whereas 
cortisol is most likely responsible for maintaining the lymphopenia and neutrophilia seen 
after prolonged exercise (184). Cortisol, unlike the catecholamines, exerts its effect after 
a lag time of hours after exercise, so it is not likely to have an acute effect during or 
immediately after a prolonged bout (185). In addition, cortisol does not increase 
significantly in brief exercise but rather comes into play in prolonged bouts, and therefore 
is likely to contribute to the neutrophilia seen after prolonged exercise (65). However, 
given that catecholamines have been shown to inhibit NP activity (152), and that NPs 
may be important effectors of exercise-induced muscle damage that occurs during 
exercise (234), it is important to blunt the increase in circulating catecholamines during 
the prolonged exercise so that NP function during the bout is not impaired. In addition, 
minimizing the detrimental effects of cortisol during recovery is of great importance for 
bolstered immune function during the open window period.  
While NPs are first on the scene of infection or injury, monocytes are also part of 
the primary leukocyte defense against a pathogenic attack.  Monocytes (MOs) are unique 
in that they react to inflammatory signals of an infection and move to the site of insult 
within hours, where they differentiate into powerful phagocytic macrophages and 
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dendritic cells. Similarly to the NP response, MOs have been shown to increase during 
exercise and remain elevated afterwards (169, 208). MOs in the early differentiation stage 
are strongly recruited into the circulation during long-term aerobic exercise, whereas 
mature monocytes (premacrophages) increase most with high intensity anaerobic exercise 
(65). Interestingly, whereas bacterial infection induces the actual maturation of immature 
monocytes, exercise does not, which demonstrates the possible difference between 
change in actual cell counts or concentration and change in the actual functional 
capacities of those cells (65). Arnold et al. (6) recently reported that injured skeletal 
muscle recruits MOs that quickly differentiate into anti-inflammatory macrophages that 
then stimulate myogenesis and fiber growth. Viewed in this light, MO are potentially 
useful in supporting myogenesis and fiber growth. Clearly, MOs are an important part of 
the immune response to exercise and may mediate more than simply host defense in the 
post-exercise period. 
Ingesting CHO during prolonged exercise has repeatedly been found to attenuate 
the typical increase in plasma stress hormones, such as cortisol, while lowering blood 
neutrophil and monocyte counts (155, 159, 166, 169, 171). Surprisingly, the potential for 
added benefits to be gained from adding protein to an exercise or recovery drink has not 
yet been investigated. Therefore, given that CHO supplementation alone significantly 
reduces some aspects of the decline in immune function in response to intense exercise 
stress, and given that CHO+PRO has many demonstrated beneficial effects on 
performance and recovery that supersede the effects of CHO alone, including reductions 
in muscle damage (11, 217), it is reasonable to hypothesize that CHO+PRO will improve 




Cytokines are potent cell-to-cell signaling proteins that regulate inflammation and 
immune responses. While they can exhibit hormone-like actions, unlike hormones, they 
are made on demand rather than stored, are effective in very small concentrations, usually 
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exert their effects in a local range, and are virtually absent in healthy, stress-free subjects. 
However, cytokine levels increase significantly, even dramatically, during disease, tissue 
injury, and repair. Their pleiotropic actions are not limited to immune response only, as 
cytokines target multiple cell types and exert a wide range of effects.  
Much of what is known about cytokines comes from sepsis research, which has 
revealed that the cytokine cascade is comprised of TNF, IL-1, IL-6, IL-1Ra, and IL-
10, in that order (3, 192). Cytokines are produced and released at the site of inflammation 
as part of the local response to infection or tissue injury. They mediate the influx of many 
types of immune cells, including neutrophils and monocytes, to the area to clear away 
antigens, debris, and facilitate healing and repair (178). The local response combined 
with the systemic response that follows is called the acute phase response and is led by 
TNF IL-1, and IL-6. The cytokine response to exercise differs somewhat from that 
brought about by severe infection, as indicated by a lack of large, significant increase in 
the pro-inflammatory cytokines TNF and IL-1 with strenuous exercise (192), although 
some studies have reported small but statistically significant TNF increases (50, 55, 
178). IL-6, however, appears to be a key, possibly main, mediator of the acute phase 
response, and its elevation is used as an indicator of inflammation because it precedes the 
increase in other acute phase proteins (154).  In addition to being the first cytokine to 
appear in response to intense exercise, Interleukin-6 (IL-6) also demonstrates the largest 
measurable increase--up to 100-fold during exercise before declining in the post-exercise 
period (59, 185, 188, 192, 232). At present, it appears that the exercise-induced cytokine 
cascade involves an increase in IL-6, followed by significant increases in the anti-
inflammatory cytokines IL-1Ra and IL-10 (185). 
IL-6 acts as both a pro and anti-inflammatory cytokine and is secreted by T and B 
cells, monocytes and macrophages to stimulate immune response to trauma or injury. 
Thus, it is often termed inflammation responsive rather than pro- or anti-inflammatory 
(178). In addition, IL-6 is released from skeletal muscle during contraction and its 
increase in response to exercise has been well documented (150, 177-179, 229, 245). A 
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versatile cytokine, IL-6 has been implicated as also having important roles in influencing 
glucose homeostasis during exercise (58) and in modulating fat metabolism (193, 249).  
Much of the current IL-6 and exercise research has been performed by Pedersen 
and colleagues at the Copenhagen Muscle Research Centre. In one investigation, they 
studied trained male marathoners to determine the extent and time course of cytokine 
response to the strenuous exercise. They found that strenuous, prolonged running elicited 
a dramatic increase in IL-6, as well as an increase in the pro-inflammatory cytokines 
TNF, IL-1two cytokines that often show no detectable increase from an exercise 
stimulus (177-179). They also found that this increase in pro-inflammatory cytokines was 
balanced by corresponding increases in cytokine inhibitors IL-1Ra and soluble TNF 
receptors, as well as the anti-inflammatory cytokine IL-10 (178). IL-10 inhibits the 
release of TNF and IL-1 (32), which may explain why these two classic pro-
inflammatory cytokines often do not show a large significant increase in exercise. IL-10 
also induces production of IL-1Ra (29, 101), which is the antagonist of the IL-1 receptor, 
again possibly explaining a lack of increase in IL-1 with exercise.  
While many investigations have reported cytokine release in response to muscle 
damaging eccentric exercise, some have questioned whether cytokines are released in 
significant amounts in response to concentric or less muscle fiber-damaging exercise 
such as cycling. However, many studies of cycling have indeed reported significant 
cytokine elevations and immune perturbations post-exercise (122, 144, 163, 169, 171, 
220, 221, 265). Also, Sprenger et al. (229) studied runners that completed a moderate-
intensity run that caused very little muscle damage as assessed by a low increase in 
creatine kinase. Despite very little evident muscle damage, levels of TNF and IL-6 were 
elevated, indicating that cytokine release occurs in response to many types of prolonged, 
strenuous exercise that is sufficient to generate a stress hormonal response and immune 
perturbation (229). Since damage to skeletal muscle can occur from the catabolic 
hormonal milieu (elevations in stress hormones such as the catecholamines and cortisol) 
that occurs after such exercise, even without a purely eccentric component, it is 
reasonable to expect an increase in cytokines in response to prolonged, strenuous 
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endurance exercise such as cycling. The findings of Sprenger et al. (229) support this 
concept.  
As mentioned previously, some studies have demonstrated a significant increase 
in plasma TNF concentrations in response to exercise (50, 55, 178, 229), but many 
others have failed to show changes in this cytokine (177, 179, 245). TNF is of interest 
because of its role as a cytokine involved in systemic inflammation. In addition to 
inducing inflammation, TNF induces many other powerful biological events, including 
apoptosis, cell proliferation, differentiation, and tumor growth, although regulation of 
immune cells appears to be its primary function. Overproduction of this cytokine has 
been implicated in cancer and many other pathologies. Whether or not it increases 
significantly in exercise is still unclear, probably due to methodological and protocol 
differences, as well as assay sensitivity issues. It is possible that there is a greater role for 
this cytokine in the exercise response, much like the response seen in trauma patients. 
Therefore, it seems clear that TNF should be investigated further given its powerful 
effects on the human body. Differentiations in its response to exercise of various 
intensities and durations should be better elucidated in order to fully understand the 
effects of exercise on the inflammatory cascade and the immune system. 
While much attention is paid to elevations in IL-6, IL-10 and IL-1Ra, as well as 
the potential increases in TNF, the IL-8 response to prolonged, strenuous exercise is 
less characterized in the literature. This chemokine is secreted by several cell types 
including macrophages and epithelial cells, and is also expressed in working skeletal 
muscle. IL-8 has important functions as a chemoattractant and potent stimulator of 
angiogenesis. The dearth of information on its response to, and role in, exercise may be 
due to the difficulty of detecting it in plasma, as it has small, transient increases that act 
locally rather than via traveling through the circulation (183). Recently however, a few 
studies have demonstrated significant increases in this chemokine in response to cycling 
exercise (2, 64), as well as knee extensor exercise (2).  
Akerstrom et al. (2) aimed to find if IL-8 is released from exercising muscle 
fibers. They had seventeen healthy subjects perform two independent trials: cycling at 
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moderate intensity for 3 h, and also performing 3 h of two-legged knee-extensor exercise 
at 60% of maximal workload. Muscle biopsies of the vastus lateralis were taken in each 
experiment. The investigators reported a significant increase in IL-8 mRNA after 
exercise, and a marked IL-8 expression in biopsy samples obtained during the recovery 
phase following 3 h of cycling. The peak actually occurred 3-6 h post-exercise. In the 
knee extensor protocol, a small transient net release of IL-8 was found at 1.5 h during 
exercise. This small release did not result in an increased plasma concentration of IL-8. 
The investigators concluded that muscle-derived IL-8 may indeed play a key local role in 
muscle fibers, such as stimulating angiogenesis (2). More recently, Frydelund-Larsen et 
al. (64) examined the effect of cycling exercise at moderate intensity on IL-8 mRNA and 
protein expression within vastus lateralis fibers. Because IL-8 has been shown to 
stimulate angiogenesis by binding to the CXC receptor 2 (CXCR2), they measured 
CXCR2 mRNA and CXCR2 protein as well. The team had healthy volunteers cycle for 3 
h at 60% VO2max. Muscle biopsies were taken from the vastus lateralis before exercise, 
immediately post-exercise, and at 4.5, 6, 9 and 24 hours post-exercise. CXCR2 mRNA 
increased post-exercise, and the protein had increased at 4.5 hours. Taking the findings of 
their earlier study (2) a few steps further, the investigators concluded that concentric 
cycling exercise induces CXCR2 mRNA and protein expression in the vascular 
endothelial cells of the muscle fibers, and reasoned that IL-8 likely acts locally to 
stimulate angiogenesis through CXCR2 receptor signaling (64). Given that angiogenesis 
is an important training adaptation that serves to increase the transport of nutrients and 
oxygen to working muscle, as well as facilitate the speedy removal of metabolic waste 
from the fibers, IL-8 is worthy of more attention in future investigations.  
There are several notable reasons for the discrepancies in the findings of cytokine 
responses to exercise. One such issue is simply detecting them in the blood. High 
sensitivity assays must be used, and even then the changes can be transient, as some of 
the cytokines disappear rapidly after exercise. According to the work of Ostrowski et al., 
(177-179) IL-6 peaks immediately after exercise, while IL-1Ra peaks 1-2 h post-exercise, 
and TNF may show a slight increase immediately post-exercise. Therefore, when 
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measuring cytokine levels in response to exercise it is critical to sample at the correct 
times. Also, most cytokine increases have been detected after eccentric exercise, since 
this type of exercise is more muscle damaging than concentric. However, large and 
significance increases are in fact found in response to endurance exercise of a concentric 
nature (i.e., cycling). However, variations in the intensity and duration of exercise 
protocols can contribute to conflicting findings.  In addition, specificity and cross-
reactivity can be a problem with detecting a cytokine of interest, as it is possible that 
more than one cytokine can be mistakenly measured, leading to inflated concentration 
values. With careful biochemical methodologies and skills employed in a well-designed 
and executed protocol, these difficulties can be overcome in detecting cytokines in 
response to prolonged, intense endurance exercise. 
It seems reasonable to hypothesize that when the immune system is functioning at 
a normal, healthy level, a system of inhibitors helps to keep the inflammatory process in 
response to strenuous exercise in check. How to encourage this process so the balance 
between allowing the right amount of post-exercise inflammation that is useful for 
clearing tissue damage and stimulating adaptation, and producing too great an 
inflammatory, immunosuppressive effect, is achieved is an area for further research and 
elucidation. At present, nutritional supplementation with carbohydrate has been well 
studied and is the most effective way to achieve an attenuation in the cytokine and 
inflammatory response to exercise. 
It is known that ingesting CHO compared to placebo during prolonged endurance 
cycling or running attenuates the significant increase in cytokines such as IL-6, IL-8, IL-
10 and IL-lra (150, 158, 159, 163, 166). CHO ingestion compared with placebo also has 
been demonstrated to attenuate exercise-induced changes in plasma cortisol and 
epinephrine. In a study of trained marathon runners, this attenuation was demonstrated, 
and as would be expected, blood glucose levels were higher in the CHO group, which 
was negatively correlated with cortisol levels (160). This decrease in cortisol levels in 
response to CHO ingestion was also correlated with decreased leukocyte trafficking 
(160). Nehlsen-Cannarella et al. (150) also reported attenuated cytokine release after 2.5 
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h of intense running at 75% of VO2max when a 6% CHO beverage was provided instead 
of placebo only. Clearly, running has an eccentric component to the exercise, but similar 
results have been shown in cycling. Recently, Scharhag et al. (220) studied the 
administration of 6% or 12% CHO beverages given during 4 h of cycling in trained 
subjects, and reported that the ingestion of at least 6% CHO beverages can sufficiently 
attenuate the exercise-induced immune response and stress, especially the phagocytic 
neutrophils and monocytes via a reduction in cortisol release. Interestingly, increasing the 
concentration to 12% CHO conferred no advantage or improvement in immune function 
over that provided by the 6% beverage, except for an attenuation in CRP (Scharhag et al., 
220).  
Taken together, these results strongly indicate that nutritional supplementation 
during exercise can have a significant positive effect in attenuating the inflammatory 
cascade and immunosupression following intense and prolonged exercise. To our 
knowledge, the combination of CHO and PRO ingested during exercise rather than 
simply CHO alone has not been investigated. It seems reasonable to hypothesize that the 
addition of protein could in fact bolster the immunobenefits of CHO ingestion by 
reducing or attenuating the catabolism of muscle protein during and after intense 
endurance exercise to provide substrate for gluconeogenesis, as well as by providing fuel 
for the immune cells themselves (the amino acid glutamine is used as a primary fuel 
source for immune cells). In addition, the addition of protein has been shown to speed the 
recovery process from intense endurance exercise, as previously discussed, and 
enhancing the recovery process inherently should translate to less immune stress and 
perturbation in the critical post-exercise period.  
 
Immune function in trained versus untrained populations 
While much is known about the effects of endurance exercise and training on 
immune function, less is understood about potential differences, if any, in the acute 
immune response to exercise between untrained and trained individuals.  Both animal and 
human studies have been performed to assess differences in these training states, but have 
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reached disparate conclusions. In a study with trained versus untrained rats, the untrained 
animals demonstrated a significantly greater suppression of immunocompetence after 
exhaustive exercise than the trained rats, which only showed a slight suppression (136). 
In this study, immunocompetence was assessed by measuring the blastogenic response to 
concanavalin A by spleen cells (136). Other investigations have used lymphocyte 
proliferation and subpopulations as an indicator of immune function. For example, Lin et 
al. (131) examined the effect of an acute bout of exercise at 70% VO2max in trained and 
sedentary rats and found that the mitogenic activity of spleen lymphocytes in the trained 
rats to staphylococcal enterotoxin B, which activates T cells, decreased compared to the 
sedentary group after the run. However, the lymphocyte proliferative response to 
lipopolysaccharide, a B cell mitogen, was bolstered (131). Therefore, while there was a 
tendency for some immune cell populations to increase or decrease activity in the trained 
versus untrained groups, no statistically significant differences were found overall (131). 
MacNeil et al. (135) investigated the effects of cycling exercise intensity and 
duration on lymphocyte proliferation in men of three fitness levels: sedentary to low 
(VO2max = ~44.9 ml/kg/min), moderate and recreationally active (VO2max = ~55.2 
ml/kg/min), and high and endurance trained (VO2max = ~63.3 ml/kg/min endurance 
trained), in addition to a mixed control group (VO2max = ~52.4 ml/kg/min). Subjects 
completed four cycling bouts ranging in duration from 30 – 120 min and in intensity from 
30% - 65% VO2max. Blood samples were obtained at various times before and after the 
exercise sessions. The investigators reported depressed mitogenesis in all groups 2 h after 
the exercise bouts, but found that the reduction in lymphocyte proliferation to the 
concanavalin A mitogen after exercise was transient, with recovery to pre-exercise levels 
within 24 h post-exercise (135). These findings suggest that acute bouts of submaximal 
exercise transiently reduce lymphocyte function in men and irrespective of the individual 
fitness level. It should be noted, however, that the VO2max values for the participants 
were higher than would normally be classified as low and moderate, and the intensity 
levels of the rides were low in a population with VO2max values of 44 ml/kg/min and 
above. 
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Using natural killer (NK) cell activity as a marker of immune function, Pedersen 
et al. (190) demonstrated increased NK cell function in highly trained cyclists compared 
to untrained controls, which may result in better resistance against infection in trained 
people versus the untrained. Recently, Selkirk et al. (223) examined endotoxin leakage 
and inflammatory activation during exertional heat stress in trained and untrained 
humans. Subjects walked at 4.5 km/h with 2% elevation in a climatic chamber heated to 
40o C until exhaustion. The team found that while heat stress increases the concentration 
of circulating endotoxin and cytokines in both groups, this response occurs at a lower 
temperature in the untrained than in the trained, suggesting a greater immune tolerance to 
heat exertion in trained people (223).  
It is important to note that none of the above studies of differences in training 
status and immune function have used nutritional supplementation as a possible way to 
mediate this response. This is likely due, in part, to the lack of consensus on what the 
difference in the trained versus untrained groups may be. As explained in a review on 
exercise and the immune system by Pedersen and Hoffman-Goetz (185), lymphocyte 
proliferative responses have been shown in many studies to increase, decrease or not even 
change when comparing athletes and the untrained, and the same applies to NP function. 
Clearly, this is an area for more research to be performed in order to understand any 
potential differences in training status, and how best to mediate them. 
 
Immune function in periods of intense training 
In a review of immune function in athletes, Mackinnon et al. (134) reported that 
extended periods of intense training are associated with decreases in immune parameters 
such as neutrophil function, suggesting possible immune suppression in trained athletes. 
In fact, it has been suggested that periods of intensified training (overreaching) lasting 1 
week or more may result in more prolonged immune dysfunction than what is observed 
after an acute bout (69). However, not all studies in trained athletes have reported such 
suppression (185, 231). Suzuki et al. (231) reported that after 1 week of intense 
endurance training by healthy, untrained men, the only parameter to show a decline was 
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resting neutrophil count. One obvious problem with extrapolating this finding to the 
effects of chronic training is the short duration used by Suzuki et al. (231), since most 
endurance athletes train for far greater periods, such as years. Decreases in total 
circulating leukocytes in response to chronic endurance training have been reported (18, 
120). It is possible that the well-documented plasma volume expansion seen in trained 
endurance athletes (40, 42, 88) is responsible for decreases observed in total leukocyte 
concentration, since with increased blood/plasma volume, the population of leukocytes as 
a percentage of the blood will decrease. Even in the case of endurance training for one 
week, plasma volume increases in response to the training sessions (10) and could 
conceivably account for the decline in resting NP levels reported by Suzuki et al. (231). 
Despite some evidence that immune function is suppressed in long-term training 
athletes, there is also evidence that a decrease in total circulating leukocytes and NPs is 
transient, with a training adaptation occurring in response to daily training (231, 234, 
242). As noted by Neiman in a review on exercise and immunity, most studies have 
failed to show major training effects on circulating total leukocyte concentrations and 
their subpopulations, and many studies of resting serum immunoglobulin levels have not 
shown a significant difference in these levels between trained and untrained subjects 
(153). 
The cytokine response to long-term endurance training is currently not very well 
characterized. Smith (225) proposed a cytokine theory of overtraining, in which exercise-
induced damage and stress to the musculoskeletal system induces a local inflammatory 
response, which causes overtraining symptoms to develop. Over time, as the athlete fails 
to recover fully and properly yet continues to train, the inflammation is compounded and 
becomes chronic. Systemic inflammation then develops as pro-inflammatory cytokines 
are released from activated monocytes, and sickness behavior results (225). Parry-
Billings et al. (180) had previously investigated overtraining and found that immune 
function was not impaired in overtrained subjects, as evidenced by no change in IL-6 or 
T-lymphocyte proliferation. More recently, Halson et al. (73) utilized an overreaching 
protocol in trained cyclists to simulate overtraining and found that in contrast to the 
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hypothesis of Smith (225), alterations in plasma cytokines were not related to 
performance declines associated with overreaching and overtraining. Their 6-week 
overreaching protocol did produce overreaching/overtraining effects in the cyclists, 
evidenced by a significant decline in performance as well as disturbances in mood states, 
and CPK was also elevated. However, there were no changes in TNF or IL-6, among 
other hematological measures (73). Clearly, more research is needed to determine the role 
of cytokines in long-term endurance training. 
It is also possible that the mild immunosupression that some investigators have 
demonstrated in response to training may represent a balance between limiting 
inflammation from the training stress while maintaining proper immune function (134, 
186). For example, NPs appear to be downregulated by strenuous exercise, which may 
alter host defense capabilities, but this could actually be protective in limiting chronic 
inflammation (186). Other investigations have reported positive responses to endurance 
training in terms of NP function and limitation of inflammation. Suzuki et al. (234) 
reported that increased catecholamine response to strenuous training can suppress NP 
activity, which may be an adaptive response in order to prevent pathophysiological 
reactions that could eventually lead to organ damage if inflammation were not attenuated. 
Thus, limiting the activity of NPs can actually serve to keep the inflammatory response to 
exercise somewhat in check. However, more longitudinal studies are needed to better 
elucidate the long-term effects of strenuous endurance training on NP activity, 
inflammation and other aspects of immune function.  
In addition to the direct effects of training on immune cells, there is some 
evidence that endurance training can deplete glutamine levels. Because this amino acid is 
a major fuel source for the cells of the immune system, chronic depletion could lead to 
increased infection in athletes (30). Glutamine is the most abundant free amino acid in 
both human muscle and plasma. Many investigators have attempted to utilize glutamine 
as a marker of suppressed immune function and, consequently, indicative of overtraining 
(73, 180), but the best method of determining the key levels of glutamine in such states 
has not yet been found (253). In fact, some investigations have found no link between 
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glutamine and indicators of immune function (80, 121, 252). If it should be determined 
that glutamine stores decreased by intense endurance exercise have a negative impact on 
immune function, then supplementing post-daily-exercise training with a CHO plus PRO 
supplement should allow glutamine levels to be better maintained, presumably leading to 
better immunity and host protection. 
 
Muscle damage 
Muscle damage is a well-documented consequence of strenuous exercise. This 
damage is due in part to the physical stress placed on the muscle fibers, particularly 
during the eccentric phase of muscle contraction (35, 56). However, muscle damage also 
occurs in concentric exercise such as cycling, albeit to a lesser degree, partly due to the 
rise in cortisol and other catabolic hormones that result in muscle protein degradation 
(253). Much research has focused on ways to mediate muscle damage and speed the 
damage recovery process in the hours following exercise. Muscle damage does not just 
occur during exercise, but can actually continue after exercise for many hours due to a 
protracted catabolic hormonal milieu, as well as an increase in free radicals and acute 
inflammation. Not only will such tissue damage limit performance in subsequent exercise 
bouts due to delayed onset muscle soreness, but it will also compromise the 
replenishment of muscle glycogen and limit muscle training adaptations (41, 175).  
Creatine phosphokinase (CPK, also known as creatine kinase or CK) and 
myoglobin are blood markers often used as indicators of muscle damage. There are three 
main isoforms of CPK specific to brain, muscle and heart, and under normal 
physiological conditions, very little CPK is detected in the blood circulation. Elevated 
levels indicate damage to muscle (smooth, cardiac or skeletal) or brain, and which type 
can be assessed by determining which isoform is present. Common clinical reasons for 
elevated CPK include myocardial infarction, muscle disease, or stroke, but CPK is also 
an indicator of skeletal muscle damage from strenuous exercise or muscle injury. 
Athletes have higher levels of serum CPK since strenuous exercise that causes damage to 
skeletal muscle cells results in increased total serum CPK (23, 147). The highest post-
exercise levels are found after prolonged exercise that include eccentric muscular 
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contractions, such as marathon running, resistance exercise, and downhill running. Total 
serum CPK activity is markedly elevated for 24 h after the exercise bout and gradually 
returns to baseline levels with adequate rest and recovery (23).  
Another marker of muscle damage is myoglobin, which is found primarily in 
muscle and in heart. Its heme group is responsible for the red pigmentation of muscle 
tissues. This protein functions as an intracellular reserve for oxygen, which is stored as 
oxymyoglobin. This is important as a reserve for prolonged exercise. Myoglobin 
increases with endurance training, as was first demonstrated in animal studies of dogs, 
cattle and rats. Lawrie (123) demonstrated increased myoglobin concentration in the 
muscles of exercised rats, and Pattengale and Holloszy (181) found an 80% increase in 
myoglobin concentration in leg muscles of endurance run trained rats. In vitro, 
myoglobin also increases the rate of oxygen transport through a fluid layer (222), and 
likely facilitates oxygen utilization in the skeletal muscle by increasing oxygen transport 
to the mitochondria (83). In addition to the roles in oxygen storage and transport, 
myoglobin is important as a marker of muscle damage. When muscle is damaged due to 
trauma, (ischemia, inflammation, intense exercise), myoglobin is released into the blood 
and excreted in urine. Clinically, increased myoglobin levels indicate a heart attack or 
muscle injury. Thus, myoglobin levels are of interest in endurance exercise, primarily due 
to its function as an indicator of muscle damage in this context. 
Significant muscle damage has been demonstrated in various eccentric protocols 
such as resistance training (11), running (57), reverse cycle pedaling against resistance 
(241) and stepping protocols (151). Some studies have compared the amounts of 
measurable muscle damage incurred from eccentric compared to concentric exercise and 
reported that increases in damage markers were only found in eccentric exercise and not 
in concentric exercise (25, 186, 226). Sorichter and colleagues (226) found that CPK and 
myoglobin was significantly increased in protocols of resistance training and downhill 
running, but not in high-force isokinetic concentric quadriceps contraction exercise. 
Bruunsgaard et al. (25) used a unique cycling protocol similar to that of Toft et al., (241) 
described above, in which subjects pedaled normally (concentric contractions) and then 
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eccentrically against a braked wheel with reversed pedaling revolutions. They found that 
only the eccentric protocol elicited an increase in CPK (25).  
Despite the findings that argue against measurable muscle damage induced by 
concentric exercise such as cycling, many other investigations have found significant 
muscle damage using concentric cycling protocols. Konig et al. (117) examined muscle 
damage markers in professional cyclists after a road race and found that both CPK and 
myoglobin were significantly increased after the strenuous event. Suzuki et al. (234) also 
found increases in these two markers when they studied the effects of 3 consecutive days 
of cycling for 90 min at a moderate intensity in healthy but untrained subjects. 
Interestingly, the increase was most profound after the first day of cycling, but with the 
daily progression the levels declined. However, catecholamines increased each day, 
which appeared to suppress the oxidative function of neutrophils, possibly leading to 
slight immunosupression (234). Other studies have detected significant increases in CPK 
after intense cycling (73, 200, 217, 243) as well as in myoglobin after a triathlon (138).  
Other investigations have focused on nutritional countermeasures for muscle 
damage that occurs in cycling exercise and found that compared to CHO alone, 
CHO+PRO taken during and after exercise decreases muscle damage (39, 209, 210, 217, 
219).  Saunders et al. (217) found that supplementing with CHO+PRO during and 
immediately post cycling exercise resulted in only a 2-fold rise in plasma CPK levels, 
whereas with CHO supplementation alone the CPK levels were increased 14-fold. The 
team of Saunders et al. (219) recently confirmed this finding using a CHO+PRO gel 
supplement rather than a beverage. Interestingly, in both of these studies, the CHO+PRO 
treatment resulted in longer times to fatigue during the cycling performance trial than did 
the CHO treatment (219). Combest et al. (39) found a similar result of reduced muscle 
damage but also reported that there is individual variation in the response to CHO+PRO. 
Nine of the 15 subjects in the Combest et al. (39) study had less CPK with the 
CHO+PRO treatment while five showed no difference in CPK between the CHO only 
and the CHO+PRO. The responders had significantly greater times to fatigue than did the 
CHO+PRO non-responders, and this response did not appear to be influenced by gender 
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(39). Other studies have shown attenuated CPK levels in response to CHO+PRO 
compared to isocaloric CHO only treatments without demonstrating a difference in time 
to exhaustion (209, 210, 246), or no significant difference in both CPK levels and 
subsequent cycling exercise performance (24, 31). Variations in performance findings 
will be discussed further below, but protocol differences amongst the studies are likely 
responsible for differences in time to fatigue data.  
CHO+PRO supplementation has been shown to attenuate muscle damage in 
resistance exercise as well as in endurance exercise. Baty et al. (11) found that 
supplementing with a CHO+PRO supplement before, during and after exercise limits the 
muscle damage that occurs during and after resistance exercise training, evidenced by 
lower levels of CPK and myoglobin than in the placebo alone treatment. Recently, 
Cockburn and colleagues (36) compared water only, a carbohydrate sports drink, milk 
and a milk-based CHO+PRO drink in assessing eccentric exercise induced increases in 
CPK and myoglobin 48 h post-exercise and found that both the milk-based CHO+PRO 
and the milk only significantly attenuated CPK and myoglobin levels compared to CHO 
and water. They also reported improved peak torque and total work in an exercise set 
with the milk-based CHO+PRO and milk compared to CHO and water (Cockburn et al., 
2008). In contrast, Wojcik et al. (260) found no change in inflammatory markers or in 
muscle function after supplementing with a milk-based CHO+PRO recovery versus CHO 
only beverage following resistance exercise, but did report a trend (p<0.08) for lower 
CPK in the milk-based CHO+PRO treatment (260). While not all investigations show 
dramatic differences in CHO+PRO and CHO alone, this is likely due to protocol 
differences. 
Long-term training adaptations may occur to help mediate muscle damage. As 
previously discussed, Suzuki et al. (234) found that levels of CPK declined over three 
days of training in untrained subjects, but catecholamines increased, potentially leading 
to slight immunosupression. Three days of training in untrained subjects still represents a 
relatively acute effect compared to the long-term training undertaken by highly trained 
endurance athletes. Evans and colleagues (57) compared trained long-distance runners 
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and untrained healthy subjects and reported chronic elevations in CPK and other 
inflammatory markers in the trained, yet no acute increases in response to a single intense 
bout. In contrast, the untrained had a lower baseline level of CPK and other markers, yet 
had a greater increase after an acute bout (57).  
Taken together, most findings in the literature suggest that, with proper 
supplementation and recovery, adaptations do occur in healthy endurance trained humans 
such that muscle damage does not become chronic or debilitating (barring injury) and 
immune function is not severely compromised. However, prospective studies using long-
term training have not been undertaken to better understand what the effects of chronic, 
intense endurance training are across the life span.  
INITIATION OF PROTEIN SYNTHESIS 
Shifting the post-exercise balance from a muscle-damaged, catabolic hormonal 
environment, which promotes protein degradation, to one that supports recovery and 
protein accretion is essential for maximizing training adaptations. Although the muscle 
can have residual catabolic activity following exercise, it is primed to shift into an 
anabolic state in the presence of the right nutrients (92). This is due, in part, to an 
increased sensitivity to insulin post-exercise (95, 97). Insulin is one of the most anabolic 
hormones in the body, stimulating increases in muscle amino acid (AA) uptake and 
protein synthesis and reducing protein degradation (17). Rapidly raising the plasma 
insulin level is key to limiting post-exercise muscle damage and stimulating protein 
accretion (143, 213). The reason for insulin’s important role is that the binding of insulin 
to its target receptor on the muscle cell activates a complex signaling cascade that 
ultimately leads to the initiation of protein translation and thus, protein synthesis, as well 
as glycogen synthesis as discussed previously. Protein synthesis is of great interest, as it 
is the key adaptation to exercise training and includes the synthesis of oxidative enzymes, 
contractile fibers, cellular organelles such as mitochondria, membrane receptors, 
hemoglobin, substrate transporters, and many other important cellular and molecular 
factors that have key functions related to physical performance.  
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While exercise (i.e., skeletal muscle contraction) itself stimulates protein 
synthesis, it also stimulates breakdown of proteins. The balance between degradation and 
synthesis is mediated in part by the availability of AA. It is becoming clearer that the 
addition of adequate protein, in particular the essential amino acids (EAA), to a post-
exercise CHO supplement is critical for optimizing protein synthesis, creating a positive 
protein balance, repairing muscle damage, and stimulating training adaptations (44, 62, 
67, 118, 127). For example, Cribb and Hayes (44) recently demonstrated that a greater 
increase in muscle mass and strength could be achieved during 10 wks of resistance 
training if a CHO+PRO/creatine supplement was provided before and immediately after 
each daily workout compared with providing the supplement in the morning and at night. 
Interestingly, when comparing milk versus soy protein ingestion after resistance exercise, 
it was shown that milk protein promotes muscle protein accretion to a greater extent than 
soy (256).  
As with the process of glycogen synthesis discussed previously, this acute, post-
exercise activation of protein synthesis lasts for a limited amount of time (128, 195). 
Compared to the knowledge of glycogen synthesis pathways, the activation states of the 
enzymes that control protein translation are less understood. Our laboratory has recently 
completed several studies addressing the effects of CHO and PRO separately and in 
combination on the insulin and mTOR signaling pathways. We have found that glycogen 
synthase, p70S6K, and rpS6 are activated post-exercise in human muscle; however, when 
subjects receive CHO+PRO post-exercise, activation of glycogen synthase and rpS6 is 
enhanced, and Akt and mTOR are activated (93). In addition, CHO+PRO 
supplementation also results in the inhibition of GSK3 (93). As mentioned previously, 
our laboratory recently demonstrated that, compared to a traditional sports drink, a cereal 
plus non-fat milk treatment ingested post-exercise lead to greater activation of glycogen 
synthase and Akt during recovery (110). Our lab also demonstrated in the rat that post-
exercise CHO+PRO supplementation increases the rate of muscle glycogen synthesis 
compared to either CHO or PRO supplementation, and that this is related to an increase 
in GSK inhibition. Moreover, CHO+PRO was associated with a greater activation (as 
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indicated by phosphorylation status) of mTOR, rpS6 and inhibition of 4E-BP1 in both red 
and white skeletal muscle. This is the first study to address the interaction of endurance 
exercise and the combination of CHO+PRO supplementation on the mTOR signaling 
pathway (145), and will be discussed in more detail below.  
Supplementation with a mixture of essential AA plus CHO has been demonstrated 
to increase protein synthesis (16, 49, 240). In addition, supplementing with mixtures 
containing whey, whey plus casein, or CHO+PRO+Leucine has also been demonstrated 
to stimulate protein synthesis following resistance exercise (118, 137, 239).  It is also 
known that activation of protein synthesis by AA is most responsive immediately after 
exercise. Raising plasma AA levels post-exercise by infusion or oral supplementation has 
been shown to transition the muscle from a negative to positive protein balance by 
stimulating protein synthesis (204). While supplementing with either PRO or AA post-
exercise may stimulate protein synthesis, there is increasing evidence that the 
combination of CHO and either protein or AA can actually have an additive effect (127, 
143).  This additive effect is likely due in part to the synergist effect that a CHO/AA or 
CHO+PRO supplement has on the plasma insulin response (227, 266), and the 
maintenance of an elevated plasma AA profile. Cellularly, this may translate into a 
greater activation of translation initiation. However, not all studies have demonstrated a 
difference in insulin response that can be associated with increased protein synthesis. 
Howarth and colleagues (89) recently assessed whole body net protein balance (WBNB) 
and muscle fractional synthetic rate (FSR) in response to CHO and CHO+PRO 
treatments following 2 h of cycling exercise. Six trained subjects were provided either 1.2 
g/kg CHO, 1.2 g/kg CHO + 0.4 g PRO, or 1.6 g/kg CHO in random order, and stable 
isotope tracers were used to measure WBNB, FSR, and protein breakdown over a 4-h 
recovery period. The investigators found that FSR was significantly greater in the 
CHO+PRO treatment than either of the CHO treatments, and that WBNB was only 
increased in the CHO+PRO treatment, due to reduced protein breakdown (89). No 
differences in plasma glucose or insulin response between treatments were found. Thus, it 
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is possible that increases in protein synthesis is due not only to elevated insulin, but to the 
availability of protein as substrate for protein synthesis.  
In addition to the many studies utilizing CHO plus different protein types or 
combinations (whey, casein, EAA, individual AAs, etc.) post-exercise, a recent 
investigation examined the effects of milk on amino acid uptake and leg protein balance 
after resistance exercise (53). In this study, fat-free milk (FFM), whole milk (WM) or a 
greater amount of FFM to match the caloric content of the whole milk was given 1 h after 
leg resistance exercise. (It should be noted that there was no placebo or CHO-containing 
treatment, nor another type of protein-containing supplement to compare the three milk 
treatments against.) While all three treatments increased protein synthesis over baseline, 
the whole milk treatment demonstrated the greatest increase in amino acid uptake (53). 
This investigation was the first to examine the effects of a common, natural food (milk) 
on the protein synthesis response after resistance exercise. 
 
Translation Initiation 
Translation initiation, which is the rate-limiting step in translation, is regulated in 
part by the mammalian target of rapamycin (mTOR) signal-transduction pathway. mTOR 
is a serine/threonine kinase that integrates signals from nutrients, skeletal muscle 
contraction and growth factors, functioning as a crucial regulator of protein synthesis. 
mTOR exists as two signaling complexes: mTOR complex-1 (TORC1) and mTOR 
complex-2 (TORC2) (139, 215, 216). The TORC1 (mTOR complex 1) consists of 
mTOR, mLST8 and raptor and is key in activating mRNA translation in response to 
hormones and growth factors (139, 254). TORC1 promotes translation by 
phosphorylating two key downstream mTOR effectors, S6K (also known as p70S6 
kinase) and the translational repressor 4E-BP1 (eukaryotic initiation factor 4E binding 
protein 1) (139, 254). Phosphorylation of 4E-BP1 decreases its binding affinity for 
eIF4E, such that eIF4E is released from 4E-BP1 and can now bind to eIF4G to form the 
eIF4F pre-initiation complex. This is an essential step in ribosomal assembly (75). This 
complex now binds to the 40S pre-initiation complex to initiate mRNA translation. 
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Concurrently, when p70S6K is phosphorylated by mTOR, it then phosphorylates other 
proteins that are involved in mRNA translation: eIF4B and eIF2kinase, both of which 
leads to mRNA translation, and most notably, rpS6. Ribosomal protein S6 is associated 
with enhanced translation of a essential class of mRNAs that have a 5'-terminal 
oligopyrimidine tract (TOP) at their transcriptional start site, and thus encode for 
ribosomal proteins as well as elongation factors (7, 54). Because mTOR/TORC1 
signaling is so essential to cell growth and protein synthesis, it is important to optimize 
activation of this complex and downstream targets in order to maximize training 
adaptations.  
It is well established that nutrient availability (and thus, insulin and AA 
availability), and exercise each activate multiple signal transduction pathways in skeletal 
muscle, leading to an enhanced rate of protein synthesis. They activate mTOR/TORC1 
directly, as well as via the upstream PI3K pathway (21, 113, 139, 215, 216), thereby 
increasing mRNA translation initiation and protein synthesis after exercise. mTOR is 
regulated through the sequential activation of a series of upstream kinases including the 
insulin signaling protein Akt (114). It is well known that the binding of insulin to its 
skeletal muscle receptors increases phosphorylation of Akt (also known as PKB), which 
in turn phosphorylates downstream enzymes that ultimately control translation (111, 149, 
182, 244). Akt phosphorylates mTOR, which then phosphorylates p70S6K, which 
activates rpS6. In addition to being an activator of mTOR, Akt in turn inhibits glycogen 
synthase kinase-3 (GSK3), which is an inhibitor of both glycogen and protein synthesis 
(45). The inhibition of GSK3 and activation of the enzyme glycogen synthase can also 
occur via p70S6K activation (5). Therefore, the activation of mTOR via an increase in 
plasma insulin and AA levels may facilitate an increase in glycogen synthase activity as 
well as mRNA translation (i.e., increased glycogen synthesis and protein synthesis). This 
should promote a faster tissue response to training adaptation.  
As mentioned previously, a recent investigation by Morrison et al. (145) shed 
light on the importance of insulin and the signaling pathways that lead to increased 
mRNA translation. Rats were exercised using a 3-h swimming protocol, and then 
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provided one of four treatments in solution immediately post-exercise: CHO (23.7% PRO 
(7.9% w/v), CHO+PRO (23.7% w/v CHO + 7.9% w/v PRO) or placebo (EX). The rats 
were sacrificed at 0, 30, and 90 min post-exercise, and phosphorylation states of mTOR, 
p70S6K, rpS6, and 4E-BP1 were analyzed in the red (RQ) and white (WQ) quadriceps. 
The phosphorylation states of the signaling proteins were transiently increased in all of 
the treatment groups compared to the placebo/exercise only group. While all the 
supplements were associated with increased phosphorylation of mTOR and p70S6K after 
exercise, only CHO+PRO increased rpS6 phosphorylation to a greater extent than the 
other supplements at 30 min post-exercise, as well as 4E-BP1 at 30 and 90 min post-
exercise. The phosphorylation states of rpS6 and 4E-BP1 were highly correlated to 
insulin concentrations in each group, suggesting a strong relationship between insulin 
levels and the activation of enzymes critical for mRNA translation. These findings 
indicate that, compared to CHO or PRO alone, CHO+PRO supplementation may be most 
effective in activating the mTOR signaling pathway post-exercise (145).  
In addition to activation through mTOR as described above, rpS6 can be activated 
by exercise alone, albeit to a lesser degree. Ivy et al. (93) found increased rpS6 
phosphorylation 45 minutes after cycling exercise with placebo and CHO+PRO 
treatments, although the rpS6 phosphorylation was significantly higher after CHO+PRO 
compared to the placebo beverage. This suggests that both insulin and exercise effect 
rpS6 phosphorylation.  As discussed previously, Morrison et al. (145) reported a 
correlation between insulin levels and rpS6 phosphorylation in rats. At 30 min post-
exercise, rpS6 phosphorylation was higher in the CHO+PRO treatments compared to the 
exercise-only group, but interestingly, rpS6 phosphorylation was significantly increased 
at 90 min post-exercise in the exercised rats that did not receive supplementation. At both 
the 30 and 90 min time points, insulin was elevated in the three treatment groups 
compared to the exercised controls. Previous studies have shown that in addition to 
activation through mTOR, S6K and rpS6 can in fact be activated by exercise through the 
extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation of p90RSK, as well 
as through the p38 mitogen-activated protein kinase (MAPK) pathway (119, 191, 211, 
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258). Taken together, these data suggest that exercise alone can increase phosphorylation 
of rpS6, but that the combined effects of exercise and CHO+PRO supplementation post-
exercise can lead to greater phosphorylation of this important protein.  
While mTOR is activated by AAs, particularly leucine, either directly or 
indirectly (20, 116, 201), the process by which this occurs remains to be fully elucidated 
(115). While mTOR is activated by resistance exercise, (21, 49), it is not directly or 
indirectly stimulated by aerobic exercise alone (4, 93, 145).  Recently, Wang and Proud 
(255) reported a link between AA and eIF2B activation independent of the 
mTOR/TORC1 complex. eIF2B is important because it catalyzes the GDP/GTP 
exchange on eIF2, which is essential for control of ribosomal formation and mRNA 
translation. They demonstrated that AA deprivation leads to inhibition of eIF2B 
independent of changes in the phosphorylation status of eIF2, such as would occur in the 
normal insulin-PI3K signaling pathway. Having established that eIF2B inhibition is 
independent of TORC1, they identified a new site of phosphorylation on eIF2B. Thus, 
Wang and Proud reported a novel way to regulate translation initiation through AA (255). 
While in many studies, increased plasma insulin correlates with increased protein 
synthesis, insulin levels are not always increased despite a demonstrated increase in 
protein synthesis. For example, Gautsch et al. (67) examined in rats the association of 
eIF4E with 4E-BP1 following recovery from running exercise. The rats were fed wither 
CHO or a complete meal containing CHO, PRO and fat. Despite having similar insulin 
responses to both treatments, only in the CHO+PRO+fat treatment stimulated a 
significant increase in protein synthesis. In addition, increased eIF4E availability was 
reported to be a key factor in this response (67). The reason for the discrepancies in the 
insulin response is not known at this time. In the case of the Gautsch et al. (67) study, 
perhaps providing a meal versus a liquid supplement could account for the difference. A 
more mechanistic explanation is that there is a critical plasma concentration of insulin 
required for protein synthesis to occur (60, 63, 68), but it is perhaps only a permissive, 
limited amount (17, 22, 141). Above this possible threshold insulin level, there may be no 
additional effect of increased insulin levels. Also, insulin has been shown to have 
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potentially less of an impact on protein synthesis than on protein degradation (17). Biolo 
et al. (17) reported that exercise itself (i.e.; muscle contraction) stimulates protein 
synthesis, and insulin infusion post-exercise reduced protein degradation, and the 
combined effects resulted in a positive net protein balance. Thus, there appears to be a 




Given that the delicate balance of protein synthesis and degradation determines 
much of the response to acute and chronic exercise, the reduction of post-exercise protein 
degradation is important for optimized recovery and adaptation to exercise training.  
Protein degradation, or proteolysis, involves the ubiquitination of proteins targeted for 
degradation, and their subsequent degradation by the proteasome. This proteolysis 
pathway is called the Ubiquitin-Proteasome Pathway (UPP), and is considered to be the 
primary degradation system for most tissues, including skeletal muscle (124, 235). Much 
of the current literature has reported changes in proteolytic gene expression, with fewer 
reports of changes in actual content of proteolytic proteins. It is known that key apoptotic 
genes in the UPP include ubiquitin E3 ligases MuRF-1 and atrogin-1, which share a 
common critical transcription factor, forkhead box 3A (FOXO3A). FOXO proteins are 
able to translocate into the nucleus and bind to DNA. Conversely, they can also 
translocate out of the nucleus upon phosphorylation due to growth factors such as insulin 
via the Akt pathway (90, 230). When Akt is phosphorylated by components of the 
insulin/IGF pathway, it translocates into the nucleus and directly phosphorylates 
FOXO3A on the N-terminus at Ser253, which causes the translocation of FOXO3A out 
of the nucleus and into the cytoplasm (90, 148). Thus, FOXO3A is unable to carry out its 
key role in promoting apoptosis because signals associated with cell survival and 
proliferation have prevailed due to growth factor activation. Few studies to date have 
examined the role of FOXO3A in exercise models, including resistance exercise (125, 
205, 259), and resistance vs running exercise (132). Generally, these studies have verified 
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a role for FOXO3A in the process of proteolysis following exercise. Therefore, FOXO3A 
is of current interest in understanding factors that can reduce protein degradation. 
Another key aspect of the Ubiquitin-Proteasome Pathway and its regulation post-
exercise is ubiquitin itself. This highly conserved, 8.5 kD protein serves to clear away 
abnormal or damaged proteins by covalently binding to such proteins, targeting them to 
be degraded by the 26S proteasome (33, 34, 81). Recently, a very few investigations have 
used total ubiquitin content of Western blot samples as an indicator of protein 
degradation (51, 197), demonstrating an increase in total ubiquitination in conditions of 
high proteolysis [injection of oxidative stress-inducing cardiotoxin (197) or hindlimb 
suspension with or without resistance exercise (51).] These studies suggest that 
measuring total ubiquitination in tissue samples is a viable way to assess the level at 
which proteins are targeted for degradation. (It should be noted that, as with any marker 
of a multi-step biological process, the targeting of a protein for degradation does not 
necessarily mean that the protein was actually degraded. The final degradation step could 
be eliminated if the proteasome is malfunctioning. Thus care must be taken when 
interpreting these types of results.) 
In summary, the initiation of protein synthesis is at the heart of endurance training 
adaptation, and the pathways by which this process is regulated are controlled by post-
exercise nutrient availability. Reduction of protein degradation is also essential to hasten 
recovery and promote adaptation to an exercise stimulus. Whether CHO+PRO 
supplementation post-exercise will increase the rate of training adaptation to an aerobic 
exercise stimulus has not been investigated. It is hypothesized that, when provided 
immediately after each exercise training bout, CHO+PRO will help sustain exercise 
performance during a progressive exercise training program, activate the mTOR 
signaling pathway, promote translation initiation and protein synthesis, reduce protein 
degradation, and bring about a faster rate of aerobic training adaptation than can be 
achieved when supplementing with CHO alone. 
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SUBSEQUENT ENDURANCE EXERCISE PERFORMANCE 
Studies of subsequent exercise performance (cycling and running) performed after 
recovering from a previous, strenuous bout have reported significantly increased 
endurance time to fatigue in the subsequent exercise bout with CHO+PRO 
supplementation versus CHO alone (173, 217, 238, 257). This improvement in 
performance was related to a greater recovery of muscle glycogen during the recovery 
period between the two bouts (257). In addition, our laboratory has reported that 
supplementing with a CHO+PRO supplement before, during and immediately after 
resistance exercise reduces muscle tissue damage during as well as in the hours after 
exercise (11).  
Other recent investigations have demonstrated similar performance increases with 
CHO+PRO compared to CHO alone in subsequent bout exercise (39, 217, 238). As 
mentioned above regarding during-exercise supplementation, Saunders’ team reported an 
improvement in TTE in an initial, fatiguing cycling bout, as well as in a subsequent 
intense cycling bout 12-15 h later (217). The subjects consumed the treatments during 
and immediately after the exercise bouts. In the initial ride to fatigue (75% VO2peak) 
subjects rode 29% longer (106.3 +/- 45.2 min) when consuming the CHO+PRO beverage 
than the CHO beverage (82.3 +/- 32.6 min). In the second ride (85% VO2peak), subjects 
performed 40% longer (43.6 +/- 12.5 min) with the CHO+PRO beverage than the CHO 
beverage (31.2 +/- 8.7 min).  These performance improvements occurred despite no 
differences in RPE, heart rate, blood glucose or blood lactate, but reported significantly 
reduced muscle damage (as indicated by CPK) in the CHO+PRO treatment (217). 
Not all investigations of subsequent endurance exercise performance have 
reported a benefit with CHO+PRO over CHO alone. A few studies have failed to 
demonstrate any significant difference in time to fatigue (176, 209, 210, 212) or time trial 
time (24, 31) in subsequent bouts performed after an initial, fatiguing cycling exercise 
bout. While the majority of the studies discussed here are performed with trained cyclists 
or triathletes, a few studies have examined the effects of CHO+PRO on subsequent 
running performance. Luden et al. (133) investigated the effects of a six-day regimen of 
CHO+PRO versus CHO post-exercise beverage consumption on muscle damage, muscle 
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soreness, and race performance in collegiate runners. Of interest to the investigators was 
how multi-day supplementation might affect performance and damage indicators, since 
most studies only administer the treatment during or post-exercise. The twenty-three 
cross-country runners completed their traditional training for six days prior to a cross-
country race, and were given a CHO+PRO or CHO only beverage immediately after each 
training session. Subjects repeated the same protocol with the alternate treatment (6 days 
of training and supplementation and then racing) following a 21-day washout period. 
Race performance was assessed using the athlete's finishing ranking, and plasma CPK 
and muscle soreness were measured. They found that while CPK and muscle soreness 
were improved with CHO+PRO, there was no significant improvement in cross-country 
race performance. However, neither group actually demonstrated high levels of muscle 
damage, so the investigators suggested that the recovery benefits of the CHO+PRO 
intervention may not have been large enough to cause clear improvements in running 
performance (133). Furthermore, a field study in which performance is assessed by race 
placement is inherently flawed, as many additional variables factor into race-day 
performance than simply glycogen levels or muscle damage levels; race performance is 
affected by logistical factors and psychological factors as well.  
A well-controlled study performed by Niles et al. (173) demonstrated a significant 
improvement in running TTE in trained endurance runners in response to CHO+PRO 
compared to an isocaloric CHO treatment. In this study, the beverages were ingested 
immediately and 1 h after a glycogen depleting exercise bout. The runners then were 
asked to run to exhaustion at a high intensity (10% above their individual anaerobic 
threshold). The run time to exhaustion was 21% longer during the CHO+PRO trial 
(540.7±91.56 sec) than the CHO only trial (446.1±97.09 sec, p<0.05). Also, the 
CHO+PRO treatment resulted in significantly higher serum insulin levels (60.84 versus 
30.1 mU/ml) 90 min into recovery than CHO only (173). It appears that the ingestion of a 
CHO+PRO drink following glycogen-depleting running exercise may speed the recovery 
process, and improve endurance during a subsequent exercise bout performed on the 
same day, compared to CHO alone. 
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Two recent investigations used chocolate milk as a CHO+PRO supplement when 
assessing the effects of supplementation on a subsequent bout of cycling exercise, which 
was preceeded hours earlier by an exhaustive cycling bout. Pritchett and colleagues (200) 
compared CM to a commercially available CHO+PRO supplement. Subjects completed a 
high-intensity interval exercise protocol, ingested the randomly-ordered supplement 
immediately post-exercise, and then returned 15-18 h later to perform a performance trial 
at 85% VO2max to exhaustion. Time to exhaustion, as well as CPK levels, did not 
significantly differ between the treatments, suggesting that chocolate milk is just as 
effective for use as a recovery supplement as a commercially available, more expensive 
CHO+PRO products (200). An investigation by Thomas and colleagues (238), however, 
assessed subsequent performance after a 4-h recovery in the lab, during which time 
subjects were given either CM, a CHO+PRO beverage, or CHO only immediately and 2 
h post-exercise. Subjects then cycled to exhaustion at 70% VO2max. Time to exhaustion 
was 51% and 43% longer after ingesting CM (32 +/- 11 min) than CHO+PRO (21 +/- 8 
min) or CHO (23 +/- 8 min) (238). These results demonstrate that chocolate milk as a 
CHO+PRO supplement is an effective recovery supplement that can improve subsequent 
exercise performance. 
Possible mechanisms for improved performance following recovery with 
CHO+PRO supplementation include increased rate of muscle glycogen replenishment, 
reduced muscle tissue damage, improved immune response and faster muscle tissue 
repair. With regard to muscle glycogen, its importance as a fuel source during prolonged 
strenuous exercise cannot be overstated. It has been clearly demonstrated that aerobic 
endurance is directly related to the initial muscle glycogen stores (14, 15), and that 
strenuous exercise cannot be maintained once these stores are depleted (1, 14, 15, 78). 
When provided immediately post-exercise and at 2-h intervals, CHO+PRO 
supplementation has been found to increase the rate of muscle glycogen synthesis beyond 
that of both isocarbohydrate and isocaloric CHO supplements, and therefore could 
contribute substantially to the improved exercise performance following CHO+PRO 
supplementation (13, 94, 250, 266). It should be noted that the rate of muscle glycogen 
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synthesis found with a CHO+PRO supplement can be reached with a CHO supplement, 
but it requires doubling the CHO amount from approximately 0.75g CHO/h to 1.50g 
CHO/h and increasing the frequency of servings. This is simply not a practical strategy 
for most athletes.  
Combest et al. (39) showed an association between performance and muscle 
damage by demonstrating not only that TTE is improved with CHO+PRO over CHO 
alone, but that the cyclists that demonstrated the greatest reduction in muscle damage as 
assessed by CPK levels also had the greatest TTE improvements. This suggests that 
potential mechanisms for improved performance may at least in part be due to reductions 
in muscle damage. In the case of the study by Luden et al. (133) described above, a lack 
of significant muscle damage may have translated to a lack of opportunity for 
demonstratable performance improvement with a CHO+PRO beverage.  
Thus, the addition of PRO to a CHO supplement appears to increase the 
efficiency of muscle glycogen synthesis while also conferring the additional advantages 
of possibly reducing muscle damage, bolstering immune function, and optimizing 
training adaptation, all while being consumed in appropriate and practical amounts post-
exercise. 
TRAINING ADAPTATIONS: MAXIMAL OXIDATIVE CAPACITY AND MAXIMAL OXYGEN 
UPTAKE 
Endurance exercise training clearly induces major adaptations in skeletal muscle. 
Important adaptations that are hallmarks of such training are the increased ability to 
transport oxygen to the muscle and the increase in the ability of the muscle to utilize the 
delivered oxygen. The former is a result of increased stroke volume and increased plasma 
volume, which improve cardiac output. The latter is controlled by the increases in 
oxidative enzymes and mitochondrial content. 
 
Maximal oxidative capacity 
The biochemical adaptations that occur in response to endurance training were 
first reported in 1967 by John Holloszy in his classic study of treadmill running in rats 
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(84). The rats ran twice daily, 5 days a week for 12 weeks, and the workload 
progressively increased over the 12-week period. Initially their bouts were 10 min at 22 
meters/min, and by the end of the 12 weeks, had increased to 120 min of continuous 
running at 31 meters/min, with 12 30-sec higher intensity sprints included in the run. 
Tissue analysis revealed a two-fold increase in the activity of many mitochondrial 
enzymes. In addition, the fraction of homogenate that was mitochondrial protein was 
increased by 60% (84). Interestingly, while some mitochondrial enzymes increase two-
fold, others may only increase 35% to 60%, and still others may not increase at all (83). 
(This accounts for the reason that mitochondrial protein increased 60% and not closer to 
two-fold.) A few years later, Benzi et al. (12) showed in a rat model that mitochondrial 
enzymes were modulated by workload and training time such that increases in those 
variables correlated with increased enzyme activity. In addition, if training level 
decreased, enzymatic activity also decreased proportionally (12). 
Two key enzymes that are indicative of increased muscle oxidative capacity are 
citrate synthase and succinate dehydrogenase (SDH), both of which are found in the 
mitochondria. Citrate synthase (CS) is found in most all living cells, playing a key role in 
the citric acid cycle (or Krebs cycle). CS is synthesized via cytoplasmic ribosomes, then 
transported into the mitochondrial matrix. As such, it is frequently used as an enzymatic 
marker of mitochondrial density and aerobic capacity of the muscle. As a key player in 
the first step of the citric acid cycle, it is inhibited by high ATP:ADP ratios, as well as 
high ratios of acetyl-CoA:CoA, and NADH:NAD, because high concentrations of ATP, 
acetyl-CoA, and NADH mean that the cell’s energy supply is sufficient for the energy 
demands of the moment. CS is also inhibited by its product, citrate, as well as succinyl 
CoA, a downstream citric acid cycle intermediate. Succinate dehydrogenase (SDH) is 
also a key mitochondrial enzyme that catalyzes the oxidation of succinate to fumarate in 
the Krebs cycle, and as such is often used as a marker of Krebs cycle activity. Because it 
is bound to the mitochondrial membrane, it is also used as an index of mitochondrial 
protein amount. Thus, like CS, SDH is also a well-established marker of oxidative 
capacity of the muscle. Both CS and SDH have been demonstrated to increase in 
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response to endurance training. 
The increase in CS in response to running in rats has been established for quite 
some time (9, 87). Many studies use it as a marker of increased muscle oxidative 
capacity, and it is increased in response to endurance training in humans (27, 61). SDH 
has also been shown to increase after an endurance training program in both rats (84, 
207) and humans (47, 77, 146, 203). The benefit of increases in such enzyme activity is 
that it leads to less homeostatic disturbance in exercise of the same given intensity in the 
trained versus untrained state. When considering this homeostatic balance, it is easy to 
understand why important training adaptations to regularly performed endurance exercise 
training include a slower rate of muscle glycogen utilization, increased reliance on fat 
oxidation and decreased lactate production during exercise of a given intensity (86). 
In addition to the two key enzymes discussed above, another protein of interest 
has direct applicability to training adaptations:  the transcription coactivator peroxisome 
proliferator-activated receptor  coactivator-1 (PGC-1). This protein is of interest 
because of its role in mitochondrial biogenesis. One of the key adaptations to endurance 
exercise training is the increase in skeletal muscle mitochondria (84, 85). Mitochondrial 
biogenesis involves complex coordination of expression of the mitochondrial genome, as 
well as nuclear genes that encode mitochondrial proteins, and PGC-1 plays a key role in 
this elaborate process (112, 129, 202). PGC-1 is a transcriptional coactivator of 
transcription factor PPAR and together, they regulate the expression of genes that 
encode mitochondrial proteins. It is known that a single bout of exercise or stimulated 
skeletal muscle contraction induces an increase in both PGC-1 mRNA and protein in 
skeletal muscle (8, 71, 91, 237). In addition to the concomitant increases in PGC-1 and 
mitochondria in response to exercise, transgenic overexpression studies in animal models 
have also shown that increasing PGC-1 content induces an increase in mitochondria 
(130, 262).  
Another mechanism though which PGC-1 mediates training adaptations may be 
through its role in fiber type determination. PGC-1 is preferentially expressed in Type I 
(slow) skeletal muscle fibers, but Lin and colleagues (130) demonstrated that when PGC-
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1 is expressed at physiological levels in transgenic mice, fiber type conversion occurs 
such that the muscles normally rich in the Type II phenotype becomes much more like 
Type I fibers (130). The fibers show greater fatigue resistance, express more genes of 
oxidative metabolism, and contain more myoglobin, all of which are normally 
characteristics of Type I fibers (130).  
The importance of PGC-1 regulating oxidative metabolism was demonstrated by 
Leone and colleague (126), who developed a knockout mouse model that could be 
studied across the life span from birth to older age. Although the knockout mice (PGC-1 
-/-) were viable, they had many significant systemic abnormalities, all stemming from an 
abnormal metabolic phenotype. Compared to normal mice, as the knockout mice aged, 
they expressed more lipogenic genes, displayed an abnormal increase in body fat, 
developed fewer mitochondria and had a lower respiratory capacity which resulted in 
reduced exercise capacity. Other abnormalities found in the knockouts included an 
impaired ability to thermoregulate, the development of hepatic steatosis (fatty liver), and 
development of vacuolar lesions in the central nervous system (126). These findings 
underscore the key role of PGC-1 in the ability to adapt to a host of metabolic and 
physiological stressors such as are encountered during endurance exercise training. 
In summary, PGC-1 clearly has an important role in regulating adaptations to 
endurance exercise training. While the adaptive increase in mitochondria may initially be 
due to increased PGC-1 activation prior to the actual increase in the amount of PGC-1 
protein content (261), the increase in PGC-1 protein itself appears to sustain and 
enhance the increased mitochondrial biogenesis (261). Therefore, an increase in PGC-1 
protein content in skeletal muscle in response to endurance exercise training can be an 
indicator of the level of adaptive response to the exercise training. To our knowledge, the 
increase in PGC-1 protein in response to any type of nutritional supplementation post-
exercise during an endurance training program has not been investigated. However, it is 
reasonable to hypothesize that the greatest amount of increase in PGC-1 protein in the 
skeletal muscle of exercisers will occur in those who are able to recover better after daily 
training sessions and possibly adapt faster to their training stimulus. 
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Maximal oxygen consumption 
A signature of endurance training is a high VO2max – the ability to use a great 
amount of oxygen during endurance exercise. It is common for professional cyclists or 
triathletes to have VO2max values in the ranges of 75-85+ ml/kg/min for men and 65 – 
75 ml/kg/min for women. Highly trained or elite non–professionals will usually fall 
between 55-75 ml/kg/min for men and 45-65 ml/kg/min for women. For comparison 
purposes, sedentary but healthy individuals are commonly in the range of 30-40 
ml/kg/min, 30-35 ml/kg/min for women. The more oxygen an individual is able to utilize, 
the longer and harder the athlete can exercise, all else being equal (hydration status, 
nutritional status, glucose availability, etc.). 
The increase in VO2max that occurs in response to undertaking an endurance 
training program is caused by two key physiological elements: stroke volume (SV) and 
oxygen extraction (arteriovenous difference, or a-vO2). The three elements that lead to 
increased SV are (1) increases in plasma volume, venous return and left ventricular 
volume, which together contribute to increased end diastolic volume (EDV), (2) 
increased myocardial contractility, and (3) decreased total peripheral resistance (TPR) 
(198). The increased ability of the muscle to extract oxygen, quantified as the 
arteriovenous difference (a-vO2), is due to two elements, listed in order of importance: 
(1) increased capillary density, and (2) increased mitochondrial density in the muscle 
(198). In young, sedentary but healthy individuals, these two elements are relatively 
equal determinants of increasing VO2max (198).  
Classic studies by Saltin et al. (214) and Ekblom et al. (52) demonstrated that 
increases in VO2max are due to increases in maximal cardiac output (CO) as well as an 
increased a-vO2 difference. Saltin et al. (214) studied 5 males after 20 days of bed rest 
and 55 days of training. Three of the subjects were previously sedentary, while the other 
two were previously active but not trained individuals. In the three previously sedentary 
subjects, CO increased by 16.5% after training, and the a-vO2 difference also increased 
by 16.5%. Thus, the improvements were equally attributed to increased CO – entirely due 
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to increased stroke volume (SV) – and increased a-vO2 difference (214). However, in the 
previously trained subjects, the changes in the above variables were less dramatic, 
indicating that with lower initial maximal oxygen uptake levels the changes were more 
pronounced. Ekblom et al. (52) trained eight male subjects for 16 weeks, and found a 
16.2% increase in VO2max, mainly due to increased SV. The a-vO2 difference after 
training was also significantly improved, and thus they concluded that the increase in 
VO2max was partly due to increased SV and CO, and partly due to the increased a-vO2 
difference (52).  
The time course for increases in maximal oxygen consumption is somewhat 
controversial, and depends upon many factors including exercise mode, frequency, 
duration, intensity, and the initial fitness level of the individual. Two separate studies 
published in 1977 examined the time course for VO2max increases in response to 
endurance training. Henriksson and Reitman (77) trained 13 healthy men on cycle 
ergometers for 20 min per day for four days a week over an 8-week period. The 
investigators increased the work load over the course of the training period in order to 
keep the subjects working at a relative rate of 80% VO2max. They examined VO2max, as 
well as SDH activity in the vastus lateralis. All three variables had significantly increased 
after only three weeks of training. After 8 weeks, VO2max had increased 19% over pre-
training levels, and SDH activity increased 32% (77). Then, they had the subjects detrain 
for six weeks before reassessing the above variables. While VO2max was still 16% above 
the pre-training levels and not significantly different from the value achieved at the end 
of the 8-week training period, SDH activity had returned to pre-training levels, indicating 
that improvements in VO2max are independent of, but associated with, skeletal muscle 
oxidative capacity adaptation (77). It is likely that increased muscle oxidative capacity is 
more important in submaximal endurance exercise than in higher intensity work loads 
(77, 84). 
In a classic study examining the effects of frequent, intense exercise on 
improvements in VO2max, Hickson et al. (79) trained eight subjects for 6 days per week 
for 10 weeks. Subjects cycled on an ergometer three days per week, performing six 5-
 57 
minute intervals during which VO2max was attained in each interval. As the subject’s 
work capacity increased over the training period, the bike work load was also increased 
to elicit their maximal VO2 during each interval. The other three days, they ran as fast as 
possible on a treadmill for 30 minutes per session in the first week, 35 minutes per 
session in the second week, and then 40 or more minutes per session thereafter. After 
only one week of training, the group average VO2max had increased by 5%. The total 
average increase after the 10 week period was ~40% (79). Interestingly, the increase in 
VO2max over the 10 week period was linear without indication of leveling off (79).  
Other investigators have shown a 17% increase in VO2peak for untrained males 
and 22% in untrained females after 7 weeks of endurance training (27), while some have 
shown a 10% improvement in VO2peak after a 31-day training period (194). Spina et al. 
(228) found a 9% VO2peak increase after only 7-10 days of training. It is important to 
note that all of these improvements are in healthy, active but untrained subjects and thus 
demonstrate higher and more rapid improvements than would moderately trained 
individuals. For example, Hickson et al. (79) found that the largest increase in VO2max, 
~53%, was evidenced in the two subjects with the lowest initial oxygen uptake values 
(79). 
In their 31-day training protocol, Phillips et al. (194) had 7 untrained subjects 
cycle for 2 h/day 5-6 days/week at 59% VO2peak. They found lower exercise blood 
lactate concentration, phosphocreatine hydrolysis and glycogen depletion after only the 
first 5 days of training, and after 31 days of training, these variables were lower still than 
at baseline. They reported that muscle oxidative potential (estimated from succinate 
dehydrogenase activity) was not increased until the end of the 31 day period. Therefore, 
they concluded that some characteristic adaptations such as lower blood lactate and 
glycogen depletion occur rapidly and precede that of the mitochondrial adaptations that 
would lead to greater oxygen utilization (194). In contrast, however, Spina et al. (228) 
reported that the adaptive increase in mitochondrial enzymes occurs much more quickly 
than previously suggested. In their study, twelve untrained subjects cycled 2 h/day for 7 
or 10 days, as referenced above, at 60% - 70% of VO2peak. VO2peak increased after this 
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period by 9% and blood lactate levels were lower at the same absolute work load as 
before training. CS and other mitochondrial enzymes were increased by approximately 
30%, providing evidence that shorter term training periods produce a significant adaptive 
response in mitochondrial enzymes. A recent study by Green et al. (72) demonstrated an 
increase in glucose and lactate transporters after only 3 days of cycling training in 
untrained subjects, but no change was found in HK. Clearly, metabolic adaptations occur 
quickly in response to endurance training, with the enzymes involved in glucose uptake 
and lactate metabolism likely increasing more quickly than the oxidative enzymes. 
However, it would appear that in untrained populations, muscle oxidative adaptations can 
occur in 7 to 10 days (228). 
As rapidly as these adaptations can occur, they can also be lost quickly as well if 
training ceases altogether. This was demonstrated in the study by Henriksson and 
Reitman (77), discussed above, as VO2max improvements were maintained after 6 weeks 
of detraining, whereas SDH activity regressed back to pre-training levels (Henriksson and 
Reitman (77).  In a classic study of the effects of 84 days of detraining in trained 
endurance runners and cyclists, Coyle et al. (43) found that VO2max decreased by 7% 
over the first 12 days of detraining, and stabilized at 56 days of detraining at 16% below 
their trained level. The initial decline of 7% in VO2max was related to a reduced SV and 
the later decline, an additional 9%, in VO2max was due to reduced a-vO2 difference. 
Cardiac output, estimated from heart rate and SV, decreased by 8% over 21 days but then 
stabilized to remain at 8-9% below trained levels for the rest of the detraining period. CS 
and SDH activity decreased 17.1% and 18.5%, respectively, in 12 days, and dropped to 
39.6% and 32.5%, respectively, below trained levels at the end of the 84 day period (43). 
While CS and SDH decreased, they still remained 50% higher than levels measured in a 
group of eight untrained, sedentary controls, and the a-vO2 difference and VO2max, as 
well as muscle capillarization, were still higher than in the control subjects after 84 days 
of detraining (43). 
Given what is known about increasing maximal and peak oxygen consumption 
through endurance training, how might CHO+PRO supplementation affect this outcome? 
 59 
Okazaki and colleagues (174) recently compared the effects of a CHO+PRO supplement 
to a placebo supplement in a model of chronic exercise training older male subjects who 
cycled for 60 min/d, 3 d/wk for 8 wk at 60-75% VO2peak and ingested either CHO+PRO 
or placebo immediately post-exercise each session. They reported a two-fold increase in 
VO2max in the CHO+PRO group compared to the placebo group with significant stroke 
volume and plasma volume increases only found in the CHO+PRO group (174). Thus, 
nutritional supplementation may increase the magnitude of training adaptations compared 
to the exercise stimulus alone. It should be noted, however, that the investigation by 
Okazaki and colleagues compared CHO+PRO supplementation to placebo only, and did 
not include any other energy-containing treatment. In the training studies of training 
adaptations proposed here, we extend these findings by including an isocaloric CHO 
treatment in addition to a CHO+PRO supplement and placebo. 
Adaptations in terms of increased lean mass and muscle hypertrophy after 12 
weeks of resistance training and supplementing with milk versus soy protein have been 
reported (76), and Flakoll et al. (62) reported that CHO+PRO supplementation during a 
54-day basic training period was associated with improved immune function, decreased 
muscle soreness and increased hydration status, but these investigations are not entirely 
applicable to what will occur with endurance training. Luden et al. (133) examined a 6-
day CHO+PRO or CHO regimen in runners and reported improved muscle soreness and 
lower CPK levels in the CHO+PRO treatment, but the subjects were already well trained 
and the exercise stimulus was not sufficient to produce abnormally high levels of muscle 
damage in this population. However, it is reasonable to hypothesize that supplementing 
post-exercise with CHO+PRO will lead to a faster rate of training adaptations by 
promoting protein synthesis, by improving recovery, and allowing for a faster 
progression in training stimulus. 
SUMMARY 
Acute endurance exercise performance, post-exercise recovery, and adaptation to 
endurance exercise training are highly complex processes that involve the integration of 
multiple systems and many components that are positively affected by proper post-
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exercise nutrition. Compared to CHO supplements alone, CHO+PRO supplementation 
during endurance exercise can increase time to exhaustion. Post-exercise CHO+PRO 
supplementation increases the rate of recovery from prolonged endurance exercise that 
depletes muscle glycogen stores and improves subsequent exercise performance. In 
addition, CHO+PRO supplementation has been shown to increase muscle glycogen 
synthesis, reduce muscle damage, and activate cellular signaling proteins that control 
both glycogen synthesis and initiation of mRNA translation for protein synthesis. 
Furthermore, a CHO+PRO supplement post-exercise has been found to increase protein 
synthesis to a greater degree than CHO, PRO or AA supplementation alone. While it has 
not previously been investigated, we hypothesize that CHO+PRO supplementation also 
can protect immune function during periods of intense training and recovery, increase the 
rate of improvement in VO2max and muscle oxidative capacity during an endurance 
training period, and improve body composition. In summary, CHO+PRO 
supplementation is a viable strategy to prove endurance exercise performance and 
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Chapter III: The Effect of a Low Carbohydrate Beverage with Added 
Protein on Cycling Endurance Performance in Trained Athletes 
 
ABSTRACT 
Ingesting carbohydrate plus protein during prolonged variable intensity exercise 
has demonstrated improved aerobic endurance performance beyond that of a 
carbohydrate supplement alone. The purpose of the present study was to determine if a 
supplement containing a mixture of different carbohydrates (glucose, maltodextrin and 
fructose) and a moderate amount of protein given during endurance exercise would 
increase time to exhaustion, despite containing 50% less total carbohydrate than a 
carbohydrate-only supplement. We also sought post priori to determine if there was a 
difference in effect based on percentage of ventilatory threshold at which the subjects 
cycled to exhaustion. Fifteen trained male and female cyclists exercised on two separate 
occasions at intensities alternating between 45% and 70% VO2max for 3 h, after which 
the work load increased to ~74-85% VO2max until exhaustion. Supplements (275 ml) 
were provided every 20 min during exercise and consisted of a 3% carbohydrate/1.2% 
protein supplement (MCP) and a 6% carbohydrate supplement (CHO). For the combined 
group (n=15), time to exhaustion (TTE) in MCP did not differ from CHO (31.06 ± 5.76 
vs 26.03 ± 4.27 min, respectively, p=0.064). However, for subjects cycling at or below 
VT (n=8), TTE in MCP was significantly greater than CHO (45.64 ± 7.38 vs 35.47 ± 
5.94 min, respectively, p=0.006). There were no significant differences in TTE for the 
above VT group (n=7). Our results suggest that, compared to a traditional 6% CHO 
supplement, a mixture of carbohydrates plus a moderate amount of protein can improve 
aerobic endurance at exercise intensities near the VT, despite containing lower total 




It has long been recognized that endurance exercise performance is significantly 
improved when carbohydrate is ingested during exercise compared to water only or 
placebo beverages (5,6,14,34,35). Several recent investigations have reported significant 
improvements in endurance exercise performance when a carbohydrate-protein 
(CHO+PRO) beverage is ingested during exercise compared to a carbohydrate-only 
(CHO) beverage (15,27,28). The added amount of protein is typically 25 to 30% of the 
total energy content of the beverage, yet appears to produce performance benefits beyond 
that of traditional carbohydrate-only beverages (3,15,25,27,28,33), as well as reduce 
muscle damage (2,27,28). However, many athletes and recreational exercisers desire a 
lower carbohydrate, lower caloric content alternative when maintaining or reducing body 
weight is a goal, in addition to improving fitness and endurance.  
 
Previous work in our laboratory demonstrated that a lower CHO beverage with added 
protein was as effective in extending time to exhaustion as higher carbohydrate and 
higher calorie beverages (24). Martinez-Lagunas et al. (24) recently compared the effects 
of a 4.5% CHO plus 1.15% PRO, and a 3% CHO plus 0.75% PRO beverage, to a 
traditional 6% CHO beverage and found that there was no difference in the times to 
exhaustion between the treatments. This suggests that the efficacy of the supplements 
was maintained despite the reduction in total CHO and total energy content with the 
substitution of a small amount of protein (24). Based on these findings, we sought to 
determine if a lower CHO, lower calorie beverage containing a moderate amount of 
protein could be optimized using a mixture of CHO sources (glucose [dextrose], 
maltodextrin and fructose) rather than a single CHO (dextrose). Previous investigations 
have shown that maximal rate of exogenous carbohydrate utilization is about 1.0-1.1 
g/min when a single carbohydrate source (e.g., dextrose) is ingested (21,22,23,31), but 
when multiple carbohydrate types (e. g., dextrose and fructose) are ingested, this rate can 
be increased significantly (17,19-21). Furthermore, Currell and colleagues (7) 
demonstrated an 8% improvement in time to complete a subsequent time trial when a 
mixture of glucose and fructose was ingested during a previous bout of prolonged 
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exercise compared to glucose only. The use of different stereospecific intestinal 
carbohydrate transporters for the different carbohydrates used is most likely the reason 
for the improved exogenous carbohydrate oxidation and thus, improved performance. 
 
Therefore, the purpose of the present study was (1) to assess the efficacy of a supplement 
containing a mixture of carbohydrates (dextrose, maltodextrin, and fructose), yet a lower 
total carbohydrate content, and a moderate amount of protein (MCP, 3.0% CHO, 1.2% 
PRO), in extending time to exhaustion, and (2) to determine if muscle damage would be 
reduced by the protein-containing supplement.  We hypothesized that time to exhaustion 
would be extended and muscle damage reduced with the MCP supplement compared to 





Experimental Approach to the Problem 
 
After first determining each subject’s VO2max, each subject completed a familiarization 
trial in which only water was provided, followed by 2 double-blinded, randomly-ordered 
experimental trials in which a 6% carbohydrate beverage (CHO) or a 3% 
carbohydrate/1.2% protein (MCP) beverage was provided during exercise. The CHO 
beverage consisted of dextrose, and the MCP beverage contained dextrose, maltodextrin, 
and fructose (1% each), and a whey protein isolate. At the beginning of exercise and 
every 20 min thereafter, 275 ml of the selected beverage (CHO or MCP) was consumed. 
The subjects performed each trial in a room of ~21 C at the same time of the day and the 
same day of the week over a 3-week period. Human Performance Laboratories, LLC 
(Austin, TX) provided the beverages in powder form, and were mixed in the laboratory to 
the concentrations specified above. The energy and macronutrient content of the 
beverages are shown in Table 3.1. The beverages were similar in color, taste, and texture 
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to allow a double-blinded and randomly ordered study design. A laboratory technician 
who was not involved in the data collection prepared the beverages for each trial.  
 
The cycling protocol for all rides is shown in Figure 3.1. Subjects rode the cycle 
ergometer at intensities alternating between 45% and 70% VO2max for 3 h, and then the 
workload was increased to ~74-85% VO2max until exhaustion. The outcome measures of 
interest were: time to exhaustion (TTE), substrate utilization, and responses of insulin, 




Fifteen trained endurance athletes (cyclists and triathletes) between the ages of 20 and 40 
years were admitted to the study (8 males, 7 females). Subject characteristics are listed in 
Table 3.2. All subjects were accustomed to cycling between 3 - 6 hours in a single ride.  
Mean years of cycling training were 6.5 yr ± 1.2 yr. Written informed consent was 
obtained from each subject, and the study was approved by The University of Texas at 
Austin Institutional Review Board. Each subject served as his/her own control and 




Preliminary testing.  Prior to beginning the 2 experimental trials, subjects reported to 
the laboratory for determination of their VO2max. The VO2max tests and all experimental 
trials were performed on the same ergometer (Velotron Dynafit Pro, Racermate, Seattle, 
WA). The protocol for establishing VO2max consisted of a 4 min warm up, then 2 min 
stages beginning at 200 watts (W) for males or 130 W for females. The workload was 
increased by 50 W (males) or 35 W (females) every 2 min until 350 W and 200 W, 
respectively. After this point, the workload increased 25 W (males) or 10 W (females) 
every minute until the subject could not continue to pedal despite constant verbal 
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encouragement. The criteria used to establish VO2max was a plateau in VO2 with 
increasing exercise intensity and RER > 1.10. During the test, subjects breathed through a 
Hans Rudolph valve, with expired gases directed to a mixing chamber for analysis of 
oxygen (O2) and carbon dioxide (CO2) (ParvoMedics TrueOne2400, ParvoMedics, 
Sandy, UT). Outputs from this system were directed to a laboratory computer for 
calculation of ventilation, O2 consumption (VO2), CO2 production (VCO2), and 
respiratory exchange ratio (RER) every 15 s.  
 
Maximum power output in Watts was calculated from the VO2max test data using the 
formula, adapted from Astrand and Rodahl (1): 
 Wmax = (VO2max mL – 300 mL O2) / 12.5 W/mL O2 
The workloads were then set as percentages of the Wattsmax as follows:  
 W = [(VO2max mL x %VO2max desired) – 300 mL O2] / 12.5 W/mL O2 
 
Each experimental trial was separated by a minimum of 7 days, not to exceed 14 days. 
 
Ventilatory threshold (post priori). Post priori, we sought to determine if the intensity 
at which subjects cycled to exhaustion relative to their individual ventilatory thresholds 
contributed to the increases in TTE. Therefore, using the minute ventilation (VE), VCO2, 
and VO2 data from the VO2max test, ventilatory threshold (VT) was calculated using a 
computer-generated plot (ParvoMedics TrueOne2400 software). VT was defined as the 
point at which the VE (minute ventilation) increased in a nonlinear fashion compared to 
increases in VO2 and was substantiated by an increase in the VE/VCO2 to VE/VO2 ratio.  
Determination of VT was performed blinded.  VO2 was then calculated for the first 5 
minutes of the performance part of the cycling protocol for each experimental trial and 
used to determine the percent of VT at which each subject was cycling. We then grouped 
the subjects as cycling at/below VT, or above VT post priori.   
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Cycling protocol.  Three to five days after the VO2max test, the subjects again reported 
to the laboratory to perform a familiarization ride, which also allowed verification and 
subsequent adjustment of the calculated workloads for the experimental trials. The 
familiarization ride followed exactly the same protocol as the experimental rides, except 
that no blood samples were collected, and only water was provided every 20 min. The 
protocol is shown in Figure 3.1. The first 30 min of the protocol were at low intensity 
(45% VO2max). For the next 1.5 h, the intensity alternated every 8 min between 45% and 
70% VO2max. From hour 2 to 3, the intensity continued to alternate between 45% and 
70% VO2max, but did so every 3 min. After the 3 h time point, the intensity increased to 
between 74% and 85% of VO2max (exhaustion protocol), and this marked the start of the 
TTE determination. Subjects were encouraged to ride as long as possible while 
maintaining a pedaling cadence of 80 to 90 revolutions per minute (rpm).  When they 
could no longer maintain a pedaling cadence of 60 rpm despite constant verbal 
encouragement, they were asked to stop, and TTE was recorded as min:sec beyond the 3 
h point. Constant verbal encouragement was given to the subjects during each trial, and 
the same investigators were present during all trials for each subject so that 
encouragement was consistent across all trials.  In addition, subjects were not aware of 
how long they rode each time, as all timing devices were removed from their line of sight 
or covered.  
 
For all trials, the subjects arrived at the laboratory after an overnight, 12 h fast, during 
which they were allowed to consume only water. Upon arrival, body weight was obtained 
and a heart rate monitor (Polar Beat, Polar Electro, Oy, Finland) was secured in place 
around the subject’s chest. For the 2 experimental trials, a catheter fitted with a three-way 
stopcock and extended with a catheter extension was inserted into an antecubital vein and 
taped in place. A resting blood sample was taken as described below, and then the subject 
was given the first dose of supplement to drink. After consuming the 275 ml beverage, 
the subject mounted the ergometer and the cycling protocol began. Supplements (275 ml) 
were provided every 20 min for the duration of the ride. If the subjects were able to ride 
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longer than 40 min during the exhaustion portion of the protocol (i.e.; 40 min beyond the 
3 h ride), and felt too full to continue to drink the entire amount of supplement provided 
each time, then they were asked to consume as much as they felt comfortable ingesting. 
During the exercise trials, the laboratory temperature was maintained at ~21 C and a fan 
was directed towards the subject to reduce thermal stress.  
 
Diet and exercise.  The subjects were instructed to maintain a training and dietary log for 
the 2 and 3 days, respectively, before the familiarization trial and to keep training and 
diet consistent with that record for the 2 and 3 days prior to the remaining experimental 
trials. The subjects provided a copy of their training and dietary logs on the day of the 
trials.  An investigator reviewed and verified the entries in the logs with the subjects at 
each session in order to verify that compliance with the previous logs was attained. The 
data from the logs were entered into Nutribase Clinical Nutrition Manager 7.17 
(CyberSoft, Inc., Phoenix, AZ) for nutritional analysis and compliance verification. All 
subjects complied with the diet and exercise requirements. Diets were not standardized 
across all subjects, as each subject served as his or her own control. 
Blood sampling.  Prior to receiving the first beverage dose and mounting the ergometer, 
a 5 ml sample of blood was collected and the catheter was flushed with saline. Five 
milliliters were drawn at 3 additional time points: at 118 min of exercise, at 177 min of 
exercise, and immediately after exercise ceased due to exhaustion. Saline flushes 
occurred every 10-15 min during the entire protocol to keep the catheter patent.  
 
Ventilation, VO2, RER, heart rate and RPE.  Ventilation, VO2, CO2 production, and 
respiratory exchange ratio (RER) were recorded using the same ParvoMedics TrueOne 
2400 system that was used during the VO2max test and familiarization trial. The system 
was calibrated immediately before each trial using medical-grade gases of known 
concentrations and a 3.0 L calibration syringe. Collections were made at 4 time points: 
10-15 min (low intensity), 46-51 min (high intensity), 130 – 136 min (low and high 
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intensity, 3 min each) and for the first 5 min of the exhaustion portion.  With the 
exception of the 130-136 min collection, respiratory gases were collected for 5 min using 
15 sec sampling, and only the last 1.5 min of each collection were used to determine 
steady state VO2 and RER.  For the 130-136 min collection (3 min of low intensity and 3 
min of high intensity), the last minute of each interval was used. Heart rate (HR) was 
recorded at the beginning of exercise and at every 10-15 min of exercise.  Subjective 
ratings of perceived exertion (RPE) on a Borg scale (ranging from 6 to 20) were obtained 
during exercise at the same time points as HR.   
 
Substrate utilization.  Determination of substrate (carbohydrate and fat) oxidation rates 
were made from VO2, VCO2, and RER values using the 5 collection times as described 
above during the experimental rides according to the method of Frayn (11).  
 
Biochemical analyses of plasma metabolites. Each 5 ml blood sample taken during the 
protocol was anticoagulated with 0.3 ml of EDTA (24mg/ml, pH 7.4), and 0.5 ml of the 
anticoagulated blood was transferred to another tube containing 1 ml 10% perchloric acid 
(PCA). All tubes were centrifuged at 4˚ C for 10 min at 3,000 rpm with a HS-4 rotor in a 
Sorvall RC6 centrifuge (Kendro Laboratory Products, Newtown, CT). After 
centrifugation, plasma and PCA extracts were separated into aliquots for each assay and 
immediately frozen and stored at -80˚ C for later analysis. Plasma insulin was measured 
using ImmuChemTM Coated Tube 125I RIA Kit (MP Biomedicals, LLC, Orangeburg, NY) 
by radioimmunoassay (12). All samples were run in duplicate, with a coefficient of 
variation (CV) of 6.0%. Plasma myoglobin concentrations were determined by solid 
phase ELISA (BioCheck, Inc., Foster City, CA), and were run induplicate with a CV of 
5.4%. Blood lactate was determined from the PCA extract by enzymatic-
spectophotometric analysis based on the oxidation of lactate to pyruvate by nicotinamide 
adenine dicnucleotide (NAD+) according to the method of Hohorst (13). Samples were 
run in duplicate and had a CV of 1.5%. Plasma glucose was measured using a 
spectophotometric Trinder reaction (no. 315, Sigma Chemical, St. Louis, MO). The 
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Trinder reagent contained the enzyme peroxidase (HPOD), 4-aminoantipyrine (4-AAP) 
and p-hydroxybenzene sulfonate (p-HBS).  Glucose was oxidized to D-gluconate by 
glucose oxidase with production of an equal amount of hydrogen peroxide. Coupled by 
hydrogen peroxide, 4-AAP and p-HBS were oxidized by HPOD and formed a 
quinoneimine dye, intensely colored in red. The absorbance of the reaction solution was 
measured using a spectrophotometer (Beckman DU 640; Beckman Coulter, Inc., 
Fullerton, CA) at a wavelength of 500 nm. The intensity of the color in the reaction 
solution was proportional to the concentration of glucose in the plasma sample. Samples 




The data were analyzed using a general linear model for repeated measures.  Time to 
exhaustion was analyzed using a one-way ANOVA.  All the other variables that included 
multiple measures per trial were analyzed using a two-way ANOVA (treatment x time). 
Post hoc analysis was performed when significance was found using Fisher’s Least 
Square Difference (LSD).  The level of significance for all analyses was set at P < 0.05.  
All data are expressed as mean ± SEM.  SPSS version 16.0 statistical software (SPSS 
Inc., Chicago, IL) was used for all statistical analyses. 
RESULTS 
 
Time to exhaustion.  Time to exhaustion (TTE) for the combined group, as well as by 
VT grouping, is shown in Figure 3.2. For the combined group (n=15), TTE was not 
significantly different between treatments (MCP, 31.06 ± 5.76 vs CHO, 26.03 ± 4.27, 
p=0.064). However, for subjects cycling at or below VT (n=8), TTE in MCP was 
significantly greater than CHO (45.64 ± 7.38 vs 35.47 ± 5.94 min, p=0.006). There were 
no significant differences in TTE for the above VT group (n=7); CHO, 15.25 ± 2.83 vs 
MCP, 14.39 ± 2.50 min, p=0.8). 
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Blood and plasma analyses. Blood samples were analyzed for plasma insulin, plasma 
glucose, blood lactate and plasma myoglobin. No significant overall treatment differences 
in plasma insulin levels were found among treatments (Fig. 3.3). However, a significant 
treatment by time difference was observed at 177 min, with plasma insulin higher in 
CHO than in MCP in the combined group (p=.023), as well as in the at or below VT 
group (p=.032). No significant differences were found when exercising above VT. 
 
Plasma glucose was significantly lower in MCP than CHO in the combined group (Fig. 
3.4). Significant treatment by time effects were also observed at minutes 118 and 177 
(p=.003 and .005, respectively). No treatment by time differences were found when 
grouped by VT. 
 
Blood lactate levels rose significantly during the time to exhaustion portion of the 
protocol (Fig. 3.5), but there were no differences between the treatments whether grouped 
or not grouped by VT. 
 
Plasma myoglobin levels rose during exercise in both treatments. Although myoglobin 
appeared to be lower at End in MCP, no significant differences were found between 
treatments (p=.189, Fig. 3.6). A similar non-significant trend was found in the group 
exercising above VT. 
 
RPE and heart rate. Although RPE and HR values were recorded at the beginning of 
exercise and at every 10-15 min of exercise, 3 time points during low intensity intervals 
(90, 130 and 161 min), 2 time points during high intensity intervals (115 and 159 min), 
and 1 time point during the TTE protocol (184 min) were chosen for analysis. Values are 
shown in Table 3.3. There were no significant differences for RPE or HR between 
treatments regardless of VT grouping. 
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Substrate utilization. There were no significant treatment differences in either 
carbohydrate oxidation rates or fat oxidation rates (g.min-1) between MCP and CHO 
whether grouped or not grouped by VT (Table 3.4).  
DISCUSSION 
 
The primary objective of the present study was to compare the effects of a beverage 
containing a lower total amount, yet multiple types of carbohydrates, and a moderate 
amount of protein (3% CHO, 1.2% PRO) with a traditional 6% carbohydrate beverage on 
time to exhaustion (TTE) during prolonged endurance exercise. The most important 
finding of this investigation was that TTE was significantly greater in the treatment that 
contained fewer calories, lower carbohydrates, and a moderate amount of protein (MCP), 
compared to the higher carbohydrate-containing beverage (CHO) when exercising at VT 
or ~2% below VT (MCP, 45.64 ± 7.38 vs CHO, 35.47 ± 5.94 min, p=0.006). This 
represents a 28.7% improvement in TTE in the MCP treatment. In the combined group of 
15 subjects, TTE in MCP was greater than CHO by 19.3% (31.06 ± 5.76 vs 26.03 ± 4.27, 
p=0.064), although it did not reach statistical significance. When exercising above VT by 
5-7%, there was no difference in TTE between treatments (15.25 ± 2.83 vs MCP, 14.39 ± 
2.50 min, p=0.8).  
 
Our finding of differences when grouped according to VT (e.g., cycling at or below VT 
or cycling above VT during the exhaustion protocol) is novel. Many investigations report 
TTE when cycling at a work rate that elicits a certain percentage of VO2max, often 70% - 
85% VO2max (26-28,30), without identifying how this percentage relates to the subjects’ 
ventilatory thresholds (VT) or lactate thresholds (LT). Recently, other investigators have 
pointed out that the relative intensity at which individuals are exercising could be a factor 
in determining the efficacy of the CHO and CHO+PRO supplements (4). Indeed, the 
ability to exercise for long periods near an individual’s LT becomes a critical component 
of performance in long events such as marathons, longer cycling races and long-distance 
triathlons. In fact, it has been shown that runners self-select a running pace just above the 
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point of blood lactate appearance and are able to maintain that intensity for the duration 
of a marathon (10). In the present study, we utilized ventilatory threshold (VT) post-
priori as a surrogate for LT, given that VT and LT have been shown to occur near the 
same VO2 (8,16). The significant differences found in TTE when cycling at or below VT 
suggest that MCP is more effective in extending endurance and delaying fatigue than 
CHO around the exercise intensity at which prolonged endurance performance is often 
crucial. While we did not observe differences in TTE when exercising above VT, it is 
possible that other factors that contribute to exhaustion when exercising at higher 
intensities, such as a significant drop in muscle pH or depletion of high energy 
phosphates, simply may not be affected by the supplement.  
 
Many investigations have demonstrated improved TTE with the addition of protein to a 
carbohydrate supplement ingested during exercise (15,27,28), although the supplements 
are usually isocaloric or isocarbohydrate compared to a 6-8% CHO supplement (15,27). 
However, Martinez-Lagunas et al. (24) recently compared the effects of a 4.5% CHO 
plus 1.15% PRO, and a 3% CHO plus 0.75% PRO beverage to a traditional 6% CHO 
beverage. The investigators found that while TTE was not significantly different between 
treatments, both of the lower CHO plus PRO treatments still maintained TTE 
performance. Although their investigation used a similar exercise protocol and low 
CHO+PRO/low calorie treatment as were utilized in the present study, there are 
methodological differences that may have contributed to their non-significant differences 
in TTE. First, the Martinez-Lagunas et al. (24) investigation did not take into 
consideration the relative intensity at which the subjects were exercising. Second, 
Martinez-Lagunas and colleagues (24) used a single carbohydrate (dextrose) rather than a 
mixture of different carbohydrates as was employed in the present study.  
 
The use of three different carbohydrates in the MCP beverage used in the present 
investigation may have enabled the optimization of the various intestinal carbohydrate 
transporters such that the rate of absorption was increased beyond that of the single-CHO 
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treatment, leading to increased exogenous CHO oxidation and decreased endogenous 
CHO oxidation. Several previous investigations have demonstrated that, compared to a 
single CHO supplement, supplements containing mixtures of carbohydrates can increase 
exogenous CHO oxidation (17-20,32), decrease endogenous CHO oxidation (17,19), and 
improve cycling exercise performance (7). Recently, Currell and Jeukendrup (7) 
compared the effects of a CHO mixture to a single CHO supplement on cycling 
performance. Subjects cycled for 120 min at 55% Wmax while ingesting a glucose-only 
supplement, an isocaloric glucose plus fructose supplement, or water, followed by a time 
trial in which the subjects had to complete a set amount of work as quickly as possible. 
Ingestion of the glucose plus fructose supplement resulted in an 8% faster time trial time 
compared to glucose only, and 19% faster than water (7). Total CHO oxidation was not 
different between the CHO treatments, and the investigators concluded that ingestion of 
the CHO mixture likely led to a sparing of endogenous CHO stores, since glucose plus 
fructose has been shown to have a greater exogenous CHO oxidation than glucose only 
(18,19). Taken together, these findings suggest that the sparing of endogenous CHO may 
be a key mechanism that resulted in the TTE improvements reported here.  
 
Others, however, have failed to show that CHO+PRO supplementation during exercise 
spares endogenous fuel supplies by decreasing muscle glycogen use or depletion of Krebs 
cycle intermediates (4). Cermak and colleagues (4) found no difference in muscle 
glycogen use or in levels of Krebs cycle intermediates when trained men ingested 6% 
CHO or 6% + 2% PRO during 90 min of cycling at ~69% VO2peak. It should be noted, 
however, that the investigators used a single carbohydrate in both treatments rather than a 
mixture of carbohydrates as was used in the present study. It is possible that using a 
mixture of carbohydrates in a CHO+PRO supplement could demonstrate a positive effect 
in the levels of muscle glycogen use and Krebs cycle intermediates compared to a 
supplement containing a single carbohydrate with added protein, although we did not 
measure these parameters in the present study.  
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Other investigators have proposed that reducing muscle damage that occurs during 
intense endurance exercise is a possible mechanism for improved performance with 
CHO+PRO supplementation.  Saunders and colleagues (27,28) have demonstrated 
significant improvements in TTE concomitant with significant reductions in markers of 
muscle damage when comparing CHO+PRO supplements to CHO only supplements 
(27,28). Others have used a resistance exercise model to demonstrate a significant 
reduction in myoglobin levels 6 h after a strenuous resistance exercise bout when subjects 
ingested a CHO+PRO beverage compared to a placebo supplement (2). However, other 
recent investigations have demonstrated significant reductions in muscle damage without 
differences in TTE (26,30).  
  
In the present investigation, however, we did not demonstrate a statistically significant 
reduction in myoglobin. Myoglobin was selected as our muscle damage marker of choice 
because it is a small molecule that leaks from the skeletal muscle cell early on during 
exercise when damage occurs, peaking in about 1 h post-exercise (9,29). In the combined 
group (Fig. 3.6), myoglobin levels continued to rise over the course of the trial with the 
CHO treatment, whereas with MCP, myoglobin increased to a lesser but non-significant 
extent (p=.189). It is possible that had we evaluated myoglobin again within hours post-
exercise rather than immediately at the end of exercise (e.g., at exhaustion), a greater 
difference in myoglobin levels may have been detected. A trend was observed for an 
increasing difference in myoglobin levels between treatments, yet without a measurement 
an hour post-exercise, we do not know if that trend would have continued, resulting in a 
significant difference. Therefore, although we cannot associate the improvement in TTE 
observed in the present study with muscle damage reduction, the possibility remains that 
reduced muscle damage could potentially help to maintain or improve performance. 
 
In summary, proper nutritional supplementation during endurance exercise is essential for 
delaying fatigue and maintaining optimal performance. Most of the commercially 
available products contain high total calories and large amounts of carbohydrate. Many 
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athletes and recreational exercisers want to maintain or improve their body composition, 
and are therefore concerned about limiting caloric intake.  The present investigation 
demonstrates that consuming a beverage containing a mixture of different carbohydrates, 
a moderate amount of protein and fewer calories than a traditional, higher single-
carbohydrate supplement during endurance exercise can extend exercise time to 
exhaustion, especially when exercising at or below the ventilatory threshold. This is an 
important finding that is highly relevant to endurance athletes and exercisers; especially 
those who wish to consume less total carbohydrate and fewer calories, and improve 
endurance capacity. The present study demonstrated that a supplement containing a 
mixture of carbohydrates plus a moderate amount of protein could significantly improve 
aerobic endurance when cycling at or below the ventilatory threshold, despite containing 
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   CHO MCP 
Kcals  24.0 16.9 
% total CHO  6.0 3.0 
     % dextrose 6 1 
     % fructose 0 1 
     % maltodextrin 0 1 
% PRO 0 1.2 
Ratio of CHO:PRO      -- 2.5:1 
CHO g  6 3 
PRO g  0 1.2 
Per 100 ml. Both treatments contained the same amounts 
of electrolytes NA+, K+, and MG++. 275 ml was provided 
immediately before exercise and every 20 min thereafter.  
 
 
Table 3.1. Energy and macronutrient content of the treatments   
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Table 3.2. Subject characteristics 
  
 
  Age (yr) Mass (kg) Height (cm) 
VO2max  
(L·min-1) 
VT   
(L·min-1) 
Mean, n = 15 28.7 ± 1.2 65.9 ± 2.4 172.0 ± 2.2 3.70 ±.20 2.80 ± .20 
     Males, n = 8 28.9 ± 1.9 69.2 ± 2.5 175.8 ± 2.0 4.50 ± .10 3.40 ± .10 
     Females, n = 7 28.6 ± 1.5 62.1 ± 4.1 167.7 ± 3.6 2.90 ± .20 2.00 ± .20 
At or below VT, n=8 29.5 ± 1.2 64.5 ± 2.5 172.6 ± 3.6 3.50 ± .30 2.70 ± .20 
Above VT, n=7 27.9 ± 2.2 67.4 ± 4.5 171.3 ± 2.6 4.00 ± .40 3.00 ± .30 




   MCP CHO 









=/< VT (n=8) > VT (n=7) 
RPE Low 90 11 ± .31 12 ± .46 11 ± .40 11 ± .33 11 ± .36 11  ± .57 
 Low 130 12 ± .28 12 ±.50 11 ± .20 12 ±.30 12 ± .53 11 ± .18 
 Low 161 12 ± .35 12 ± .55 12 ± .43 12 ± .33 12 ± .44 11 ± .41 
 High 115 14 ± .22 14 ± .27 13 ± .36 14 ± .31 14 ± .38 14 ± .53 
 High 159 14 ± .34 14 ± .31 14 ± .65 14 ± .37 14 ± .45 14 ± .61 
 High/TTE 184 16 ± .32 16 ±.41 16 ± .53 16 ± .30 16 ±.42 16 ± .43 
HR Low 90 119.4 ± 3.3 121.9 ± 5.1 116.6 ± 4.0 120.9 ± 2.9 123.9 ± 3.8 117.4 ± 4.5 
 Low 130 124.9 ± 3.3 126.8 ± 4.9 122.9 ± 4.6 127.6 ± 3.8 130.6 ± 5.7 124.1 ± 5.0 
 Low 161 130.0 ± 3.5 129.4 ± 5.2 130.7 ± 5.2 132.1 ± 3.5 134.0 ± 5.0 129.9 ± 5.1 
 High 115 143.7 ± 4.2 143.5 ± 7.0 144.0 ± 4.9 148.7 ± 3.9 148.8 ± 5.7 148.6 ± 5.7 
 High 159 145.1 ± 4.3 143.5 ± 7.2 147.0 ± 4.5 149.3 ± 3.5 149.4 ± 4.9  149.1 ± 5.3 
 High/TTE 184 162.7 ± 3.8 160.5 ± 5.8 165.3 ± 4.9 162.9 ± 3.7 160.5 ± 5.2 165.6 ± 5.5 
Values are mean ± SE.  
 
 
Table 3.3. RPE and heart rate during cycling protocol   
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CHO (g.min-1) Low 1.50 ± .11 1.44 ± .12 1.59 ± .20 1.54 ± .11 1.47 ± .13 1.64 ± .19 
 High 2.67 ± .19 2.53 ± .24 2.84 ± .30 2.70 ±.19 2.50 ± .23 2.94 ± .30 
 High/TTE 3.56 ± .25 3.18 ± .29 3.99 ± .38 3.65 ± .27 3.25 ± .31 4.11 ± .40 
Fat (g.min-1) Low 0.24 ± .03 0.22 ± .03 0.28 ± .06 0.21 ± .02 0.20 ± .02 0.23 ± .04 
 High 0.19 ± .03 0.18 ± .05 0.23 ± .06 0.17 ± .03 0.17 ± .05 0.17 ± .04 
 High/TTE 0.06 ± .02 0.08 ±.04 0.05 ± .03 0.02 ± .02 0.05 ± .03 0.00 ± .00 
Values are mean ± SE. 
 













Figure 3.2.  Time to exhaustion. Time to exhaustion (TTE) for (a) the combined group 
(n=15), (b) at or below VT (n=8), and (c) above VT (n=7). *Significantly different than 







Figure 3.3.  Plasma insulin. Insulin was measured from blood samples taken at rest, at 
the end of the 8-min intervals (118 min) at the end of the 3 min intervals (177 min) and at 
exhaustion. †Significantly higher than MCP at 177 min in the combined group (p=.023). 
Insulin was also higher in the CHO treatment at minute 177 in the group exercising at or 
below VT (p=.032) but no differences were observed above VT (data not shown). A 








Figure 3.4.  Plasma glucose. Glucose was measured from blood samples taken at rest, at 
the end of the 8-min intervals (118 min) at the end of the 3 min intervals (177 min) and at 
exhaustion. †Significantly higher than MCP at 118 and 177 min in the combined group 
(p=.003 and .005, respectively). A significant time effect was present in both treatments 
(p=.000 for both) in the combined group, but only existed for the CHO treatment when 







Figure 3.5.  Blood lactate. Lactate was measured from blood samples taken at rest, at the 
end of the 8-min intervals (118 min) at the end of the 3 min intervals (177 min) and at 
exhaustion. A significant time effect was observed in both treatments, as blood lactate 
rose during the exhaustion protocol (†CHO, p=.000; *MCP, p=.000). At or below VT, as 
well as above VT, there was also a significant time effect (data not shown) (p=<.05 for 








Figure 3.6. Plasma myoglobin. Myoglobin was measured from blood samples taken at 
rest, at the end of the 8-min intervals (118 min) at the end of the 3 min intervals (177 
min) and at exhaustion. A significant time effect was observed in the combined group 





Chapter IV: Post-Exercise Carbohydrate-Protein Supplementation 
Improves Subsequent Exercise Performance and Intracellular 
Signaling for Protein Synthesis 
 
ABSTRACT 
Post-exercise carbohydrate-protein supplementation has been proposed to improve 
recovery and subsequent endurance performance compared to carbohydrate. This study 
compared the effects a carbohydrate-protein supplement in the form of chocolate milk 
(CM), isocaloric carbohydrate (CHO), and placebo (PLA) on recovery and subsequent 
exercise performance. Ten cyclists performed 3 trials, cycling 1.5 h at 70% VO2max plus 
10 min of intervals. They ingested supplements immediately post-exercise and 2 h into a 
4-h recovery. Biopsies were performed at recovery minutes 0, 45 and 240 (R0, R45, 
REnd). Post-recovery, subjects performed a 40 km time trial (TT). TT time was faster in 
CM than CHO and PLA (79.43±2.11 vs 85.74±3.44 and 86.92±3.28 min, P<0.05). 
Muscle glycogen resynthesis was higher in CM and CHO than PLA (23.58 and 30.58 vs 
7.05 mol/g wet wt, P<0.05). mTOR phosphorylation was greater at R45 in CM than 
CHO or PLA (174.4 ± 36.3 vs. 131.3 ± 28.1 and 73.7 ± 7.8% standard, P<0.05), and at 
REnd in CM than PLA (94.5 ± 9.9 vs 69.1 ± 3.8%, P<0.05). rpS6 phosphorylation was 
greater in CM than PLA at R45 (41.0 ± 8.3 vs 15.3 ± 2.9%, P<0.05) and REnd (16.8 ± 
2.8 vs 8.4 ± 1.9%, P<0.05). FOXO3A phosphorylation was greater at R45 in CM and 
CHO than PLA (84.7 ± 6.7 and 85.4 ± 4.7 vs 69.2 ± 5.5, P<0.05). These results indicate 
that chocolate milk is an effective post-exercise supplement that can improve subsequent 
exercise performance and provide a greater intracellular signaling stimulus for protein 
synthesis compared to carbohydrate and placebo. 
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INTRODUCTION 
Recovering from strenuous endurance exercise is central to the ability to perform 
at one’s best day after day in training sessions and competitive events. Endurance athletes 
must often perform multiple bouts of prolonged, strenuous activity with little time to 
recover in between. Studies of subsequent endurance exercise performance performed 
after recovering from a previous bout have reported significantly increased endurance 
time to exhaustion in the subsequent exercise bout with carbohydrate-protein 
supplementation (CHO+PRO) compared to carbohydrate (CHO) alone (3, 34, 45, 56). 
The improvements in performance have been associated with a greater recovery of 
muscle glycogen during the recovery period between the two bouts in CHO+PRO 
compared to a non-isocaloric CHO beverage (4, 56), as well as with reduced muscle 
damage (45). However, not all investigations have demonstrated a significant difference 
in subsequent time to exhaustion (36, 42-44), or time trial performance (4, 7, 8) between 
CHO+PRO and CHO treatments.  
 
In addition to the importance of post-exercise supplementation in restoring muscle 
glycogen and attenuating muscle damage for improved recovery, nutrients play a key role 
in facilitating muscle protein synthesis. Strenuous exercise stimulates protein synthesis as 
well as protein breakdown, and the balance between degradation and synthesis is largely 
mediated by nutrient availability, especially that of amino acids (AA), and activation of 
the mTOR (mammalian target of rapamycin) signal transduction pathway. mTOR is a 
serine/threonine kinase that integrates signals from nutrients, skeletal muscle contraction 
and growth factors, functioning as a crucial regulator of protein synthesis (30, 52). 
Because the mTOR pathway is critical for protein synthesis and cell growth, it is 
important to optimize activation of this pathway in order to maximize training 
adaptations. While post-exercise CHO+PRO supplementation has been shown to alter the 
phosphorylation of signaling proteins related to protein synthesis (20, 32), the effects 
when compared to CHO only and placebo in an endurance exercise model has not been 
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well characterized, nor has muscle protein degradation-specific signaling been 
characterized in response to CHO+PRO supplementation post-endurance exercise. 
 
While there are many CHO+PRO supplements commercially available, several recent 
investigations have used low-fat chocolate milk (CM) as a post-endurance exercise 
CHO+PRO supplement. Pritchett and colleagues compared CM and a commercially 
available CHO+PRO post-exercise supplement and found no difference between the two 
in markers of muscle damage and in time to exhaustion in a subsequent bout of exercise 
(39). This finding was in agreement with another investigation that compared CM to a 
CHO-replacement beverage and a fluid-replacement beverage, and found that time to 
exhaustion (TTE) after a 4 h recovery was significantly longer in CM than the other 2 
treatments (49). Taken together, these findings suggest that CM may be a viable 
CHO+PRO supplement for use post-exercise to aid recovery, improve subsequent 
exercise performance, activate signaling pathways for initiation of protein translation, 
while also reducing protein degradation signaling beyond that afforded by CHO 
supplementation alone. However, to our knowledge, no single investigation has examined 
all of these aspects together, along with markers of muscle damage, inflammation, and 
muscle glycogen resynthesis. 
 
Therefore, the purpose of this study was to investigate the effects of a dairy-based 
carbohydrate-protein recovery supplement (chocolate milk, CM) on post-exercise muscle 
glycogen synthesis, activation of key signaling proteins involved in protein synthesis 
(mTOR, rpS6, and eIF2B) and degradation (FOXO3A and ubiquitination), biochemical 
measures of muscle damage and inflammation, and subsequent aerobic endurance 
performance. We hypothesized that, compared to an isocaloric CHO supplement, the CM 
supplement would improve recovery by increasing muscle glycogen synthesis and 
attenuate indicators of muscle damage and inflammation after a strenuous exercise bout 
and thus, improved subsequent time trial performance. We also hypothesized that the CM 
supplement would more effectively modulate the phosphorylation of intracellular 
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signaling proteins that lead to increased protein synthesis and reduced protein 
degradation during recovery compared to a CHO supplement or placebo. 
METHODS 
 
Subjects. Ten healthy, trained cyclists and triathletes (5 males, 5 females) between the 
ages of 18 and 39 years were admitted to the study. Subject characteristics are listed in 
Table 4.1. Written informed consent was obtained from all subjects, and the study was 
approved by The University of Texas at Austin Institutional Review Board. 
Research design. This study followed a randomized, double-blinded, placebo-controlled, 
crossover design. Subjects reported to the laboratory before the start of their experimental 
trials for maximal oxygen consumption (VO2max) and maximal workload (Wmax) 
determination. This test was performed on a VeloTron DynaFit Pro cycle ergometer  
(RacerMate, Seattle, WA). The protocol for establishing VO2max consisted of a 4 min 
warm up, then 2 min stages beginning at 200 watts (W) for males or 130 W for females. 
The work load was increased by 50 W (males) or 35 W (females) every 2 min until 350 
W and 200 W, respectively. After this point, the workload increased 25 W (males) or 10 
W (females) every minute until the subject could not continue to pedal despite constant 
verbal encouragement. The criteria used to establish VO2max was a plateau in VO2 with 
increasing exercise intensity and RER > 1.10. VO2max was measured using a 
TrueOne2400 system (ParvoMedics, Sandy, UT). Subjects breathed through a Hans 
Rudolph valve, with expired gases directed to a mixing chamber for analysis of oxygen 
(O2) and carbon dioxide (CO2). Outputs were directed to a computer for calculation of 
ventilation, O2 consumption (VO2), CO2 production (VCO2), and respiratory exchange 
ratio (RER) every 15 s.  
 
Maximum power output in Watts was calculated from the VO2max test data using the 
formula, adapted from Ǻstrand and Rodahl (1): 
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 Wmax = (VO2max mL – 300 mL O2) / 12.5 W/mL O2  
 
The workload for each intensity level (45%, 70% and 90% of VO2max) was then set as 
percentages of the Wmax as follows:  
 
 W = [(VO2max mL x %VO2max desired) – 300 mL O2] / 12.5 W/mL O2 
 
Three to five days after the VO2max test, the subjects again reported to the laboratory 
after an overnight 12-h fast for a familiarization session. Using the same VeloTron cycle 
ergometer on which the VO2max test was performed, subjects performed a 40 min 
portion of the glycogen depletion ride, including the intervals at the end, and gas 
collections taken during this ride allowed verification and subsequent adjustment of the 
calculated workloads for the experimental trials. Subjects then rested in the laboratory for 
1 h, and then performed the 40 km cycling time trial. No muscle or blood samples were 
collected during the familiarization session.   
 
The protocol for the experimental trials is shown in Figure 4.1. For each trial, subjects 
reported to the laboratory having fasted overnight for 12 h. After being weighed and 
fitted with a heart rate monitor (Cardiosport, Waterlooville, Hampshire, UK), a catheter 
with a 3-way stopcock and catheter extension was inserted into a forearm vein and taped 
in place. A resting blood sample was drawn, and resting heart rate recorded. Then, the 
subject mounted the cycle ergometer and began the glycogen depletion ride.  
 
Subjects cycled at 70% VO2max for 1.5 h, followed by 1 min alternating intervals at 45% 
and 90% VO2max for a total of 10 min. This bout was designed to deplete muscle 
glycogen stores. Subjects received 250 mL of water at 15 min intervals during the ride, 
and floor fans were used to circulate air over the individual to minimize thermal stress. 
Subjects then recovered in the laboratory for 4 h and received one of 3 experimental 
treatments immediately and at 2-h post-exercise. Muscle biopsies were performed 
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immediately following the first exercise bout, at 45 min into recovery, and 4 h after the 
start of recovery to assess muscle glycogen resynthesis. Blood collections were taken at 
the same time points as the biopsies, as well as at 2 h into the recovery period. Subjects 
were allowed to work, read, or study at a desk set up for their use in the laboratory, and 
were under constant observation by investigators during this time. They were provided 
water ad libitum during this time. At four time points during recovery, RER 
measurements were made while the subject rested quietly in a cushioned chair for 10 
min. The catheters were flushed every 10 - 15 min throughout the recovery period. 
 
Following the recovery period, subjects completed a 40-km time trial (TT) using the 
same VeloTron on which they performed the earlier exercise bout. The simulated TT 
course was designed with VeloTron 3D software (RacerMate, Seattle, WA). The subjects 
were instructed to cycle this fixed distance as fast as possible, and the measure of 
performance was the time to complete the TT. The course included rolling hills and a 3-
km uphill finish. Subjects were fan cooled and were provided 250 ml of water at 15 min 
intervals during the TT. Verbal encouragement was given consistently to all subjects, and 
the same investigators provided encouragement to the same subjects for each TT. Each 
experimental trial was separated by a minimum of 7 days, but did not exceed 14 days. 
 
Experimental beverages. The 3 treatment beverages were chocolate milk (CM; Kirkland 
Organic Low-Fat Chocolate Milk, Costco Inc.), carbohydrate (CHO; dextrose and canola 
oil) or placebo (PLA; water flavored with Splenda and non-caloric Kool Aid flavoring). 
Energy and macronutrient composition of the beverages is shown in Table 4.2. The CM 
and CHO were isocaloric. The supplements were provided immediately post-exercise 
after the first biopsy was performed, and again 2 h later. Subjects were instructed to drink 
the amount provided within 5 min. The amounts of supplement provided were stratified 
according to body weight ranges. Subjects weighing <63.6 kg (140 lbs) received 500 mL 
per supplement (395.25 kcals each), totaling 1000 mL and 790.5 kcals during the 
recovery period. Subjects weighing between 63.6 kg (140 lbs) and 77.2 kg (170 lbs) 
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received 600 mL per supplement (474.3 kcals), totaling 1200 mL and 948.6 kcals during 
recovery. Subjects weighing >77.2 kg (170 lbs) received 700 mL per supplement (553.35 
kcals), totaling 1400 mL and 1106.7 kcals during recovery. For the carbohydrate 
treatment, the amount of fat matched that of the CM as measured for the individual’s 
weight range. Overall, the CM treatment provided an average of 1.9 g CHO, 0.6 g PRO, 
and 0.3 g fat per kg body weight. The CHO treatment provided an average of 2.5 g CHO 
and 0.3 g fat per kg body weight. 
 
Diet and exercise. The subjects were instructed to maintain training and dietary logs for 
the 2 and 3 days, respectively, before the familiarization trial and to keep training and 
diet consistent with that record for the days prior to the remaining 3 experimental trials. 
The subjects provided a copy of their training and dietary logs on the day of each trial.  
An investigator reviewed and verified the entries in the logs with the subjects at each 
session in order to verify that compliance with the previous logs was attained. The data 
from the logs were entered into Nutribase Clinical Nutrition Manager 7.17 (CyberSoft, 
Inc., Phoenix, AZ) for nutritional analysis. Diets were not standardized, as each subject 
served as his or her own control. All subjects complied with the diet and exercise 
requirements. 
 
Blood sampling and analyses.  Blood sampling occurred at 6 time points during the 
protocol as shown in Figure 4.1. Saline flushes occurred every 10-15 min during the 
entire protocol to keep the catheter patent. Each 6 ml blood sample was mixed with 0.5 
ml of EDTA (24 mg/mL, pH 7.4), and 0.3 ml of the anticoagulated blood was transferred 
to another tube containing 0.6 ml 10% perchloric acid (PCA). All tubes were centrifuged 
at 4˚ C for 10 min at 3,000 rpm with a HS-4 rotor in a Sorvall RC6 centrifuge (Kendro 
Laboratory Products, Newtown, CT). After centrifugation, plasma and PCA extracts were 
separated into aliquots for each assay and immediately frozen and stored at -80˚ C for 
later analysis. For all assays, all samples were run in duplicate. Plasma glucose was 
measured using a spectophotometric Trinder reaction (no. 315, Sigma Chemical, St. 
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Louis, MO), and had a coefficient of variation (CV) of 3.7%. Plasma insulin was 
measured using ImmuChemTM Coated Tube 125I  RIA  Kit (MP Biomedicals, LLC, 
Orangeburg, NY) by radioimmunoassay with a CV of 6.0%. Blood lactate was 
determined from the PCA extract by enzymatic-spectophotometric analysis method based 
on the oxidation of lactate to pyruvate by nicotinamide adenine dicnucleotide (NAD+). 
(18), and had a CV of 1.5%. Plasma free fatty acids (FFA) were measured using the 
colorimetric assay procedure of Duncombe (13) but modified by using the extraction 
reagent of Noma et al. (35) and the copper reagent of Laurell and Tribbling (24). The CV 
for this assay was 5.3%. Plasma glycerol was measured from the PCA extract according 
to the protocol of Weiland (55). Plasma myoglobin concentrations were determined by 
solid phase ELISA (BioCheck, Inc., Foster City, CA), with a CV of 5.4%. Plasma CPK 
was determined spectrophotometrically using the Creatine Kinase Reagent Kit (Pointe 
Scientific, Inc., Canton, MI). The CV for this assay was 1.0%. Plasma cortisol was 
measured using ImmuChemTM Coated Tube 125I  RIA  Kit (MP Biomedicals, LLC, 
Orangeburg, NY) by radioimmunoassay. The CV for this assay was 6.1%. Total plasma 
concentrations of interleukin-1 receptor antagonist (IL-1Ra), interleukin-6 (IL-6), 
interleukin-8 (IL-8), interleukin-10 (IL-10), and tumor necrosis factor alpha (TNF) were 
determined using Millipore High Sensitivity Multiplex Human Cytokine Assay kits 
(Millipore, Billerica, MA) with a Bio-Plex 200 multiplex suspension array system with 
Luminex xMAP detection technology (Luminex Corp., Austin, TX).  
 
Substrate oxidation. Substrate utilization during the recovery period was estimated from 
the periodic measurements of RER, VCO2 and VO2 (min 30-40, 90-100, 150-160 and 
210-220 of the recovery period, as shown in Figure 4.1). Fat and carbohydrate oxidation 
rates were calculated from the VCO2 and VO2 values using the equation of Frayn (15). 
Energy expenditure (kcal·min-1) from carbohydrate and fat was calculated from the 
oxidation rates by applying the Atwater general conversion factors for CHO and fat (2). 
Results are shown in Table 4.4. 
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Heart rate and RPE. Heart rate was recorded using Polar heart rate monitors at the 
beginning of each exercise bout, and every 30 min during exercise, as well as every 30 
min during the recovery phase. Subjective RPE ratings on a Borg-scale (ranging from 6 
to 20) were obtained during exercise at the same time points as heart rate during exercise 
bouts.  
 
Muscle biopsy procedure.  Prior to each biopsy, the subject’s thigh was cleansed with 
10% betadine solution and 1.4 mL of  1% Lidocaine Hydrochloride (Elkins-Sinn, Inc., 
Cherry Hill, NJ) was injected. The first biopsy of each trial (R0) was taken from the 
vastus lateralis through a 5-8 mm incision made through the skin and fascia, 6 inches 
from the midline of the thigh on the lateral side and 2.5 inches above the patella. The 
second biopsy (R45) was taken from the same incision as the R0 sample. A new incision 
was made for the third biopsy (R End), one inch above the previous incision. The same 
leg was used for the first and third experimental trials, with the other leg biopsied in the 
second trial. The incisions for the third trial were made one inch above and proximal to 
the incisions from the first trial. Approximately ~45-60 mg wet wt of tissue was taken 
during each biopsy. The tissue samples were trimmed of adipose and connective tissue 
and immediately frozen in liquid nitrogen at -80o C for subsequent analysis. 
 
Muscle tissue processing.  The muscle samples were weighed and homogenized in ice-
cold buffer containing 20 mM Hepes, 2 mM EGTA, 50 mM sodium fluoride, 100 mM 
potassium chloride, 0.2 mM EDTA, 50 mM glycerophosphate, 1 mM DTT, 0.1 mM 
PMST, 1 mM benzamidine, and 0.5 mM sodium vanadate (pH 7.4) at a dilution of 1:100. 
Homogenization was performed on ice using Caframo RZRl Stirrer (Caframo Limited, 
Warton, Ontario, Canada). Half of the homogenate was used immediately for the 
determination of muscle glycogen concentration. The other half of the homogenate was 
immediately centrifuged at 14,000 g for 10 min at 4°C and the supernatant aliquoted to 
several test tubes and stored at -80°C for later signaling protein analysis. Phosphorylation 
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of mTOR, rpS6, eIF2B, and FOXO3A, total ubiquitination, and total tubulin was 
determined by Western blotting. 
 
Muscle glycogen analysis.  Muscle glycogen concentrations were determined from the 
freshly homogenized muscle samples after the complete enzymatic degradation from 
glycogen to glucose with amyloglucosidase (37). Liberated glucose was then measured 
using a spectophotometric Trinder reaction (no. 315, Sigma Chemical, St. Louis, MO).  
Muscle intracellular signaling protein analyses.  Using the supernatant aliquoted for 
use in signaling protein analysis, protein concentration was determined using a modified 
Lowry Assay (29). Aliquots of homogenized muscle sample supernatants and standards 
were slowly thawed over ice and diluted 1:1 with sample buffer containing 1.25M Tris, 
pH 6.8, glycerol, 20% SDS, 2-mercaptoethanol, 0.25% bromophenol blue solution, and 
deionized water. 3 gels were electrophoresed for each subject’s 9 samples: one for 
detection of p-mTOR and p-FOXO3A, one for p-eIF2B and p-rpS6, and one for 
ubiquitination. Total -tubulin, measured as a housekeeping protein, was also detected on 
each gel.  
Samples containing 60 g of total protein were separated on 10% polyacrylamide gels 
SDS-PAGE for 48 min (eIF2B and rpS6), 104 min (mTOR and FOXO3A), or 45 min 
(ubiquitnation) at 200 V (Bio-Rad Laboratories, Hercules, CA.) After electrophoresis, the 
gels were electrotransferred using 25 V for 15 min (eIF2B, rpS6 and ubiquitination) or 
22 min (mTOR and FOXO3A) to 0.4 m polyvinylidine fluoride (PVDF) membranes 
(Millipore, Bedford, MA). The membranes were blocked in TTBS (TBS, 50 mM Tris, 
150 mM NaCl, containing 0.06% Tween-20), and 6% nonfat dry milk (or 5% BSA in the 
case of eIF2B) for 1 h at room temperature on a rocking platform at medium speed. The 
membranes were then washed in 1x TTBS 3 times for 5 min each wash. Using the 
molecular weight markers visible on the membranes in three lanes as a guide, the 
membrane for mTOR (~289 kD), FOXO3A (~97 kD), and a-tubulin (~55 kD) was cut 
into three sections at the 150 and 75 kD markers. The membranes for eIF2B (~82 kD), 
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rpS6 (~32 kD), and a-tubulin (~55 kD) were cut into 3 sections at the 75 and 50 kD 
markers. The membrane for ubiquitination was not cut. (After probing for ubiquitination, 
the membrane section was stripped, reblocked in 6% NFDM-TTBS, and reprobed for -
tubulin).   
Each membrane or section of membrane was incubated overnight at 4°C on a rocking 
platform at low speed with antibodies directed against p-mTOR (Ser2448, no. 2971S, 
Cell Signaling, Danvers, MA), p-rpS6 (Ser235/236, no. 9205S, Cell Signaling, Danvers, 
MA.), p-eIF2B (Ser539, no. PS1017, EMD Calbiotech/Merck KGaA, Darmstadt, 
Germany), p-FOXO3A (Ser318/321, no. 9465, Cell Signaling, Danvers, MA), ubiquitin 
(no. 9133, Santa Cruz Biotechnology, Santa Cruz, CA,) and -tubulin (no. 2144, Cell 
Signaling, Danvers, MA). The antibodies were diluted 1:800 (mTOR), 1:900 (-tubulin), 
1:500 (FOXO3A and ubiquitin), and 1:1000 (rpS6 and eIF2B ) in TTBS containing 2% 
nonfat dry milk for mTOR, -tubulin, and ubiquitin; for FOXO3A and eIF2B, primary 
incubation was done in TTBS with 5% and 1% BSA (no. 105033, ICN Biochemicals, 
Costa Mesa, CA), respectively. Following the overnight incubation, membranes were 
washed 3 times with TTBS for 5 min each wash and incubated for 1.5 h for mTOR, 
eIF2B and FOXO3A, and 2 h for -tubulin and ubiquitin) with a secondary antibody 
(goat anti-rabbit, HRP-linked IgG, no. 7074, Cell Signaling, Danvers, MA). Dilutions 
were 1:800 (mTOR), 1:1000 (-tubulin), 1:1500 (FOXO3A), and 1:2000 (rpS6) in TTBS 
containing 2% nonfat dry milk. For eIF2Bsecondary incubation was in TTBS with 1% 
BSA  (no. 105033, ICN Biochemicals, Costa Mesa, CA.) at a dilution of 1:3000. The 
antibody-bound proteins on the immunoblots were visualized by enhanced 
chemiluminescence according to the manufacturer’s protocol (Perkin Elmer, Boston, 
MA) using a Bio-Rad ChemiDoc detection system, and the mean density of each band 
was quantified using Quantity One 1-D Analysis software (Bio-Rad Laboratories, 
Hercules, CA.).  A molecular weight ladder (Precision Plus Protein Standard, Bio-Rad) 
and a rodent internal control standard prepared from insulin-stimulated mixed skeletal 
muscle were also included on each gel. All blots were compared with the rodent control 
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standard and the values of each sample were represented as a percent of standard for each 
blot. 
 
Statistical analyses. Plasma insulin, glucose, lactate, myoglobin, CPK, FFA, glycerol, 
cortisol, and cytokines were analyzed using two-way (treatment x time) analysis of 
variance (ANOVA) for repeated measures. Time trial measures (TT time, average power 
output, average heart rate, and average RPE) were analyzed using one-way ANOVA for 
repeated measures. Differences in muscle glycogen resynthesis from R0 to R45, R45 to R 
End and Total resynthesis (R0 to R End) was analyzed using a two-way (treatment x 
time) ANOVA for repeated measures. Signaling protein phosphorylation or content was 
analyzed using two-way ANOVAs for repeated measures (treatment x time and time x 
treatment). Substrate oxidation and energy expenditure during the recovery period were 
analyzed using two-way (treatment x time) ANOVA for repeated measures. For all 
measures, post hoc analysis was performed when significance was found using Least 
Significant Difference (LSD). Differences were considered significant at P<0.05. Data 
were expressed as mean  SE. All statistical analyses were performed using SPSS version 
16.0 statistical software (SPSS Inc., Chicago, IL). 
RESULTS 
 
Time trial performance. Time trial time (TTT) is shown in Figure 4.2A. TTT was 
significantly shorter in CM compared to both CHO and PLA (P<0.05). Average power 
output (Watts) was significantly higher in CM compared to both CHO and PLA (Figure 
4.2B; P <0.05). Heart rate during the TT was significantly higher in CM than in CHO or 
PLA (162.8 ± 5.6 vs 145.9 ± 7.4 and 148.9 ± 7.1, respectively, P <0.05), while RPE was 
not significantly different between the 3 treatments (14.5 ± 0.5 vs 14.0 ± 0.5 and 14.0 ± 
0.5, respectively, P <0.05). 
 
Muscle glycogen. Muscle glycogen resynthesis values are shown in Figure 4.3. Total 
muscle glycogen resynthesis over the 4 h recovery period was significantly greater in 
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both the CM and CHO treatments than PLA (23.58 and 30.58 mol/g wet wt, 
respectively, vs 7.05 mol/g wet wt, P <0.05). CHO was not significantly different from 
CM, although significance was approached (P = 0.06). 
 
Blood and plasma analyses. A significant treatment effect existed for plasma glucose in 
CHO compared to CM and PLA, and in CM compared to PLA (Figure 4.4A; P <0.05). 
At R45, plasma glucose in CHO was significantly higher than CM and PLA, and CM was 
significantly higher than PLA (P <0.05). At R120, both CHO and CM were higher than 
PLA (P <0.05), with no significant differences between CHO and CM. At R End and TT 
End, no differences existed between the 3 treatments (Figure 4.4A). Plasma insulin 
(Figure 4.4B) was also significantly higher in the CHO treatment compared to CM and 
PLA, and CM compared to PLA (P <0.05). Both CHO and CM were significantly higher 
than PLA at R45 (P <0.05).  At R120 and R End, plasma insulin levels in CM had 
decreased to near baseline levels but were still significantly higher than PLA (P <0.05). 
However, plasma insulin in CHO was significantly higher at R120 and R End than CM 
and PLA. At TT End, no treatment differences were detected (Figure 4.4B; P <0.05).  
 
A significant overall treatment effect for blood lactate was observed between CM and 
PLA (P <0.05). As shown in Figure 4.5, blood lactate levels rose significantly during the 
first exercise bout (Pre to R0) in all treatment groups (P <0.05), although a slight but 
significantly lower blood lactate level was found in the PLA treatment at R0 and R45 
compared to CM (P <0.05). No differences existed between the 3 treatments at R120 and 
R End. At TT End, blood lactate was significantly higher in CM and CHO than PLA (P 
<0.05). For both plasma glycerol and free fatty acids (FFAs), significant treatment effects 
were found in PLA compared to CHO and CM (P <0.05), and between CM and CHO 
(Figure 4.6A and B; P <0.05). At R45, plasma glycerol was significantly higher in PLA 
than CM only, and FFAs were significantly higher in PLA than both CM and CHO (P 
<0.05). At R120 and R End, plasma glycerol and FFAs were significantly higher in PLA 
than CHO and CM, and in CM compared to CHO (P <0.05). At TT End, plasma glycerol 
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in CHO was significantly lower than CM and PLA (P <0.05), and plasma FFAs were 
higher in PLA compared to both CHO and CM at TT End (P <0.05), suggesting that 
more fat was available to be used as fuel in the PLA and CM treatments compared to 
CHO.  
 
 As is shown in Table 4.3, plasma myoglobin, CPK, cortisol, and cytokines IL-6, IL-8, 
IL-1Ra, and TNF rose significantly over time in all treatments (P <0.05), with no 
significant differences found between the treatments. The increase in all of these analytes 
from Pre to R0, as well as in blood lactate, indicate that the subjects were cycling at a 
high intensity during the initial bout. All decreased from the R0 values during the 4-h 
recovery period, and increased at TT End, with no significant treatment differences 
detected.  
 
Intracellular signaling proteins. Significant differences in mTOR phosphorylation are 
shown in Figure 4.7. A significant overall treatment difference was found for mTOR 
phosphorylation between CM and PLA (P<0.05). No difference in phosphorylation status 
of mTOR was detected between treatments at R0. However, at 45 min of recovery (R45), 
mTOR phosphorylation was significantly greater in the CM treatment compared to the 
CHO and PLA treatments (Figure 4.7). At the end of recovery (R End), phosphorylation 
was greater in CM compared to PLA (P<0.05). At R45, phosphorylation in both CM and 
CHO was significantly greater than at R0 for the respective treatments, and at R End, this 
elevated phosphorylation status persisted only in CM (Figure 4.7; P<0.05).   
 
The phosphorylation pattern of rpS6 (Figure 4.8) was similar to that of mTOR, with a 
significant overall treatment difference between CM vs CHO and PLA (P<0.05). At R0, 
no differences in rpS6 phosphorylation were detected between treatments. At R45, 
phosphorylation of rpS6 was increased significantly, with the increase in CM 
significantly greater than CHO and PLA (P<0.05). At R End, phosphorylation in CM 
remained elevated compared to the R0 value, and was significantly greater than CHO and 
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PLA (P<0.05), while phosphorylation in CHO and PLA had returned to levels that were 
not significantly greater than their respective R0 values (Figure 4.8). 
 
FOXO3A phosphorylation is shown in Figure 4.9. A significant overall treatment 
difference existed for FOXO3A phosphorylation between CHO and PLA (P<0.05). At 
R0, no differences in FOXO3A phosphorylation existed between treatments. At R45, 
FOXO3A phosphorylation was significantly greater in CHO and CM compared to PLA, 
as well as compared to the respective R0 levels (all P<0.05). By R End, phosphorylation 
remained elevated only in CHO compared to CM and PLA, and compared to the R0 level 
(Figure 4.9, P<0.05).  
 
No differences were detected for p-eIF2B (Figure 4.10), total ubiquitination (Figure 
4.11A), or percent change in ubiquitination (Figure 4.11B) for treatment, time or 
treatment x time interactions. 
 
Substrate utilization during recovery. Carbohydrate and fat energy expenditure, and 
carbohydrate and fat oxidation rates during the recovery period are shown in Table 4.4. 
Average carbohydrate energy expenditure (kcal·min-1) and carbohydrate oxidation 
(g.min-1) was significantly lower in PLA than CM or CHO (P<0.05). Average fat energy 
expenditure (kcal·min-1) and fat oxidation (g.min-1) was significantly lower in the CHO 
treatment than CM or PLA (both P<0.05). 
DISCUSSION 
 
The present study aimed to characterize the roles of an initial bout of strenuous exercise 
and nutritional supplementation on subsequent exercise performance and key aspects of 
exercise recovery, namely muscle glycogen resynthesis, markers of muscle damage and 
inflammation, and activation states of intramuscular signaling proteins involved in 
protein synthesis and degradation. The key finding of the present study is that a popular 
dairy beverage containing both carbohydrate and protein (low fat chocolate milk, CM), 
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was more effective in improving cycling time trial performance in a subsequent bout 
compared to an isocaloric carbohydrate or a placebo supplement. This performance 
improvement occurred despite there being no increase in the subjective ratings of 
perceived exertion (RPE), suggesting that they did not perceive their effort as more 
difficult although they were able to exercise at a higher intensity with the CM treatment 
compared to CHO and PLA. Furthermore, we report here that CM increased the 
activation status of signaling proteins associated with increased mRNA translation and 
protein synthesis compared to placebo. These findings are novel because the recovery 
supplement used in comparison to CHO and placebo is a commonly available, organic 
dairy beverage, CM, rather than a CHO+PRO supplement commercially designed for 
exercise recovery. In addition, the present investigation examines many aspects of the 
recovery process with the aim of addressing possible mechanisms of improved recovery 
and performance.  
 
The finding of improved subsequent performance is in agreement with several other 
studies that reported improved endurance performance in a subsequent bout when 
ingesting a CHO+PRO supplement compared to CHO alone (3, 10, 34, 45, 56), as well as 
with those of investigations comparing CM to other CHO+PRO supplements (39) and to 
both CHO+PRO and CHO only supplements (49). However, not all investigations report 
improvements in subsequent performance with CHO+PRO supplementation compared to 
CHO (7, 8, 42-44). Differences in protocol design may lead to the inconsistent findings 
across investigations of CHO+PRO (including CM) supplementation. In some studies, 
supplements were given during the initial exercise bout (7,8) or both during and post-
exercise (45), while in the present study and others, the supplements were given 
immediately post-exercise and again during the recovery period (34, 56). The timing of 
the subsequent exercise trials also varied between studies, including ~15 h later (45, 39), 
22-24 h later (7, 8, 42-44, 36) 1 and 2 days following the initial bout (44) or following a 
3-4 h recovery, as in the current study (39, 49, 56). Differences also exist for the type of 
exercise trial employed to assess subsequent performance and recovery: time trial time 
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(7, 8), time to exhaustion (36, 42, 43, 45), or repeated sprint performance (44). Therefore, 
these and other methodological differences must be considered when interpreting results 
of CHO+PRO vs CHO investigations.  
 
One proposed mechanism for improved performance following recovery with CHO+PRO 
supplementation is increased muscle glycogen resynthesis during the recovery period. 
Several investigations have shown that CHO+PRO supplementation can increase the rate 
of muscle glycogen synthesis beyond that of CHO alone (4, 21, 51, 56, 58), and therefore 
may contribute to improved exercise performance in a subsequent bout. In the present 
study, we did not find a significant difference between CM and CHO in muscle glycogen 
resynthesis, although both were significantly greater than PLA. However, only in the CM 
treatment was TT performance significantly improved compared to CHO and PLA. 
Interestingly, although CHO demonstrated a slight, non-significantly higher (P<0.06) 
total muscle glycogen resynthesis compared to CM, this did not result in improved TT 
performance in CHO compared to PLA. Therefore, the data suggest that muscle glycogen 
synthesis is not the mechanism through which subsequent performance was improved in 
the current study. Possible reasons for the lack of a relationship between TT performance 
and muscle glycogen resynthesis are that muscle and liver glycogen levels were perhaps 
not sufficiently depleted in the initial bout, and the length of the subsequent bout (40 km) 
may not have been long enough for muscle glycogen to be a rate-limiting factor in 
performance. 
 
The lack of a significant difference in muscle glycogen resynthesis between CM and 
CHO may be due to the observed difference in the insulin response. Although we found a 
lower plasma insulin response with CM compared to CHO in the current study, previous 
investigations have shown higher insulin responses with CHO+PRO compared to CHO 
(47, 56, 58). However, most prior investigations of CHO+PRO supplementation have 
used a whey protein-containing CHO+PRO beverage rather than CM. It is likely that the 
different osmolarity and gastric emptying rate of CM compared to CHO could have 
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slowed the intestinal transport of carbohydrates and amino acids, resulting in a lower 
plasma glucose and insulin response, as well as their subsequent availability to the 
muscle, in CM compared to CHO. This likely explains the lack of a significant difference 
in muscle glycogen resynthesis between these two nutrient-containing treatments. In 
addition, CM contains many micronutrients that may not be found in other CHO+PRO 
supplements, and the effects of these components on the measures investigated here are 
unknown at this time.  
 
Another proposed mechanism for subsequent performance improvement with a 
CHO+PRO-containing supplement is muscle damage attenuation. Saunders and 
colleagues (45) demonstrated that CHO+PRO supplementation improved recovery from 
an initial strenuous exercise bout such that subsequent exercise performance was 
improved, and noted that muscle damage marker creatine phosphokinase (CPK) was 
suppressed in the CHO+PRO treatment. In the current study, however, this association 
between improved subsequent performance and reduced muscle damage indicators 
myoglobin and CPK was not demonstrated. In addition, we did not detect treatment 
differences in any of the pro- or anti-inflammatory cytokines (Table 4.3). Taken together, 
our findings suggest that neither reduced muscle damage nor a reduced inflammatory 
response during the recovery period underlies the subsequent performance differences 4 h 
later.  
 
In addition to plasma markers of muscle damage and inflammation, we assessed two 
proteins in the skeletal muscle samples that regulate protein degradation—FOXO3A and 
ubiquitin. Protein degradation involves the Ubiquitin-Proteasome Pathway (UPP), the 
primary degradation system for skeletal muscle (25, 48). A key component of the UPP is 
ubiquitin itself. This highly conserved, 8.5 kD protein covalently binds to abnormal or 
damaged proteins, targeting them to be degraded by the 26S proteasome (9, 17). 
Recently, a few investigations have used total ubiquitin content of Western blot samples 
as an indicator of protein degradation, demonstrating an increase in total ubiquitination in 
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conditions of high proteolysis (14, 38). This method was employed in the current study to 
assess total ubiquitination in the biopsy samples during the recovery period, and despite a 
trend for slightly increased ubiquitination in the CHO treatment, there was not a 
statistically significant difference in treatment or in time between the three treatments 
(Figure 4.11). 
 
Key apoptotic genes in the UPP share a common critical transcription factor, forkhead 
box 3A (FOXO3A). When the insulin signaling pathway is activated, Akt is 
phosphorylated, translocates into the nucleus, and phosphorylates FOXO3A on serine 
residues including 253, 318 and 321, which causes the nuclear export of FOXO3A into 
the cytoplasm (19, 33, 46). Thus, FOXO3A is deactivated and prevented from promoting 
apoptosis. A few studies have verified a role for FOXO3A in proteolysis following 
resistance exercise (26, 28, 41, 57), and running exercise (28). In the present study, we 
hypothesized that we would detect greater FOXO3A phosphorylation in the CM 
treatment compared to CHO and PLA. FOXO3A phosphorylation increased significantly 
from R0 to R45 in both CM and CHO (Figure 4.10, P<0.05), and while phosphorylation 
in both CM and CHO was significantly greater than in PLA, no difference was found 
between CM and CHO. At R End, FOXO3A phosphorylation remained elevated from R0 
only in CHO, and was significantly greater compared to PLA. Since FOXO3A is 
activated through the insulin signaling pathway, the increased phosphorylation of 
FOXO3A at R45 in CHO and CM and at R End in CHO likely demonstrates the effect of 
insulin. Since the insulin response in CHO at R End was higher than in CM or PLA, it 
appears that this was responsible for the greater FOXO3A phosphorylation at R End in 
CHO compared to PLA. However, it also appears that the small increase in 
phosphorylation in FOXO3A was not sufficient to limit protein degradation in the CM 




Our finding that degradation signaling was not significantly reduced with 
supplementation in the present study is supported by the lack of reductions in the plasma 
muscle damage and inflammatory markers. Given that the CM and CHO treatments did 
not appear to block the processes of muscle damage and degradation, it may be that 
providing supplementation after the initial exercise bout, rather than both during and 
post-exercise as has been done previously (45), minimized the effect of supplementation 
in these areas. Therefore, these data suggest that while attenuation of muscle damage or 
decreased protein degradation during recovery from strenuous exercise may occur in 
response to CHO+PRO/CM supplementation, these are not the mechanisms by which TT 
performance was improved in the current study.  
 
Activation of protein synthesis is an important metabolic response in the recovery 
process, and is paramount for muscle tissue repair and training adaptation. As mentioned 
previously, the balance between protein degradation and synthesis post-exercise is 
mediated in part by the availability of nutrients, most importantly, the availability of 
AAs.  AA infusion or ingestion has been shown to stimulate muscle protein synthesis 
both at rest (5, 13) and after resistance exercise (6, 50), as has the combination of 
essential AA and CHO following resistance exercise (11, 40). There is increasing 
evidence that the combined ingestion of CHO and either protein or AA post-exercise can 
have an additive effect on protein synthesis (27, 31).  This is likely due in part to the 
synergistic effect of CHO/AA or CHO+PRO supplementation on the plasma insulin 
response (47, 58), and the maintenance of an elevated plasma AA profile. This may lead 
to a greater activation of translation initiation. As the rate-limiting step in mRNA 
translation, translation initiation is regulated in part by the mTOR pathway. mTOR 
phosphorylates two downstream targets, including p70S6K (30). p70S6K then 
phosphorylates ribosomal protein S6 (rpS6), which enhances translation of a class of 
mRNAs that encode ribosomal proteins, elongation factors, and binding proteins (23). 
This results in an increase in the capacity of the cell to synthesize protein. The eukaryotic 
initiation factor 2B (eIF2B) also plays a key role in translation initiation. eIF2B catalyzes 
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the GDP/GTP exchange on eIF2, which is essential for control of ribosomal formation 
and mRNA translation (22). eIF2B is the largest catalytic subunit of this protein and is 
phosphorylated by GSK-3 at Ser 539 (53), which inhibits the guanine nucleotide 
exchange activity of eIF2B. Phosphorylation of GSK-3 via the insulin signaling 
pathway inhibits GSK-3, releasing its inhibition of eIF2B.  
 
In the present study, mTOR phosphorylation increased significantly from R0 to R45 only 
in CM and CHO, and mTOR phosphorylation in CM was significantly greater than in 
CHO or PLA. At R End, mTOR phosphorylation in both CM and CHO was still 
significantly greater than in PLA, which remained unchanged throughout recovery. Only 
in CM was mTOR phosphorylation still significantly elevated compared to R0. rpS6 
phosphorylation increased from R0 to R45 in all treatments, but only CM was 
significantly higher than PLA. At R End, rpS6 phosphorylation in CM remained elevated 
compared to R0, and the treatment difference between CM and PLA remained 
significant. The increased phosphorylation of mTOR and rpS6 in CM compared to CHO 
and PLA at R45 is likely due to the combined effects of AA and insulin, while the 
increase in CHO over PLA is likely due to the effect of insulin.  
 
Based on previous results from our laboratory that demonstrated significantly increased 
phosphorylation of GSK-3 with CHO+PRO supplementation post-endurance exercise 
compared to exercise only (20), we hypothesized that we would demonstrate reduced 
phosphorylation of eIF2B, a downstream target of GSK-3, with the CM treatment 
compared to CHO and PLA. However, we did not detect a significant difference in 
treatment or time for eIF2B phosphorylation in the present study. This finding is 
supported by that of Glover and colleagues (16), who found that while eIF2B 
phosphorylation was significantly decreased by a strenuous resistance exercise bout 
compared to a baseline measure, post-exercise supplementation containing CHO, PRO 
and fat had no additional effect during a 6-h recovery (16). Despite demonstrating 
increased activation of some of the key components of the mTOR pathway in the present 
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study, it may be that eIF2B phosphorylation may not be responsive to nutrient 
intervention, since eIF2B can be activated independent of the mTOR pathway (54). 
Therefore, it is possible that the effects of exercise alone are sufficient for activation of 
this enzyme, as demonstrated by Glover and colleagues (16).  
 
The greater phosphorylation status of many of the key proteins involved in mRNA 
translation initiation and protein synthesis in the present investigation is in agreement 
with previous findings from our laboratory. Recently, Ivy and colleagues (20) 
investigated the effects of a CHO+PRO supplement compared to placebo on intracellular 
signaling proteins involved in increased protein and glycogen synthesis. Trained cyclists 
cycled at 75% VO2max for 45 min, followed by 5 one-min sprints alternating between 
90% and 45% VO2max. Immediately post-exercise and again 15 min later, subjects 
ingested 400 ml of a CHO+PRO beverages (7.8% dextrose and 1.8% protein-electrolyte) 
or placebo. Biopsies of the vastus lateralis were taken before exercise and at 45 min of 
recovery. At 45 min, phosphorylation of mTOR and rpS6 were increased above pre-
exercise levels in the CHO+PRO treatment compared to placebo (20). The results of the 
present study extend these previous findings by comparing a CHO+PRO supplement, 
CM, to an isocaloric CHO as well as to placebo. Taken together, these results suggest that 
while providing nutritional supplementation post-exercise is more effective in increasing 
the stimulus for protein synthesis and reducing protein degradation than when post-
exercise nutritional intake is absent, a CHO+PRO-containing supplement such as CM is 
more effective overall than CHO alone in promoting an anabolic intracellular 
environment post-exercise. 
 
In conclusion, CM is more effective than isocaloric carbohydrate or placebo in improving 
subsequent time trial performance. CM is also more effective in modulating the 
activation of key intracellular signaling proteins involved in protein synthesis during 
recovery from endurance exercise. This greater stimulus for protein synthesis, in addition 
to the possible attenuation of muscle protein degradation and faster tissue repair, during 
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recovery may be advantageous under conditions when rapid recovery between race 
events or training sessions is necessary. CM supplementation may also lead to increased 
training adaptations over time if the exercise and supplementation is performed on a 
regular basis. More research is necessary to determine the effects of CM in other models 
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Table 4.1. Subject characteristics  
 
 Mean (10) Males (5) Females (5) 
Age (y) 31.8 ± 1.6 32.2 ± 2.4 31.4 ± 2.5 
Mass (kg) 67.8 ± 2.6 72.5 ± 3.1 63.1 ± 3.2 
Height (cm) 171.1 ± 3.4 176.8 ± 3.1 165.4 ± 5.1 
VO2max  (L·min-1) 3.6 ± 0.2 4.2 ± 0.2 3.0 ± 0.1 
VO2max  (ml·kg·min-1) 52.6 ± 2.3 57.7 ± 2.8 47.6 ± 1.5 




 CM CHO PLA 
CHO, g/100 ml 11.48 15.15 0 
PRO, g/100 ml 3.67 0 0 
Fat, g/100 ml 2.05 2.05 0 
kcals/100 ml 79.05 79.05 0 
Ratio of CHO:PRO 3.12:1 -- -- 
Per 100 ml. CM, chocolate milk; CHO, carbohydrate + fat; PLA, placebo.  
 





 Pre R0 R45 R120 R End TT End 
Myoglobin (nmol/L)       
   CM 1.26 ± 0.11 1.44 ± 0.06 2.16 ± 0.32 -- 1.53 ± 0.16 1.87 ± 0.14 
g 
   CHO 1.26 ± 0.12 1.45 ± 0.11 2.01 ± 0.36 -- 1.91 ± 0.35 2.16 ± 0.32 g 
   PLA 1.35 ± 0.13 1.68 ± 0.20 2.37 ± 0.42 -- 1.73 ± 0.10 1.99 ± 0.21 g 
CPK (U/L)       
   CM 125.80 ± 27.42 157.97 ± 38.30 -- 146.69 ± 46.22 161.85 ± 45.96 206.03 ± 64.97 g 
   CHO 94.56 ± 22.85 114.34 ± 25.81 -- 107.50 ± 23.20 124.78 ± 35.97 167.19 ± 35.53 g 
   PLA 179.25 ± 76.91 207.82 ± 86.59 -- 178.79 ± 62.46 207.69 ± 69.82 240.39 ± 69.75 g 
Cortisol (pmol/L)       
   CM 729.1 ± 96.7 837.4 ± 62.1 595.3 ± 61.0 433.9 ± 69.7 382.8 ± 57.5 902.1 ± 69.1
 g 
   CHO 698.9 ± 70.0 787.4 ± 119.7 668.4 ± 82.8 539.2 ± 80.1 414.7 ± 53.9 1154.8 ± 143.0
 g 
   PLA 720.2 ± 84.2 894.5 ± 133.3 606.3 ± 73.0 491.9 ± 75.4 370.0 ± 44.8 874.7 ± 103.3
 g 
IL-6 (pg/mL)       
   CM 38.48 ± 17.01 62.18 ± 21.29 40.24 ± 15.95 57.32 ± 18.38 47.16 ± 15.24 97.39 ± 33.02 g 
   CHO 55.00 ± 20.14 93.01 ± 38.17 58.49 ± 19.23 79.93 ± 23.39 67.01 ± 19.53 97.16 ± 38.56 g 
   PLA 60.17 ± 31.19 109.79 ± 52.59 85.01 ± 38.69 81.86 ± 22.47 81.00 ± 27.10 139.72 ± 57.34 g 
IL-8 (pg/mL)       
   CM 24.51 ± 4.73 38.38 ± 8.26 28.69 ± 5.35 30.35 ± 5.84 26.69 ± 5.21 39.02 ± 8.63 g 
   CHO 29.12 ± 7.18 42.22 ± 9.86 31.65 ± 7.31 29.50 ± 6.32 24.97 ± 5.29 40.82 ± 7.37 g 
   PLA 29.16 ± 6.79 41.68 ± 9.90 37.64 ± 9.04 34.76 ± 8.34 34.21 ± 8.53 40.52 ± 17.14 g 
IL-10 (pg/mL)       
   CM 133.78 ± 87.28 213.63 ± 114.98 174.48 ± 99.87 157.20 ± 78.88 140.04 ± 71.90 286.63 ± 135.93 
   CHO 124.18 ± 59.86 258.56 ± 130.82 225.11 ± 116.35 237.41 ± 119.95 187.66 ± 86.92 219.92 ± 92.27 
   PLA 162.30 ± 101.89 264.18 ± 159.08 188.65 ± 88.52 229.49 ± 115.90 206.59 ± 111.96 367.82 ± 210.10 
IL-1Ra (pg/mL)       
   CM 67.45 ± 8.64 86.19 ± 10.07 67.21 ± 7.16 45.38 ± 11.17 55.27 ± 9.40 54.31 ± 9.74 g 
   CHO 69.83 ± 12.84 78.54 ± 10.49 66.38 ± 8.76 36.32 ± 6.41 47.97 ± 8.72 56.33  ± 7.07 g 
   PLA 65.31 ± 7.60 79.11 ± 6.55 59.52 ± 9.09 49.93 ± 6.29 63.66 ± 7.54 58.15 ± 8.90 g 
TNF(pg/mL)       
   CM 8.21 ± 1.86 9.23 ± 1.64 6.22 ± 1.16 5.10 ± 1.07 6.43 ± 1.43 6.95 ± 1.83 g 
   CHO 9.51 ± 2.81 9.45 ± 1.83 5.82 ± 0.77 5.20 ± 0.88 5.12 ± 1.19 6.48 ± 1.36 g 
   PLA 8.15 ± 1.65 9.12 ± 1.95 7.13 ± 1.46 5.51 ± 1.22 6.62 ± 1.57 6.76 ± 1.22 g 
Values are mean ± SE.  gSignificant change over time only, P<0.05. 
 
 
Table 4.3. Plasma markers of muscle damage and inflammation 
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 CM CHO PLA 
CHO oxidation (g.min-1) 0.159 ± 0.023 0.183 ± 0.028 0.079 ± 0.024 b 
Fat oxidation (g.min-1) 0.093 ± 0.009 0.066 ± 0.010 d 0.102 ± 0.010  
CHO EE (kcals.min-1) 0.669 ± 0.096 0.770 ± 0.119 0.332 ± 0.099 b 
Fat EE (kcals.min-1) 0.843 ± 0.078 0.599 ± 0.093 d 0.926 ± 0.090  
Average of 4 10-min gas collections (minutes 30, 90, 150 and 210) of recovery period. EE, energy 
expenditure. Values are mean ± SE. b PLA vs CM and CHO, P<0.05; d CHO vs CM and PLA, P<0.05 
 
 








Figure 4.2.  Time trial performance. A. Average time to complete a 40 km cycling time 
trial. B. Average Watts during time trial. Values are mean ± SE. Significant treatment 




Figure 4.3.  Muscle glycogen resynthesis during 4 h recovery. Biopsies were taken 
immediately (R0), 45 min (R45), and 4 h post-exercise (R End). Doses of supplement 
were provided immediately after the biopsy occurred at R0, and at 2 h into recovery. 
Resynthesis that occurred between R0 and R45 and R45 to R End are shown, as well as 
the total resynthesis over the 4 h period (R0 to R End). Values are mean ± SE. Significant 
treatment differences: b CM and CHO vs PLA (P<0.05).  
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Figure 4.4.  Plasma glucose and insulin. A. Plasma glucose measured at 6 time points 
throughout the exercise, recovery and time trial protocol. Significant treatment 
differences were found for CHO vs CM and PLA, and CM vs PLA (P<0.05). B. Plasma 
insulin measured at the same time points throughout the protocol. Significant treatment 
differences were found for CHO vs CM and PLA, and CM vs PLA (P<0.05). Values are 
mean ± SE. Significant treatment by time differences: b CM and CHO vs PLA; c CM vs 




Figure 4.5.  Blood lactate. Values are mean ± SE. Significant treatment differences were 
found for CM vs PLA (P<0.05). Significant treatment by time differences: b CM and 
CHO vs PLA; c CM vs PLA (P<0.05).   
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Figure 4.6.  Plasma glycerol (A) and plasma free fatty acids (B). Values are mean ± 
SE. Significant treatment differences were found for PLA vs CM and CHO, and CM vs 
CHO (P<0.05). Significant treatment by time differences: b CM and CHO vs PLA; d 







Figure 4.7.  mTOR phosphorylation (Ser2448). A significant overall treatment 
difference existed between CM and PLA (P<0.05). Significant treatment by time 
differences: b CM vs CHO and PLA; c CM vs PLA; f CM vs CHO; h within-treatment 






Figure 4.8.  rpS6 (Ser 235/236) phosphorylation. A significant overall treatment 
difference existed between CM vs CHO and PLA (P<0.05). Significant treatment by time 






Figure 4.9.  FOXO3A (Ser318/321) phosphorylation. A significant overall treatment 
difference existed between CHO and PLA (P<0.05). Significant treatment by time 
differences:  b CM and CHO vs PLA; e CHO vs PLA; h within-treatment significant 






Figure 4.10.  eIF2B (Ser539) phosphorylation. No significant treatment, time, or 








Figure 4.11.  Ubiquitination. No significant treatment, time, or treatment x time 
differences were found. A. Total ubiquitination of tissue samples during the recovery 
period. B. Percent change in total ubiquitination. C. Example of Western blot 




Chapter V: Aerobic Exercise Training Adaptations are Increased by Post-




Carbohydrate-protein supplementation post-endurance exercise has been proposed 
to improve aspects of acute exercise recovery beyond that of a carbohydrate supplement 
alone. Provided as a supplement post-resistance exercise, it has been found to increase 
the rate of training adaptation. The purpose of the present study was to compare the 
effects of a carbohydrate and protein supplement in the form of chocolate milk (CM), an 
isocaloric carbohydrate supplement (CHO), and placebo (PLA) on cardiovascular and 
intramuscular adaptations that occurred in response to a 4.5 week aerobic exercise 
training program in healthy, untrained subjects. Thirty-two untrained males and females 
cycled for 1 h/, 5 d/wk for 4.5 wks at 75-80% of maximal oxygen consumption 
(VO2max). Supplements were ingested immediately and 1 h after each session. VO2max 
and lactate threshold were assessed at baseline, the midpoint of training, and end of the 
training period. Muscle biopsies were performed at baseline, midpoint, and end of the 
training period to assess changes in citrate synthase and succinate dehydrogenase activity, 
as well as for total PGC-1 content. Improvements in VO2max were significantly greater 
in CM than CHO and PLA. Lactate threshold improved in all groups, with no differences 
found between treatments. Activity of citrate synthase and succinate dehydrogenase and 
total PGC-1 content increased in all groups over time with no significant differences 
between treatments. We conclude that improvements in VO2max occur faster when 
supplementing with CM as compared with CHO or placebo, and that this faster rate of 




 It is well established that aerobic endurance exercise training leads to cardiovascular, 
skeletal muscle and metabolic adaptations. Cardiovascular adaptations include increased 
stroke volume and cardiac output, which contributes greatly to increased maximal 
oxygen consumption (VO2max) (9, 31). Skeletal muscle adaptations include increased 
mitochondrial content and activity of oxidative enzymes such as citrate synthase and 
succinate dehydrogenase (4, 8, 10, 13-16, 30). While many investigations have 
addressed the effects of endurance exercise training on such adaptations, few have 
examined the role of post-exercise nutritional supplementation in facilitating the 
adaptive process.  
 
The beneficial effects of post-exercise supplementation in the form of carbohydrate 
(CHO) or carbohydrate-protein (CHO+PRO) supplements following an acute exercise 
bout has been the focus of many investigations. Several studies performed by our 
laboratory and others have demonstrated a greater improvement in acute exercise 
recovery with CHO+PRO supplementation compared to CHO alone (3, 24, 32, 38). 
Okazaki and colleagues (26) recently compared the effects of a CHO+PRO supplement 
to a placebo supplement in a model of chronic exercise training older male subjects who 
cycled for 60 min/d, 3 d/wk for 8 wk at 60-75% VO2peak. They reported a two-fold 
increase in VO2max in the CHO+PRO group compared to the placebo group (26). Thus, 
nutritional supplementation may increase the magnitude of training adaptations 
compared to the exercise stimulus alone. However, it was not possible to determine from 
their results if the increase in VO2max was due to cellular or systemic adaptations. 
Moreover, their experimental design did not allow for macronutrient specific 
comparisons, as they did not include a CHO-only supplement.  
 
Recently, chocolate milk (CM) has been investigated as a practical and effective 
carbohydrate and protein-containing supplement when ingested after an acute bout of 
strenuous endurance exercise. (5, 19, 29, 37). Therefore, the purpose of the present study 
was to investigate training adaptations that occurred after a 4.5 wk aerobic endurance 
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exercise (cycling) training program when supplementing after each daily exercise session 
with a CHO+PRO supplement in the form of CM, CHO or placebo. We aimed to 
determine if nutritional supplementation resulted in a greater increase in VO2max and 
skeletal muscle oxidative enzyme activity. Although the exercise training was expected to 
induce positive adaptations in VO2max and muscle oxidative capacity, we hypothesized 
that post-exercise CM supplementation would induce these adaptations faster than would 
occur with CHO or PLA supplementation. 
METHODS 
 
Subjects. Thirty-two healthy, recreationally active but untrained males and females (16 
males and 16 females) between 18 and 35 years old completed the study. Subject 
characteristics are listed in Table 5.1. In order to be classified as recreationally active but 
not endurance trained, subjects could not have exercised regularly more than 3 h/wk over 
the last 2 years, and had VO2max values of <40 mL/kg/min for females and <45 
mL/kg/min for males. Potential subjects who did not meet these criteria were screened out 
of the study. A total of 36 subjects were admitted to the study, and 4 subjects voluntarily 
withdrew due to illness or work scheduling conflicts. Ten to twelve subjects per group 
were matched for age, gender and body composition, and then the subjects were 
randomized into one of the 3 treatment groups for the duration of the training period. 
Written informed consent was obtained from all subjects, and the study was approved by 
The University of Texas at Austin Institutional Review Board. 
 
Research design and experimental protocol. This study followed a randomized, 
double-blinded, placebo controlled design. The protocol for the training period is shown 
in Table 5.2. The entire protocol period was 7 wk long and consisted of the following: a 
baseline testing week; the first and second weeks of training; a midpoint testing week in 
which subjects repeated the testing performed at baseline and trained 2 days; training 
weeks 3 and 4; and a partial week during which the end testing was performed. Subjects 
reported to the laboratory before the start of their training period on two occasions, once 
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for a baseline biopsy (described below), and again the following day for determination of 
lactate threshold (LT), maximal oxygen consumption (VO2max) and maximal workload 
(Wmax). This same test battery and schedule was repeated at the midpoint and at the end 
of the training period (Table 5.2).  
 
The LT test was performed first, followed by the VO2max test after a 5-min cool-down 
between the two tests. These tests were performed on a VeloTron DynaFit Pro cycle 
ergometer  (RacerMate, Seattle, WA). LT was determined using 5-min stages beginning 
at 70 Watts (W) for males and 50 W for females. The Watts were increased by 25 W 
(males) or 20 W (females) each stage for the first 3-4 stages, followed by increases of 15 
W (males) or 10 W (females) for the last 2-3 stages. A drop of blood was collected onto a 
lactate test strip after a finger stick during the last minute of each stage, and lactate levels 
were measured using a Lactate Pro LT-1710 lactate analyzer (Arkray, Inc., Minami-ku, 
Kyoto, Japan). LT was defined as the breakpoint at which lactate levels begin to rise 
above baseline levels. After the 5-min cool-down in which the subjects pedaled easily 
and drank water ad libitum, the VO2max test began. VO2max was measured using a 
TrueOne2400 system (ParvoMedics, Sandy, UT). Subjects breathed through a Hans 
Rudolph valve, with expired gases directed to a mixing chamber for analysis of oxygen 
(O2) and carbon dioxide (CO2). Outputs were directed to a computer for calculation of 
ventilation, O2 consumption (VO2), CO2 production (VCO2), and respiratory exchange 
ratio (RER) every 15 s.  
 
The protocol for establishing VO2max consisted of 2 min stages beginning at 125 W for 
males or 75 W for females. The work load was increased by 50 W (males) or 30 W 
(females) every 2 min until 275 W and 200 W, respectively. After this point, the 
workload increased 25 W (males) or 20 W (females) every minute until the subject could 
not continue to pedal despite constant verbal encouragement. The criteria used to 




Maximum power output in Watts was calculated from the VO2max test data using the 
formula, adapted from Astrand and Rodahl (1): 
 
 Wmax = (VO2max mL – 300 mL O2) / 12.5 W/mL O2  
 
The workload for the desired intensity level of the training rides (75% of VO2max for the 
first 3.5 weeks and 80% for week 4) was then set as percentages of the Wmax as follows:  
 
 W = [(VO2max mL x %VO2max desired) – 300 mL O2] / 12.5 W/mL O2 
 
With the exception of determining Wmax for the purposes of setting ride intensity levels, 
the baseline, midpoint and end testing consisted of the same tests in the same order.  
 
During the training weeks, subjects reported to the training laboratory each morning after 
fasting overnight. All subjects began the rides as a group at the same time each day (6:00 
AM or 7:30 AM), Monday – Friday. On Fridays, the subjects performed a cycling time 
trial (TT) that was designed to take about 1 h to complete. After each session including 
the TTs, subjects were provided one dose of supplement immediately post-exercise and 
were required to drink it in the laboratory. Subjects were then provided a second dose in 
an opaque to-go cup with a lid and straw and instructed to drink it 1 h later. They were 
also instructed to not ingest anything other than water until 1 h after ingesting the second 
dose.  
 
The daily training rides and time trials were performed on Kona Dew bicycles (Kona, 
Ferndale, WA) mounted on CompuTrainer stationary trainers (RacerMate, Seattle, WA) 
interfaced with MultiRider III software (RacerMate, Seattle, WA). Six bicycles and 
CompuTrainers were interfaced with the system to allow for training groups of 6 subjects 
at one time. The bikes were set up based on each subject’s physical measurements. The 
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CompuTrainers were calibrated each morning. To minimize thermal stress, air was 
circulated over the subjects with standing floor fans, and water was provided ad libitum. 
Investigators encouraged the subjects to drink as needed. 
 
The first week of training served to get the subjects accustomed to cycling for prolonged 
periods. The first ride was 30 min in duration, the second was 40 min, the third ride, 50 
min, and the fourth, 60 min. The first TT was a shortened version (16 km) of the 24-km 
TT course that was performed the next 3 wk and served to familiarize them with the 
concept of time trialing, while providing a shorter, more intense session. With the 
exception of 3 rides the first week, all rides on Monday – Thursday were 1 h in duration 
throughout the training period. The Friday TTs were ~50-70 min in duration. 
 
Each training ride and TT began with a 10-min warm up at 60% VO2max, after which the 
work rate was increased to elicit ~75% VO2max for duration of each training ride. At the 
midpoint, VO2max was reassessed and the workloads were adjusted accordingly to keep 
the subjects exercising at 75% VO2max for the third week. For the fourth week, the 
intensity was increased to 80% VO2max. A 5-min VO2 measurement was performed at 
the beginning of each week to verify that the workload corresponded to the calculated 
intensity (%VO2max) for each subject. The Wattage calculated for each subject was set 
by the investigators, and subjects were asked to maintain a cadence of ~70 rpms in order 
to maintain the Wattage. Subjects were not allowed to shift gears or vary their cadence 
during the rides on Monday – Thursday. For the TTs, subjects were allowed to shift gears 
on the bicycles in order to cycle the predetermined course as fast as possible. 
 
Experimental beverages. After each daily session, subjects ingested the experimental 
beverages (CM, CHO, or PLA) immediately and l h post-exercise. The CM (Kirkland 
Organic Low-Fat Chocolate Milk, Costco Inc.) and CHO beverages were isocaloric and 
contained the same amount of fat. The placebo was an artificially flavored and artificially 
sweetened supplement that resembled the CHO beverage in taste and appearance, but 
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contained no calories. The energy and macronutrient composition of the beverages is 
shown in Table 5.3. 
 
The amounts of supplement provided were stratified according to body weight ranges. 
Subjects weighing less than 63.6 kg (140 lbs) received 250 mL per supplement (197.5 
kcals each), totaling 500 mL and 395 kcals. Subjects weighing between 63.6 kg (140 lbs) 
and 77.2 kg (170 lbs) received 300 mL per supplement (237 kcals), totaling 600 mL and 
474 kcals. Subjects weighing between 77.2 kg (170 lbs) and 90.9 kg (200 lbs) received 
350 mL per supplement (277 kcals), totaling 700 mL and 554 kcals. Subjects weighing 
over 90.9 kg (200 lbs) received 375 mL per supplement (296.5 kcals), totaling 750 mL 
and 593 kcals. For the CHO treatment, the amount of carbohydrate (dextrose) and fat 
(canola oil) matched that provided in the CM as measured for the individual’s weight 
range. Both the CHO and Placebo beverages were flavored with grape-flavored non-
caloric Kool-Aid. The CM supplement provided an average of 0.94 g carbohydrate, 0.31 
g protein, and 0.17 g fat per kg body weight. The CHO supplement provided an average 
of 1.25 g carbohydrate and 0.17 g fat per kg body weight. 
 
Diet and exercise. Subjects were asked to keep their diets and activity levels consistent 
for the duration of the study (i.e.; no significant changes in caloric intake, dietary habits, 
or activity levels outside of the study’s training sessions). The subjects were instructed to 
maintain a dietary and activity log for the 2 days prior to their baseline, midpoint and end 
biopsies and testing. They were also instructed to keep a 2-day dietary and activity log 
each week on Wednesdays and Thursdays before the Friday TT so that compliance in 
keeping their normal dietary habits and activity levels consistent prior to the TTs could be 
verified. In addition, the subjects were asked to replicate their diet and activity on the 
days the logs are kept, such that the diet and activity was the same on the 2 days prior to 
each TT or each biopsy session. Subjects were required to turn the logs in each week, and 
the logs were analyzed for macronutrient composition and total caloric intake using 
Nutritionist V Dietary Analysis Software (First Data Bank, Inc, San Bruno, CA). All 
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subjects complied with the diet and activity requirements. Subjects were instructed to 
arrive at the laboratory having fasted overnight for 12 h for every exercise session and 
laboratory visit, except for the LT and VO2max testing sessions.  
 
Lactate threshold and VO2max. These measures were determined at baseline, the 
midpoint and at the end of the 4.5 wk training period, as shown in Table 5.2. The 
protocol for these tests is detailed above. 
 
Time trial performance. Each Friday of training weeks 2, 3, and 4, subjects performed a 
25-km time trial. The 25-km distance was selected because it was a reasonable distance 
to cover in 1 h or less when riding at a high intensity. Subjects were asked to ride the 
course as fast and intensely as they felt was possible, as if it were a race. During all TTs, 
subjects were blinded to their elapsed time or distance covered. 
 
Muscle biopsy procedure.  Muscle biopsies were taken at baseline, the midpoint, and 
the end of the training period, as shown in Table 5.2. Prior to each biopsy, the subject’s 
thigh was cleansed with 10% betadine solution and 1.4 mL of  1% Lidocaine 
Hydrochloride (Elkins-Sinn, Inc., Cherry Hill, NJ) was injected to prepare the leg for the 
muscle biopsy. Approximately ~45-60 mg wet wt of tissue was taken from the vastus 
lateralis through a 5-8 mm incision made through the skin and fascia, 6 inches from the 
midline of the thigh on the lateral side and 2.5 inches above the patella. The tissue 
samples were trimmed of adipose and connective tissue and immediately frozen in liquid 
nitrogen at -80o C for subsequent analysis. 
 
Muscle tissue processing.  The muscle samples were weighed and cut in half. One half 
of the tissue sample was used for determination of citrate synthase and succinate 
dehydrogenase activity, and the other half for measurement of total PGC-1 content. For 
the enzymatic analyses, samples were homogenized in ice-cold buffer containing 20 mM 
Hepes, 2 mM EGTA, 50 mM sodium fluoride, 100 mM potassium chloride, 0.2 mM 
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EDTA, 50 mM glycerophosphate, 1 mM DTT, 0.1 mM PMST, 1 mM benzamidine, and 
0.5 mM sodium vanadate (pH 7.4) at a dilution of 1:10. Homogenization was performed 
on ice using 3 x 5 s bursts with a Caframo RZRl Stirrer (Caframo Limited, Warton, 
Ontario, Canada). The homogenate was immediately centrifuged at 14,000 g for 10 min 
at 4°C, the supernatant aliquoted to storage tubes for each assay and stored at -80°C. For 
determination of total PGC-1 content, the tissue samples were homogenized at a 
dilution of 1:10 in a modified RIPA buffer based on a previously described protocol (39) 
containing: 50 mM Tris-HCL (pH 7.4); 150 mM NaCl (pH 7.4); 1% each Igepal CA-630 
and sodium deoxycholate; 1 mM each EDTA (pH 7.4), Na3VO4  (pH 10), NaF, and 
phenylmethylsulfonyl fluoride; 1 g/ml each aprotinin, leupeptin and pepstatin. 
Homogenization was performed on ice using 4 x 5 s bursts with a Caframo RZRl Stirrer 
(Caframo Limited, Warton, Ontario, Canada). The homogenates were sonicated on ice 
for 10 s and then centrifuged at 5,000 g for 20 min at 4°C. The supernatant was aliquoted 
to storage tubes and stored at -80°C. Protein concentration was determined from the 
supernatant using a modified version of the Lowry Assay (21) for each sample, and was 
measured before each of the assays were performed. 
PGC-1 content. Total PGC-1 content was determined by Western blotting. Total 
tubulin content was also determined as a housekeeping protein. Aliquots of 
homogenized muscle sample supernatants and standards were slowly thawed over ice and 
diluted 1:1 with sample buffer containing 1.25M Tris, pH 6.8, glycerol, 20% SDS, 2-
mercaptoethanol, 0.25% bromophenol blue solution, and deionized water. Samples 
containing 70 g of total protein were separated on 10% polyacrylamide gels by SDS-
PAGE for 75 min at 200 V (Bio-Rad Laboratories, Hercules, CA.) After electrophoresis, 
the gels were electrotransferred using a semi-dry transfer cell (Bio-Rad Laboratories, 
Hercules, CA.) using 25 V for 18 min to 0.4 m polyvinylidine fluoride (PVDF) 
membranes (Millipore, Bedford, MA). The membranes were blocked in TTBS (TBS, 50 
mM Tris, 150 mM NaCl, containing 0.1% Tween-20), and 10% nonfat dry milk for 2 h at 
room temperature on a rocking platform at medium speed. The membranes were then 
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washed in 1x TTBS 3 times for 5 min each wash. Using the molecular weight markers 
visible on the membranes as a guide, the membranes were cut at the 75 kD marker. The 
upper section was used for detection of PGC-1, and the lower section was used to detect 
-tubulin. Each membrane section was incubated overnight at 4°C on a rocking platform 
at low speed with antibodies directed against PGC-1 (no. 515667, EMD 
Calbiotech/Merck KGaA, Darmstadt, Germany), and -tubulin (no. 2144, Cell Signaling, 
Danvers, MA). The antibodies were diluted 1:1000 for PGC-1, and 1:900 for -tubulin 
in TTBS containing 2% nonfat dry milk. Following the overnight incubation, membranes 
were washed three times with TTBS for 5 min each wash and incubated for 1.5 h with a 
secondary antibody (goat anti-rabbit, HRP-linked IgG, no. 7074, Cell Signaling, Danvers, 
MA). Dilutions were 1:7500 for PGC-1 and 1:1000 for -tubulin. The immunoblots 
were visualized by enhanced chemiluminescence (Perkin Elmer, Boston, MA) using a 
Bio-Rad ChemiDoc detection system, and the mean density of each band was quantified 
using Quantity One 1-D Analysis software (Bio-Rad Laboratories, Hercules, CA.).  A 
molecular weight ladder (Precision Plus Protein Standard, Bio-Rad) and a rodent internal 
control standard prepared from insulin-stimulated mixed skeletal muscle were also 
included on each gel. All blots were compared with the rodent control standard and the 
values of each sample were represented as a percent of standard for each blot. 
 
Citrate synthase and succinate dehydrogenase. Citrate synthase (CS) activity was 
determined according to the protocol of Srere et al. (35) on the homogenates after further 
dilution of 1:10 (wt/vol) with 0.1 M Tris-HCI and 0.4% Triton X-100 buffer (pH 8.1). 
The rate of appearance of DTNB was determined spectrophotometrically over 5 min at 
412 nm and 37o C using a Beckman DU 640 spectrophotometer (Fullerton, CA), and was 
proportional to CS activity. Succinate dehydrogenase  (SDH) activity was measured 
according to the method of Lowry and Passonneau (20). The amount of NADH produced 
during a 5 min incubation time was read on a Varian Cary Eclipse fluorometer with an 
excitation wavelength of 340 nm and emission wavelength of 450 nm (Varian, Inc., Palo 
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Alto, CA) and corresponded to SDH activity in the sample. CS and SDH activities were 
expressed as mols/g/min protein. 
 
Statistical analyses. VO2max, LT, TT time and TT Watts were analyzed using two-way 
(treatment x time) analysis of variance (ANOVA) for repeated measures. Muscle enzyme 
activity and PGC-1 content was analyzed using two-way (treatment x time) analysis of 
variance (ANOVA) for repeated measures. For all measures, post hoc analysis was 
performed when significance was found using Least Significant Difference (LSD). 
Differences were considered significant at P<0.05. Data were expressed as mean  SE. 
All statistical analyses were performed using SPSS version 16.0 statistical software 
(SPSS Inc., Chicago, IL). 
RESULTS 
 
VO2max.   Absolute and relative changes in VO2max are shown in Figure 5.1. No 
significant differences existed between the groups at baseline. All treatment groups 
experienced significant increases in absolute and relative VO2max over the 4.5 wk 
training period. The change in both absolute and relative VO2max was significantly 
greater in the CM group compared to CHO and PLA. The increases in the CHO and PLA 
groups were not statistically different from each other (Figure 5.1).  
 
Lactate threshold and time trial performance.   Although lactate threshold increased 
significantly over time in all 3 treatment groups, no significant treatments differences 
were observed (Table 5.4). Decreases in weekly TT time, and increases in average TT 
Watts, were significant in all groups over the duration of the training period, but no 
significant treatment differences were detected (Table 5.5).  
 
Citrate synthase and succinate dehydrogenase.  No significant treatment or treatment 
by time effects were found for CS or SDH (Figure 5.2A and B). Significant time effects 
existed for both enzymes in all treatment groups (P<0.05). 
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PGC-1.  Changes in total PGC-1 content are shown in Figure 5.3. No significant 
treatment or treatment by time effects were found. However, significant time effects 
existed in all treatment groups (P<0.05). 
DISCUSSION 
 
The key finding of the present study was that the increase in VO2max was significantly 
greater in the CM group than the CHO or PLA groups. The average increase in absolute 
VO2max for the CM group was 12.5% higher than baseline levels, a two-fold 
improvement over the increase found in the CHO and PLA groups. The average absolute 
VO2max (L/min) increase for all subjects and treatment groups combined was 9.2% over 
the 4.5 wk training period, which is in agreement with other investigations of aerobic 
training and VO2max improvements using a similar time period (27, 34).  
 
It has been established that the primary determinants of VO2max are an increased ability 
of the cardiovascular system to transport oxygen to the working skeletal muscle, and the 
improved ability of the muscle to utilize the delivered oxygen. The former is a result of 
increased stroke volume, which improves cardiac output; the latter is determined by the 
increases in oxidative enzymes and mitochondrial content (9, 31). We measured the 
activity of two key oxidative enzymes that are indicative of muscle oxidative capacity, 
CS and SDH. Both are found in the mitochondria and are key enzymes of the Kreb’s 
cycle, and each has been demonstrated to increase in response to endurance training.  (4, 
8, 10, 13, 14, 16, 22, 30). We also measured total content of the transcription coactivator 
PGC-1 (peroxisome proliferator-activated receptor  coactivator-1) as a marker for 
increased mitochondrial biogenesis. PGC-1 is a transcriptional coactivator of 
transcription factor PPAR and together, they regulate the expression of genes that 
encode mitochondrial proteins. An acute bout of exercise or stimulated skeletal muscle 
contraction induces an increase in both PGC-1 mRNA and protein in skeletal muscle (2, 
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12, 17, 36), and it has been shown that increased PGC-1 activation and total protein 
amount leads to increased mitochondrial biogenesis (39).  
 
In the present study, we demonstrated that the activity of CS and SDH and the total 
content of PGC-1 increased significantly in response to 4.5 wks of training. However, 
no significant treatment differences in those measures were detected. There was a slight 
but non-significant trend for a greater increase in CS and SDH activity in CM compared 
to CHO and PLA. It may be that the training period was not long enough to detect any 
potential differences that could emerge in response to chronic nutritional 
supplementation. Thus, our results suggest that the greater VO2max improvements with 
CM supplementation are most likely due to cardiovascular adaptations rather than 
increases in oxidative enzymes or in mitochondrial biogenesis.  
 
As mentioned previously, endurance training leads to an adaptive increase in cardiac 
output, and this increase is due to augmented stroke volume (9). While we did not 
measure these variables in the present study, our results suggest that the significant 
improvement in VO2max in the CM group is likely due to increased stroke volume and 
cardiac output, which is likely due to increased plasma volume. Plasma volume 
expansion is a hallmark of aerobic endurance training (33), and is directly associated 
with increased plasma albumin content. Increased albumin in the plasma causes water to 
be retained in the vasculature due to increases in the colloid osmotic pressure gradient (6, 
11). Hepatic albumin synthesis has been shown to increase in response to endurance 
exercise training (23, 40). It has been previously demonstrated that plasma albumin 
content was increased 23 h after an acute bout of cycling exercise when CHO+PRO 
supplementation was provided post-exercise compared to placebo (25). These results, 
along with the findings of the present study, suggest that hepatic albumin synthesis may 
have been increased to a greater extent in the CM group compared to the CHO or PLA 
groups, and contributed to the significantly greater increase in VO2max in the CM group. 
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Okazaki and colleagues (26) recently demonstrated that CHO+PRO supplementation 
provided immediately after daily cycling exercise training in older male subjects 
increased stroke volume and plasma volume compared to a placebo group. Their subjects 
cycled for 60 min/d, 3 d/wk for 8 wk at 60-75% VO2peak and ingested either CHO+PRO 
or placebo immediately post-exercise each session. VO2peak increased 3.3% in the 
control group and 6.8% in the CHO+PRO group, with significant stroke volume and 
plasma volume increases only found in the CHO+PRO group (26).  In the present study, 
we extend the findings of Okazaki and colleagues (26) by demonstrating that the effect of 
nutritional supplementation on VO2max increases is nutrient specific. In comparing CM 
against an isocaloric CHO only supplement and a placebo, we have shown that the 
increased VO2max response is not due to simply providing calories post-exercise. In the 
present study, the VO2max increase in the CHO and PLA groups was not significantly 
different. Thus, these results suggest that the benefit from a CHO+PRO or CM 
supplement in improving VO2max is due to the combined ingestion of carbohydrate and 
protein. 
 
In addition to well-documented increases in VO2max with training, it is known that 
lactate threshold improves with endurance exercise training of moderate to high intensity 
(28). In the current study, LT improved significantly over the 4.5 wks of training, 
although there were no significant treatment differences detected (Table 5.4). It has been 
shown that the respiratory capacity of the muscle is the key determinant of LT (18). 
Given that muscle oxidative enzyme activity and PGC-1 content increased significantly 
over time without demonstrating a treatment effect, it would be expected that LT would 
follow a parallel pattern. Therefore, the results suggest that while LT is increased by 
exercise training in parallel with muscle oxidative capacity, it likewise may not be 
affected by nutritional supplementation. 
 
In order to assess exercise performance as a measure of adaptive progress in the groups, 
subjects performed 25 km time trials on Fridays of weeks 2, 3 and 4. We hypothesized 
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that the CM group would adapt to the training stimulus faster than the CHO or PLA 
groups and would thus be able to cycle at a faster, “race” pace during these time trials 
than the CHO or PLA groups. Although all groups significantly improved their time to 
completion over the weeks of training, there were no treatment differences. Previous 
investigations have established that endurance performance is related to oxidative 
capacity of the muscle (14, 15), and that lactate threshold is a better determinant of 
endurance performance than VO2max (7). Given that muscle oxidative capacity and 
lactate threshold increased in parallel in all treatment groups, it may have been difficult to 
detect treatment differences in time trial performance in the present study, especially in 
previously untrained, non-competitive subjects who were unaccustomed to time trialing 
at a race-like pace.  
 
In summary, CM supplementation increased adaptations to a 4.5 wk aerobic exercise 
training program, demonstrated by greater improvements in VO2max compared to CHO 
or PLA. This is likely due to increased plasma volume and thus, increased cardiac output. 
Muscle oxidative capacity, lactate threshold, and time trial performance improved 
significantly in all groups, with no differences found between treatments. Therefore, our 
findings suggest that improvements in VO2max occur faster when supplementing with 
CM as compared with CHO or placebo, and that this faster rate of adaptation is systemic 
rather than cellular in nature. We conclude that CM is an effective post-exercise recovery 
supplement that can induce greater increases in aerobic training adaptations in healthy, 
untrained humans.  
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 All subjects (32) CM (11) CHO (11) PLA (10) 
Age (y) 22.0 ± 0.5 22.1 ± 0.7 21.3 ± 0.9 22.6 ± 1.0 
Weight (kg) 71.7 ± 2.4 70.9 ± 5.1 71.2 ± 3.1 73.2 ± 4.5 
Height (cm) 168.6 ± 1.5 169.1 ± 2.3 168.0 ± 2.7 168.8 ± 3.1 
VO2max  (L·min-1) 2.6 ± 0.2 2.7 ± 0.3 2.6 ± 0.2 2.6 ± 0.2 
VO2max  (mL·kg·min-1) 35.9 ± 1.9 36.8 ± 1.4 35.7 ± 2.2 35.2 ± 2.1 
Values are mean ± SE. 
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 Mon Tue Wed Thurs Fri Sat Sun 








60 min 60 min 60 min 60 min TT Rest Rest 








60 min 60 min 60 min 60 min TT Rest Rest 
End LT/VT and VO2max testing; biopsy 
 







 CM CHO PLA 
CHO, g/100 mL 11.48 15.15 0 
PRO, g/100 mL 3.67 0 0 
Fat, g/100 mL 2.05 2.05 0 
kcals/100 mL 79.05 79.05 0 
Ratio of CHO:PRO 3.12:1 -- -- 
Per 100 mL. CM, chocolate milk; CHO, carbohydrate + fat; 
PLA, placebo.  
 
 
Table 5.3. Energy and macronutrient content of supplements   
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 Baseline Midpoint End 
LT (VO2, L/min)    
   CM 1.61 ± 0.16 -- 1.83 ± 0.16 b 
   CHO 1.47 ± 0.10 -- 1.67 ± 0.11 b 
   PLA 1.53 ± 0.11 -- 1.70 ± 0.13 b 
Values are mean ± SE. Significant differences: b time only (P<0.05). 
 
Table 5.4.  Lactate threshold 
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 TT 2 TT 3 TT 4 
TT Time (min)    
   CM 53.4 ± 1.2 52.4 ± 1.5 51.8 ± 1.5 b 
   CHO 54.8 ± 1.6 52.8 ± 1.3 51.1 ± 1.2 b 
   PLA 59.1 ± 2.0 56.3 ± 2.2 54.7 ± 2.2 b 
Power (Avg Watts)    
   CM 143.1 ± 10.3 148.9 ± 12.8 152.6 ± 13.1 b 
   CHO 135.8 ± 10.3 143.3 ± 10.9 155.2 ± 10.0 b 
   PLA 126.5 ± 10.0 138.9 ± 11.2 143.2 ± 13.8 b 
Values are mean ± SE. Significant differences:  b time only (P<0.05). 
 







Figure 5.1.  VO2max changes after 4.5 wks of aerobic endurance training.  A. 
Change from baseline in absolute VO2max. B. Change from baseline in relative VO2max. 
Values are mean ± SE. Significant treatment differences: a CM vs PLA and CHO 
(P<0.05).   
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Figure 5.2.  Oxidative enzyme activity. A. Citrate synthase activity. B. Succinate 
dehydrogenase activity. Biopsies were taken at baseline (before starting the training 
period), at the midpoint and at the end of the 4.5 wk training period. No significant 




Figure 5.3.  PGC-1 content before and after 4.5 wks of cycling exercise training. 









Chapter VI: Effects of Aerobic Exercise Training and Supplementation 




Investigations of resistance training have demonstrated body composition 
improvements when a CHO+PRO supplement is ingested post-exercise compared to 
CHO. However, no investigation has examined the effects of CHO+PRO 
supplementation in a model of aerobic endurance exercise training on body composition 
changes as well as markers of metabolic health. The purpose of the present study was to 
compare the effects of post-exercise CHO+PRO supplementation in the form of 
chocolate milk (CM), isocaloric carbohydrate (CHO), and placebo (PLA) on body 
composition changes and  markers of immune system stress, inflammation and metabolic 
homeostasis that occurred in response to a 4.5 week aerobic exercise training program in 
healthy, untrained subjects. Thirty-two males and females were randomized into one of 
the 3 treatment groups. Subjects cycled for 1 h/d, 5 d/wk for 4.5 wks at 75-80% of 
VO2max. Supplements were ingested immediately and 1 h after each session. Body 
composition analysis and fasting blood collections were performed at baseline, midpoint, 
and the end of the training period. Pre-and post-exercise blood samples were taken 
weekly. Greater improvements in body composition, represented by a calculated lean and 
fat mass differential for whole body and trunk region, were found in the CM group 
compared to CHO. No significant differences were found between baseline, midpoint and 
end time points for fasting insulin, cortisol, cytokines or immune cell counts. These 
results suggest that ingesting a CM supplement post-exercise during 4.5 wks of aerobic 





 The importance of regular physical activity for improving or maintaining overall 
health has been well established. The cardiovascaular benefits of exercise are well 
documented (6, 26, 39, 40), and increasing evidence suggests that the possible anti-
inflammatory effects of aerobic exercise may underlie the cardioprotective effects (14, 
24, 43, 47). Regular exercise is also associated with metabolic improvements, such as in 
insulin sensitivity and glucose metabolism (22, 25). In addition, participating in regular 
physical activity is inversely associated with risk of developing an upper respiratory tract 
infection (10), although many investigations have reported little or no effect of exercise 
training on immune function (2, 7, 28) despite some alterations in circulating immune 
cell levels (28). In addition to participating in regular exercise to improve or maintain 
overall health, exercise training is often undertaken as a means to facilitate weight loss 
and improve body composition.  
 
The beneficial effects of post-exercise supplementation in the form of carbohydrate 
(CHO) or carbohydrate-protein (CHO+PRO) in promoting recovery from, and 
adaptation to, acute exercise has been demonstrated (3, 19, 46, 53, 54). Others have 
reported the efficacy of milk-based supplements in increasing protein synthesis (11) and 
lean mass accrual (15, 21, 52) in response to resistance exercise. Recently, chocolate 
milk (CM) has been investigated as a practical and effective CHO+PRO post-exercise 
recovery supplement after aerobic exercise (23, 41, 51.). However, the effects of aerobic 
endurance exercise training and nutritional supplementation on body composition 
changes, as well as other markers of health such as immune system changes, 
inflammatory markers, plasma glucose, and metabolic hormones, have not been 
investigated. 
 
Therefore, the purpose of the present study was to determine the effects of a 4.5 wk 
aerobic endurance exercise (cycling) training program when supplementing after each 
daily exercise session with a carbohydrate and protein containing beverage (chocolate 
milk, CM), carbohydrate only (CHO) or placebo. We aimed to determine if 
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supplementation resulted in a greater increase in lean mass, and a greater decrease in fat 
mass. We also sought to determine if immune cell levels were better maintained, and 
inflammatory markers better attenuated, in the CM group compared to the CHO or PLA 
groups. We hypothesized that the CM group would demonstrate greater lean body mass 
increases and fat mass decreases, and less immune cell and inflammatory cytokine 
perturbations during aerobic exercise training compared to the CHO and PLA groups. 
METHODS 
 
Subjects. Thirty-two healthy, recreationally active but untrained males and females (16 
males and 16 females) between 18 and 35 years old completed the study. Subject 
characteristics are listed in Table 6.1. In order to be classified as recreationally active but 
not endurance trained, subjects could not have exercised regularly more than 3 h/wk over 
the last 2 years, and had VO2max values of <40 mL/kg/min for females and <45 
mL/kg/min for males. Potential subjects who did not meet these criteria were screened out 
of the study. A total of 36 subjects were admitted to the study, and 4 subjects voluntarily 
withdrew due to illness or work scheduling conflicts. Ten to twelve subjects per group 
were matched for age, gender and body composition, and then the subjects were 
randomized into one of the 3 treatment groups for the duration of the training period. 
Written informed consent was obtained from all subjects, and the study was approved by 
The University of Texas at Austin Institutional Review Board. Of the 32 subjects who 
completed the entire study, two subjects were excluded from blood analyses due to 
extreme difficulties in collecting blood from the antecubital veins, and two subjects were 
also excluded from body composition analysis due to exclusion criteria for DEXA scans. 
 
Research design and experimental protocol. This study followed a randomized, 
double-blinded, placebo controlled design. The protocol for the training period is shown 
in Table 6.2. The entire protocol period was 7 wk long and consisted of the following: a 
baseline testing week; the first and second weeks of training; a midpoint testing week 
with 2 days of training; training weeks 3 and 4; and a partial week during which the end 
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testing was performed. Subjects reported to the laboratory before the start of their training 
period on two occasions, once for a baseline blood collection and DEXA scan for body 
composition determination (described below), and again the following day for 
determination of maximal oxygen consumption (VO2max) and maximal workload 
(Wmax). The blood collections were performed again at the midpoint of the study and at 
the end. DEXA scans were repeated at the end of the training period.  
 
The VO2max/Wmax test was performed on a VeloTron DynaFit Pro cycle ergometer  
(RacerMate, Seattle, WA). VO2max was measured using a TrueOne2400 system 
(ParvoMedics, Sandy, UT). Subjects breathed through a Hans Rudolph valve, with 
expired gases directed to a mixing chamber for analysis of oxygen (O2) and carbon 
dioxide (CO2). Outputs were directed to a computer for calculation of ventilation, O2 
consumption (VO2), CO2 production (VCO2), and respiratory exchange ratio (RER) every 
15 s. Subjects cycled at 125 W for males or 75 W for females for 4 min as a warm-up 
before beginning the VO2max test. The protocol for establishing VO2max consisted of 2 
min stages beginning at 125 W for males or 75 W for females. The work load was 
increased by 50 W (males) or 30 W (females) every 2 min until 275 W and 200 W, 
respectively. After this point, the workload increased 25 W (males) or 20 W (females) 
every minute until the subject could not continue to pedal despite constant verbal 
encouragement. The criteria used to establish VO2max was a plateau in VO2 with 
increasing exercise intensity and RER > 1.10.  
 
Maximum power output in Watts was calculated from the VO2max test data using the 
formula, adapted from Astrand and Rodahl (1): 
 
 Wmax = (VO2max mL – 300 mL O2) / 12.5 W/mL O2  
 
The workload for the desired intensity level of the training rides (75% of VO2max for the 
first 3.5 weeks and 80% for week 4) was then set as percentages of the Wmax as follows:  
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 W = [(VO2max mL x %VO2max desired) – 300 mL O2] / 12.5 W/mL O2 
 
During the training weeks, subjects reported to the training laboratory each morning after 
fasting overnight. All subjects began the rides as a group at the same time each day (6:00 
AM or 7:30 AM), Monday – Friday. On Fridays, the subjects performed a cycling time 
trial (TT) that was designed to take about 1 h to complete. A pre- and post-exercise blood 
collection was taken for TTs 2, 3, and 4. After each session including the TTs, subjects 
were provided one dose of supplement immediately post-exercise and were required to 
drink it in the laboratory. The beverages and doses provided are described in detail 
below. Subjects were then provided a second dose in an opaque to-go cup with a lid and 
straw and instructed to drink it 1 h later. They were also instructed to not ingest anything 
other than water until 1 h after ingesting the second dose.  
 
The daily training rides and time trials were performed on Kona Dew bicycles  (Kona, 
Ferndale, WA) mounted on CompuTrainer stationary trainers (RacerMate, Seattle, WA) 
interfaced with MultiRider III software (RacerMate, Seattle, WA). Six bicycles and 
CompuTrainers were interfaced with the system to allow for training groups of 6 subjects 
at one time. The bikes were set up based on each subject’s physical measurements. The 
CompuTrainers were calibrated each morning. To minimize thermal stress, air was 
circulated over the subjects with standing floor fans, and water was provided ad libitum. 
Investigators encouraged the subjects to drink as needed. 
 
The first week of training served to get the subjects accustomed to cycling for prolonged 
periods. The first ride was 30 min in duration, the second was 40 min, the third ride, 50 
min, and the fourth, 60 min. The first TT was a shortened version (16 km) of the 24-km 
TT course that was performed the next 3 wk and served to familiarize them with the 
concept of time trialing, while providing a shorter, more intense session. With the 
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exception of 3 rides the first week, all rides on Monday – Thursday were 1 h in duration 
throughout the training period. The Friday TTs were ~50-70 min in duration. 
 
Each training ride and TT began with a 10-min warm up at 60% VO2max, after which the 
work rate was increased to elicit ~75% VO2max for duration of each training ride. At the 
midpoint, VO2max was reassessed and the workloads were adjusted accordingly to keep 
the subjects exercising at 75% VO2max for the third week. For the fourth week, the 
intensity was increased to 80% VO2max. A 5-min VO2 measurement was performed at 
the beginning of each week to verify that the workload corresponded to the calculated 
intensity (%VO2max) for each subject. The Wattage calculated for each subject was set 
by the investigators, and subjects were asked to maintain a cadence of ~70 rpms in order 
to maintain the Wattage. Subjects were not allowed to shift gears or vary their cadence 
during the rides on Monday – Thursday. Each Friday of training weeks 2, 3, and 4, 
subjects performed a 25-km time trial, which took ~1 h or less to complete when riding at 
a high intensity. The subjects were allowed to shift gears on the bicycles in order to cycle 
the predetermined course as fast as possible, and were asked to ride the course as if it 
were a race.  
 
(Data from the VO2max tests and the TT data are presented in Study 3/Chapter V.) 
 
Experimental beverages. After each daily session, subjects ingested the experimental 
beverages (CM, CHO, or PLA) immediately and l h post-exercise. The CM (Kirkland 
Organic Low-Fat Chocolate Milk, Costco Inc.) and CHO beverages were isocaloric and 
contained the same amount of fat. The placebo was an artificially flavored and artificially 
sweetened supplement that resembled the CHO beverage in taste and appearance, but 
contained no calories. The energy and macronutrient composition of the beverages is 
shown in Table 6.3. 
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The amounts of supplement provided were stratified according to body weight ranges. 
Subjects weighing less than 63.6 kg (140 lbs) received 250 mL per supplement (197.5 
kcals each), totaling 500 mL and 395 kcals. Subjects weighing between 63.6 kg (140 lbs) 
and 77.2 kg (170 lbs) received 300 mL per supplement (237 kcals), totaling 600 mL and 
474 kcals. Subjects weighing between 77.2 kg (170 lbs) and 90.9 kg (200 lbs) received 
350 mL per supplement (277 kcals), totaling 700 mL and 554 kcals. Subjects weighing 
over 90.9 kg (200 lbs) received 375 mL per supplement (296.5 kcals), totaling 750 mL 
and 593 kcals. For the CHO treatment, the amount of carbohydrate (dextrose) and fat 
(canola oil) matched that provided in the CM as measured for the individual’s weight 
range. Both the CHO and Placebo beverages were flavored with grape-flavored non-
caloric Kool-Aid. The CM supplement provided an average of 0.94 g carbohydrate, 0.31 
g protein, and 0.17 g fat per kg body weight. The CHO supplement provided an average 
of 1.25 g carbohydrate and 0.17 g fat per kg body weight. 
 
Diet and exercise. Subjects were asked to keep their diets and activity levels consistent 
for the duration of the study (i.e.; no significant changes in caloric intake, dietary habits, 
or activity levels outside of the study’s training sessions). The subjects were instructed to 
maintain a dietary and activity log for the 2 days prior to their baseline, midpoint and end 
biopsies and testing. They were also instructed to keep a 2-day dietary and activity log 
each week on Wednesdays and Thursdays before the Friday TT so that compliance in 
keeping their normal dietary habits and activity levels consistent prior to the TTs could be 
verified. In addition, the subjects were asked to replicate their diet and activity on the 
days the logs are kept, such that the diet and activity was the same on the 2 days prior to 
each TT or each blood collection session. Subjects were required to turn the logs in each 
week, and the logs were analyzed for macronutrient composition and total caloric intake 
using Nutritionist V Dietary Analysis Software (First Data Bank, Inc, San Bruno, CA). 
All subjects complied with the diet and activity requirements. Subjects were instructed to 
arrive at the laboratory having fasted overnight for 12 h for every exercise session and 
laboratory visit.  
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Blood sampling and analyses.  Blood collections occurred at 6 time points during the 
training protocol, as shown in Table 6.2. All blood collections were performed by 
venipunctures in an antecubital vein with a 10 mL syringe. For baseline, midpoint and 
end blood collections, 5 mL of the total blood sample was mixed with 0.5 mL of EDTA 
(24 mg/mL, pH 7.4), and 0.3 mL of the anticoagulated blood was transferred to another 
tube containing 0.6 mL 10% perchloric acid (PCA). The remaining 5 mL was transferred 
directly into a K2EDTA-coated Vacutainer tube for the white blood cell count with 
differentiation, performed by a clinical hematology laboratory (LabCorp, Austin, TX). 
The tubes were centrifuged at 4˚ C for 10 min at 3,000 rpm with a HS-4 rotor in a Sorvall 
RC6 centrifuge (Kendro Laboratory Products, Newtown, CT). After centrifugation, 
plasma and PCA extracts were separated into aliquots for each assay and immediately 
frozen and stored at -80˚C for later analysis. For the pre- and post-exercise collections 
that occurred for the time trials during weeks 2 and 4, 10 mL sample was collected and 
processed in the same manner as described above. For the week 3 TT, only 5 mLs were 
collected and no white blood cell analyses were performed. 
 
Plasma glucose was measured using a spectophotometric Trinder reaction (no. 315, 
Sigma Chemical, St. Louis, MO) and had a CV of 3.7%. Plasma insulin was measured 
using ImmuChemTM Coated Tube 125I  RIA  Kit (MP Biomedicals, LLC, Orangeburg, 
NY) by radioimmunoassay. All samples were run in duplicate, with a coefficient of 
variation (CV) of 6.0%. A fasting glucose-to-insulin ratio was calculated from the plasma 
glucose and insulin values [(glucose, mg/dL)/insulin, IU/mL)] at baseline, midpoint and 
end as described by Legro and colleagues (27), with values <4.5 being indicative of 
decreased insulin sensitivity (27). Blood lactate was determined from the PCA extract by 
enzymatic-spectophotometric analysis method based on the oxidation of lactate to 
pyruvate by nicotinamide adenine dicnucleotide (NAD+). (17), and had a CV of 1.5%. 
Plasma cortisol was measured using ImmuChemTM Coated Tube 125I  RIA  Kit (MP 
Biomedicals, LLC, Orangeburg, NY) by radioimmunoassay, with a CV of 6.1%. Total 
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plasma concentrations of interleukin-1 receptor antagonist (IL-1ra), interleukin-6 (IL-6), 
interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-1 beta (IL-1), and tumor 
necrosis factor alpha (TNF) were determined using Millipore High Sensitivity 
Multiplex Human Cytokine Assay kits (Millipore, Billerica, MA) with a Bio-Plex 200 
multiplex suspension array system with Luminex xMAP detection technology (Luminex 
Corp., Austin, TX). All assays were run in duplicate. 
 
Routine complete blood counts (CBC) with differentiation for total leukocytes and 
subsets (lymphocytes, neutrophils, and monocytes) were performed on 5 mLs of the 
blood samples collected at baseline, midpoint, end and pre- and post-exercise for TTs 2 
and 4 as described above. The samples were transported on ice the same day as the 
collections occurred to a local clinical hematology laboratory (LabCorp, Austin, TX). 
 
Body composition. Dual Energy X-Ray Absorbency (Medical Systems Prodigy, General 
Electric, Madison, WI) was used to determine both whole body and regional (trunk and 
legs) changes in fat mass and lean mass, as well as bone mineral density (BMD). A three-
compartment model design for assessing body composition was used, dividing the body 
into bone, fat mass, and fat-free mass. The total region percentage of fat mass and lean 
mass were used to assess the subjects' body fat and lean mass levels. The trunk region 
and legs region were used to assess fat and lean mass changes in the trunk and legs 
independently. The DEXA machine was calibrated each morning prior to subject 
measurement. Measurements were performed at baseline and at the end of the training 
period on the same day as the blood collections were performed. The same trained 
technician performed all of the DEXA scans for the entire study. 
 
The body composition differentials (Figure 6.1A-C) were calculated according to the 
formula: 
 
 (LMkgEnd – LMkgBaseline) – (FMkgEnd – FMkgBaseline) = Differential (kg)  
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Using this formula, a gain in lean mass and a loss of fat mass would result in a higher 
differential value than a loss in lean mass and gain in fat mass, or no change in lean and 
fat mass. This differential was calculated for whole body as well as regional (trunk and 
legs) changes (Figure 6.1A-C). Therefore, the whole body differential was calculated as 
follows, using the CM treatment group values as an example: 
 
1.408 kg – (-1.363 kg) = 2.771 kg 
 
The regional differentials were calculated by the same formula using the values from 
those specific regions. 
 
Statistical analyses. Absolute changes from baseline to end in the body composition 
differentials were analyzed using a one-way ANOVA. Differences in baseline, midpoint 
and end blood and plasma measures were analyzed using two-way (treatment x time) 
analysis of variance (ANOVA). Differences in pre- and post-TT blood and plasma 
measures for TT2 and TT4 were analyzed using two-way (treatment x time) ANOVA, 
while the absolute change in each TT (TTwas analyzed using a one-way ANOVA. 
Differences in the TT2 absolute change compared to TT4 absolute change (TT2 vs 
TT4) were analyzed using a two-way (treatment x time) ANOVA. For all measures, 
post hoc analysis was performed when significance was found using Least Significant 
Difference (LSD). Differences were considered significant at P<0.05. Data were 
expressed as mean  SE. All statistical analyses were performed using SPSS version 16.0 
statistical software (SPSS Inc., Chicago, IL). 
RESULTS 
 
Body composition. Changes in body weight, lean mass and fat mass (assessed for whole 
body, trunk, and legs) are shown in Table 6.4. Whole-body lean mass increased in all 
treatment groups, with no treatment differences detected (P<0.05). Although whole-body 
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fat mass decreased in all groups, the change was not significant for treatment or time. In 
the trunk region, a significantly greater gain in lean mass was found in the CM group 
compared to PLA (P<0.05). Trunk region fat mass differences were not significantly 
different between treatments, although a significant time effect was found for all groups 
(P<0.05). In the legs region, significant time effects were found for lean mass increases 
and fat mass decreases in all groups (P<0.05).  
 
The whole body and regional differentials are shown in Figure 6.1A-C. The whole body 
differential and the trunk differential was significantly greater in the CM group compared 
to CHO (P<0.05). Whole body and trunk differentials for PLA were not significantly 
different than those for CM or CHO. The differential for the legs region was not 
significantly different among the three treatments. No significant treatment or time 
differences existed for BMD (Table 6.4). 
 
Baseline, midpoint and end plasma analyses. No treatment or time effects were found 
for plasma insulin, cortisol, or cytokine levels (Table 6.5). Plasma glucose was 
significantly higher at the end of the training period in the PLA group compared to CM 
and CHO (Table 6.5) (P<0.05). No significant treatment or time effect was found for the 
fasting glucose-to-insulin ratio (Table 6.5). 
 
Pre- and post exercise blood and plasma analyses. No treatment or time differences 
were found for plasma glucose in the pre- to post-TT measures (Table 6.6). Blood lactate 
was significantly lower at the end of TT4 in PLA than CM or CHO (P<0.05). A 
significant time effect (pre- to post-exercise) existed for lactate in all treatments. No 
significant time effect was found for the pre- to post-exercise measures for plasma 
cortisol. However, a significant treatment difference existed for both TT2 and TT4 in the 
CM group, which demonstrated higher pre- and post-exercise cortisol levels than CHO or 
PLA (Table 6.6). Levels of cytokines IL-1B, IL-6, IL-8, and IL-10 rose significantly from 
pre- to post-exercise for each TT in all treatment groups (P<0.05). With the exception of 
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IL-6, no significant differences were found between the treatments. IL-6 was higher in 
TT4 in the PLA group compared to CHO and CM (P<0.05) (Table 6.6). No significant 
treatment differences were detected for the TTs in any of the blood or plasma measures. 
 
Immune cell counts. Concentrations of leukocytes and subpopulations (lymphocytes, 
neutrophils, and monocytes) are shown in Table 6.7. No significant treatment or time 
differences existed for the baseline, midpoint and end measures. No significant treatment 
differences existed for any of the TT pre- and post-exercise measures. Significant pre- to 
post-exercise time effects were found for total while blood cells, lymphocytes, 
neutrophils, and monocytes in all treatments for both TTs (Table 6.7, P<0.05), but there 




In the present study, we aimed to determine the effects of 4.5 wks of aerobic endurance 
exercise and post-exercise nutritional supplementation on body composition changes, 
and changes in immune cells and inflammatory markers. The most important finding was 
that body composition improvements, represented by a calculated lean and fat mass 
differential, was significantly greater in the CM group than the CHO group. Compared to 
the CHO group, the CM group lost more fat mass and gained more lean mass measured 
in the whole body, as well as in the trunk region only (P<0.05). While these differentials 
were also greater for CM compared with PLA, the differences were not significant. This 
improvement in body composition with CM is in agreement with the findings of Josse 
and colleagues (21), who recently demonstrated significantly greater muscle mass 
accretion, fat mass loss and strength gains with milk supplementation compared to soy 
and CHO after a 12-wk resistance training program (21). However, the training in the 
present study was aerobic exercise only, and thus, the body composition improvements 
are remarkable given the relatively short length of the training period (4.5 wks), the lack 
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of a resistance training component, and the lack of any type of energy restriction or 
dietary intake control.  
 
As shown in Table 6.4, all groups demonstrated significant changes over time in whole-
body lean mass, trunk fat mass, and legs lean and fat mass, and the CM group 
demonstrated a significant treatment effect compared to CHO when whole body and 
regional differentials were calculated (Figure 6.1A-C). The whole body and trunk 
differentials for PLA were slightly greater than CHO, although not significantly different 
from either CM or CHO. The lack of difference in the PLA treatment from CHO 
suggests that a component of the CM treatment facilitated the significant body 
composition change; simply supplementing with an energy-containing supplement 
(CHO) did not have a significant effect compared to PLA. In fact, a slight, non-
significant increase in fat mass in the legs region was detected with CHO, whereas fat 
mass of the legs decreased in CM and PLA during the training period. To our 
knowledge, no evidence exists in the literature to suggest that post-exercise CHO 
supplementation would mediate this type of change, given that the subjects’ diets were 
not standardized and controlled during the study. However, this finding further 
underscores the difference in supplementing with a CHO+PRO-containing supplement 
versus calories from CHO alone in facilitating body composition changes. 
 
There are two possible explanations for the difference found with the CM treatment 
compared to CHO: first, the availability of amino acids (AA) in the milk for anabolism 
and muscle mass accretion, and second, a fat-loss promoting effect of dairy calcium and 
protein. It is known that AA, along with a permissive amount of insulin, is required for 
muscle protein accretion to occur in response to exercise (4, 5). The CHO treatment 
would increase plasma insulin levels and provide glucose as an energy and glycogen-
synthesizing substrate, but would provide no AA for the synthesis of new muscle protein. 
Thus, AA availability from the milk proteins whey and casein provided substrate for this 
adaptive process. In addition, Zemel and colleagues (55, 56) have shown that the 
 188 
increased consumption of dietary calcium is associated with reduced adiposity and 
greater weight loss in energy restricted diets. Moreover, the fat and weight loss effects 
were greater when the source of the dietary calcium was from dairy products rather than a 
calcium supplement (55, 56). Additional evidence that the dairy component of the CM 
treatment likely underlies some of the body composition changes is found in the 
resistance training study of Hartman and colleagues (15), who demonstrated that fat mass 
decreased, and lean mass increased, in groups provided either milk, soy, or CHO post-
exercise, but that milk significantly promoted increased hypertrophy compared to soy and 
CHO (15). Another well-known benefit of dairy calcium consumption is improved bone 
mineral density. We did not detect treatment or time differences in BMD (Table 6.4); 
however, this is not surprising, given the relatively short duration of the training program 
and the lack of a resistance training component. Taken together, these data suggest that 
the dairy component of the CM treatment was instrumental in facilitating the fat mass 
changes compared to the CHO and PLA groups, while the AA from milk proteins 
provided substrate for lean mass accretion in the present study. 
 
As shown in Table 6.5, we found no significant treatment or time differences in any of 
the blood measures taken at baseline, midpoint and the end of the training period except 
in plasma glucose, which was higher at the end of the training period in the PLA group 
compared to CM or CHO, although still within a normal fasting range. While there were 
no significant differences in the baseline glucose values among the three treatments, the 
baseline values in PLA were slightly higher in this group than the CM or CHO groups, 
which led to the treatment difference. Plasma insulin was not different between the three 
groups, and there was no treatment or time difference for the fasting glucose-to-insulin 
ratio, which is an indicator of insulin sensitivity (27). It is known that those individuals 
who train regularly have greater glucose tolerance and a lowered insulin response to a 
glucose challenge than age and weight-matched sedentary individuals (18), and that 
fasting plasma glucose decreases in obese, insulin resistant individuals after 6-10 wks of 
aerobic training (44). Since the subjects in the present study were young, healthy, and not 
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obese or insulin resistant, it is not likely that an exercise or treatment effect in these 
measures would be detected.   
 
Significant treatment differences were found for three analytes in the pre- to post-exercise 
measures in the present study: plasma IL-6, plasma cortisol, and blood lactate. Plasma IL-
6 was found to be significantly higher post-exercise in the PLA group for TT4 compared 
to both CM and CHO, whereas plasma cortisol in the CM group was higher pre- and 
post-exercise in TT2 and TT4 than CHO or PLA (Table 6.6; P<0.05). IL-6 is often used 
as marker of inflammation because it is the first cytokine to appear in response to intense 
exercise, and demonstrates the largest measurable increase. This increase can reach up to 
100-fold during exercise before declining in the post-exercise period (13, 36-38, 49). It is 
known that ingesting CHO during prolonged, intense exercise attenuates the increase in 
both pro- and anti-inflammatory cytokines, as well as the increase in cortisol, but the 
effects of training and post-exercise supplementation on the cytokine response after a 
fasted exercise bout, such as was performed in the present study, has not previously been 
characterized.  
 
While it is difficult to make a general interpretation based on a single cytokine response, 
it is important to note that IL-6 has been implicated as having important roles in 
influencing glucose homeostasis during exercise by increasing endogenous glucose 
production (12). Therefore, it may be that the increased IL-6 post-exercise found in the 
PLA group is related to a possible reduction in muscle glycogen storage in the hours after 
the daily training rides. The significantly lower lactate response during exercise in the 
PLA group appears to support this hypothesis. In the final pre-post exercise assessment 
(TT4), the PLA group had a significantly lower lactate response to the bout compared to 
the CM and CHO groups. Taken together, these data suggest that the PLA group likely 
experienced diminished muscle glycogen resynthesis during the consecutive days of 




Ostrowski and colleagues (33) previously demonstrated that strenuous, prolonged 
running elicited a dramatic increase in IL-6, as well as an increase in the pro-
inflammatory cytokines TNF and IL-1 (32-34). They also found that this increase in 
pro-inflammatory cytokines was balanced by corresponding increases in cytokine 
inhibitors IL-1Ra and soluble TNF receptors, as well as the anti-inflammatory cytokine 
IL-10 (33). IL-10 inhibits the release of TNF and IL-1 (9), which may explain why 
these two classic pro-inflammatory cytokines often do not show a large significant 
increase in exercise. IL-10 also induces production of IL-1Ra (8, 20), which is the 
antagonist of the IL-1 receptor, again possibly explaining a lack of increase in IL-1 
detection after exercise in many investigations. In the present study, however, IL-10 
increased significantly in both TTs across all groups, but IL-1Ra did not. This lack of 
significant increase during exercise in IL-1Ra may explain the significant increase in IL-
1, which increased significantly pre- to post-exercise in both TTs in all treatment 
groups. This suggests that muscle damage and inflammation, evidenced by IL-1 
elevations, was not influenced by treatment. While the pro-inflammatory cytokine TNF 
increased during both TTs, this increase reached statistical significance only in TT4 and 
in all treatment groups. Therefore, the findings of the current study suggest that the post-
exercise supplementation does not affect the inflammatory or muscle damage response to 
an acute, intense exercise bout performed in the fasted state. These results would likely 
be different if supplementation were provided during the bout itself. 
 
The significantly higher plasma cortisol in the pre- and post-TT exercise cortisol values 
in the CM group compared to the CHO group in TT2, and compared to both the CHO and 
PLA groups in TT4, is likely due to the slightly higher pre-TT (resting) levels. While no 
statistically significant treatment or time differences existed in the baseline, midpoint or 
end fasting cortisol measures, the CM group had higher plasma cortisol levels at all three 
time points than CHO or PLA. Therefore, the elevated exercise values for cortisol in the 
CM group is primarily due to higher resting values in this group compared to CHO and 
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PLA. In moderately vigorous exercise of 1 h, such as occurred in the present study, 
cortisol normally does not increase significantly. Typically, it comes into play in 
prolonged bouts, and exerts its effect hours after exercise ceases (36). Due to that lag-
time effect, cortisol is most likely responsible for maintaining the lymphocytopenia and 
neutrophilia normally seen after prolonged exercise (35). Despite the known effects on 
immune cell function and concentrations, especially on neutrophil levels and function 
(16, 48, 50), no treatment group differences existed for the immune cell counts, and the 
increases from pre- to post-exercise found in the leukocyte subpopulations are typical of 
the exercise response in these cells (29-31, 36).   
 
It is important to note that in the present investigation, we did not test immune function 
directly with measures such as lymphocyte proliferation or oxidative burst activity, but 
rather used resting and pre/post exercise immune cell concentration changes as an 
indicator of the immune response to the training and supplementation. In a previous study 
of cycling exercise training on immune function, Rhind and colleagues (45) had 
sedentary subjects perform 12 wk of cycling training at 65-70% VO2max for 30 min/d, 4-
5 d/wk (45). An acute bout of exercise (1 h at 60% VO2max) was performed before and 
after the training period, and blood was collected at rest and after exercise. Compared to 
baseline and control measures, the individuals exhibited a larger increase in the natural 
killer (NK) cell count, reduced lymphocytopenia and attenuation of exercise-induced 
suppression of lymphocyte proliferation after the training period (45), which suggests the 
possibility for improved immune system function. In the present study, we did not 
observe a significant treatment or time difference in the resting nor the pre/post exercise 
lymphocyte counts after training for 4.5 wks. It may be that the training program length 
was not long enough to sufficiently impact the immune system, and therefore detect a 
change in the cell counts. We also did not assess NK cell concentrations or activity, 
which may have yielded a better indication of immune system function or stress. At this 
time, we can conclude that 4.5 wks of cycling training for 1 h/d, 5 d/wk at ~75% VO2max 
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appears to have no deleterious or advantageous effects on immune cell concentrations at 
rest and in response to an acute, intense exercise bout. 
 
In summary, CM supplementation significantly improved body composition as defined 
by the combination of an increase in lean mass and a decrease in fat mass compared to 
CHO in response to a 4.5 wk aerobic exercise training program. In addition, these results 
also suggest that 4.5 wks of aerobic exercise training does not appear to perturb resting 
immune cell concentrations or most markers of inflammation, although no differences 
existed between the energy-containing treatments (CM and CHO) and exercise only 
(PLA). Therefore, we conclude that ingesting a CM supplement post-exercise during 4.5 
wks of aerobic exercise training can improve body composition more effectively than 
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 All subjects (32) CM (11) CHO (11) PLA (10) 
Age (y) 22.0 ± 0.5 22.1 ± 0.7 21.3 ± 0.9 22.6 ± 1.0 
Weight (kg) 71.7 ± 2.4 70.9 ± 5.1 71.2 ± 3.1 73.2 ± 4.5 
Height (cm) 168.6 ± 1.5 169.1 ± 2.3 168.0 ± 2.7 168.8 ± 3.1 
VO2max  (L·min-1) 2.6 ± 0.2 2.7 ± 0.3 2.6 ± 0.2 2.6 ± 0.2 
VO2max  (mL·kg·min-1) 35.9 ± 1.9 36.8 ± 1.4 35.7 ± 2.2 35.2 ± 2.1 
Values are mean ± SE. 
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60 min 60 min 60 min 60 min TT/blood Rest Rest 








60 min 60 min 60 min 60 min TT/blood Rest Rest 
End Blood collection, CBC, DEXA 
 
Table 6.2.  Protocol for training period 





 CM CHO PLA 
CHO, g/100 mL 11.48 15.15 0 
PRO, g/100 mL 3.67 0 0 
Fat, g/100 mL 2.05 2.05 0 
kcals/100 mL 79.05 79.05 0 
Ratio of CHO:PRO 3.12:1 -- -- 
Per 100 mL. CM, chocolate milk; CHO, carbohydrate + fat; 
PLA, placebo.  
 
 

































 Baseline End 
Weight (kg)   
   CM 71.7 ± 5.5 71.7 .± 5.5 
   CHO 71.4 ± 3.4 71.4 ± 3.4 
   PLA 73.2 ± 4.5 72.9 ± 4.4 
Lean mass,  whole 
body (kg)   
   CM 49.56 ± 4.10 50.96 ± 4.07 a 
   CHO 49.42 ± 3.74 50.06 ± 3.74 a 
   PLA 47.73 ± 3.69 48.51 ± 3.55 a 
Fat mass, whole body 
(kg)   
   CM 19.09 ± 2.18 17.72 ± 2.15  
   CHO 19.03 ± 2.13 18.46 ± 1.91  
   PLA 22.54 ± 2.57 21.54 ± 2.57 
Lean mass, trunk (kg)   
   CM 23.67 ± 1.78 24.57 ± 1.67 c 
   CHO 22.60 ± 1.69 22.74 ± 1.67 
   PLA 20.92 ± 1.64 21.32 ± 1.58 
Fat mass, trunk (kg)   
   CM 11.61 ± 1.60 10.75 ± 1.61 a 
   CHO 10.16 ± 1.26 9.59 ± 1.06 a 
   PLA 10.70 ± 1.32 10.04 ± 1.27 a 
Lean mass, legs (kg)   
   CM 17.85 ± 1.41 18.27 ± 1.39 a 
   CHO 16.68 ± 1.27 17.14 ± 1.32 a 
   PLA 15.64 ± 1.21 15.98 ± 1.16 a 
Fat mass, legs (kg)   
   CM 6.96 ± 0.89 6.57 ± 0.90 a 
   CHO 6.74 ± 0.79 6.80 ± 0.81 a 
   PLA 7.72 ± 0.83 7.49 ± 0.82 a 
Bone mineral density 
(g/cm2)   
   CM 1.24 ± 0.04 1.24 ± 0.05 
   CHO 1.21 ± 0.04 1.21 ± 0.04 
   PLA 1.18 ± 0.02 1.18 ± 0.02 
Values are mean ± SE. Significant differences:  a significant time 
effect; c CM vs CHO (P<0.05).  
 






 Baseline Midpoint End 
Glucose (mmol/L)    
   CM 4.32 ± 0.14 4.22 ± 0.13 4.20 ± 0.10 
   CHO 4.20 ± 0.22 4.13 ± 0.16 4.20 ± 0.17 
   PLA 4.55 ± 0.11 4.40 ± 0.12 4.66 ± 0.19 d 
Insulin (pmol/L)    
   CM 102.7 ± 9.1 104.1 ± 10.3 101.3 ± 7.0 
   CHO 119.8 ± 12.6 115.4 ± 16.5 123.4 ± 16.7 
   PLA 127.8 ± 13.6 112.2 ± 19.1 129.5 ± 28.9 
Glucose-insulin ratio    
   CM 5.8 ± 0.6 5.6 ± 0.6 5.5 ± 0.4 
   CHO 4.8 ± 0.5 5.3 ± 0.7 5.1 ± 0.7 
   PLA 4.8 ± 0.5 5.7 ± 0.6 5.4 ± 0.6 
Cortisol (nmol/L)    
   CM 1047.6 ± 157.9 1264 ± 228.7 1082 ± 186.3 
   CHO 953.3 ± 62.0 860.3 ± 47.5 825.0 ± 61.8 
   PLA 837.8 ± 105.3 909.8 ± 103.9 898.0 ± 95.3 
IL-1B (pg/mL)    
   CM 2.06 ± 0.72 2.22 ± 1.55 2.77 ± 1.71 
   CHO 11.60 ± 5.17 9.45 ± 6.03 6.26 ± 2.42 
   PLA 6.11 ± 2.35 5.18 ± 1.79 6.98 ± 2.95 
IL-6 (pg/mL)    
   CM 3.36 ± 1.73 3.43 ± 1.96 3.56 ± 1.93 
   CHO 8.23 ± 5.79 2.98 ± 1.95 8.52 ± 5.93 
   PLA 11.16 ± 4.46 15.85 ± 7.90  17.23 ± 7.51 
IL-8 (pg/mL)    
   CM 6.19 ± 1.56 5.30 ± 1.53 5.05 ± 1.52 
   CHO 15.73 ± 9.15 10.11 ± 6.35 13.39 ± 6.49 
   PLA 19.93 ± 8.63 18.40 ± 6.15 28.49 ± 17.42 
IL-10 (pg/mL)    
   CM 4.49 ± 2.11 4.67 ± 3.19 4.71 ± 3.07 
   CHO 4.39 ± 1.85 1.78 ± 0.85 2.45 ± 1.06 
   PLA 9.94 ± 7.84 10.28 ± 6.78 9.63 ± 7.43 
IL-1Ra (pg/mL)    
   CM 1.33 ± 0.81 7.39 ± 5.36 3.24 ± 2.10 
   CHO 1.73 ± 0.70  1.90 ± 1.41 1.59 ± 1.23 
   PLA 9.88 ± 6.60 7.51 ± 4.98 8.37 ± 5.62 
TNF(pg/mL)    
   CM 9.92 ± 3.83 11.52 ± 4.85 8.77 ± 3.26 
   CHO 8.43 ± 1.71 8.38 ± 1.76 9.48 ± 2.63 
   PLA 13.90 ± 6.11 10.80 ± 2.28 15.86 ± 5.11 
Values are mean ± SE. Significant difference: d PLA vs CM and CHO (P<0.05). 
 
 




Table 6.6. Pre- and post-exercise blood and plasma measures 
  
 
 TT2 Pre TT2 Post TT2 TT 4 Pre TT 4 Post TT4 
Glucose (mmol/L)       
   CM 4.17 ± 0.11 4.15 ± 0.17 -0.02 ± 0.6 4.26 ± 0.12 4.34 ± 0.22 0.08 ± 0.10 
   CHO 4.05 ± 0.14 4.22 ± 0.24 0.17 ± 10.0 4.11 ± 0.18 4.42 ± 0.31 0.31 ± 0.17 
   PLA 4.41 ± 0.14 4.35 ± 0.22 -0.06 ± 0.8 4.55 ± 0.12 4.64 ± 0.22  0.09 ± 0.10 
Lactate (mmol/L)       
   CM 0.88 ± 0.07 5.53 ± 0.80 a 4.65 ± 0.73 0.90 ± 0.07 5.15 ± 0.83 a 4.25 ± 0.76 
   CHO 1.00 ± 0.20 4.76 ± 0.76 a 3.76 ± 0.56 0.78 ± 0.04 6.37 ± 0.80 a 5.59 ± 0.76 
   PLA 0.99 ± 0.24 4.33 ± 0.73 a 3.34 ± 0.49 0.78 ± 0.08 3.84 ± 0.73 a e 3.06 ± 0.65 
Cortisol (pmol/L)       
   CM 1137 ± 211.8 1289.0 ± 210.6 c 152.0 ± 1.2 1236.4 ± 248.2 1309.5 ± 201.1 f 73.1 ± 47.1 
   CHO 843.3 ± 46.0 834.7 ± 63.4 -8.6 ± 17.4 766.4 ± 54.9  903.6 ± 73.2 137.2 ± 18.3 
   PLA 872.3 ± 81.0 886.5 ± 112.0 14.2 ± 31.0 945.3 ± 116.2 864.0 ± 122.2 -81.3 ± 8.0 
IL-1B (pg/mL)       
   CM 2.87 ± 1.59 3.15 ± 1.41 a 0.28 ± 0.18 2.45 ± 1.30 7.38 ± 3.27 a 4.93 ± 1.97 
   CHO 5.46 ± 1.61 9.09 ± 3.10 a 3.63 ± 1.49 4.46 ± 1.59 8.55 ± 3.03 a 4.09 ± 1.44 
   PLA 5.27 ± 2.08 6.27 ± 1.63 a 1.00 ± 0.45 6.00 ± 2.94 7.28 ± 2.62 a 1.28 ± 0.32 
IL-6 (pg/mL)       
   CM 3.81 ± 2.15 6.76 ± 4.24 a 2.95 ± 2.09 3.69 ± 2.49 8.62 ± 3.03 a 4.93 ± 0.54 
   CHO 7.38 ± 5.56 14.29 ± 8.32 a 6.91 ± 2.76 6.74 ± 3.57 7.76 ± 2.48 a 1.02 ± 1.09 
   PLA 11.73 ± 5.77 16.57 ± 7.35 a 4.84 ± 1.58 14.98 ± 7.92 26.70 ± 10.81 a e 11.72 ± 2.89 
IL-8 (pg/mL)       
   CM 3.45 ± 1.16 6.12 ± 1.83 a 2.67 ± 0.67 4.89 ± 1.53 7.97 ± 2.61 a 3.08 ± 1.08 
   CHO 13.43 ± 7.56 19.15 ± 10.21 a 5.72 ± 2.65 12.59 ± 5.82 20.21 ± 8.20 a 7.62 ± 2.38 
   PLA 15.67 ± 7.24 21.07 ± 8.79 a 5.40 ± 1.55 17.25 ± 7.56 24.85 ± 9.87 a 7.60 ± 2.31 
IL-10 (pg/mL)       
   CM 5.08 ± 3.68 9.26 ± 5.02 a 4.18 ± 1.34 5.03 ± 3.77 9.97 ± 4.07 a 4.94 ± 0.30 
   CHO 2.62 ± 1.23 4.85 ± 1.68 a 2.23 ± 0.22 2.12 ± 1.07 4.47 ± 2.34 a 2.35 ± 1.27 
   PLA 9.10 ± 7.32 13.25 ± 7.03 a 4.15 ± 0.29 9.71 ± 7.89 12.13 ± 7.72 a 2.42 ± 0.17 
IL-1Ra (pg/mL)       
   CM 2.58 ± 1.75 9.30 ± 5.99 6.72 ± 4.24 3.31 ± 2.92 8.60 ± 4.11 5.29 ± 1.19 
   CHO 0.55 ± 0.29 1.29 ± 0.71 0.74 ± 0.42 0.95 ± 0.71 1.88 ± 1.57 0.93 ± 0.86 
   PLA 5.82 ± 3.98 8.90 ± 5.90 3.08 ± 1.92 7.34 ± 5.19 10.69 ± 6.67 3.35 ± 1.48 
TNF(pg/mL)       
   CM 8.90 ± 3.31 11.04 ± 3.96 2.14 ± 0.65 8.89 ± 3.22 10.35 ± 2.86 a 1.46 ± 0.36 
   CHO 8.68 ± 2.16 9.65 ± 2.53 0.97 ± 0.37 9.03 ± 2.30 9.92 ± 2.45 a 0.89 ± 0.15 
   PLA 11.51 ± 2.89 16.84 ± 6.91 5.33 ± 4.02 10.89 ± 2.74 17.49 ± 5.50 a 6.60 ± 2.76 
Values are mean ± SE.  Significant differences:   a significant time effect from pre- to post-exercise; c CM vs CHO; e 
PLA vs CHO; f CM vs CHO and PLA  (P<0.05). 
 203 
   
Table 6.7.  Leukocytes and subpopulations 
  
 
 Baseline Midpoint End 
Pre- and Post Exercise 
TT 2 Pre TT2 Post TT 4 Pre TT 4 Post 
WBCs (x103/L)        
CM 5.59 ± 0.36 5.75 ± 0.68 5.36 ± 0.49 6.45 ± 0.43 10.44 ± 0.69 a 6.15 ± 0.46 10.22 ± 0.77 a 
CHO 6.08 ± 0.52 5.77 ± 0.26 6.15 ± 0.42 6.15 ± 0.30 8.77 ± 0.45 a 6.63 ± 0.28 9.95 ± 0.68 a 
PLA 6.14 ± 0.65 5.02 ± 0.54 5.57 ± 0.56 6.32 ± 0.50 10.20 ± 1.38 a 5.98 ± 0.34 10.24 ± 0.91 a 
Lymphocytes 
(x103/L)        
CM 2.36 ± 0.14 2.30 ± 0.28 2.38 ± 0.24 2.52 ± 0.25 3.96 ± 0.27 a 2.48 ± 0.17 4.35 ± 0.35 a 
CHO 2.71 ± 0.23 2.32 ± 0.15 2.33 ± 0.22 2.39 ± 0.08 3.52 ± 0.26 a 2.80 ± 0.22 4.33 ± 0.29 a 
PLA 2.47 ± 0.31 2.06 ± 0.22 2.25 ± 0.23 2.52 ± 0.20 3.26 ± 0.21 a 2.50 ± 0.22 3.70 ± 0.28 a 
Neutrophils 
(x103/L)        
CM 2.54 ± 0.32 2.81 ± 0.51 2.33 ± 0.28 3.32 ± 0.28 5.65 ± 0.60 a 2.97 ± 0.35 5.05 ± 0.62 a 
CHO 2.50 ± 0.45 2.72 ± 0.17 2.93 ± 0.50 2.99 ± 0.21 4.10 ± 0.30 a 3.02 ± 0.18 4.41 ± 0.51 a 
PLA 3.08 ± 0.39 2.28 ± 0.31 2.89 ± 0.36 3.12 ± 0.33 6.25 ± 1.49 a 2.62 ± 0.26 5.59 ± 0.97 a 
Monocytes (x103/L)        
CM 0.46 ± 0.05 0.39 ± 0.06 0.48 ± 0.06 0.43 ± 0.04 0.65 ± 0.06 a 0.46 ± 0.04 0.60 ± 0.06 a 
CHO 0.51 ± 0.05 0.41 ± 0.03 0.58 ± 0.05 0.48 ± 0.04 0.70 ± 0.05 a 0.51 ± 0.04 0.80 ± 0.09 a 
PLA 0.43 ± 0.06 0.39 ± 0.05 0.44 ± 0.06 0.47 ± 0.05 0.73 ± 0.09 a 0.44 ± 0.05 0.78 ± 0.09 a 










Figure 6.1.  Body composition lean and fat mass differentials. A. Whole body 
differential. Lean mass (kg) gained and fat mass (kg) lost was used to calculate a whole-
body differential to quantify overall body mass changes in response to 4.5 wks of cycling 
exercise training. (LM) – (FM) = differential. Example: (0.900 kg lean mass) - (-0.350 kg 
fat mass) = 1.250 kg. B. Lean and fat mass differential for the legs. C. Lean and fat mass 
differential for the trunk region. Values are mean ± SE. Significant treatment differences: 






Chapter VII: General Discussion 
 The goal of this series of dissertation studies was to determine the effects of 
CHO+PRO supplementation on measures of endurance exercise performance, acute 
recovery and subsequent exercise performance, and adaptations to chronic exercise 
training at the whole body, systemic and cellular levels. The results of these studies are 
summarized below. 
Several recent investigations have reported significant improvements in 
endurance exercise performance when a CHO+PRO beverage is ingested during exercise 
compared to a traditional, isocaloric 6-8% CHO beverage (9, 13-14). However, many 
athletes and recreational exercisers desire a lower carbohydrate, lower calorie alternative 
when maintaining or reducing body weight is a goal, in addition to improving fitness and 
endurance. Therefore, in the first study, we compared a supplement containing a mixture 
of CHO (dextrose, maltodextrin and fructose) plus a moderate amount of protein to a 
higher CHO (dextrose) supplement on time to exhaustion and a muscle damage marker 
(myoglobin) during prolonged intense cycling exercise in trained subjects. We found that 
the lower-CHO, moderate PRO supplement significantly improved aerobic endurance in 
an intensity-dependent manner. The significant improvement in time to exhaustion was 
found when subjects were cycling at or below the ventilatory threshold, but above that 
threshold, there was no difference between treatments in time to exhaustion. No 
difference in myoglobin was detected between treatments regardless of ventilatory 
threshold stratification. The improvement in performance occurred in the CHO+PRO 
treatment despite the supplement containing 50% less CHO and 30% fewer calories 
relative to the CHO beverage. The data suggest that the use of multiple CHO sources that 
utilize different intestinal transporters, along with the addition of protein, improved time 
to exhaustion when cycling at or below the ventilatory threshold. Thus, we conclude that 
ingestion of a lower-CHO, moderate-PRO supplement taken during endurance exercise 
can improve time to exhaustion in an intensity-dependent manner, despite containing less 
carbohydrate and fewer calories than a traditional CHO supplement.  
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In addition to the benefits of CHO+PRO supplementation when ingested during 
endurance exercise, several investigations have demonstrated that post-exercise 
CHO+PRO supplementation can restore muscle glycogen (2, 17), reduce muscle damage 
(13), and increase time to exhaustion in a subsequent exercise bout (1, 12-13, 17) 
compared to CHO alone. Post-exercise CHO+PRO supplementation has also been shown 
to alter the phosphorylation of signaling proteins related to protein synthesis (6, 11), 
although the effects when compared to CHO only and placebo (PLA) in an endurance 
exercise model has not been thoroughly characterized. Muscle protein degradation-
specific signaling has also not been well characterized in endurance exercise in response 
to CHO+PRO supplementation. While most investigations have used commercially-
available CHO+PRO supplements, we investigated the effects of a natural food, flavored 
chocolate milk (CM) as a post-endurance exercise CHO+PRO supplement compared to 
CHO and PLA on measures of recovery from an intense exercise bout in the second 
study. We found no difference between CM and CHO in muscle glycogen resynthesis 
over a 4 h recovery, although both treatments were significantly higher than PLA. 
However, subsequent time trial performance was significantly faster in the CM treatment, 
and the activation states of proteins involved in the initiation of mRNA translation for 
protein synthesis was greater than CHO or PLA. Both the CM and CHO treatments were 
more effective than PLA in reducing the signaling for protein degradation as assessed by 
FOXO3A phosphorylation.  
Additional important findings with regard to signaling protein activation were that 
the timing, as well as the nutrient content, of supplementation is critical for optimizing 
the recovery and adaptive processes. It has previously been shown that the increase in 
muscle mass is greater (3-5, 8, 15-16), and recovery and subsequent performance is 
improved (1) when supplementation is provided immediately rather than several hours 
post-exercise. In the second study, we demonstrated that when either CM or CHO 
supplementation is provided immediately post-exercise, the phosphorylation of key 
signaling proteins involved in muscle protein synthesis (e.g., mTOR and rpS6) is greater 
at 45 min of recovery (R45) than at baseline (R0), whereas in the absence of nutrients 
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(e.g., placebo), the phosphorylation status did not change. By the end of recovery, the 
signal in CM was lower than at R45, although still significant from R0. In the CHO 
treatment, mTOR and rpS6 phosphorylation had returned to the R0 value at the end, and 
PLA remained unchanged. The phosphorylation status of the muscle protein degradation 
signaling protein FOXO3A followed the same pattern at R45, with both nutrient-
containing treatments showing significantly greater phosphorylation from R0. At the end 
of recovery, the signal was still elevated in CHO compared to the R0 value. These 
lowered or non-significant end of recovery phosphorylation signals occurred despite 
ingestion of another dose of supplement at 2 h into recovery. Thus, these data suggest 
that if supplementation was delayed rather than ingested immediately post-exercise, the 
phosphorylation status of these important proteins involved in protein synthesis and 
degradation would have been diminished, and the opportunity for positive adaptation and 
optimized adaptation lessened. 
The nutrient content of the post-exercise supplementation is also of great 
importance. The findings from the second study also show that mTOR phosphorylation is 
greater in CM than CHO or PLA (e.g., exercise only) at R45, and in CM compared to 
PLA at the end of recovery. For rpS6 the findings are similar except that CHO is non-
significantly different from CM or PLA at R45. FOXO3A phosphorylation was greater in 
both CM and CHO compared to PLA at R45, and at 4 h, the phosphorylation signal was 
higher in CHO compared to PLA. Previous data from our lab have shown significantly 
greater phosphorylation of mTOR and rpS6 at 45 min post-exercise when a CHO+PRO 
supplement was ingested compared to PLA immediately after cycling exercise (6), and 
others have shown that the combination of CHO and either protein or amino acids can 
have an additive effect on protein synthesis (7, 10). Thus, it can be concluded that while 
provision of nutrients in the form of carbohydrate or carbohydrate plus protein has 
significant advantages in activating key proteins involved in protein synthesis compared 
to the absence of nutrient intake post-exercise, a CM supplement provides the greatest 
stimulus for protein synthesis. In terms of reducing degradation signaling, both CM and 
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CHO were more effective than PLA, but CHO demonstrated a stronger signaling 
stimulus at the end of recovery.  
While we demonstrated that post-exercise CHO+PRO supplementation in the 
form of CM can improve aspects of acute exercise recovery beyond that of CHO alone, 
the effects of such supplementation in a model of chronic aerobic exercise training has 
not been previously investigated. Therefore, in the third study, we compared the effects 
CM, isocaloric CHO, and PLA on cardiovascular and intramuscular adaptations that 
occurred in response to a 4.5 wk aerobic exercise training program in healthy, untrained 
subjects. Thirty-two male and female subjects were randomized into treatment groups, 
and cycled for 1 h/, 5 d/wk for 4.5 wks at 75-80% of VO2max. Supplements were 
ingested immediately and 1 h after each session. We found that while aerobic endurance 
exercise training alone increases VO2max, muscle oxidative enzyme activity, and the 
stimulus for mitochondrial biogenesis, exercise training plus CM supplementation 
yielded greater improvements in cardiorespiratory fitness (VO2max). Exercise training 
plus CHO supplementation did not demonstrate this effect. Thus, we concluded that post-
exercise CM supplementation during 4.5 wks of aerobic exercise training improved the 
magnitude of cardiovascular adaptations more effectively than isocaloric CHO or PLA.  
The fourth study demonstrated that post-exercise CM supplementation during 4.5 
wks of aerobic training improves body composition more effectively than isocaloric CHO 
or PLA. While all groups lost fat mass and gained lean mass in response to the exercise 
training, only in the CM group was this change significant from PLA when expressed as 
a whole body differential. This is a significant and novel finding, given the relatively 
short duration of the training program, the lack of a resistance training component, and 
the lack of a controlled, calorie-restricted dietary intervention.  
In the fourth study, we also demonstrated that 4.5 wks of training does not appear 
to perturb resting immune cell concentrations or markers of inflammation and muscle 
damage. Resting leukocytes and subpopulations were not significantly affected by the 
treatments or by the exercise training itself. Resting inflammatory markers also 
demonstrated no detectable perturbations from normal resting levels or between the 
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treatment groups. The expected increases in immune cells and most inflammatory 
markers from pre- to post-exercise were also not significantly affected by treatment. 
Thus, cycling at a moderately vigorous intensity for 1 h/d, 5d/wk for 4.5 wks does not 
appear to stress the immune system or increase the inflammatory response in untrained 
subjects. 
Taken together, the collective findings of these studies four suggest that 
CHO+PRO supplementation extends endurance performance, and that CHO+PRO 
supplementation in the form of CM improves recovery and increases training adaptations 
more effectively than CHO or PLA. Key applications of these findings may be important 
to several populations, such as athletes and recreational exercisers who seek to improve 
their fitness level and body composition, or those who have endurance and stamina-
requiring occupations, such as firefighters, search and rescue personnel and military 
Special Forces. Clinically relevant applications can extend to older people who exercise 
regularly and seek to maintain muscle mass and strength, or individuals of any age who 
must regain muscle mass and strength following an illness or injury.  
FUTURE DIRECTIONS 
 This series of studies has demonstrated many strengths of CHO+PRO 
supplementation and has addressed some of the potential mechanisms through which this 
supplementation is beneficial for endurance exercise performance, recovery and training 
adaptation. However, several areas warrant further investigation.  
 The most elusive aspect of these investigations is determining the exact 
mechanism(s) through which CHO+PRO supplementation actually works to improve 
performance. This could perhaps be elucidated by investigating additional measures of 
substrate utilization during exercise such as Kreb’s cycle intermediates, measuring the 
gastric emptying rate of the supplements, and using stable isotope methodology to 
determine the oxidation rates of the different types of carbohydrates in the supplements.   
In addition, there are expensive and sophisticated techniques that could address 
some of the most complex issues of both glycogen and protein synthesis, but these would 
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have to been done in collaboration with outside facilities. For example, it would be less 
invasive to address how supplementation affects liver glycogen replenishment through 
the use of NMR spectroscopy. The use of stable isotope infusions to determine the effects 
of CHO+PRO supplementation on whole-body protein kinetics and fractional synthetic 
rates in a training protocol similar to the one employed here would be beneficial as well. 
The effects of endurance exercise and nutritional supplementation on the immune 
system remains open to more investigation. Dividing training groups into intensity 
categories (e.g., low, moderate, and high intensity training groups) or administering an 
inhaled rhinovirus challenge would be interesting ways of further characterizing effects 
of exercise and supplementation on immune response. Characterizing the response of NK 
cells, and measuring functional properties of phagocytic cells would also better elucidate 
the effects of exercise and supplementation in periods of training in previously untrained 
individuals. In addition, methodological modifications such as adding a resting control 
(no exercise or supplementation) group, providing supplementation during as well as 
after each exercise bout, and increasing the duration of the training program to ~10-12 
wks would possibly allow for significant differences to be found. 
Expanding investigations of CHO+PRO supplementation on acute exercise 
recovery to other populations such as elderly subjects, or using a different exercise mode, 
such as running or resistance exercise, would broaden our understanding of how exercise 
and supplementation affects recovery from, and adaptation to, different types of exercise, 
and make results more generalizable to a wider group of exercisers. Expanding the 
training model by adding groups including a resistance training only group, and an 
aerobic exercise plus resistance training group, would lead to greater understanding of the 
effects of exercise and supplementation on body composition and measures of health. 
Applying this model to populations such as obese, insulin resistant, or elderly subjects 
would have important implications for improving our understanding of how exercise and 
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Blood Collection and Sample Preparation 
Immediately upon collection, each blood sample was anticoagulated with 0.3 ml 
of EDTA (24mg/ml, pH 7.4). An 0.5 ml aliquot of the anticoagulated blood was 
transferred to another tube containing 1 ml 10% perchloric acid (PCA). All tubes were 
centrifuged at 4˚ C for 10 min at 3,000 rpm with a HS-4 rotor in a Sorvall RC6 
centrifuge. Plasma and PCA extracts were then aliqoutted to the appropriate number of 
separate storage tubes and stored at -80˚ C until analyzed. 
Plasma Glucose  
Plasma glucose was measured using Glucose Color Reagent Kits 
(Cliniqa/Raichem, San Diego, CA). This method used glucose oxidase (GOD) and a 
modified Trinder color reaction (Trinder, 1969), catalyzed by peroxidase. GOD oxidized 
glucose to D-gluconate and formed an equimolar amount of hydrogen peroxide. 
Hydrogen peroxide oxidatively coupled 4-aminoantipyrine (4-AAP) and p-
hydroxybenzene sulfonate (p-HBS) to form a quinoneimine dye in the presence of 
peroxidase. This dye was intensely red in color, and the intensity of the color in the 
reaction solution was proportional to the glucose concentration in the sample. Three 
different concentrations of glucose were used as standards and controls to monitor the 
performance of assay procedures. All samples were run in duplicate. The coefficient of 
variation for this assay is shown in the table below. If the difference between duplicate 
results of a sample was >7% CV, the sample measurement was repeated. According to 
the manufacture’s specifications for this kit, normal fasting ranges were 70-99 mg/dl in 
healthy, non-diabetic subjects. 
Within and between assay variation was performed on three standards containing 
varying concentrations of glucose. Data (% CV) shown are from two duplicate 
determinations of each sample in seven separate assays.  
Sample No. Mean mg/dl Within % CV Between % CV 
1 50 1.9 9.3 
2 100 3.7 7.3 
3 200 3.8 2.1 
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Plasma Insulin  
Plasma insulin was measured using ImmuChemTM Coated Tube  125I  RIA  Kit 
(MP Biomedicals, LLC, Orangeburg, NY) by radioimmunoassay, which was dependent 
on the binding of an antibody to its antigen. A labeled antigen, Insulin 125I, was added to 
anti-insulin coated tubes along with the plasma samples or the insulin standards. The 
labeled antigen and the unlabeled antigen competed to bind with the insulin antibody. 
The coated tubes were then counted in a gamma counter (1470 Wizard Automatic 
Gamma Counter, PerkinElmer, Inc., Waltham, MA) calibrated for 125I to measure the 
concentration of the labeled antigen-antibody complex. Seven insulin standards (0, 5.5, 
15, 35, 175, and 310 IU/mL) were provided in the kit and were used to generate a 
standard curve. After determining the average counts per sample, the percentage of 
radioactive insulin bound to the antibody (%B/Bo) was calculated by the following 
formula: 
%B/Bo = (CPM of standard or sample/ CPM of 0 IU/mL) x 100 
The insulin concentrations of the plasma samples were then calculated using the 
equation of the standard curve. According to the manufacturer’s specifications, fasting 
levels of insulin using the ImmuChemTM Insulin RIA kit generally yielded a range of 4.3-
19.9 µIU/mL (mean = 9.6, n = 24). The minimum detectable dose using this kit was 
specified to be 4.6 µIU/mL. Intra-assay and inter-assay variations are shown in the table 
below. 
  Intra-Assay Variation(m=1) Inter-Assay Variation(m=12) 
Control n Mean SD CV% Mean SD CV% 
Pool-1 12 18.19 1.50 8.25 19.07 1.68 8.81 
Pool-2 12 36.49 1.54 4.22 35.89 3.04 5.66 
Pool-3 12 91.42 4.93 5.39 8.81 8.47 6.36 
m=number of assays   n=number of determinations 
 
All samples were run in duplicate, and 2 controls were used as a quality control 




Blood Lactate  
Blood lactate was determined from the PCA extract by an enzymatic-
spectrophotometric method based on oxidation of lactate to pyruvate by nicotinamide 
adenine dicnucleotide (NAD+) according to the protocol of Hohorst (1963). Lactate 
dehyrdogenase catalyzed the following reaction: 
Lactic Acid + NAD+  pyruvic acid + NADH  
Lactic acid was converted to pyruvate with the addition of excess NAD+ and 
LDH. NADH was measured spectrophotometrically at 340 nm (Hohorst, 1963). To 
ensure that the reaction went to completion, pyruvate was removed by the addition of 
hydrazine, which formed a complex with pyruvic acid. All samples were run in duplicate. 
Normal resting, fasted lactate levels ranged between 0.8 and 1.5 mM. 
Plasma Free Fatty Acids  
Plasma free fatty acid (FFA) concentration was measured using the colorimetric 
assay procedure of Duncombe  (1964) but modified by using the extraction reagent of 
Noma et al. (1973) and the copper reagent of Laurell and Tribbling (1967). The principle 
of the assay was based on the extraction of FFAs from the plasma using a low 
concentration of methanol with the nonpolar solvents chloroform and heptane. Using this 
combined solvent, FFAs formed copper salts when added to a copper-TEA 
(triethanolamine) solution. Then, the copper salts reacted with the sodium salt of 
diethyldithiocarbamic acid (DDC), forming a colored product. Absorbance at 436 nm is 
read 10 min after the addition of the DDC to the nonpolar solvent, the copper-TEA 
solution. Five concentrations of FFAs were used as standards for the formation of a 
standard curve: 0.125 mM, 0.25 mM, 0.5 mM, 1 mM, and 2 mM. Values were obtained 
from a standard curve calculated from a linear regression equation (y = a + bx) derived 
from the absorbance of standards. A control sample of known FFA concentration was 
used as a quality control for the instrument, reagents and technique. Within and between 
assay variation calculations were performed on four standards containing varying 
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concentrations of FFAs. The %CV from two duplicate determinations of each sample in 4 
separate assays is shown in the table below.   
Sample No. Mean µmol/mL Within % CV Between % CV 
1 0.25 5.5 5.7 
2 0.5 5.6 5.9 
3 1 4.9 2.7 
4 2 5.1 2.1 
 
If the difference between duplicate results of a sample was >10% CV, the sample 
measurement was repeated. All samples were read in duplicate. The normal fasting range 
for FFA concentration is 0.3-0.8 mM. 
Plasma Glycerol 
Plasma glycerol concentration was measured from the PCA extract according to 
the protocol of Weiland (1974).The principle of this assay is based upon the 
phosphorylation of glycerol, followed by its metabolism to dihydroxyacetone phosphate 
(DHAP), with concomitant production of NADH. Glycerol kinase (GK) converts glycerol 
and ATP to glycerol-3-phosphate and ADP. Glycerol-3-phosphate, along with NAD+, is 
then converted into DHAP and NADH, respectively, by glycerol-3-phosphate 
dehydrogenase (GPDH). The amount of NADH produced is proportional to the amount 
of glycerol present in the sample and can be read fluorometrically or 
spectrophotometrically at 340 nm (Varian Cary Eclipse, Varian, Inc., Palo Alto, CA). A 
standard curve was generated from the concentration values (y axis) vs fluorescence (x 
axis), and sample concentrations were calculated from the linear regression equation. 
Values were then multiplied by the dilution factor of 3, and values are expressed in mM. 
All samples were read in duplicate. Normal values typically are expected to range from 
0.01 - 0.3 mM. 
Plasma Cortisol 
Cortisol levels in plasma were measured using ImmuChemTM Coated Tube  125I  
RIA  Kit (MP Biomedicals, LLC, Orangeburg, NY) by radioimmunoassay, which is 
dependent on the binding of an antibody to its antigen. A labeled antigen, Cortisol 125I, 
was added to anti-cortisol coated tubes along with the plasma samples or the cortisol 
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standards. The labeled antigen and the unlabeled antigen compete to bind with the 
cortisol antibody. The coated tubes were then counted in a gamma counter (1470 Wizard 
Automatic Gamma Counter, PerkinElmer, Inc., Waltham, MA) calibrated for 125I to 
measure the concentration of the labeled antigen-antibody complex. Six standards (0, 1.0, 
3.0, 10, 30, and 100 µg/dL) were provided in the kit and were used to generate a standard 
curve. After determining the average counts per sample, the percentage of radioactive 
cortisol bound to the antibody (%B/Bo) was calculated by the following formula: 
%B/Bo = (CPM of standard or sample/ CPM of 0 µg/dL) x 100] 
The percent bound was plotted versus the concentration of the cortisol standards, 
yielding the standard curve. The cortisol concentrations of the plasma samples were then 
calculated using the equation of the standard curve. The intra-assay CV for this assay was 
8.9% for low concentration ranges (4.7 µg/dl), 5.3% of medium concentration ranges 
(18.1 µg/dl), and 6.1% for high concentration ranges (47.4 µg/dl). Inter-assay CVs were 
9.3% for low concentration ranges (4.96 µg/dl), 7.5% for medium concentration ranges 
(18.7 µg/dl), and 7.6% for high concentration ranges (50.0 µg/dl). According to the 
manufacturer’s specifications, the assay sensitivity was approximately 0.17µg/dl. All 
samples were run in duplicate, and 2 controls were used as a quality control for the 
instrument, reagents and technique. 
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Myoglobin was determined by solid phase ELISA (BioCheck, Inc., Foster City, 
CA). The test is based on directing a monoclonal antibody against a distinct antigenic 
determinant on the myoglobin molecule. Solid phase immobilization is accomplished by 
binding with mouse monoclonal anti-myoglobin antibody. A goat anti-myoglobin 
antibody is contained in the antibody-enzyme conjugate solution (horseradish 
peroxidase). When the test sample reacts with the two antibodies, the myoglobin 
molecules become sandwiched between the solid phase and enzyme-linked antibodies. 
After incubating at room temperature for 45 min, the wells were washed to remove any 
unbound labeled antibodies. Then, the wells incubated in tetramethyl benzidine (TMB) 
reagent for 20 min, which resulted in the development of a blue color. This color 
development was stopped with the addition of a stop solution, which changes the color to 
yellow. Myoglobin concentration was directly proportional to the color intensity of the 
sample, with the absorbance measured spectrophotometrically at 450 nm. All samples 
were run in duplicate, and 2 controls were used as a quality control for the instrument, 
reagents and technique. According to manufacturer’s specifications, the lowest detectable 
concentration of myoglobin by this assay is ~5 ng/ml. Precision (intra-assay and inter-
assay) is shown in the tables below: 
Intra-assay precision 
Sample 1 2 3 4 5 
# replicates 20 20 20 20 20 
Mean Myo 
(ng/ml) 55.6 214.3 294.9 505.9 1,437 
Std Dev 2.2 12.9 16.2 26.3 94.0 
% CV 3.9% 6.0% 5.5% 5.2% 6.6% 
 
Inter-assay precision 
Sample 1 2 3 4 5 
# replicates 35 35 35 35 35 
Mean Myo   59.2 244.4 330.5 568.3 1451.7 
Std Dev 4.6 12.8 38.9 52.7 104.7 




Creatine phosphokinase (CPK) was determined spectrophotometrically using the 
Creatine Kinase Reagent Kit (Pointe Scientific, Inc., Canton, MI). CPK catalyzes the 
reversible phosphorylation of ADP to form ATP from ADP and creatine phosphate. 
However, CPK activity is determined by the rate of production of NADH from additional 
reactions that follow the initial CPK-catalyzed reaction, as shown below:  
   CPK 
  ADP   +  Creatine Phosphate         Creatine    +    ATP 
          HK 
             ATP   +   Glucose          ADP   +   Glucose-6-Phosphate (G6P) 
    G6PDH 
              G6P   +   NAD+          6-Phosphogluconate  +  NADH  H+ 
 
Glucose is phosphorylated by hexokinase to form glucose-6-phosphate (G6P). G6P 
is then oxidized to 6-phosphogluconate, with concomitant NADH production. The rate of 
NADH formation is directly proportional to CPK activity when measured 
spectrophotometrically at 340 nm. According to the manufacturer’s specifications, 
within-run CV is reported to be 0.9%, and run-to-run CV is reported to be 1.0%. 
Regarding sensitivity, 1 u/L of CPK is expected to yield a Abs/min of 0.00015. 
Expected resting values for males are up to 160 U/L, and females range up to 130 U/L 
when the assay is performed at 37o C. All samples were run in duplicate. 
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Total plasma concentrations of interleukin-1 receptor antagonist (IL-1ra), 
interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), and tumor necrosis 
factor alpha (TNF) were determined using Millipore High Sensitivity Multiplex 
Cytokine Assay kits (Millipore, Billerica, MA) read on a Bio-Plex 200 multiplex 
suspension array system (Bio-Rad, Hercules, CA). This system uses Luminex xMAP 
detection technology (Luminex Corp., Austin, TX), in which fluorescently dyed 5.6 m 
polystyrene microspheres (or beads) to which antibodies are bound as the solid phase of 
the assay rather than a coated well used in traditional ELISA. Each bead set is is 
conjugated with a specific reactant for a single cytokine. A bead set for each cytokine of 
interest is provided in the kit, and the beads are carefully mixed by sonication and 
vortexing prior to being added to the sample wells. In order to optimize detection, high 
sensitivity kits were used, as well as an overnight (17 h) incubation period according to 
the manufacturer’s recommendations. 
The assays utilize a sandwich capture format. Antibody against the specific 
cytokine of interest is covalently coupled to the beads and reacts with a sample 
containing an unknown quantity of cytokine (or standard with known cytokine quantity).  
After performing a series of washes to remove any unbound protein, a biotinylated 
detection antibody specific to a different epitope on the cytokine of interest is introduced, 
resulting in the formation of a sandwich of antibodies around the specific cytokine. The 
reaction mixture is then incubated with streptavidin-phycoerythrin (streptavidin-PE) 
conjugate, which serves as the reporter molecule as it gives a fluorescent signal when 
passing through a laser as described below. The reporter binds to the detection antibodies, 
completing the reaction on the bead surface. The beads in each well are drawn up in to 
the Bio-Plex suspension array system’s flow cytometer, where they pass rapidly through 
a first laser which excites the dyes that mark the bead set specific to each individual 
cytokine. The beads then pass through a second laser that excites the streptavidin-PE, 
which is the fluorescent dye on the reporter molecules. This step allows the number of 
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reactions occurring on the surface of each cytokine-specific bead to be quantified. A 
high-speed digital signal processor identifies each individual bead and quantifies the 
cytokine assay results based on fluorescent reporter signals to determine the total amount 
of each cytokine present in each sample well. All samples were run in duplicate, and 2 
controls were used as a quality control for the instrument, reagents and technique. The 
average %CV for this assay was 10%. The Bio-Plex 200 system was validated prior to 
running the kits in each study, and the system was calibrated each day before the plates 
were read.  
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The subject’s thigh was cleansed with 10% betadine solution and then 1.6 ml of a 
local anesthesia (1% Lidocaine Hydrochloride Injection, Elkins-Sinn, Inc., Cherry Hill, 
NJ) was injected into the subcutaneous region above the vastus lateralis using a 25-guage 
hypodermic needle. A 5 mm incision was made through the anesthetized skin and fascia 
with a sterile scalpel, 2.5 inches from the midline of the thigh on the lateral side and 6.0 
inches above the patella. Once the bleeding was stopped with direct pressure over the 
incision, the muscle biopsy was taken using a 3.5 to 5 mm sterile biopsy needle with 
accompanying suction. The sample size was approximately 50 to 80 mg. Pressure was 
immediately reapplied to the incision area to stop any bleeding. The biopsy sample was 
trimmed of adipose and connective tissue and immediately frozen in liquid nitrogen at -
80o C for subsequent analysis. Once bleeding had stopped, the incision was closed with 
two skin closure strips, and a Band-Aid was applied on top of the strips. A pressure pack 
was affixed firmly over the incision and taped in place with athletic tape and adhesive 
wrap. The subjects were given verbal and written instructions on how to care for the 




Appendix E: Homogenization for Glycogen Measurement and Western 





Homogenization buffer, pH 7.4 (for 200 mL): 
 
0.9532 g  of 20 mM HEPES (H-3375)     
0.1522 g  of 2 mM EGTA (E-4378)      
0.418 g of 50 mM NaF (S-7920)      
1.492 g of 100 mM KCL (P-9333)     
0.0148 g of 0.2 mM EDTA (E-5134)     
2.16 g 50 mM Glycerophosphate (G-6521)    
0.03 g of 1 mM DTT (D-0632)      
200 L of PMSF stock (0.1 mM)    
0.03132 g of 1 mM benzamidine (B-6506)     








1. Weigh muscle samples  
2. Homogenize in 9x volume of ice-cold homogenization buffer, pH 7.4, using 3 x 5 
sec bursts with a Caframo RZR1 Homogenizer at speed 3-4. 
3. Measure exact volume of homogenate using micropipette. 
4. Centrifuge homogenates at 1000 rpm for 2 min at 4oC to collect all sample from 
tube walls. 
5. Transfer half of supernatant into separate tube for immediate use in muscle 
glycogen assay. The remaining half is immediately prepared for use in protein 
assay. 





Appendix F: Modified RIPA Buffer Preparation and Homogenization 






Modified radioimmunoprecipitation (RIPA) buffer:  
Stock Solutions (make in advance and store at 2-8oC until ready for use) 
 
Tris-Hcl, 500 ml (1M, pH 7.4). Sigma T-6066 
Add 60.55g Tris base to 400 ml deionized water.  
Stir the solution until all solid are dissolved.  
Using HCl, adjust pH to 7.4.  
Adjust volume of the solution to 500 ml using a graduate cylinder.  
Store at 2-8°C. 
 
NaCl, 100 ml (5M, pH 7.4). Fisher S271-3 
Add 29.22g NaCl to 60ml deionized water.  
Adjust pH to 7.4. Bring volume to 100 ml.  
Store at 2-8°C. 
 
Na-deoxycholate, 10 ml (10%). Sigma D5670 
Add 1g Na-deoxycholate to 10 ml deionized water.  
Store at 2-8°C. Protect stock solution from light. 
(Solution will gel after refrigeration; vortex well before use.) 
 
EDTA, 100ml (100mM, pH 7.4). Sigma ED2SS 
Add 3.722g EDTA to 80 ml deionized water.  
Adjust pH to 7.4.  
Bring solution to 100 ml using deionized water. 
Store at 2-8°C. 
 
Protease and phosphatase inhibitor stocks: 
 
NaF, 10ml (200mM). Sigma S7920 
84 mg NaF to 8 ml deionized water.  
Bring solution to 10 ml. Store at RT. 
 
Leupeptin (Sigma L2884) & Aprotinin (Sigma A1153) 
1mg/ml stock in deionized water. 
Aliquot and store at -20°C. 
 
Pepstatin (Sigma P5318) 
1mg/ml stock in HPLC-grade methanol.  
Aliquot and store at -20°C. 
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Sodium Orthovanadate 10 ml (200 mM, pH 10) Fisher S454-50 
Activation: 
Prepare a 200 mM solution of sodium orthovanadate.  
Adjust the pH to 10.0 using either 1 N NaOH or 1 N HCl.  
At pH 10.0 the solution will be yellow. Boil the solution until it turns colorless  (approx. 
3 minutes). Cool to room temperature.  
Readjust the pH to 10.0 and repeat the boiling and cooling steps until the solution 
remains colorless and the pH stabilizes at 10.0.  
Aliquot and store at -20°C. 
 
Phenylmethansulfonyl Fluoride 10ml (PMSF, 200mM) Sigma P7626 
Add 348 mg PMSF to 10ml isopropanol. Store at RT. 
(PMSF is very unstable in aqueous solution and has a half-life of ~30 min. Add 
immediately  before use.) 
 
Modified RIPA buffer preparation: 
Chemical  Stock  Final  30 ml 
Tris-Hcl, pH 7.4 1M  50mM  600 µl 
NaCl, pH 7.4  5M  150mM 90 µl 
*Igepal CA-630 10%  1%  300 µl 
Na-deoxycholate 10%  1%  300 µl 
EDTA pH 7.4  100mM 1mM  300 µl 
Na3VO4 pH 10 200mM 1mM  150 µl 
Aprotinin  1mg/ml 1mg/L  30 µl 
Leupeptin  1mg/ml 1mg/L  30 µl 
Pepstatin  1mg/ml 1mg/L  30 µl 
NaF   200mM 1mM  150 µl 
Water       28.2 ml 
PMSF   200mM 1mM  150 µl 
*Igepal CA-630 (Sigma I8896) is used in place of NP-40. 
 
PROCEDURE: 
1. Prepare modified RIPA buffer and add inhibitors to the buffer stock. 
2. Weigh muscle samples. 
3. Homogenize in 9x volume of ice-cold modified RIPA homogenization buffer 
using 4 x 5 sec bursts with a Caframo RZR1 Homogenizer at speed 3-4. 
4. Freeze at -80oC for 30 min, and thaw over ice (30 min). Vortex well. 
5. Repeat freeze-thaw-vortex steps two more times. 
6. Sonicate thawed homogenates on ice for 10 sec. 
7. Centrifuge homogenates at 5000xg for 20 min at 4oC. 










1 N KOH (for 500 mL): 
28.01 g KOH (Fisher P250) into 500 mL ddH2O 
 
1 N NaOH (for 200 mL): 
8 g NaOH (Fisher S318-3) into 200 mL ddH2O 
 
50% glacial acetic acid (for 200 mL): 
100 mL glacial acetic acid (Sigma A9967) 
100 mL ddH2O 
 
10 mg/ml amyloglucosidase in sodium acetate (for 40 mL): 
40 mg amyloglucosidase (Sigma 10115) 




1. Homogenize muscle tissue samples as described in Appendix E. 
2. Add 1 ml of ice-cold 1N KOH into each homogenate tube specified for use in the 
glycogen assay. 
3. Incubate the homogenate + 1 ml of 1N KOH at 60oC for 20 min, vortexing 
vigorously every 5 min.  
4. Transfer 100 µl aliquot of the KOH-digested homogenate to 250 µl of 0.3 M sodium 
acetate, pH 4.8, and vortex.  
5. Add 10µl of 50% of glacial acetate acid to each of the tubes. 
6. Add 250 µl of 0.3 M sodium acetate, pH 4.8, containing 10 mg/ml amyloglucosidase 
to each tube and vortex.  
7. Seal tubes with parafilm and incubate overnight at room temperature. 
8. The following day, add 25 µl of 1 N NaOH to each sample tube and vortex to 
terminate reaction. 
9. Set up 12 x 75 mm test tubes for Raichem Trinder assay for determination of 
liberated glucose.  
10. Prepare Raichem color reagent according to product insert and pipet 1.5 mL of 
reagent into each tube, including two standards and samples in duplicate and a 
blank. 
11. Pipet duplicate 100 µl aliquots into test tubes for the Trinder reaction to begin. Use 2 
duplicate glucose standards (4.505 mg and 9.01 mg glucose/dL dH2O) to run in 
parallel with the muscle samples.   
12. Incubate at 37 oC for 15 min in a skaing bath set to speed of 50. 
13. Read the absorbance at 500 nm, setting the instrument to 0 by blanking with the 






1. (Ab sample / Ab standard) × (standard conc. = 4.505 mg/dl) = mg/dl 
2. Dilution factors 
DF1: (1000 l + half volume in µl of muscle homogenate)/100l = l 
DF2: [(0.25 ml + 0.01 ml + 0.25 ml + 0.025 ml) + 0.1 ml]/0.1 ml = 6.35 
DF3: volume in cuvette, same in standard = 1 
3. Final Calculation: 
 [(mg/dl) × (0.1 ml/100 ml) × DF1 × DF2 × DF3]/half muscle weight (g) = mg 
glycogen/g muscle  
{[(mg glycogen/g muscle)/1000]/180.2}*106 = mol glycogen/g muscle  
  
 235 
Appendix H: Determination of Muscle Protein Concentration  





2% Sodium carbonate 
20 g Sodium carbonate into 1 L 0.1 N NaOH 
 
0.1 N NaOH 
4 g NaOH (Fisher S-318-3) into 1000 mL ddH2O 
 
1% Cupric sulfate 
2 g cupric sulfate (Fisher C-489) in 200 mL ddH2O 
 
2% Sodium potassium tartrate 




1. Thaw 1 aliquot of 5 mg/mL BSA stock on ice. 
2. Using the half of total homogenized muscle sample as described in Appendix E, 
centrifuge at 14,000 G for 10 min.  
3. For each sample, transfer 7 l of supernatant to labeled microcentrifuge tube 
containing 273 l ddH2O and vortex. 
4. Aliquot the remaining supernatant into 4 0.5 mL microcentrifuge tubes per sample. 
(Each aliquot will contain was ~30 l of sample supernatant.) Freeze in liquid nitrogen 
immediately and quickly store in -80OC freezer. (Freeze pellet separately at -80O.) 
5.  Perform serial dilution: 
 ddH2O (mL) Std protein (mL) [protein] (mg/mL) 
Blank 1.0 0 0 
A 1.8 0.2 of BSA Stock .5 
B 0.2 0.8 of A .4 
C 0.5 0.5 of B .2 
D 0.5 0.5 of C .1 
E 0.5 0.5 of D .05 
F 0.5 0.5 of E .025 
 
6. Dilute samples 1:30 with ddH2O (10 l of sample + 290 l ddH2O) or 1:40 with 
ddH2O (7 l of sample + 273 l ddH2O) and keep on ice.  
7. Make Solution A (1 mL per tube needed) in a 125 mL Erlenmeyer flask: 
 
96 mL 2% Sodium carbonate  Stir with stir bar 
2 mL 2% Sodium potassium tartrate  Gently layer 
2 mL 1% Cupric sulfate  Gently layer 
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8. Add 0.1 mL of each standard or sample to each corresponding tube and duplicates. 
9. Add 1.0 mL of Solution A to every tube except blank. Vortex each tube after Solution 
A is added to all.  
10. Incubate at room temperature for 10 min.  
11.  Dilute Folin & Ciocalteu’s Phenol Reagent (Sigma F-9252) 1:2 with ddH2O. Stir 
briefly. 
12.  After 10 min incubation, pipet 0.1 mL of phenol solution directly into the center of 
each tube (standards & samples) while vortexing each tube, and without touching sides of 
tube.  
13. Incubate 30 min at room temperature.  
14. Turn on spectrophotometer and set to 750 nm. 
15. After incubation, and after blanking the spectrophotometer to the prepared blank, read 
absorbance of all standards and samples in duplicate at 750 nm.  
16. Generate standard curve from absorbances of the 6 standards. Using the equation 
from the standard curve, to calculate the protein amount in the sample (average of each 
sample and its duplicate). Multiply the amount by the dilution factor (30 or 40) for the 
final protein concentration in each sample.  
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The following directions are for making stock solutions for the SDS-PAGE procedure: 
 
2x Sample buffer (for 50 mL):  
5 mL of 1.25M Tris, pH 6.8 
26.2 mL ddH2O       
10 mL glycerol      
5 mL 20% SDS (Sigma L-3771)      
2.25 mL of 2-mercaptoethanol (Sigma M-6250) (add under fume hood) 
1.6 mL of 0.25% bromophenol blue solution 
  
0.25% Bromophenol blue (for 5 mL): 
0.0125 g bromophenol blue (Sigma B-5525) in 5 mL ddH2O 
 
Acrylamide mix (30% mixed acrylamide and 1% bisacrylamide) (for 200 mL): 
58 g acrylamide (Sigma A8887) 
2 g bisacrylamide (Sigma M7279) 
Bring final volume to 200 mL with ddH2O 
Filter through Whatman No. 1 filter paper. Store at 4oC in a dark bottle. 
 
1.5 M Tris, pH 8.8 (for 500 mL): 
90.82 g Trisbase (Sigma T-6066) into 400 mL ddH2O. 
Adjust to 8.8 pH with concentrated HCl. 
Bring final volume to 500 mL with ddH2O and recheck pH. 
Store at room temperature. 
 
1.0 M Tris, pH 6.8 (for 500 mL): 
60.57 g Trisbase (Sigma T-6066) into 400 mL ddH2O. 
Adjust to 6.8 pH with concentrated HCl. 
Bring final volume to 500 mL with ddH2O and recheck pH. 
Store at room temperature. 
 
20% Sodium dodecyl sulfate (SDS) (for 100 mL): 
20 g molecular biology-grade SDS (Sigma L-3771) into 100 mL ddH2O. 
Filter through Whatman No. 1 filter paper. Store at room temperature. 
 
10% Ammonium persulfate (APS) (for 1 mL): 
100 mg of APS (Sigma A-3678) into 900 L ddH2O. 
Prepare fresh daily. 
  
TEMED (N,N,N’,N’-Tetramethylethylenediamine) 
Sigma T9281. Store at 4oC. 
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10x Running buffer (for 1 L): 
800 mL ddH2O 
30.28 g Trisbase (Sigma T-6066) 
144.2 g Glycine (Sigma G-8898) 
Bring to 1000 mL ddH2O 
 
1x Running buffer (for 1 L): 
100 mL 10x Running buffer 
5 mL of 20% SDS (Sigma L-3771) 
900 mL ddH2O 
 
Resolving Gel (10%) 
 For 2 gels (mL) For 4 gels (mL) 
ddH2O 4.0 7.9 
Acrylamide mix 3.3 6.7 
1.5 M Tris, pH 8.8 2.5 5.0 
20% SDS 0.1 0.2 
10% APS 0.1 0.2 
TEMED 0.004 0.008 
Stacking Gel 
 For 2 gels (mL) For 4 gels (mL) 
ddH2O 3.4 6.8 
Acrylamide mix 0.83 1.7 
1.5 M Tris, pH 8.8 0.63 1.25 
20% SDS 0.05 0.1 
10% APS 0.05 0.1 




1. Assemble gel apparatus in casting stands according to manufacturer’s 
instructions. 
2. Prepare resolving gel solution for the number of gels to be cast. 
3. Gently swirl solution. Use a transfer pipette to fill the caster ~3/4 full. Overlay 
resolving gel with 200 L butanol.  
4. Allow ~45 min for gel to polymerize. 
5. Pour butanol off of the resolving gel and rinse well with ddH2O. Dry between 
casting plates as much as possible with a KimWipe. 
6. Prepare stacking gel solution for the number of gels to be cast. 
7. Gently swirl solution. Use transfer pipette to completely fill rest of the caster to 
the top with the stacking gel solution. Carefully insert 15-well comb, avoiding any 
bubble formation. 
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8. Allow ~45 min for polymerization. 
9. During polymerization, prepare samples with sample buffer. Thaw and vortex 
samples. Dilute the samples 1:2 with 2x sample buffer in 0.5 mL microcentrifuge 
tubes (e.g., 10.2 l sample + 10.2 l sample buffer). 
10. Vortex samples + buffer after all samples are prepared. Place tubes in a tube 
holder, and allow to float in boiling water (~99oC) for 6 min. 
11. Transfer tubes into microcentrifuge and spin for ~5 seconds to collect all sample 
+ buffer solution into the bottom of the microcentrifuge tube. 
12. Prepare 1x Running buffer. 
13. After gels have polymerized, carefully remove the 15-well combs and assemble 
the gel apparatus and electrophoresis chamber according to the manufacturer’s 
instructions. Fill inner chamber with 1x Running buffer and the outer chamber to 
~1/3 full with 1x Running buffer. 
14. Load 60 g muscle homogenate (~10 – 20 L sample + buffer) and  rat muscle 
standard into wells. Load molecular weight marker in 2-3 wells per gel. 
15. Electrophorse at 200 V for 1:34 for gel used for p-mTOR, p-FOXO3A and -
tubulin, 45 min for the gel used for ubiquitination, p-rpS6, p-eIF2B and -tubulin, 
and 75 min for PGC-1. 
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The following directions are for making stock solutions for the procedure: 
 
Anode I (for 1 L): 
800 mL ddH2O 
36.33 g Trisbase (Sigma T-6066) 
0.5 g SDS (Sigma L-3771)  
100 mL Methanol (Fisher A-411-4) 
0.78 mL 2-mercaptoethanol (Sigma M-6250) (add under fume hood) 
Bring volume to 1000mL with ddH2O 
 
Anode II (for 1 L): 
800mL ddH2O 
3.025 g Trisbase (Sigma T-6066) 
0.5 g SDS (Sigma L-3771)  
100 mL Methanol (Fisher A-411-4) 
0.78 mL 2-mercaptoethanol (Sigma M-6250) (add under fume hood) 
Bring volume to 1000mL with ddH2O 
 
Cathode (for 1 L): 
800mL ddH2O 
3.025 g Trisbase (Sigma T-6066) 
0.5 g SDS (Sigma L-3771)  
5.248 g 6-Aminocaproic acid (Sigma A-2504) 
100 mL Methanol (Fisher A-411-4) 
0.78 mL 2-mercaptoethanol (Sigma M-6250) (add under fume hood) 




1. During the last few minutes of the SDS-PAGE procedure, pre-wet the PVDF 
membranes in methanol, and then soak in Anode I solution for 10 minutes. 
(Use one PVDF membrane per gel, cut to ~6 cm x 9 cm each. Mark the left 
edge to identify each membrane to correspond to each gel.) 
2. When the gel electrophoresis is complete, remove the resolving gel from the 
casting plates and soak in Anode I solution for at least 5 min. Make a small cut 
on the top corner of gel above lane 1 for identification purposes. 
3. Briefly soak 2 sheets of filter paper (one think and one thin) in Anode II 
solution. Place the thin sheet on the Bio-Rad Trans-Blot Semi-Dry electrode. 
Place the thick sheet directly on top of the thin sheet. Using a glass test tube, 
press and roll the tube across the sheets to eliminate any bubbles and assure 
even contact between the two sheets. 
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4. Remove the PVDF membrane from the Anode I solution and place on top of 
the filter papers. Remove air bubbles carefully with a glass test tube, wet with 
Anode I solution. 
5. Carefully remove the gel from the Anode I solution and place on top of the 
PVDF membrane. Remove air bubbles very carefully with a glass test tube, 
wet with Anode I solution. Take extra care to assure that the gel is straight on 
the membrane and does not tear. 
6. Briefly soak 2 sheets of filter paper (one think and one thin) in Cathode 
solution. Place the thick sheet on top of the gel and carefully smooth the sheet 
out with a glass test tube. Place the thin sheet directly on top of the thick sheet. 
Using a glass test tube, press and roll the tube across the sheets to eliminate 
any bubbles.  
7. Repeat the above process for additional gels. Place the top electrode plate atop 
the stacks, and place the transfer unit cover securely on the unit. 
8. Transfer the proteins from the gel to the PVDF membrane at 25 V for 18 min 
for the gels and membranes used for p-mTOR and p-FOXO3A, and PGC-1, 
and at 25 V for 15 min for gels and membranes used for ubiquitination, p-
eIF2B, and p-rpS6. 
9. Following the transfer, place the PVDF membrane in ddH2O and refrigerate at 




Appendix K: Immunoblotting Procedures 
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SOLUTIONS: 
The following directions are for making stock solutions: 
 
10x Tris-buffered saline (TBS; pH 7.5) (for 1 L): 
800 mL ddH2O 
60.05 g Trisbase (Sigma T-6066) 
87.6 g NaCl (Fisher S271-3) 
Bring to pH 7.5 with concentrated HCl. 
Bring to 1000 mL ddH2O 
 
1x Tris-buffered saline + 0.06% Tween-20 (1 xTTBS) (for 1 L): 
100 mL of 10x Tris-buffered saline (TBS; pH 7.5) 
900 mL ddH2O 
0.6 mL Tween-20 (Sigma P-1379) 
 
1x Tris-buffered saline + 0.1% Tween-20 (for 1 L - for PGC-1) 
100 mL of 10x Tris-buffered saline (TBS; pH 7.5) 
900 mL ddH2O 
1.0 mL Tween-20 (Sigma P-1379) 
 
Blocking solution: 6% Non-fat dry milk (NFDM) and 1x TTBS (for 100 mL, enough 
for 2 membranes) (for p-mTOR, p-FOXO3A, p-rpS6 and -tubulin membranes) 
100 mL of 1x TTBS 
6 g NFDM 
 
Blocking solution: 5% BSA and 1x TTBS (for 100 mL, enough for 2 membranes) 
(for p-eIF2B membranes) 
100 mL of 1x TTBS 
5 g BSA (ICN 105033) 
Stir gently on ice for ~1 h until dissolved. 
 
Blocking solution: 10% NFDM and 1x TBS + 0.1% Tween 20 (for 100 mL, enough 
for 2 membranes) (for PGC-1 membranes) 
100 mL of 1x TBS + 0.1% Tween 20 





 Dilution ratio Dilution solution Company and Catalog # 
p-mTOR 1:800 2% NFDM-TTBS Cell Signaling, 2971 
p-FOXO3A 1:500 5% BSA-TTBS Cell Signaling, 9465 
p-rpS6 1:1000 2% NFDM-TTBS Cell Signaling, 2211 
p-eIF2B 1:1000 1% BSA-TTBS EMD/Calbiochem, PS1017 
Ubiquitin 1:500 2% NFDM-TTBS Santa Cruz, 9133 
PGC-1 1:1000 3% NFDM-TTBS* EMD/Calbiochem, 516557 
-tubulin 1:900 2% NFDM-TTBS Cell Signaling, 2144 
 
Secondary Antibody: 
Protein of Interest Dilution ratio Dilution solution Secondary Antibody 
p-mTOR 1:800 2% NFDM-TTBS  
 
Goat Anti-rabbit IgG 
(Cell Signaling 7074) 
p-FOXO3A 1:1500 5% NFDM-TTBS 
p-rpS6 1:1500 2% NFDM-TTBS 
p-eIF2B 1:3000 1% BSA-TTBS 
Ubiquitin 1:1500 2% NFDM-TTBS 
PGC-1 1:7500 3% NFDM-TTBS* 
-tubulin 1:1000 2% NFDM-TTBS 
 
Stripping buffer,  pH 6.7 (for 1 L): 
850 mL ddH2O 
20g of 2% sodium dodecyl sulphate (SDS) (Sigma L-3771)  
7.5 g Trisbase (Sigma T-6066) 
Stir, then add 7 mL of 100 mM 2-mercaptoethanol (perform this step under fume hood) 
Measure pH 




1. Block PVDF membranes in appropriate blocking solution (above) for 1 h at 
room temperature with gentle shaking. (For PGC-1, block for 2 h) 
2. Perform 3 x 5  min washes in 30 mL TTBS 
3. Cut PVDF membranes in sections according to molecular weight markers to 
probe individually for proteins of interest. 
4. Incubate each PVDF membrane/membrane section in 10 mL of the respective 
primary antibody solutions overnight on a rocking platform at low speed (1.5) 
in 4oC refrigerator. 
5. Perform 3 x 5 min washes for each membrane section in 30 mL TTBS. 
6. Incubate each PVDF membrane/membrane section in 10 mL of the respective 
secondary antibody solutions for 100 min (p-mTOR, p-FOXO3A, p-eIF2B, 
 248 
PGC-1 and -tubulin) or 120 min (ubiquitination and p-rpS6) with gentle 
shaking at room temperature. 
7. Perform 3 x 5 min washes for each membrane section in 30 mL TTBS. 
8. Visualize bands using ECL detection (ECL Western Lighting Plus kit, Perkin 
Elmer) with a Bio-Rad ChemiDoc. Analyze bands (intensity x mm2) using 
Quantity One 1.0 1-D Analysis software.  
 
Exposure times: 









9. Store membranes in ddH2O in 4oC. 
10. If stripping to reprobe, perform 2 x 5 min washes in 30 mL TTBS.  
11. Wash membrane in 30 mL stripping buffer for 1 h in 60oC shaking water bath 
at 65 rpm. 
12. Perform 3 x 5 min washes for each stripped membrane section in 30 mL 
TTBS. 




Appendix L: Measurements of Muscle Enzyme Activity 
 
 
Succinate Dehydrogenase Activity 
 







Homogenization buffer (for 500 mL): 
35 L 2-mercaptoethanol, 10mM (Sigma M6250) 
25 mg BSA (0.05%) (ICN 105033)  
500 mL potassium phosphate buffer, 0.17 M, pH 7.4 
 
0.17 M phosphate buffer, pH 7.4 (for 500 mL): 
11.6 potassium phosphate (Sigma P-0662) 
500 mL ddH2O 
 
Incubation medium (for 1 mL):  
160 mg sodium succinate (Sigma 52378) 
2.6 mg potassium ferricyanide (Sigma 702587) 
1 mL 0.17 M phosphate buffer, pH 7.4.  
 
Fluorometric reaction medium (25 mL): 
25 mL hydrazine-HCl buffer, 0.2 M, pH 9.2  
90 L 0.1 M NAD, 0.36 mM 
 
Hydrazine-HCl buffer, 0.2 M, pH 9.2 (for 500 mL): 
4.9 mL hydrazine hydrate (Sigma H-9507) into 495.1 mL ddH2O 
Bring to pH 9.2 with HCl 
 
NAD, 0.1 M (for 3 ml): 
198 mg NAD (Sigma N-7004) into 3 mL ddH2O 
 
Enzyme mix stock with 10 g/mL fumarase and 200 g/mL MDH (for 5 mL): 
4.528 mL of 0.17 M phosphate buffer, pH 7.4 
454 L MDH (2.2 mg/mL) (Sigma F-1757) 
17.2 L fumarase (2.9 mg/mL) (Sigma M-9004) 
 
NADH standard, 1 mM (for 10 mL): 
7.09 mg NADH (Sigma N-4505) into 10 mL ddH2O 
 
Deproteinizing and neutralizing reagents: 
3 M PCA (for 100 mL): 
[(3 x 100.46 MW)/10]/0.70 = 43 mL 70% PCA (Fisher A229) into 57 mL ddH2O 
 
3 M KOH (for 100 mL): 





1. Homogenize ~20 mg of frozen tissue in the homogenizing buffer. Dilute 1:70.  
2. For each homogenate sample, prepare three 12 x 75 glass culture tubes on ice. 
Pipet 0.1 mL homogenate into each tube in duplicate (third tube is for blank). 
3. Place incubation medium into a 37oC water bath, followed by the sample tubes. 
Allow about 1 min to reach proper temperature. (Keep blanks on ice.) 
4. Add 0.1 mL incubation medium to each sample tube, mix gently, and incubate for 
exactly 5 min.  
5. After the 5 min incubation, stop the reaction by adding 0.1 mL PCA into each 
tube. Mix and return the tube to the ice bath.  
6. Pipet 0.1 mL PCA into blank tubes, followed by adding 0.1 mL incubation 
medium to each blank. 
7. On ice, add 0.1 mL KOH to each tube including blanks. Total volume should be 
0.4 mL. 
8. Centrifuge all tubes briefly to pellet the potassium perchlorate precipitate and 
return then to the ice bath. 
9. Pipet 1 mL of hydrazine/NAD cocktail into 10 x 75 glass culture tubes. 
10. Pipet 50 L of each sample and blank into a corresponding cocktail tube. Make a 
tube of 50 L thawed NADH to use as standard. 
11. Add 1.9 mL ddH2O to each tube. 
12. On fluorescent spectrophotometer, read and record initial fluorescence of each 
tube. 
13. Add 25 L aliquot of enzyme mix to each tube and mix. Let stand at room 
temperature for 1 hour. 
14. Read and record final fluorescence of all tubes. Subtract initial fluorescence from 
final fluorescence value, as well as the change in the blank fluorescence from the 




Calculate the results by the following formula: 
 
      (dFsamp/dFstd) x (mM[std] x mLstd) x dilutionsamp + grams of tissue + timemin = 
mol/min/g 
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Citrate Synthase  
 
SOLUTIONS: 
Homogenizing buffer, pH 7.4 (for 500 mL): 
6.525 g 0.175 M KCl (Fischer P217) 
0.37225 g 2 mM EDTA (sigma E-5134) 
500 mL ddH2O 
Bring to pH 7.4 with HCl 
 
Tris buffer, 100 mM, pH 8.3 (for 500 mL): 
6.055 g Trizma base (Sigma T-6066) into 500 mL ddH2O 
Bring to pH 8.3 with HCl 
 
DTNB, 1 mM (for 10 mL): 
4 mg DTNB (Sigma D-8130) in 10 mL of 100 mM Tris buffer, pH 8.3 
 
Oxalacetate, 10 mM (for 10 mL): 
Dissolve 13.2 mg oxalacetate (Sigma O-4126) in 10 mL of 100 mM Tris buffer, pH 8.3 
 
Acetyl Co-A, 3 mM (for 1 mL): 
10 mg Coenzyme-A (Sigma C-3144) in 0.9 mL ddH2O 
0.1 mL 1 M KHCO3  
0.013 mL acetic anhydride (Fischer A-10) 
 
KHCO3,1 M (for 100 mL): 
10.012 mg KHCO3 (Sigma P-184) in 100 mL ddH2O 
 
0.4% Triton 100 in 0.1 M Tris buffer, pH 8.3 (for 1 mL): 
0.8 mL Triton 100 stock solution (Sigma T8787) in 200 mL of 100 mM Tris buffer, pH 
8.3 
 
Reagent Cocktail: (Prepare each assay tube individually in the cuvette that will go into 
the spectrophotometer according to protocol below) 
770 L Tris buffer 
30 L acetyl-CoA 
100 L DTNB (light sensitive; protect from light with foil wrap)  




1. Homogenize ~20 mg frozen tissue in 1:30 dilution and centrifuge 5 min. Pipet 
supernatant for 100 L aliquots. Freeze overnight at -20oC. 
2. Next day: Set spectrophotometer for enzyme kinetic assay at 412 nm and 37oC. 
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3. Thaw the 100 L homogenates on ice before adding 900 L 0.4% Triton 100 in 
0.1 M Tris buffer. Incubate at room temperature for 20  min. 
4.  Place empty cuvettes into the spectrophotometer to keep them at 37oC.  
5. Add the reagent cocktail reagents (above) to each one, pipet-mixing each time. 
6. Blank the spectrophotometer. 
7. Measure absorbance for ~90 sec to see if the reagent cocktail is stable. 
8. Quickly add 60 L oxalacetate to each cuvette, pipet-mixing vigorously. Begin 
reading absorbance at 30 sec intervals. Run for a total of 6 minutes and use the 




Calculate results based on the molar extinction coefficient for DTNB at 412 nm 
(13,600) and dilutions of the tissue, as follows: 
 
(Abs/min) x )1/13.6) x dil. of homogenate x dil of tissue in assay vol = mol/min/g 
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Fat and Carbohydrate Oxidation Rate Calculations 
 




Subjects breathed through a Hans Rudolph valve, with expired gases directed to a 
mixing chamber for analysis of oxygen (O2) and carbon dioxide (CO2) using a 
ParvoMedics TrueOne2400 metabolic system (ParvoMedics, Sandy, UT). Ventilation, O2 
consumption (VO2), CO2 production (VCO2), and respiratory exchange ratio (RER) was 
calculated and recorded by the system every 15 s. 
 
Fat and Carbohydrate Oxidation Rate Calculations 
Fat and carbohydrate oxidation rates were calculated from the VCO2 and VO2 
values using the equations of Frayn (1983): 
   
CHO oxidation (g·min-1) = [(4.55 x VCO2) – (3.21 x VO2) – (2.87n)] 
 
  Fat oxidation (g·min-1) = [(1.67 x VO2) – (1.67 x VCO2) – (1.92n)] 
 
Where VO2 and VCO2 are expressed in L·min-1, and n is the nitrogen excretion rate, 
based on the average of 135 g/kg/min (Romijn et al, 2000) and estimated for all subjects 
to be 0.002 g/kg/min. 
 
Energy Expenditure Rate Calculations 
 
Average CHO and fat energy expenditure rates (EE, kcal·min-1) were calculated from the 
above CHO and fat oxidation rates using the Atwater general conversion factors for CHO 
and fat (1909): 
 
CHO EE (kcal·min-1) = [(4.55 x VCO2) – (3.21 x VO2) – (2.87n)] x 4.2 
 
  Fat EE (kcal·min-1) = [(1.67 x VO2) – (1.67 x VCO2) – (1.92n)] x 9.1 
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(L/min) HRmax Wattsmax 
Weight 
(kg) 
BM M 33 175 4.540 68.85 3.54 189 339 65.9 
CJ M 20 175 4.490 67.85 3.37 197 335 66.6 
CW M 36 180 4.780 55.70 3.49 171 358 85.8 
DF M 26 171 4.005 61.80 3.00 203 296 64.8 
EM M 28 177 4.380 60.90 3.29 207 326 71.9 
EMC F 27 164 2.890 46.15 2.14 172 207 62.6 
JB F 27 159 3.125 53.25 2.31 196 226 58.7 
JC F 26 163 2.275 44.45 1.73 176 158 51.2 
JG M 26 171 4.700 73.45 3.43 186 352 64 
JL M 27 170 4.490 68.80 3.46 178 335 65.3 
KJ F 35 160 1.860 40.40 1.40 189 125 46 
KM F 32 179 3.310 47.00 2.58 183 241 70.4 
LM F 30 183 3.450 46.80 2.59 169 252 73.7 
MP M 35 187 4.465 64.75 3.48 196 333 68.9 
MU F 23 166 3.405 47.05 2.52 186 248 72.4 
AVG   28.7 172.0 3.7 56.5 2.8 186.5 275.4 65.9 
SEM   1.2 2.2 0.2 2.8 0.2 3.0 19.1 2.4 
 











(L/min) HRmax Wattsmax 
Weight 
(kg) 
CJ M 20 175 4.490 67.85 3.37 197 335 66.6 
CW M 36 180 4.780 55.70 3.49 171 358 85.8 
EM M 28 177 4.380 60.90 3.29 207 326 71.9 
JG M 26 171 4.700 73.45 3.43 186 352 64.0 
JL M 27 170 4.490 68.80 3.46 178 335 65.3 
KJ F 35 160 1.860 40.40 1.40 189 125 46.0 
MU F 23 166 3.405 47.05 2.52 186 248 72.4 
AVG   27.9 171.3 4.0 59.2 3.0 187.7 297.0 67.4 
SEM   2.2 2.6 0.4 4.6 0.3 4.5 31.8 4.5 
 











(L/min) HRmax Wattsmax 
Weight 
(kg) 
BM M 33 175 4.540 68.85 3.54 189 339 65.9 
DF M 26 171 4.005 61.80 3.00 203 296 64.8 
EMC F 27 164 2.890 46.15 2.14 172 207 62.6 
JB F 27 159 3.125 53.25 2.31 196 226 58.7 
JC F 26 163 2.275 44.45 1.73 176 158 51.2 
KM F 32 179 3.310 47.00 2.58 183 241 70.4 
LM F 30 183 3.450 46.80 2.59 169 252 73.7 
MP M 35 187 4.465 64.75 3.48 196 333 68.9 
AVG   29.5 172.6 3.5 54.1 2.7 185.5 256.5 64.5 






 Time to Exhaustion Time to Exhaustion Time to Exhaustion 
Combined Group At or Below VT Above VT 
Subject CHO MCP Subject CHO MCP Subject CHO MCP 
BM 42.20 42.48 BM 42.20 42.48 CJ 27.73 23.45 
CJ 27.73 23.45 DF 34.35 41.38 CW 14.57 12.63 
CW 14.57 12.63 EMC 16.08 24.08 EM 12.82 13.27 
DF 34.35 41.38 JB 31.63 38.68 JG 20.7 12.08 
EM 12.82 13.27 JC 31.7 46.52 JL 17.05 9.17 
EMC 16.08 24.08 KM 42.27 65.75 KJ 5.58 23.50 
JB 31.63 38.68 LM 68.93 84.67 MU 8.27 6.62 
JC 31.7 46.52 MP 16.62 21.58 AVG 15.25 14.39 
JG 20.7 12.08 AVG 35.47 45.64 SEM 2.83 2.50 
JL 17.05 9.17 SEM 5.94 7.38 
KJ 5.58 23.50 
KM 42.27 65.75 
LM 68.93 84.67 
MP 16.62 21.58 
MU 8.27 6.62 
AVG 26.03 31.06 





Study 1 Insulin (pmol/L) - Combined Group CHO MCP 
Subject Pre Min 118 Min 177 End Pre Min 118 Min 177 End 
BM 55.35 56.19 55.84 37.09 59.59 50.49 41.18 43.41 
CJ 65.07 48.96 76.33 31.67 58.06 46.11 45.14 27.22 
CW 101.12 82.23 85.98 76.40 111.61 101.47 97.92 75.42 
DF 83.34 65.21 71.81 35.28 72.99 62.99 56.74 38.34 
EM 42.02 22.64 27.15 21.53 38.68 18.33 25.35 14.86 
EMC 68.82 55.84 76.67 57.78 56.12 54.87 41.88 47.43 
JB 73.27 23.40 47.78 10.83 55.56 36.67 27.50 12.78 
JC 90.56 100.91 80.35 42.71 141.40 116.33 75.63 58.41 
JG 63.48 47.23 78.48 25.35 72.23 42.43 34.52 30.91 
JL 92.92 85.63 78.96 52.37 115.22 61.25 92.09 54.59 
KJ 48.48 73.62 74.59 46.25 56.46 59.24 40.98 36.48 
KM 57.50 51.60 40.07 27.15 68.06 60.28 58.27 39.86 
LM 58.82 61.95 87.51 42.78 74.24 47.43 50.21 39.59 
MP 109.94 82.51 94.38 82.44 132.09 80.01 67.57 68.62 
MU 162.93 108.62 125.57 57.37 189.46 132.79 138.90 88.55 
AVG 78.24 64.44 73.43 43.13 86.78 64.71 59.59 45.10 
SEM 7.91 6.45 6.12 5.11 10.83 7.97 7.95 5.47 
 
 
Insulin (pmol/L) - At or Below VT 
CHO MCP 
Subject Pre Min 118 Min 177 End Pre Min 118 Min 177 End 
BM 55.35 56.19 55.84 37.09 59.59 50.49 41.18 43.41 
DF 83.34 65.21 71.81 35.28 72.99 62.99 56.74 38.34 
EMC 68.82 55.84 76.67 57.78 56.12 54.87 41.88 47.43 
JB 73.27 23.40 47.78 10.83 55.56 36.67 27.50 12.78 
JC 90.56 100.91 80.35 42.71 141.40 116.33 75.63 58.41 
KM 57.50 51.60 40.07 27.15 68.06 60.28 58.27 39.86 
LM 58.82 61.95 87.51 42.78 74.24 47.43 50.21 39.59 
MP 109.94 82.51 94.38 82.44 132.09 80.01 67.57 68.62 
AVG 74.70 62.20 69.30 42.01 82.51 63.63 52.37 43.55 
SEM 6.72 8.03 6.87 7.50 12.13 8.76 5.48 5.77 
 
 
Insulin (pmol/L) - Above VT 
CHO MCP 
Subject Pre Min 118 Min 177 End Pre Min 118 Min 177 End 
CJ 65.07 48.96 76.33 31.67 58.06 46.11 45.14 27.22 
CW 101.12 82.23 85.98 76.40 111.61 101.47 97.92 75.42 
EM 42.02 22.64 27.15 21.53 38.68 18.33 25.35 14.86 
JG 63.48 47.23 78.48 25.35 72.23 42.43 34.52 30.91 
JL 92.92 85.63 78.96 52.37 115.22 61.25 92.09 54.59 
KJ 48.48 73.62 74.59 46.25 56.46 59.24 40.98 36.48 
MU 162.93 108.62 125.57 57.37 189.46 132.79 138.90 88.55 
AVG 82.29 66.99 78.15 44.42 91.67 65.95 67.84 46.86 





Study 1 Glucose (mmol/L) - Combined Group CHO MCP 
Subject Pre Min 118 Min 177 End Pre Min 118 Min 177 End 
BM 4.52 5.48 5.61 5.58 3.74 4.29 5.27 5.00 
CJ 4.42 3.80 3.90 4.26 4.87 3.89 4.05 5.04 
CW 3.94 3.48 3.85 4.49 3.90 3.21 3.38 3.81 
DF 4.38 4.12 3.99 4.33 3.92 3.95 3.82 4.15 
EM 3.82 3.81 3.68 4.84 4.20 3.43 3.45 4.66 
EMC 4.14 4.50 4.86 5.67 4.23 3.73 3.74 5.50 
JB 4.29 4.41 4.60 4.62 4.28 3.97 3.84 3.88 
JC 4.19 4.03 4.31 3.87 4.64 4.01 3.91 4.29 
JG 4.52 3.96 5.17 5.81 4.40 3.34 4.28 4.77 
JL 4.39 4.38 4.12 5.69 4.74 4.23 4.14 4.41 
KJ 4.12 4.44 4.28 4.05 3.64 3.68 3.84 3.79 
KM 4.01 4.09 4.28 5.16 4.59 4.05 4.26 4.48 
LM 3.97 4.72 4.97 4.80 3.91 3.91 4.30 4.26 
MP 3.60 3.59 3.61 4.12 4.43 3.77 4.04 5.68 
MU 4.60 4.44 5.42 4.53 4.52 4.34 5.03 4.91 
AVG 4.19 4.22 4.44 4.79 4.27 3.85 4.09 4.58 
SEM 0.07 0.13 0.16 0.17 0.10 0.09 0.13 0.15 
 
 
Glucose (mmol/L) - At or Below VT 
CHO MCP 
Subject Pre Min 118 Min 177 End Pre Min 118 Min 177 End 
BM 4.52 5.48 5.61 5.58 3.74 4.29 5.27 5.00 
DF 4.38 4.12 3.99 4.33 3.92 3.95 3.82 4.15 
EMC 4.14 4.50 4.86 5.67 4.23 3.73 3.74 5.50 
JB 4.29 4.41 4.60 4.62 4.28 3.97 3.84 3.88 
JC 4.19 4.03 4.31 3.87 4.64 4.01 3.91 4.29 
KM 4.01 4.09 4.28 5.16 4.59 4.05 4.26 4.48 
LM 3.97 4.72 4.97 4.80 3.91 3.91 4.30 4.26 
MP 3.60 3.59 3.61 4.12 4.43 3.77 4.04 5.68 
AVG 4.14 4.37 4.53 4.77 4.22 3.96 4.15 4.65 
SEM 0.10 0.20 0.22 0.23 0.12 0.06 0.18 0.23 
 
 
Glucose (mmol/L)  - Above VT 
CHO MCP 
Subject Pre Min 118 Min 177 End Pre Min 118 Min 177 End 
CJ 4.42 3.80 3.90 4.26 4.87 3.89 4.05 5.04 
CW 3.94 3.48 3.85 4.49 3.90 3.21 3.38 3.81 
EM 3.82 3.81 3.68 4.84 4.20 3.43 3.45 4.66 
JG 4.52 3.96 5.17 5.81 4.40 3.34 4.28 4.77 
JL 4.39 4.38 4.12 5.69 4.74 4.23 4.14 4.41 
KJ 4.12 4.44 4.28 4.05 3.64 3.68 3.84 3.79 
MU 4.60 4.44 5.42 4.53 4.52 4.34 5.03 4.91 
AVG 4.26 4.04 4.35 4.81 4.32 3.73 4.02 4.48 





Study 1 Lactate (mmol/L) - Combined Group 
CHO MCP 
Subject Pre Min 118 Min 177 End Pre Min 118 Min 177 End 
BM 0.92 0.72 0.83 1.83 0.39 0.83 0.48 1.41 
CJ 0.52 1.21 0.69 4.15 0.55 1.30 1.06 5.45 
CW 0.75 1.56 1.09 2.69 0.57 1.50 1.25 4.09 
DF 1.28 3.14 1.27 3.25 1.05 2.52 1.49 3.37 
EM 0.66 1.47 1.12 4.57 0.74 1.59 1.37 5.15 
EMC 0.88 2.27 1.82 4.36 0.85 1.96 1.58 4.35 
JB 0.64 0.96 0.77 1.63 0.71 1.12 0.95 1.69 
JC 1.22 1.04 1.00 2.11 1.47 1.28 0.98 2.05 
JG 0.73 1.42 1.09 7.82 0.81 1.14 1.02 5.70 
JL 1.27 1.38 1.07 5.50 0.84 1.34 1.02 4.22 
KJ 0.68 0.99 0.90 3.36 1.03 1.53 1.06 3.56 
KM 0.61 1.09 1.25 3.07 0.86 1.24 0.97 2.30 
LM 0.34 1.37 1.13 1.41 0.37 1.00 0.93 1.31 
MP 1.04 1.24 1.01 6.98 1.36 1.42 1.18 7.59 
MU 1.17 1.17 1.00 2.25 1.47 1.23 1.25 3.76 
AVG 0.85 1.40 1.07 3.67 0.87 1.40 1.11 3.73 
SEM 0.08 0.15 0.07 0.50 0.09 0.11 0.07 0.46 
 
 
Lactate (mmol/L) - At or Below VT 
CHO MCP 
Subject Pre Min 118 Min 177 End Pre Min 118 Min 177 End 
BM 0.92 0.72 0.83 1.83 0.39 0.83 0.48 1.41 
DF 1.28 3.14 1.27 3.25 1.05 2.52 1.49 3.37 
EMC 0.88 2.27 1.82 4.36 0.85 1.96 1.58 4.35 
JB 0.64 0.96 0.77 1.63 0.71 1.12 0.95 1.69 
JC 1.22 1.04 1.00 2.11 1.47 1.28 0.98 2.05 
KM 0.61 1.09 1.25 3.07 0.86 1.24 0.97 2.30 
LM 0.34 1.37 1.13 1.41 0.37 1.00 0.93 1.31 
MP 1.04 1.24 1.01 6.98 1.36 1.42 1.18 7.59 
AVG 0.87 1.48 1.13 3.08 0.88 1.42 1.07 3.01 
SEM 0.11 0.29 0.12 0.66 0.14 0.20 0.12 0.75 
 
 
Lactate (mmol/L) - Above VT 
CHO MCP 
Subject Pre Min 118 Min 177 End Pre Min 118 Min 177 End 
CJ 0.52 1.21 0.69 4.15 0.55 1.30 1.06 5.45 
CW 0.75 1.56 1.09 2.69 0.57 1.50 1.25 4.09 
EM 0.66 1.47 1.12 4.57 0.74 1.59 1.37 5.15 
JG 0.73 1.42 1.09 7.82 0.81 1.14 1.02 5.70 
JL 1.27 1.38 1.07 5.50 0.84 1.34 1.02 4.22 
KJ 0.68 0.99 0.90 3.36 1.03 1.53 1.06 3.56 
MU 1.17 1.17 1.00 2.25 1.47 1.23 1.25 3.76 
AVG 0.83 1.32 0.99 4.33 0.86 1.37 1.15 4.56 





Myoglobin (nmol/L) - Combined Group 
CHO MCP 
Subject Pre Min 118 Min 177 End Pre Min 118 Min 177 End 
BM 0.85 0.95 0.91 1.18 0.83 0.86 0.91 0.99 
CJ 0.99 1.41 1.29 1.52 1.05 1.21 1.25 1.53 
CW 0.84 0.89 0.87 0.84 0.84 0.95 0.85 0.85 
DF 1.30 1.36 1.54 1.34 1.13 1.28 1.31 1.38 
EM 1.29 1.32 1.40 1.75 1.27 1.27 1.29 1.36 
EMC 1.04 1.08 1.04 1.15 0.85 0.88 0.86 1.02 
JB 1.27 1.27 1.28 1.30 1.27 1.28 1.27 1.27 
JC 0.87 0.87 0.89 0.88 0.90 0.97 0.98 0.92 
JG 1.85 2.54 2.24 3.35 1.43 1.35 1.53 1.67 
JL 1.31 1.31 1.35 1.49 1.27 1.44 1.43 1.37 
KJ 0.68 0.67 0.70 0.73 0.82 0.67 0.61 0.65 
KM 1.05 1.05 1.44 1.77 1.07 1.27 1.34 1.68 
MP 0.83 1.14 1.00 1.08 0.97 0.97 1.06 1.15 
MU 0.95 0.95 1.05 1.17 0.96 0.99 1.03 1.12 
AVG 1.08 1.20 1.22 1.40 1.05 1.10 1.12 1.21 
SEM 0.08 0.11 0.10 0.17 0.05 0.06 0.07 0.08 
 
 
Myoglobin (nmol/L) - At or Below VT 
CHO MCP 
Subject Pre Min 118 Min 177 End Pre Min 118 Min 177 End 
BM 0.85 0.95 0.91 1.18 0.83 0.86 0.91 0.99 
DF 1.30 1.36 1.54 1.34 1.13 1.28 1.31 1.38 
EMC 1.04 1.08 1.04 1.15 0.85 0.88 0.86 1.02 
JB 1.27 1.27 1.28 1.30 1.27 1.28 1.27 1.27 
JC 0.87 0.87 0.89 0.88 0.90 0.97 0.98 0.92 
KM 1.05 1.05 1.44 1.77 1.07 1.27 1.34 1.68 
LM 0.96 0.98 0.98 0.93 1.02 0.98 1.02 1.02 
MP 0.83 1.14 1.00 1.08 0.97 0.97 1.06 1.15 
AVG 1.02 1.09 1.13 1.20 1.00 1.06 1.09 1.18 
SEM 0.06 0.06 0.09 0.10 0.05 0.06 0.07 0.09 
 
 
Myoglobin (nmol/L) - Above VT 
CHO MCP 
Subject Pre Min 118 Min 177 End Pre Min 118 Min 177 End 
CJ 0.99 1.41 1.29 1.52 1.05 1.21 1.25 1.53 
CW 0.84 0.89 0.87 0.84 0.84 0.95 0.85 0.85 
EM 1.29 1.32 1.40 1.75 1.27 1.27 1.29 1.36 
JG 1.85 2.54 2.24 3.35 1.43 1.35 1.53 1.67 
JL 1.31 1.31 1.35 1.49 1.27 1.44 1.43 1.37 
KJ 0.68 0.67 0.70 0.73 0.82 0.67 0.61 0.65 
MU 0.95 0.95 1.05 1.17 0.96 0.99 1.03 1.12 
AVG 1.13 1.30 1.27 1.55 1.09 1.13 1.14 1.22 




RPE: Low Intensity Intervals 
Combined Group 
CHO MCP 
Subject Min 90 Min 130 Min 161 Min 90 Min 130 Min 161 
BM 9 9 10 9 9 9 
CJ 11 11 12 12 12 12 
CW 8 11 10 9 11 11 
DF 12 12 12 11 12 11 
EM 11 11 11.5 11 11 11 
EMC 12 11.5 11 13 12 12 
JB 12 13 12 12 12 13 
JC 12 14 14 12 13 13 
JG 12 12 11 12 12 13 
JL 9 11 9 11 11 11 
KJ 11 11 11 11 11 10 
KM 11.5 13 13 11 12 13 
LM 11 12 13 13 14 14 
MP 11.5 11.5 12 12 12 12 
MU 12 12 12 12 12 13 
AVG 11 12 12 11 12 12 
SEM 0.33 0.30 0.33 0.31 0.28 0.35 
 
 
At or Below VT 
CHO MCP 
Subject Min 90 Min 130 Min 161 Min 90 Min 130 Min 161 
BM 9 9 10 9 9 9 
DF 12 12 12 11 12 11 
EMC 12 11.5 11 13 12 12 
JB 12 13 12 12 12 13 
JC 12 14 14 12 13 13 
KM 11.5 13 13 11 12 13 
LM 11 12 13 13 14 14 
MP 11.5 11.5 12 12 12 12 
AVG 11 12 12 12 12 12 






# Min 90 Min 130 Min 161 Min 90 Min 130 Min 161 
CJ 11 11 12 12 12 12 
CW 8 11 10 9 11 11 
EM 11 11 11.5 11 11 11 
JG 12 12 11 12 12 13 
JL 9 11 9 11 11 11 
KJ 11 11 11 11 11 10 
MU 12 12 12 12 12 13 
AVG 11 11 11 11 11 12 





RPE: High Intensity Intervals 
Combined Group 
CHO MCP 
Subject Min 115 Min 159 Min 184 Min 115 Min 159 Min 184 
BM 13 13.5 15 13 13 15 
CJ 15 15 16 14 15 18 
CW 11 11 14 13 13 15 
DF 15 15 16 15 14 17 
EM 14 15 17 13.5 11 18 
EMC 14 12 16 14 14 17 
JB 16 16 17 14.5 16 15 
JC 13 15 16 13 14 15.5 
JG 13 12 15 12 14 15 
JL 14 13 15 13 14 16 
KJ 13 15 17 13 12 15 
KM 13.5 13.5 14 13.5 14 15 
LM 14 15 16 14 14 16 
MP 13 15 18 13 15 18 
MU 15 14 15 15 16 15 
AVG 14 14 16 14 14 16 
SEM 0.31 0.37 0.30 0.22 0.34 0.32 
 
 
RPE: High Intensity Intervals 
At or Below VT 
CHO MCP 
Subject Min 115 Min 159 Min 184 Min 115 Min 159 Min 184 
BM 13 13.5 15 13 13 15 
DF 15 15 16 15 14 17 
EMC 14 12 16 14 14 17 
JB 16 16 17 14.5 16 15 
JC 13 15 16 13 14 15.5 
KM 13.5 13.5 14 13.5 14 15 
LM 14 15 16 14 14 16 
MP 13 15 18 13 15 18 
AVG 14 14 16 14 14 16 
SEM 0.38 0.45 0.42 0.27 0.31 0.41 
 
 
RPE: High Intensity Intervals 
Above VT 
CHO MCP 
Subject Min 115 Min 159 Min 184 Min 115 Min 159 Min 184 
CJ 15 15 16 14 15 18 
CW 11 11 14 13 13 15 
EM 14 15 17 13.5 11 18 
JG 13 12 15 12 14 15 
JL 14 13 15 13 14 16 
KJ 13 15 17 13 12 15 
MU 15 14 15 15 16 15 
AVG 14 14 16 13 14 16 




HR (bpm): Low Intensity Intervals 
Combined Group 
CHO MCP 
Subject Min 90 Min 130 Min 161 Min 90 Min 130 Min 161 
BM 106 113 117 109 114 121 
CJ 125 127 138 124 130 142 
CW 101 109 114 104 108 112 
DF 139 151 147 143 148 145 
EM 126 142 148 131 137 140 
EMC 126 126 135 119 114 120 
JB 135 154 151 137 140 147 
JC 115 125 138 131 131 137 
JG 119 121 123 113 119 134 
JL 102 110 120 104 106 110 
KJ 117 120 121 115 127 138 
KM 122 128 134 115 129 134 
LM 120 110 110 100 108 103 
MP 128 138 140 121 130 128 
MU 132 140 145 125 133 139 
AVG 120.9 127.6 132.1 119.4 124.9 130.0 
SEM 2.9 3.8 3.5 3.3 3.3 3.5 
 
 
HR (bpm): Low Intensity Intervals 
At or Below VT 
CHO MCP 
Subject Min 90 Min 130 Min 161 Min 90 Min 130 Min 161 
BM 106 113 117 109 114 121 
DF 139 151 147 143 148 145 
EMC 126 126 135 119 114 120 
JB 135 154 151 137 140 147 
JC 115 125 138 131 131 137 
KM 122 128 134 115 129 134 
LM 120 110 110 100 108 103 
MP 128 138 140 121 130 128 
AVG 123.9 130.6 134.0 121.9 126.8 129.4 
SEM 3.8 5.7 5.0 5.1 4.9 5.2 
 
 
HR (bpm): Low Intensity Intervals 
Above VT 
CHO MCP 
Subject Min 90 Min 130 Min 161 Min 90 Min 130 Min 161 
CJ 125 127 138 124 130 142 
CW 101 109 114 104 108 112 
EM 126 142 148 131 137 140 
JG 119 121 123 113 119 134 
JL 102 110 120 104 106 110 
KJ 117 120 121 115 127 138 
MU 132 140 145 125 133 139 
AVG 117.4 124.1 129.9 116.6 122.9 130.7 




HR (bpm): High Intensity Intervals 
Combined Group 
CHO MCP 
Subject Min 115 Min 159 Min 184 Min 115 Min 159 Min 184 
BM 138 135 145 134 135 150 
CJ 161 161 176 153 159 166 
CW 125 130 139 125 130 152 
DF 172 168 180 172 169 182 
EM 163 168 185 161 158 189 
EMC 138 147 156 134 135 148 
JB 174 172 180 162 164 176 
JC 134 140 152 143 145 156 
JG 147 137 166 140 147 159 
JL 132 139 157 131 131 152 
KJ 151 151 168 145 151 173 
KM 143 144 158 143 142 153 
LM 137 137 143 107 104 139 
MP 154 152 170 153 154 180 
MU 161 158 168 153 153 166 
AVG 148.7 149.3 162.9 143.7 145.1 162.7 
SEM 3.9 3.5 3.7 4.2 4.3 3.8 
 
 
HR (bpm): High Intensity Intervals 
At or Below VT 
CHO MCP 
Subject Min 115 Min 159 Min 184 Min 115 Min 159 Min 184 
BM 138 135 145 134 135 150 
DF 172 168 180 172 169 182 
EMC 138 147 156 134 135 148 
JB 174 172 180 162 164 176 
JC 134 140 152 143 145 156 
KM 143 144 158 143 142 153 
LM 137 137 143 107 104 139 
MP 154 152 170 153 154 180 
AVG 148.8 149.4 160.5 143.5 143.5 160.5 
SEM 5.7 4.9 5.2 7.0 7.2 5.8 
 
 
HR (bpm): High Intensity Intervals 
Above VT 
CHO MCP 
Subject Min 115 Min 159 Min 184 Min 115 Min 159 Min 184 
CJ 161 161 176 153 159 166 
CW 125 130 139 125 130 152 
EM 163 168 185 161 158 189 
JG 147 137 166 140 147 159 
JL 132 139 157 131 131 152 
KJ 151 151 168 145 151 173 
MU 161 158 168 153 153 166 
AVG 148.6 149.1 165.6 144.0 147.0 165.3 




CHO Utilization, g/min 
Combined Group 
CHO MCP 
Subject Min 10 Min 50 Min 130 Min 135 Min 184 Min 10 Min 50 Min 130 Min 135 Min 184 
BM 1.83 3.39 1.75 3.02 4.49 1.91 3.27 1.65 3.47 4.24 
CJ 1.94 3.69 1.80 2.87 4.53 1.76 3.61 1.66 2.62 4.34 
CW 2.12 3.64 1.87 3.36 4.83 1.55 3.07 1.23 2.31 4.53 
DF 1.62 3.48 1.96 3.05 3.63 1.79 3.49 1.77 2.84 3.54 
EM 1.97 3.78 1.95 3.15 4.58 2.07 3.56 1.88 3.42 4.50 
EMC 1.35 2.41 1.14 2.36 2.74 1.28 2.51 1.03 1.93 2.68 
JB 1.22 2.35 1.39 2.42 3.03 1.22 2.43 1.31 2.23 3.02 
JC 0.92 1.66 1.26 1.39 2.15 1.09 1.82 1.22 1.60 2.14 
JG 2.08 3.84 1.79 2.98 4.72 2.32 3.64 1.84 3.14 4.65 
JL 1.52 3.10 1.99 3.24 4.72 1.99 3.37 1.93 3.57 4.73 
KJ 0.64 1.51 0.74 1.37 2.02 0.68 1.44 0.83 1.51 2.07 
KM 1.15 1.92 1.08 1.66 2.97 1.26 1.92 1.13 1.86 2.87 
LM 1.37 2.57 1.35 2.09 2.51 1.22 2.38 1.36 2.07 2.47 
MP 1.75 3.40 2.28 2.76 4.52 1.86 3.62 1.98 2.98 4.47 
MU 1.24 2.20 1.36 2.40 3.35 1.27 2.06 1.14 2.40 3.07 
AVG 1.51 2.86 1.58 2.54 3.65 1.55 2.81 1.46 2.53 3.56 
SEM 0.11 0.21 0.11 0.17 0.27 0.12 0.20 0.10 0.18 0.25 
  
 268 
           
Study 1 
Fat Utilization, g/min 
Combined Group 
CHO MCP 
Subject Min 10 Min 50 Min 130 Min 135 Min 184 Min 10 Min 50 Min 130 Min 135 Min 184 
BM 0.25 0.17 0.39 0.34 0.00 0.21 0.22 0.37 0.17 0.13 
CJ 0.17 0.06 0.20 0.26 0.00 0.24 0.11 0.32 0.50 0.07 
CW 0.19 0.18 0.36 0.30 0.00 0.47 0.34 0.73 0.70 0.14 
DF 0.22 0.00 0.13 0.15 0.00 0.20 0.00 0.24 0.25 0.05 
EM 0.22 0.00 0.26 0.22 0.00 0.19 0.11 0.31 0.17 0.00 
EMC 0.12 0.00 0.22 0.04 0.00 0.14 0.00 0.23 0.17 0.00 
JB 0.23 0.12 0.19 0.12 0.00 0.23 0.08 0.21 0.20 0.00 
JC 0.18 0.08 0.04 0.16 0.00 0.10 0.00 0.06 0.08 0.00 
JG 0.14 0.00 0.29 0.33 0.00 0.07 0.06 0.35 0.28 0.00 
JL 0.40 0.28 0.22 0.22 0.00 0.18 0.17 0.26 0.11 0.00 
KJ 0.12 0.02 0.10 0.09 0.00 0.11 0.07 0.07 0.05 0.00 
KM 0.22 0.31 0.33 0.43 0.15 0.21 0.31 0.29 0.36 0.14 
LM 0.22 0.13 0.22 0.34 0.22 0.27 0.27 0.26 0.40 0.28 
MP 0.17 0.11 0.07 0.25 0.00 0.17 0.00 0.22 0.27 0.00 
MU 0.28 0.25 0.19 0.16 0.00 0.24 0.28 0.30 0.21 0.15 
AVG 0.21 0.11 0.21 0.23 0.02 0.20 0.13 0.28 0.26 0.06 







CHO Utilization, g/min 
At or Below VT 
CHO MCP 
Subject Min 10 Min 50 Min 130 Min 135 Min 184 Min 10 Min 50 Min 130 Min 135 Min 184 
BM 1.83 3.39 1.75 3.02 4.49 1.91 3.27 1.65 3.47 4.24 
DF 1.62 3.48 1.96 3.05 3.63 1.79 3.49 1.77 2.84 3.54 
EMC 1.35 2.41 1.14 2.36 2.74 1.28 2.51 1.03 1.93 2.68 
JB 1.22 2.35 1.39 2.42 3.03 1.22 2.43 1.31 2.23 3.02 
JC 0.92 1.66 1.26 1.39 2.15 1.09 1.82 1.22 1.60 2.14 
KM 1.15 1.92 1.08 1.66 2.97 1.26 1.92 1.13 1.86 2.87 
LM 1.37 2.57 1.35 2.09 2.51 1.22 2.38 1.36 2.07 2.47 
MP 1.75 3.40 2.28 2.76 4.52 1.86 3.62 1.98 2.98 4.47 
AVG 1.40 2.65 1.53 2.35 3.25 1.45 2.68 1.43 2.37 3.18 
SEM 0.11 0.25 0.15 0.21 0.31 0.12 0.25 0.12 0.23 0.29 
           
Study 1 
Fat Utilization, g/min 
At or Below VT 
CHO MCP 
Subject Min 10 Min 50 Min 130 Min 135 Min 184 Min 10 Min 50 Min 130 Min 135 Min 184 
BM 0.25 0.17 0.39 0.34 0.00 0.21 0.22 0.37 0.17 0.13 
DF 0.22 0.00 0.13 0.15 0.00 0.20 0.00 0.24 0.25 0.05 
EMC 0.12 0.00 0.22 0.04 0.00 0.14 0.00 0.23 0.17 0.00 
JB 0.23 0.12 0.19 0.12 0.00 0.23 0.08 0.21 0.20 0.00 
JC 0.18 0.08 0.04 0.16 0.00 0.10 0.00 0.06 0.08 0.00 
KM 0.22 0.31 0.33 0.43 0.15 0.21 0.31 0.29 0.36 0.14 
LM 0.22 0.13 0.22 0.34 0.22 0.27 0.27 0.26 0.40 0.28 
MP 0.17 0.11 0.07 0.25 0.00 0.17 0.00 0.22 0.27 0.00 
AVG 0.20 0.11 0.20 0.23 0.05 0.19 0.11 0.24 0.24 0.08 





CHO Utilization, g/min 
Above VT 
CHO MCP 
Subject Min 10 Min 50 Min 130 Min 135 Min 184 Min 10 Min 50 Min 130 Min 135 Min 184 
CJ 1.94 3.69 1.80 2.87 4.53 1.76 3.61 1.66 2.62 4.34 
CW 2.12 3.64 1.87 3.36 4.83 1.55 3.07 1.23 2.31 4.53 
EM 1.97 3.78 1.95 3.15 4.58 2.07 3.56 1.88 3.42 4.50 
JG 2.08 3.84 1.79 2.98 4.72 2.32 3.64 1.84 3.14 4.65 
JL 1.52 3.10 1.99 3.24 4.72 1.99 3.37 1.93 3.57 4.73 
KJ 0.64 1.51 0.74 1.37 2.02 0.68 1.44 0.83 1.51 2.07 
MU 1.24 2.20 1.36 2.40 3.35 1.27 2.06 1.14 2.40 3.07 
AVG 1.64 3.11 1.64 2.77 4.11 1.67 2.97 1.50 2.71 3.99 
SEM 0.21 0.34 0.17 0.26 0.40 0.21 0.33 0.16 0.27 0.38 
           
Study 1 
Fat Utilization, g/min 
Above VT 
CHO MCP 
Subject Min 10 Min 50 Min 130 Min 135 Min 184 Min 10 Min 50 Min 130 Min 135 Min 184 
CJ 0.17 0.06 0.20 0.26 0.00 0.24 0.11 0.32 0.50 0.07 
CW 0.19 0.18 0.36 0.30 0.00 0.47 0.34 0.73 0.70 0.14 
EM 0.22 0.00 0.26 0.22 0.00 0.19 0.11 0.31 0.17 0.00 
JG 0.14 0.00 0.29 0.33 0.00 0.07 0.06 0.35 0.28 0.00 
JL 0.40 0.28 0.22 0.22 0.00 0.18 0.17 0.26 0.11 0.00 
KJ 0.12 0.02 0.10 0.09 0.00 0.11 0.07 0.07 0.05 0.00 
MU 0.28 0.25 0.19 0.16 0.00 0.24 0.28 0.30 0.21 0.15 
AVG 0.22 0.11 0.23 0.23 0.00 0.21 0.16 0.34 0.29 0.05 


















BF 37 67.6 169 3.51 51.8 
BH 41 57.1 157 2.72 47.6 
DF 26 64.7 171 4.01 61.9 
EM 28 71.3 177 4.42 62.0 
EW 29 67.1 171 3.02 44.9 
JB 30 58.8 157 2.67 45.4 
JCB 27 58.7 159 3.13 53.2 
JP 32 82.1 182 4.08 49.7 
LM 30 73.7 183 3.45 46.8 
MJ 38 76.6 185 4.83 63.0 
AVG 31.8 67.8 171.1 3.6 52.6 




Study 2 Time Trial Data 
Time Trial Time (min)   Average  Watts 
Subject CM CHO PLA   Subject CM CHO PLA 
EM 75.7 78.72 0   EM 179 164 145 
LM 74.34 79.01 78.86   LM 188 162 162 
EW 78.46 86.99 82.93   EW 163 127 142 
JB 91.16 104.99 97.95   JB 114 83 96 
MJ 70.47 67.22 71.74   MJ 228 246 209 
JCB 85.91 89.79 91.55   JCB 131 118 112 
BF 83.45 97.62 100.94   BF 141 99 92 
DF 78.07 80.12 89.8   DF 170 157 118 
BH 84.7 92.03 91.4   BH 135 111 113 
JP 72.02 80.86 77.15   JP 206 157 174 
AVG 79.43 85.74 86.92   AVG 165.50 142.40 136.30 
SEM 2.11 3.44 3.28   SEM 11.37 14.62 11.80 
                  
Average  Heart Rate   Average  RPE 
Subject CM CHO PLA   Subject CM CHO PLA 
EM 157 147 145   EM 14.75 14.33 15 
LM 141 126 133   LM 14.6 16.33 15.75 
EW 204 192 201   EW 14.58 12.75 14.75 
JB 152 128 148   JB 13 10.75 11.71 
MJ 178 176 168   MJ 15.4 14.4 13.2 
JCB 162 148 147   JCB 15.33 14.67 14.57 
BF 153 128 117   BF 13.33 14.43 13.78 
DF 169 159 151   DF 15.67 15.33 14.7 
BH 158 125 136   BH 15.58 15 15 
JP 154 130 143   JP 12.6 13.5 12 
AVG 162.8 145.9 148.9   AVG 14.48 14.15 14.05 







Subjects Pre R0 R45 R120 R End TT End 
BF 10.667 7.188 31.625 14.357 12.093 3.046 
BH 20.395 11.557 119.19 16.535 18.521 9.775 
DF 11.139 6.759 39.337 12.556 20.481 6.937 
EM 9.713 6.384 23.107 11.53 15.271 9.299 
JB 8.52 8.458 33.863 21.166 24.064 6.97 
JCB 13.218 5.995 48.086 18.797 12.41 5.506 
JP 8.973 6.078 36.925 8.688 10.319 5.24 
LM 21.878 15.623 75.459 14.846 11.756 7.18 
MJ 11.05 4.16 18.07 10.421 15.246 5.669 
AVE 12.84 8.02 47.30 14.32 15.57 6.62 
SE 1.64 1.17 10.54 1.34 1.53 0.69 
              
CHO 
  Pre R0 R45 R120 R End TT End 
BF 8.482 5.96 38.172 23.463 34.502 4.063 
BH 15.314 13.11 85.708 22.725 24.485 8.96 
DF 13.986 11.94 84.263 14.128 54.968 7.76 
EM 13.086 7.339 61.372 15.173 27.865 6.577 
JB 9.989 10.171 50.245 44.769 53.049 14.192 
JCB 13.444 8.129 37.902 20 13.933 4.945 
JP 7.179 3.563 50.889 25.968 27.415 5.37 
LM 19.716 13.97 49.415 20.502 29.209 12.331 
MJ 15.774 9.459 70.384 13.523 43.71 6.415 
AVE 13.00 9.29 58.71 22.25 34.35 7.85 
SE 1.31 1.14 6.01 3.17 4.55 1.14 
              
PLA 
  Pre R0 R45 R120 R End TT End 
BF 9.29 3.161 65.787 3.929 5.548 3.99 
BH 13.651 11.736 17.501 11.921 11 8.744 
DF 15.529 8.353 8.77 9.063 8.931 4.262 
EM 7.779 6.222 5.871 8.06 8.578 7.044 
JB 15.391 21.187 13.286 13.552 13.202 6.094 
JCB 14.901 9.018 8.41 9.745 10.117 8.253 
JP 9.86 5.718 5.721 7.597 6.489 5 
LM 11.88 9.801 9.984 8.115 8.055 8.336 
MJ 13.209 7.096 6.918 8.088 8.987 6.075 
AVE 12.39 9.14 15.81 8.90 8.99 6.42 







Subjects Pre R0 R45 R120 R End TT End 
BF 70.65 59.15 91.28 73.39 70.66 50.22 
BH 77.75 73.25 89.28 71.37 73.12 69.29 
DF 81.36 80.97 76.08 78.71 73.94 61.11 
EM 73.02 53.93 77.38 71.51 64.07 49.21 
JB 76.25 84.05 77.17 77.67 72.28 72.18 
JCB 75.20 69.77 72.39 82.69 68.70 61.27 
JP 58.35 72.86 72.89 73.05 65.09 57.07 
LM 86.79 90.02 60.63 61.44 57.62 62.91 
MJ 77.58 63.61 72.42 82.64 83.04 46.41 
AVE 75.22 71.96 76.61 74.72 69.83 58.85 
SE 2.62 3.94 3.08 2.22 2.40 2.98 
              
CHO 
  Pre R0 R45 R120 R End TT End 
BF 74.59 56.27 116.21 90.79 67.77 40.53 
BH 72.95 77.14 106.86 56.95 60.55 68.72 
DF 79.50 111.00 104.59 76.29 92.71 59.02 
EM 69.54 55.15 102.45 61.93 66.35 49.58 
JB 77.15 84.12 110.02 92.23 96.20 68.96 
JCB 73.65 61.19 78.86 101.46 45.89 58.33 
JP 63.86 51.90 99.74 91.07 68.39 41.52 
LM 76.04 72.54 98.23 81.87 62.19 49.36 
MJ 82.28 109.35 97.88 80.53 87.66 57.82 
AVE 74.40 75.41 101.65 81.46 71.97 54.87 
SE 1.81 7.49 3.47 4.87 5.57 3.48 
              
PLA 
  Pre R0 R45 R120 R End TT End 
BF 76.17 51.76 56.66 53.69 51.11 33.27 
BH 76.38 84.15 72.11 70.10 70.20 68.21 
DF 80.74 76.47 66.79 72.58 72.20 57.43 
EM 72.44 65.94 58.80 64.64 64.79 38.35 
JB 82.62 94.72 61.41 61.29 63.35 58.15 
JCB 75.46 65.90 71.53 72.76 62.10 62.03 
JP 63.85 61.83 57.21 60.53 56.46 35.00 
LM 68.56 78.42 68.30 66.02 65.22 65.18 
MJ 88.22 83.29 74.82 82.58 83.44 73.02 
AVE 76.05 73.61 65.29 67.13 65.43 54.52 






  CM 
Subjects Pre R0 R45 R120 R End TT End 
BF 0.650 3.995 1.205 1.265 1.114 1.656 
BH 1.582 3.121 2.040 1.273 1.016 2.845 
DF 1.163 7.299 1.774 0.861 0.873 1.872 
EM 0.525 3.612 0.955 0.451 0.577 1.479 
JB 0.510 3.773 1.179 0.881 0.697 2.486 
JCB 0.592 4.127 1.118 0.763 1.052 2.279 
JP 0.502 4.272 1.428 0.874 0.911 1.859 
LM 0.537 1.666 1.109 0.936 0.922 1.584 
MJ 0.628 5.579 1.725 0.785 0.779 1.279 
AVE 0.74 4.16 1.39 0.90 0.88 1.93 
SE 0.13 0.52 0.12 0.08 0.06 0.17 
              
CHO 
  Pre R0 R45 R120 R End TT End 
BF 0.574 3.423 0.743 0.586 0.778 1.549 
BH 1.149 2.207 1.905 1.003 0.651 1.562 
DF 1.012 7.002 1.951 1.170 1.175 2.273 
EM 0.903 5.025 1.155 0.936 1.081 1.799 
JB 0.565 3.105 1.179 0.836 0.885 1.008 
JCB 0.462 1.732 0.720 0.643 0.510 1.285 
JP 0.589 3.333 0.829 0.576 0.823 1.690 
LM 0.592 2.362 1.409 1.172 0.767 1.453 
MJ 0.624 6.393 1.898 1.518 1.189 2.332 
AVE 0.72 3.84 1.31 0.94 0.87 1.66 
SE 0.08 0.63 0.17 0.11 0.08 0.14 
              
PLA 
  Pre R0 R45 R120 R End TT End 
BF 0.521 1.819 0.640 0.660 0.733 1.187 
BH 0.979 2.747 0.855 0.946 0.901 1.179 
DF 1.199 5.066 1.019 0.801 0.734 1.274 
EM 0.531 1.115 0.718 0.492 0.774 0.787 
JB 0.736 2.213 1.185 1.285 1.071 1.015 
JCB 1.405 2.229 0.530 0.451 0.394 0.400 
JP 0.860 3.985 1.627 1.217 0.972 1.100 
LM 0.718 2.364 0.920 0.972 0.920 0.775 
MJ 0.830 5.579 1.609 1.034 1.044 1.723 
AVE 0.86 3.01 1.01 0.87 0.84 1.05 





Study 2                                    Free Fatty Acids (mmol/L) 
CM 
Subjects Pre R0 R45 R120 R End TT End 
BF 0.2679 0.7811 0.0696 0.1124 0.0946 0.7896 
BH 0.4323 0.9002 0.1954 0.2449 0.1708 0.8323 
DF 0.2395 0.2776 0.0847 0.1644 0.0509 0.6776 
EM 0.1406 0.4354 0.1343 0.3494 0.1530 0.6914 
JB 0.4281 1.0939 0.4937 0.4380 0.2058 0.9206 
JCB 0.4190 0.4986 0.3973 0.2657 0.2608 0.6717 
JP 0.5979 0.6908 0.4664 0.4810 0.2695 0.7123 
LM 0.2489 0.4131 0.1676 0.1594 0.0952 0.3041 
MJ 0.1630 0.1982 0.1610 0.2842 0.1947 0.3779 
AVE 0.33 0.59 0.24 0.28 0.17 0.66 
SE 0.05 0.10 0.06 0.04 0.03 0.07 
CHO 
  Pre R0 R45 R120 R End TT End 
BF 0.1406 0.4214 0.1139 0.0246 0.0811 0.5995 
BH 0.3616 0.4627 0.4058 0.1009 0.0784 0.5270 
DF 0.1442 0.2847 0.0545 0.1095 0.0264 0.2547 
EM 0.1425 0.4230 0.1142 0.0363 0.0343 0.4729 
JB 0.6390 0.7091 0.4720 0.4112 0.2571 1.0327 
JCB 0.1656 0.4773 0.0837 0.1177 0.0869 0.7262 
JP 0.6772 0.8640 0.2898 0.0684 0.0339 0.4704 
LM 0.3662 0.4208 0.2645 0.0633 0.1152 0.3456 
MJ 0.1244 0.2645 0.1384 0.1876 0.0749 0.3318 
AVE 0.31 0.48 0.22 0.12 0.09 0.53 
SE 0.07 0.06 0.05 0.04 0.02 0.08 
PLA 
  Pre R0 R45 R120 R End TT End 
BF 0.4122 1.0034 0.7149 0.9445 0.5645 1.4318 
BH 0.4738 0.6371 0.6580 0.6085 0.6200 0.7288 
DF 0.3435 0.3150 0.3735 0.7441 0.8309 0.8398 
EM 0.1767 1.2141 0.7238 0.6342 0.6563 1.2262 
JB 0.5031 1.3695 0.7359 0.7935 0.8488 1.4072 
JCB 0.5125 0.6782 0.6674 0.4730 0.4297 0.8867 
JP 0.5126 0.7538 0.8275 0.4119 0.4871 0.8000 
LM 0.1120 0.3325 0.2981 0.4012 0.5003 0.5393 
MJ 0.0676 0.2007 0.8599 0.6640 0.3597 0.2868 
AVE 0.35 0.72 0.65 0.63 0.59 0.91 








Subjects Pre R0 R45 R120 R End TT End 
BF 0.0591 0.2967 0.0621 0.0704 0.0527 0.3446 
BH 0.1192 0.4081 0.1187 0.1211 0.0869 0.4221 
DF 0.0554 0.2895 0.0592 0.0602 0.0358 0.2837 
EM 0.0340 0.2238 0.0639 0.0706 0.0575 0.2876 
JB 0.0814 0.4397 0.1710 0.0664 0.0414 0.3793 
JCB 0.0816 0.4555 0.0702 0.0740 0.0940 0.4446 
JP 0.0894 0.4482 0.1135 0.0908 0.0485 0.3613 
LM 0.0801 0.3288 0.0880 0.0517 0.0400 0.2626 
MJ 0.0285 0.2320 0.0732 0.0570 0.0520 0.2184 
AVE 0.0699 0.3469 0.0911 0.0736 0.0566 0.3338 
SE 0.01 0.03 0.01 0.01 0.01 0.03 
              
CHO 
  Pre R0 R45 R120 R End TT End 
BF 0.0374 0.2922 0.0522 0.0330 0.0144 0.2104 
BH 0.0894 0.2856 0.1206 0.0571 0.0280 0.2688 
DF 0.0320 0.2373 0.0851 0.0216 0.0191 0.1276 
EM 0.0378 0.2593 0.0548 0.0320 0.0223 0.2437 
JB 0.0685 0.4082 0.0996 0.0398 0.0353 0.3065 
JCB 0.0317 0.2906 0.0442 0.0658 0.0378 0.2932 
JP 0.1394 0.3905 0.0685 0.0466 0.0234 0.2129 
LM 0.0987 0.2829 0.0969 0.0507 0.0369 0.2199 
MJ 0.0288 0.2690 0.0858 0.0677 0.0421 0.2174 
AVE 0.0626 0.3017 0.0786 0.0460 0.0288 0.2334 
SE 0.01 0.02 0.01 0.01 0.00 0.02 
              
PLA 
  Pre R0 R45 R120 R End TT End 
BF 0.0921 0.4028 0.1240 0.1010 0.0986 0.3461 
BH 0.0897 0.3723 0.1177 0.1379 0.1000 0.4186 
DF 0.0645 0.2753 0.0906 0.1014 0.1237 0.3678 
EM 0.0415 0.1724 0.1230 0.1018 0.1051 0.3014 
JB 0.0753 0.4667 0.1447 0.1160 0.1046 0.4446 
JCB 0.2098 0.4276 0.1229 0.0817 0.1137 0.2583 
JP 0.0787 0.3541 0.1384 0.0851 0.0977 0.4000 
LM 0.0335 0.2757 0.0909 0.0999 0.1319 0.3491 
MJ 0.0303 0.1736 0.0709 0.0646 0.0566 0.2830 
AVE 0.0795 0.3245 0.1137 0.0988 0.1036 0.3521 








Subjects Pre R0 R45 R120 R End TT End 
BF 24.95 33.49 19.20 13.86 15.34 35.81 
BH 49.19 31.41 31.86 31.62 25.59 37.39 
DF 9.87 20.69 14.00 7.90 7.44 30.78 
EM 27.15 24.87 17.52 10.64 13.45 27.42 
JB 20.42 29.89 22.99 12.62 9.55 37.61 
JCB 23.29 34.49 21.95 13.11 21.89 23.28 
JP 27.00 30.99 17.83 12.53 7.37 35.54 
LM 23.65 23.90 16.24 14.20 12.42 21.67 
MJ 32.31 43.43 32.60 25.07 11.85 44.78 
AVE 26.42 30.35 21.58 15.73 13.88 32.70 
SE 3.50 2.25 2.21 2.53 2.08 2.50 
              
CHO 
  Pre R0 R45 R120 R End TT End 
BF 23.88 23.55 17.28 25.05 17.19 47.18 
BH 34.77 32.70 28.90 35.53 28.81 70.40 
DF 13.31 35.62 30.09 14.12 8.89 16.91 
EM 21.72 23.81 17.74 15.42 12.65 30.33 
JB 17.89 23.13 25.96 17.77 16.14 36.13 
JCB 23.36 13.09 15.80 8.79 10.32 31.34 
JP 31.22 32.34 23.23 15.27 13.70 53.82 
LM 25.52 15.85 15.88 14.05 11.72 41.68 
MJ 36.33 56.78 43.15 29.89 15.88 48.92 
AVE 25.33 28.54 24.23 19.54 15.03 41.86 
SE 2.54 4.34 3.00 2.90 1.95 5.18 
              
PLA 
  Pre R0 R45 R120 R End TT End 
BF 28.90 31.54 22.33 21.36 14.97 37.84 
BH 41.38 36.22 27.39 24.73 22.40 30.72 
DF 13.85 28.99 19.44 11.82 5.44 16.89 
EM 23.82 32.94 24.44 17.52 10.44 26.03 
JB 14.12 24.45 17.63 12.25 12.29 39.56 
JCB 26.44 23.28 18.11 14.82 12.79 19.57 
JP 29.07 30.29 15.68 10.98 11.69 42.00 
LM 21.29 16.39 13.16 11.44 12.04 22.93 
MJ 36.06 67.71 39.60 35.56 18.66 49.79 
AVE 26.10 32.42 21.98 17.83 13.41 31.70 








Subjects Pre R0 R45 R End TT End 
BF 17.95 24.83 73.14 30.19 38.02 
BH 13.08 17.24 15.72 12.35 19.60 
DF 14.92 26.64 32.57 20.11 36.45 
EM 27.32 28.08 37.53 29.48 29.37 
JB 25.49 25.24 51.91 43.18 41.52 
JCB 22.77 25.08 31.57 26.72 34.03 
JP 28.70 28.87 39.87 29.69 41.96 
LM 25.46 25.39 25.35 25.28 25.24 
MJ 23.67 25.60 32.01 23.73 28.70 
AVE 22.15 25.22 37.74 26.75 32.77 
SE 1.85 1.10 5.52 2.79 2.53 
            
CHO 
  Pre R0 R45 R End TT End 
BF 10.02 14.37 15.26 13.29 23.61 
BH 14.04 18.71 21.96 17.60 29.22 
DF 18.84 31.76 46.79 39.46 52.02 
EM 26.90 28.03 30.43 28.89 31.32 
JB 25.21 25.62 25.43 25.41 27.67 
JCB 23.73 25.58 26.17 28.01 26.44 
JP 29.53 30.54 77.25 73.20 56.97 
LM 25.64 25.81 25.66 25.61 25.23 
MJ 24.47 27.51 48.13 48.85 68.68 
AVE 22.04 25.33 35.23 33.37 37.91 
SE 2.14 1.84 6.38 6.11 5.57 
            
PLA 
  Pre R0 R45 R End TT End 
BF 12.66 18.84 39.28 29.69 30.63 
BH 15.72 23.61 21.16 28.00 28.45 
DF 19.21 53.90 54.11 31.92 37.67 
EM 31.73 35.55 68.92 40.10 38.25 
JB 25.29 25.56 25.55 25.23 29.54 
JCB 21.15 22.48 23.56 24.35 24.89 
JP 29.48 28.65 33.86 30.74 38.00 
LM 25.70 25.48 25.35 25.66 25.38 
MJ 31.40 30.87 81.81 37.63 60.32 
AVE 23.59 29.44 41.51 30.37 34.79 






Subjects Pre R0 R120 R End TT End 
BF 291.78 422.99 489.85 487.26 687.58 
BH 45.20 59.74 40.06 39.70 52.20 
DF 75.88 96.10 93.27 93.78 159.47 
EM 97.31 114.17 78.91 142.61 147.40 
JB 152.59 181.08 148.34 158.05 194.73 
JCB 203.47 220.74 189.80 250.72 282.87 
JP 150.26 182.25 159.29 148.05 183.26 
LM 47.93 61.05 47.64 50.61 50.96 
MJ 67.76 83.67 73.07 85.86 95.82 
AVG 125.80 157.97 146.69 161.85 206.03 
SE 27.42 38.30 46.22 45.96 64.97 
            
CHO 
  Pre R0 R120 R End TT End 
BF 50.07 52.71 50.93 48.30 75.83 
BH 50.18 61.13 48.92 49.94 93.08 
DF 63.09 98.66 88.99 92.31 139.32 
EM 96.27 102.76 87.84 106.75 131.03 
JB 119.62 141.71 139.82 131.42 175.28 
JCB 96.14 126.89 124.42 106.30 117.01 
JP 264.48 303.58 270.68 397.30 411.50 
LM 47.94 55.69 48.80 50.87 102.42 
MJ 63.25 85.93 107.13 139.85 259.28 
AVG 94.56 114.34 107.50 124.78 167.19 
SE 22.85 25.81 23.20 35.97 35.53 
            
PLA 
  Pre R0 R120 R End TT End 
BF 63.7 82.0 96.1 120.7 116.3 
BH 35.8 52.3 36.3 37.3 83.3 
DF 119.4 151.2 127.5 140.4 162.2 
EM 776.9 880.2 652.9 703.3 655.2 
JB 116.5 137.9 209.6 359.9 523.3 
JCB 84.5 87.7 78.9 80.2 111.4 
JP 203.7 239.1 182.4 202.4 245.0 
LM 46.7 53.8 54.8 54.5 54.5 
MJ 166.0 186.2 170.6 170.6 212.3 
AVG 179.25 207.82 178.79 207.69 240.39 






CPK, Change from Baseline (percent) 
CM 
Subjects R0 R120 R End TT End 
BF 0.450 0.679 0.670 1.357 
BH 0.322 -0.114 -0.122 0.155 
DF 0.266 0.229 0.236 1.102 
EM 0.173 -0.189 0.465 0.515 
JB 0.187 -0.028 0.036 0.276 
JCB 0.085 -0.067 0.232 0.390 
JP 0.213 0.060 -0.015 0.220 
LM 0.274 -0.006 0.056 0.063 
MJ 0.235 0.078 0.267 0.414 
AVG 0.24 0.07 0.20 0.50 
SE 0.03 0.09 0.08 0.15 
          
CHO 
  R0 R120 R End TT End 
BF 0.053 0.017 -0.035 0.514 
BH 0.218 -0.025 -0.005 0.855 
DF 0.564 0.410 0.463 1.208 
EM 0.067 -0.088 0.109 0.361 
JB 0.185 0.169 0.099 0.465 
JCB 0.320 0.294 0.106 0.217 
JP 0.148 0.023 0.502 0.556 
LM 0.162 0.018 0.061 1.137 
MJ 0.359 0.694 1.211 3.100 
AVG 0.23 0.17 0.28 0.93 
SE 0.05 0.08 0.13 0.29 
          
PLA 
  R0 R120 R End TT End 
BF 0.288 0.510 0.896 0.826 
BH 0.459 0.012 0.040 1.325 
DF 0.266 0.067 0.175 0.358 
EM 0.133 -0.160 -0.095 -0.157 
JB 0.183 0.799 2.089 3.491 
JCB 0.038 -0.067 -0.051 0.318 
JP 0.174 -0.105 -0.006 0.203 
LM 0.152 0.173 0.167 0.167 
MJ 0.122 0.028 0.028 0.279 
AVG 0.20 0.14 0.36 0.76 




Plasma IL-6 (pg/mL) 
CHO 
  Pre R0 R45 R120 R End TT End 
DF 137.39 251.52 105.01 188.99 115.47 153.87 
MJ 138.57 316.80 182.83 187.64 159.00 359.90 
LM 12.88 13.22 14.37 36.63 17.58 31.09 
BH 6.13 8.95 39.83 69.33 125.82 4.81 
BF 126.11 81.99 68.48 81.64 90.06 174.15 
JP 7.70 17.44 7.50 15.10 14.84 35.18 
JCB 6.34 6.22 5.04 13.45 2.60 8.56 
EM 16.46 39.92 28.73 14.69 9.18 38.18 
JB 43.45 100.93 74.67 111.94 68.57 68.71 
AVG 55.00 93.00 58.49 79.93 67.01 97.16 
SEM 20.14 38.17 19.23 23.39 19.53 38.56 
              
    
CM 
  Pre R0 R45 R120 R End TT End 
DF 31.35 148.74 50.95 74.55 60.99 107.06 
MJ 158.55 179.56 155.68 174.72 136.16 301.14 
LM 6.49 18.94 9.74 24.84 26.55 25.82 
BH 0.00 6.17 0.79 1.66 1.66 29.64 
BF 66.91 84.80 58.45 101.69 95.36 200.62 
JP 5.99 11.15 15.37 26.16 23.61 15.98 
JCB 3.98 14.46 4.82 3.54 0.00 11.74 
EM 16.65 31.42 26.62 43.16 18.71 56.76 
JB 56.43 64.41 39.77 65.59 61.47 127.78 
AVG 38.48 62.18 40.24 57.32 47.16 97.39 
SEM 17.01 21.29 15.95 18.38 15.24 33.02 
              
    
PLA 
  Pre R0 R45 R120 R End TT End 
DF 107.37 231.84 185.60 118.45 70.94 98.64 
MJ 290.21 479.82 359.29 220.56 263.71 534.83 
LM 6.73 18.99 20.36 35.45 31.08 23.31 
BH 1.66 5.49 19.46 105.49 95.00 86.27 
BF 53.76 69.60 58.92 65.00 53.65 124.15 
JP 9.76 15.09 28.55 43.33 35.22 45.00 
JCB 3.59 12.75 5.58 5.53 5.11 8.54 
EM 7.08 22.33 29.85 20.21 23.89 37.16 
JB 61.34 132.23 57.51 122.79 150.46 299.61 
AVG 60.17 109.79 85.01 81.86 81.00 139.72 




Plasma IL-8 (pg/mL) 
CHO 
  Pre R0 R45 R120 R End TT End 
DF 75.82 86.90 54.07 59.23 49.02 69.90 
MJ 29.17 65.78 52.93 39.19 34.23 62.04 
LM 36.11 43.73 31.55 31.08 24.26 47.75 
BH 29.61 32.43 19.89 24.42 31.46 28.05 
BF 12.52 10.84 10.31 11.41 8.96 17.15 
JP 7.20 11.13 7.25 8.69 6.78 32.24 
JCB 3.73 4.17 3.24 3.75 1.77 2.88 
EM 37.87 54.59 54.25 40.14 31.36 53.56 
JB 30.07 70.46 51.38 47.63 36.90 53.83 
AVG 29.12 42.22 31.65 29.50 24.97 40.82 
SEM 7.18 9.86 7.31 6.32 5.29 7.37 
CM 
  Pre R0 R45 R120 R End TT End 
DF 36.64 83.07 46.53 45.31 46.23 26.60 
MJ 23.62 30.31 36.73 34.55 28.49 51.30 
LM 31.04 40.56 30.25 35.38 39.63 41.77 
BH 25.17 29.68 30.03 26.34 22.04 47.12 
BF 8.28 20.06 10.79 11.62 13.28 21.96 
JP 12.12 15.54 11.12 15.17 10.27 9.70 
JCB 3.65 6.69 4.73 3.31 2.12 3.71 
EM 33.53 60.02 45.25 54.47 42.38 68.62 
JB 46.60 59.46 42.80 47.04 35.84 80.39 
AVG 24.51 38.38 28.69 30.35 26.69 39.02 
SEM 4.73 8.26 5.35 5.84 5.21 8.63 
PLA 
  Pre R0 R45 R120 R End TT End 
DF 55.67 85.34 71.00 57.56 47.51 42.93 
MJ 37.59 60.28 54.68 38.30 36.86 54.89 
LM 29.92 39.67 28.85 33.44 33.02 33.55 
BH 28.83 28.77 29.89 29.30 29.00 27.15 
BF 6.27 14.40 9.12 7.64 7.50 14.64 
JP 10.89 9.56 13.83 10.20 9.47 10.00 
JCB 3.50 4.95 3.51 2.59 3.12 3.70 
EM 28.59 53.42 78.25 67.27 65.00 92.40 
JB 61.20 78.74 49.67 66.56 76.45 166.19 
AVG 29.16 41.68 37.64 34.76 34.21 30.52 






Plasma IL-10 (pg/mL) 
CHO 
  Pre R0 R45 R120 R End TT End 
DF 5.06 27.86 39.09 8.19 6.94 26.34 
MJ 138.57 316.80 182.83 187.64 159.00 359.90 
LM 12.88 13.22 14.37 36.63 17.58 31.09 
BH 6.13 8.95 39.83 69.33 125.82 4.81 
BF 126.11 81.99 68.48 81.64 90.06 174.15 
JP 7.70 17.44 7.50 15.10 14.84 35.18 
JCB 12.40 9.72 9.79 9.45 4.82 39.84 
EM 273.72 847.87 879.08 879.13 586.27 534.78 
JB 535.08 1003.19 785.08 849.65 683.61 773.24 
AVG 124.18 258.56 225.11 237.41 187.66 219.92 
SEM 59.86 130.82 116.35 119.95 86.92 92.27 
    
CM 
  Pre R0 R45 R120 R End TT End 
DF 4.75 17.46 18.69 8.18 6.31 77.83 
MJ 158.55 179.56 155.68 174.72 136.16 301.14 
LM 6.49 18.94 9.74 24.84 26.55 25.82 
BH 0.00 6.17 0.79 1.66 1.66 29.64 
BF 66.91 84.80 58.45 101.69 95.36 200.62 
JP 5.99 11.15 15.37 26.16 23.61 15.98 
JCB 9.44 23.14 20.42 10.84 2.70 14.98 
EM 139.35 601.81 390.86 361.51 323.96 733.65 
JB 812.58 979.61 900.32 705.19 644.11 1180.03 
AVG 133.78 213.63 174.48 157.20 140.04 286.63 
SEM 87.28 114.98 99.87 78.88 71.90 135.93 
              
PLA 
  Pre R0 R45 R120 R End TT End 
DF 5.06 40.61 33.33 10.05 6.93 6.94 
MJ 290.21 479.82 359.29 220.56 263.71 534.83 
LM 6.73 18.99 20.36 35.45 31.08 23.31 
BH 1.66 5.49 19.46 105.49 90.00 86.27 
BF 53.76 69.60 58.92 65.00 53.65 124.15 
JP 9.76 15.09 28.55 43.33 35.22 40.00 
JCB 10.32 23.46 18.05 10.49 9.27 11.53 
EM 147.62 260.19 384.71 529.20 319.94 534.20 
JB 935.57 1464.41 775.19 1045.86 1049.48 1949.17 
AVG 162.30 264.18 188.65 229.49 206.59 367.82 






Plasma IL-1Ra (pg/mL) 
CHO 
  Pre R0 R45 R120 R End TT End 
DF 59.35 55.25 42.66 8.20 51.78 68.93 
MJ 36.36 92.88 39.70 30.84 17.35 34.38 
LM 136.22 126.68 96.23 65.44 76.16 67.12 
BH 128.44 107.28 78.07 31.47 90.44 62.92 
BF 57.24 98.83 100.14 54.12 27.20 78.11 
JP 71.36 80.37 89.97 55.69 73.04 73.14 
JCB 56.44 45.81 40.69 39.97 24.63 24.62 
EM 62.29 71.22 37.55 14.90 33.20 27.34 
JB 20.79 28.59 72.46 26.31 37.99 70.43 
AVG 69.83 78.54 66.38 36.32 47.97 56.33 
SEM 12.84 10.49 8.76 6.41 8.72 11.18 
              
CM 
  Pre R0 R45 R120 R End TT End 
DF 51.03 79.33 44.81 15.52 53.73 18.35 
MJ 55.02 71.40 74.55 49.76 48.23 75.31 
LM 99.17 113.63 60.15 97.93 83.31 73.37 
BH 117.91 134.52 100.51 26.06 100.51 95.46 
BF 76.58 106.39 65.91 53.48 55.93 28.54 
JP 66.76 48.09 56.33 17.72 54.62 23.66 
JCB 52.01 72.17 34.78 21.52 11.30 34.07 
EM 44.54 46.49 94.89 101.35 70.73 53.61 
JB 44.07 103.75 72.97 25.11 19.07 86.40 
AVG 67.45 86.19 67.21 45.38 55.27 54.31 
SEM 8.64 10.07 7.16 11.17 9.40 9.74 
              
PLA 
  Pre R0 R45 R120 R End TT End 
DF 48.27 62.41 41.50 28.90 44.61 37.41 
MJ 43.45 77.63 24.40 44.39 62.49 42.05 
LM 91.12 109.59 80.74 80.41 107.60 80.32 
BH 96.51 106.88 91.40 64.02 74.00 51.65 
BF 36.94 74.69 84.21 55.32 78.30 114.50 
JP 86.89 83.18 64.48 29.62 62.63 75.20 
JCB 51.53 71.14 41.35 26.75 52.05 44.42 
EM 54.65 47.30 23.06 54.12 27.05 32.32 
JB 78.42 79.16 84.53 65.87 64.27 45.49 
AVG 65.31 79.11 59.52 49.93 63.66 58.15 








  Pre R0 R45 R120 R End TT End 
DF 4.45 5.35 3.70 3.98 4.32 4.62 
MJ 3.61 7.39 5.75 3.70 2.92 3.98 
LM 23.71 18.73 11.10 10.73 3.48 16.27 
BH 24.32 17.68 5.11 7.57 14.08 7.56 
BF 4.36 7.08 4.22 2.97 3.37 3.98 
JP 8.40 10.07 7.23 6.48 6.53 9.03 
JCB 6.71 5.81 5.12 4.70 3.86 4.03 
EM 7.52 10.26 6.54 4.41 5.02 4.45 
JB 2.52 2.71 3.68 2.26 2.52 4.43 
AVG 9.51 9.45 5.82 5.20 5.12 6.48 
SEM 2.81 1.83 0.77 0.88 1.19 1.36 
              
CM 
  Pre R0 R45 R120 R End TT End 
DF 3.42 6.03 2.87 1.96 3.62 2.34 
MJ 4.41 4.71 4.58 3.02 3.48 5.29 
LM 18.82 15.91 8.90 12.68 14.59 15.69 
BH 16.25 19.20 14.38 6.55 12.51 17.14 
BF 6.17 8.15 4.69 5.15 5.63 3.58 
JP 8.78 6.36 3.86 4.14 5.62 3.01 
JCB 6.61 8.71 5.33 4.77 4.21 5.16 
EM 6.03 6.77 5.93 5.27 6.29 5.42 
JB 3.46 7.27 5.45 2.41 1.96 4.97 
AVG 8.21 9.23 6.22 5.10 6.43 6.95 
SEM 1.86 1.64 1.16 1.07 1.43 1.83 
    
PLA 
  Pre R0 R45 R120 R End TT End 
DF 4.41 6.03 4.43 2.39 2.99 3.19 
MJ 3.50 5.92 4.35 3.42 3.70 3.76 
LM 16.40 18.77 16.79 13.23 17.58 16.78 
BH 16.10 18.40 12.29 10.05 10.70 8.70 
BF 4.34 11.30 4.52 3.62 5.41 6.67 
JP 9.73 3.55 6.19 4.74 6.23 6.50 
JCB 7.05 8.15 5.46 4.95 5.55 5.67 
EM 6.90 6.05 5.48 3.95 3.94 5.29 
JB 4.92 3.89 4.66 3.25 3.49 4.26 
AVG 8.15 9.12 7.13 5.51 6.62 6.76 

































Average CHO g/min for Recovery Period (based on the averages of 4 8-min collection periods) 
PLA 
CHO, g/min Fat, g/min 
Subjects R30 R50 R90 R210 AVG R30 R50 R90 R210 AVG 
BF 0.057 0.105 0.096 0.090 0.087 0.122 0.091 0.090 0.106 0.102 
BH 0.106 0.029 0.153 0.059 0.087 0.093 0.109 0.066 0.102 0.093 
DF -0.058 0.066 0.032 0.252 0.073 0.172 0.100 0.102 0.010 0.096 
EM 0.290 0.132 0.220 0.209 0.213 0.095 0.088 0.071 0.090 0.086 
EW 0.018 0.008 0.009 0.044 0.020 0.112 0.092 0.131 0.077 0.103 
JB -0.012 0.037 0.077 0.092 0.048 0.110 0.098 0.072 0.072 0.088 
JCB 0.060 0.069 0.092 0.079 0.075 0.104 0.095 0.072 0.062 0.083 
JP -0.080 -0.047 0.032 0.080 -0.004 0.190 0.224 0.101 0.108 0.156 
LM 0.079 0.027 0.075 0.038 0.055 0.118 0.127 0.102 0.115 0.116 
MJ 0.090 0.138 0.163 0.153 0.136 0.098 0.101 0.096 0.086 0.095 
CHO 
CHO, g/min Fat, g/min 
  R30 R50 R90 R210 AVG R30 R50 R90 R210 AVG 
BF 0.064 0.189 0.169 0.243 0.166 0.060 0.129 0.061 0.039 0.072 
BH 0.164 0.209 0.267 0.311 0.238 0.045 0.069 0.041 0.009 0.041 
DF 0.013 0.237 0.144 0.145 0.135 0.061 0.137 0.088 0.049 0.084 
EM 0.257 0.227 0.161 0.320 0.241 0.074 0.072 0.093 0.049 0.072 
EW 0.190 0.161 0.251 0.225 0.206 0.023 0.053 0.025 0.018 0.030 
JB -0.035 0.049 0.057 0.151 0.055 0.085 0.129 0.079 0.048 0.085 
JCB 0.170 0.153 0.211 0.194 0.182 0.045 0.073 0.046 0.035 0.050 
JP -0.047 0.080 0.221 0.145 0.100 0.114 0.214 0.078 0.108 0.129 
LM 0.153 0.193 0.148 0.237 0.183 0.047 0.076 0.063 0.036 0.055 























CHO, g/min Fat, g/min 
  R30 R50 R90 R210 AVG R30 R50 R90 R210 AVG 
BF -0.016 0.132 0.200 0.167 0.121 0.179 0.112 0.099 0.097 0.122 
BH 0.250 0.182 0.232 0.154 0.205 0.066 0.063 0.082 0.061 0.068 
DF 0.114 0.150 0.212 0.256 0.183 0.124 0.078 0.072 0.057 0.083 
EM 0.194 0.205 0.210 0.244 0.213 0.130 0.067 0.104 0.092 0.098 
EW 0.049 0.159 0.088 0.229 0.131 0.148 0.078 0.119 0.048 0.098 
JB 0.155 0.139 -0.001 0.087 0.095 0.077 0.079 0.130 0.081 0.092 
JCB 0.077 0.089 0.126 0.132 0.106 0.117 0.099 0.094 0.070 0.095 
JP -0.016 0.079 0.143 0.223 0.107 0.189 0.134 0.115 0.051 0.123 
LM 0.213 0.179 0.185 0.219 0.199 0.069 0.067 0.069 0.062 0.067 
MJ 0.222 0.210 0.340 0.159 0.233 0.083 0.104 0.062 0.079 0.082 
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Average CHO kcals/min for Recovery Period (based on the averages of 4 8-min collection periods) 
PLA 
CHO, kcals/min Fat, kcals/min 
Subjects R30 R50 R90 R210 AVG R30 R50 R90 R210 AVG 
BF 0.443 0.239 0.402 0.378 0.365 0.829 1.112 0.961 0.821 0.931 
BH 0.121 0.445 0.642 0.249 0.364 0.990 0.849 0.929 0.602 0.842 
DF 0.276 -0.242 0.135 1.057 0.307 0.910 1.568 0.087 0.924 0.872 
EM 0.556 1.217 0.922 0.877 0.893 0.804 0.861 0.818 0.648 0.783 
EW 0.033 0.075 0.039 0.185 0.083 0.837 1.018 0.698 1.195 0.937 
JB 0.154 -0.052 0.324 0.388 0.203 0.890 1.004 0.659 0.656 0.802 
JCB 0.292 0.254 0.388 0.333 0.317 0.865 0.945 0.568 0.659 0.759 
JP -0.196 -0.338 0.133 0.338 -0.016 2.036 1.728 0.985 0.919 1.417 
LM 0.114 0.330 0.317 0.158 0.230 1.158 1.075 1.047 0.929 1.052 
MJ 0.581 0.378 0.684 0.641 0.571 0.922 0.891 0.785 0.876 0.869 
CHO 
CHO, kcals/min Fat, kcals/min 
  R30 R50 R90 R210 AVG R30 R50 R90 R210 AVG 
BF 0.793 0.269 0.709 1.022 0.698 0.546 1.178 0.554 0.355 0.658 
BH 0.877 0.689 1.121 1.306 0.998 0.407 0.628 0.374 0.079 0.372 
DF 0.995 0.053 0.606 0.608 0.565 0.553 1.249 0.800 0.445 0.762 
EM 0.952 1.077 0.677 1.345 1.013 0.669 0.658 0.842 0.446 0.654 
EW 0.675 0.796 1.053 0.944 0.867 0.210 0.480 0.232 0.162 0.271 
JB 0.206 -0.149 0.241 0.634 0.233 0.777 1.171 0.722 0.436 0.776 
JCB 0.643 0.713 0.886 0.814 0.764 0.411 0.660 0.419 0.320 0.453 
JP 0.334 -0.196 0.928 0.610 0.419 1.037 1.946 0.712 0.983 1.170 
LM 0.812 0.644 0.621 0.994 0.768 0.424 0.691 0.576 0.324 0.504 
MJ 1.605 1.003 1.598 1.291 1.374 0.234 0.707 0.172 0.358 0.368 
CM 
CHO, kcals/min Fat, kcals/min 
  R30 R50 R90 R210 AVG R30 R50 R90 R210 AVG 
BF -0.069 0.556 0.840 0.700 0.507 1.630 1.021 0.903 0.884 1.110 
 290 
BH 1.050 0.766 0.973 0.649 0.859 0.600 0.571 0.742 0.557 0.618 
DF 0.478 0.632 0.889 1.075 0.769 1.125 0.708 0.659 0.516 0.752 
EM 0.816 0.863 0.881 1.027 0.897 1.180 0.605 0.949 0.833 0.892 
EW 0.207 0.666 0.370 0.963 0.551 1.348 0.714 1.083 0.433 0.895 
JB 0.650 0.583 -0.004 0.366 0.399 0.696 0.723 1.185 0.739 0.836 
JCB 0.325 0.372 0.529 0.552 0.445 1.067 0.899 0.855 0.635 0.864 
JP -0.067 0.330 0.601 0.935 0.450 1.723 1.224 1.049 0.465 1.115 
LM 0.893 0.751 0.779 0.921 0.836 0.628 0.606 0.629 0.561 0.606 





Study 2 p-mTOR, % of standard 
  PLA CM CHO 
Subject R0 R45 R End RO R45 R End RO R45 R End 
BF 87.6 74.8 87.6 66.8 58.7 41.1 62.8 56.9 72.1 
BH 79.3 132.1 52.0 78.2 215.3 111.8 107.8 101.9 76.6 
DF 57.4 79.9 88.8 51.1 150.2 126.1 95.8 122.9 96.3 
EM 62.3 34.8 59.1 41.9 94.6 62.0 51.4 86.4 67.4 
EW 116.2 68.5 69.1 105.1 389.6 112.0 17.7 202.6 111.5 
JB 46.1 59.9 58.9 54.7 101.0 74.2 52.6 81.8 56.3 
JCB 74.6 70.3 71.6 134.5 374.6 142.4 126.0 357.2 171.0 
JP 73.7 84.4 74.6 67.9 149.5 109.9 53.3 88.8 94.3 
LM 72.5 67.3 67.9 72.0 112.0 84.5 54.3 130.1 73.7 
MJ 62.1 64.6 61.0 48.3 148.4 81.0 74.9 84.3 80.1 
AVG 73.2 73.7 69.1 72.0 179.4 94.5 69.6 131.3 89.9 
SEM 6.1 7.8 3.8 9.0 36.3 9.9 10.1 28.1 10.3 
 
Study 2 p-rpS6, % of standard 
  PLA CM CHO 
Subject R0 R45 R End RO R45 R End RO R45 R End 
BF 12.8 7.3 7.6 6.4 26.6 7.5 5.8 9.7 9.0 
BH 6.1 12.2 10.2 6.9 42.7 5.7 6.4 35.5 4.5 
DF 7.0 12.5 5.4 7.7 49.7 17.8 23.8 38.0 11.4 
EM 7.4 17.2 6.4 4.3 48.2 24.2 6.0 43.3 5.0 
EW 1.5 13.0 2.2 8.5 48.4 34.5 5.0 18.6 24.3 
JB 4.3 31.1 22.3 4.3 16.6 22.3 4.0 4.8 2.5 
JCB 6.3 9.2 2.4 7.1 17.7 8.0 5.9 34.0 6.7 
JP 6.2 4.3 13.7 4.9 39.5 12.8 5.6 24.5 3.8 
LM 4.4 14.6 7.0 4.5 16.3 14.3 5.9 14.3 9.9 
MJ 9.5 31.7 6.7 20.1 104.5 21.3 7.7 107.4 37.1 
AVG 6.5 15.3 8.4 7.5 41.0 16.8 7.6 33.0 11.4 





Study 2 p-eIF2B, % of standard 
  PLA CM CHO 
Subject R0 R45 R End RO R45 R End RO R45 R End 
BF 76.5 80.3 82.4 74.8 65.7 64.7 62.0 68.1 72.0 
BH 61.5 49.6 43.9 55.7 47.8 52.9 56.6 47.4 54.9 
DF 76.2 91.9 86.9 75.2 105.2 86.8 82.1 79.5 84.1 
EM 79.2 84.0 78.3 78.3 70.6 96.2 77.7 94.2 86.2 
EW 61.5 86.9 68.9 82.2 90.4 92.1 73.3 81.0 79.9 
JB 70.1 93.9 89.9 65.3 70.7 76.3 83.1 91.4 84.2 
JCB 86.4 67.3 67.1 61.9 70.3 72.2 72.9 80.1 81.9 
JP 69.0 70.0 67.0 64.2 70.6 80.3 57.0 64.4 64.1 
LM 84.7 76.0 70.4 81.9 70.7 94.2 59.9 52.9 44.2 
MJ 48.4 43.1 38.6 49.8 37.5 41.2 51.0 45.7 40.3 
AVG 71.4 74.3 69.3 68.9 69.9 75.7 67.6 70.5 69.2 
SEM 3.7 5.4 5.4 3.5 6.0 5.8 3.7 5.6 5.5 
 
Study 2 p-FOXO3A, % of standard 
  PLA CM CHO 
Subject R0 R45 R End RO R45 R End RO R45 R End 
BF 96.3 84.6 92.9 73.8 84.3 77.8 87.2 90.9 95.3 
BH 62.9 79.8 63.3 74.3 85.1 69.5 64.7 90.3 72.6 
DF 41.4 58.0 50.4 55.4 68.2 54.8 66.1 74.2 50.0 
EM 79.6 81.3 83.6 70.1 96.7 69.2 69.9 107.0 78.5 
EW 61.8 42.9 58.3 55.1 75.4 58.1 62.9 88.7 83.0 
JB 81.7 83.6 72.9 123.0 132.4 125.0 81.5 102.4 89.4 
JCB 48.0 47.7 46.9 62.4 71.1 66.0 64.0 82.5 70.7 
JP 42.4 57.1 55.0 41.1 57.1 52.6 42.9 55.6 58.0 
LM 102.2 93.2 98.1 85.8 100.9 98.2 83.5 88.4 98.3 
MJ 63.2 64.0 62.2 54.4 75.6 50.0 63.7 74.4 74.5 
AVG 67.9 69.2 68.4 69.5 84.7 72.1 68.6 85.4 77.0 





Study 2 Total ubiquitination, % of standard 
  PLA CM CHO 
Subject R0 R45 R End RO R45 R End RO R45 R End 
BF 62.8 146.0 65.6 57.2 173.1 50.8 55.1 57.6 55.9 
BH 66.8 64.1 63.3 82.1 69.2 90.6 150.7 77.7 65.9 
DF 92.8 81.5 104.7 84.0 82.8 87.8 84.4 116.1 163.8 
EM 108.1 119.5 101.2 107.1 163.1 188.2 109.0 175.3 119.8 
EW 90.3 90.8 83.2 100.5 142.5 146.9 129.7 144.5 224.8 
JB 63.9 168.9 79.4 164.7 71.1 80.6 68.7 71.8 137.2 
JCB 77.3 119.1 82.8 109.1 106.0 90.8 83.4 266.9 202.5 
JP 92.1 112.3 92.9 127.6 106.4 133.7 93.3 89.0 96.5 
LM 235.4 87.6 96.5 216.2 89.2 133.9 105.4 154.6 85.4 
MJ 109.7 98.6 202.3 117.9 98.1 125.1 85.2 108.1 100.4 
AVG 99.9 108.8 97.2 116.6 110.1 112.8 96.5 126.2 125.2 




% change in total ubiquitination 




R45 to R 
End 












RO to R 
End 
BF 132.5 -55.0 4.6 202.7 -70.6 -11.1 4.6 -2.9 1.5 
BH -3.9 -1.3 -5.1 -15.8 31.0 10.3 -48.4 -15.2 -56.3 
DF -12.2 28.4 12.8 -1.4 6.1 4.5 37.7 41.0 94.1 
EM 10.6 -15.3 -6.4 52.3 15.4 75.7 60.8 -31.7 9.9 
EW 0.6 -8.4 -7.9 41.8 3.1 46.2 11.4 55.6 73.3 
JB 164.2 -53.0 24.1 -56.8 13.4 -51.1 4.6 91.1 99.9 
JCB 54.1 -30.4 7.2 -2.8 -14.3 -16.7 220.0 -24.1 142.8 
JP 22.0 -17.3 0.9 -16.6 25.7 4.8 -4.7 8.5 3.4 
LM -62.8 10.2 -59.0 -58.8 50.1 -38.1 46.7 -44.8 -19.0 
MJ -10.1 105.2 84.4 -16.8 27.6 6.1 26.9 -7.2 17.8 
AVG 29.5 -3.7 5.5 12.8 8.7 3.1 36.0 7.0 36.8 
SEM 22.0 14.6 11.2 23.9 10.4 11.7 22.6 13.6 19.7 
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AVG     22.0 168.6 71.7 27.5 11.0 M=16 
SEM     0.5 1.5 2.4 3.0 2.4 F=16 
CM 
CG 1 4 19 176.0 75.96 41.5 3.17 M 
DIT 1 3 19.3 166.1 55.75 2.15 38.00 F 
EV 1 4 20.8 159.3 62.4 37.8 2.42 F 
JF 1 2 22.8 172.0 67 38.90 2.63 M 
MF 1 3 26.1 157.5 51.1 1.86 35.35 F 
MP 1 3 24.5 162.6 63 1.63 25.40 F 
NG 1 4 20.7 168.1 81.3 42.0 3.48 M 
PB 1 2 22.2 179.6 64.2 35.35 2.32 M 
PD 1 1 24.4 181.1 113.9 41.70 4.78 M 
VE 1 3 22.9 168.4 74.4 2.54 33.96 F 
YL 1 1 20 169.7 70.8 35.45 2.55 M 
AVG     22.1 169.1 70.9 25.5 14.0   
SEM     0.7 2.3 5.1 5.7 4.7   
CHO 
CF 2 1 19.4 178.6 81.34 47.70 3.90 M 
GM 2 2 20.2 157.5 67.5 28.60 1.97 F 
JQ 2 4 22.8 149.9 51.9 34.5 1.81 F 
KH 2 2 20.6 171.5 67.1 27.05 1.84 M 
LM 2 4 29.2 163.3 65.4 36.2 2.41 F 
MM 2 2 22.8 170.2 84 39.80 3.40 M 
NF 2 4 18.8 175.3 60.53 46.4 2.85 M 
RC 2 1 18.9 178.6 83.6 38.05 3.21 M 
RM 2 4 22.8 168.1 80.4 37.9 3.04 M 
SB 2 3 20.6 163.8 69.7 2.04 28.70 F 
TR 2 4 18.3 171.7 71.76 27.9 2.04 F 
AVG     21.3 168.0 71.2 33.3 5.0   
SEM     0.9 2.7 3.1 3.7 2.4   
PLA 
AR 3 3 21.4 150.1 58.2 1.70 28.90 F 
BM 3 3 19.4 169.7 70.31 2.50 34.65 F 
DT 3 2 22.1 180.3 99.1 33.30 3.30 M 
JH 3 4 20 175.8 73.8 52.3 3.85 M 
JL 3 3 28.5 165.1 61.3 1.91 30.65 F 
JM 3 2 26.3 180.3 97.9 36.20 3.57 M 
JO 3 1 24.9 164.6 75.6 30.77 2.35 F 
JW 3 4 22.8 177.3 66 38.0 2.59 M 
MN 3 1 18.8 158.2 64.4 35.85 2.34 F 
VR 3 3 21.3 166.4 65.4 2.11 31.70 F 
AVG     22.6 168.8 73.2 23.5 14.4   
SEM     1.0 3.1 4.5 6.1 4.7   




Study 3 Performance and Cardiovascular Fitness Measures 
CM 
 
Absolute VO2max (L/min) Relative VO2max (mL/kg/min) 
Subject Base Mid End Base Mid End 
CG 3.17 3.48 3.20 41.5 46.6 43.1 
DIT 2.15 2.31 2.60 38.00 40.50 45.80 
EV 2.42 2.50 2.71 37.8 39.0 41.3 
JF 2.63 2.98 3.25 38.90 44.05 48.30 
MF 1.86 2.10 2.23 35.35 39.55 43.50 
MP 1.63 1.63 2.01 25.40 25.20 31.65 
NG 3.48 3.60 3.81 42.0 43.5 45.5 
PB 2.32 2.50 2.71 35.35 38.45 41.40 
PD 4.78 4.81 5.00 41.70 42.50 44.00 
VE 2.54 2.65 2.75 33.96 34.50 37 
YL 2.55 2.84 2.95 35.45 40.05 41.90 
AVE 2.68 2.85 3.02 36.85 39.44 42.13 
SE 0.26 0.26 0.25 1.43 1.73 1.37 
CHO 
 
Absolute VO2max (L/min) Relative VO2max (mL/kg/min) 
Subject Base Mid End Base Mid End 
CF 3.90 3.86 3.96 47.70 47.07 48.75 
GM 1.97 2.04 1.99 28.60 29.65 29.05 
JQ 1.81 1.84 1.75 34.5 35.3 33.2 
KH 1.84 2.39 2.26 27.05 33.85 31.70 
LM 2.41 2.67 2.62 36.2 41.2 40.5 
MM 3.40 3.51 3.55 39.80 42.20 42.80 
NF 2.85 2.82 2.87 46.4 45.8 46.5 
RC 3.21 3.45 3.62 38.05 41.40 42.95 
RM 3.04 3.17 3.36 37.9 39.5 42.4 
TR 2.04 2.14 2.20 27.9 28.7 29.5 
AVE 2.64 2.79 2.82 36.41 38.45 38.73 
SE 0.23 0.22 0.24 2.28 2.01 2.29 
PLA 
 
Absolute VO2max (L/min) Relative VO2max (mL/kg/min) 
Subject Base Mid End Base Mid End 
AR 1.70 1.81 1.79 28.90 30.15 29.90 
BM 2.50 2.69 2.72 34.65 38.05 39.50 
DT 3.30 3.37 3.55 33.30 33.60 35.20 
JH 3.85 3.91 4.10 52.3 53.5 55.9 
JL 1.91 2.13 2.29 30.65 34.35 36.65 
JM 3.57 3.62 3.77 36.20 36.50 38.70 
JO 2.35 2.37 2.37 30.77 31.40 31.40 
JW 2.59 2.57 2.68 38.0 38.4 39.9 
MN 2.34 2.35 2.25 35.85 36.28 34.00 
VR 2.11 2.17 2.28 31.70 32.55 33.90 
AVE 2.62 2.70 2.78 35.23 36.48 37.50 





Study 3:  Lactate Threshold 
Subject Base End % Change 
CM 
CG 1.9 1.95 2.6 
DIT 1.65 1.8 9.1 
EV 1.35 1.55 14.8 
JF 1.2 1.65 37.5 
MF 1.26 1.6 27.0 
MP 1.25 1.28 2.4 
NG 1.65 2 21.2 
PB 1.25 1.55 24.0 
PD 3 3.33 11.0 
VE 1.55 1.8 16.1 
YL 1.7 1.65 -2.9 
AVG 1.61 1.83 14.80 
SEM 0.16 0.16 3.64 
CHO 
CF 1.83 1.95 6.6 
JQ 1.05 1.25 19.0 
KH 1.15 1.55 34.8 
LM 1.4 1.85 32.1 
MM 1.5 1.9 26.7 
NF 1.6 1.6 0.0 
RC 1.84 1.86 1.1 
RM 1.95 2.2 12.8 
TR 1.15 1.15 0.0 
GM 1.25 1.35 8.0 
AVG 1.47 1.67 14.11 
SEM 0.10 0.11 4.21 
PLA 
AR 0.95 1 5.3 
BM 1.55 1.6 3.2 
DT 1.7 2.1 23.5 
JH 1.8 2.5 38.9 
JL 1.25 1.45 16.0 
JM 2.05 1.85 -9.8 
JO 1.6 1.78 11.3 
JW 1.65 1.72 4.2 
MN 1.7 1.75 2.9 
VR 1 1.25 25.0 
AVG 1.53 1.70 12.06 






Study 3:    Time Trial Performance Data 
CM TT Time (min) TT Average Watts (W) TT2 TT3  TT4 TT2 TT3  TT4 
CG 52.61 49.07 46.61 138 170 185 
DIT 55.18 55.29 54.71 125 121 121 
EV 54.33 51.13 51.14 119 132 134 
JF 58.26 58.85 56.74 112 110 119 
MF 52.11 54.78 53.09 142 123 130 
MP 58.30 61.28 61.97 123 103 101 
NG 46.43 45.69 45.12 188 195 202 
PB 57.41 54.6 53.23 112 126 132 
PD 43.38 42.68 42.36 254 269 271 
VE 54.41 52.37 54.31 132 141 129 
YL 54.44 51.07 50.8 129 148 154 
AVE 53.35 52.44 51.83 143.09 148.91 152.55 
SE 1.42 1.63 1.67 12.76 14.44 14.81 
CHO TT Time (min) TT Average Watts (W) TT2 TT3  TT4 TT2 TT3  TT4 
CF 45.16 43.47 42.3 212 233 248 
GM   58.99 64.05   107 93 
JQ 55.04 56.13 53.78 111 107 116 
KH 64.2 57.49 53.61 92 114 133 
LM 49.67 48.86 48.24 153 159 164 
MM 50.33 49.96 46.33 164 169 202 
NF 48.26 47.30 48.82 161 167 158 
RC 52.47 51.55 53.45 144 152 139 
RM 62.48 55.91 48.71 100 121 166 
TR 65.11 58.67 52.08 85 104 133 
AVE 54.75 52.83 51.14 135.78 143.30 155.20 
SE 2.48 1.69 1.85 13.94 12.96 14.01 
PLA TT Time (min) TT Average Watts (W) TT2 TT3  TT4 TT2 TT3  TT4 
AR 81.51 85.02 73.97 69 71 76 
BM 52.66 51.74 53.94 142 146 137 
DT 56.06 52.66 50.68 144 164 173 
JH 44.08 44.22 43.44 214 213 224 
JL 63.71 55.51 54.26 93 118 122 
JM 49.15 47.6 46.36 184 196 205 
JO 56.45 52.68 52.42 123 144 139 
JW 61.00 52.00 48.84 97 134 155 
MN 61.33 58.63 61.33 97 107 97 
VR 64.64 63.24 61.32 102 96 104 
AVE 59.06 56.33 54.66 126.50 138.90 143.20 
SE 3.24 3.60 2.81 14.26 13.90 14.93 
 298 
 


















AVG     22.0 168.6 71.7 27.5 11.0 M=16 
SEM     0.5 1.5 2.4 3.0 2.4 F=16 
CM 
CG 1 4 19 176.0 75.96 41.5 3.17 M 
DIT 1 3 19.3 166.1 55.75 2.15 38.00 F 
EV 1 4 20.8 159.3 62.4 37.8 2.42 F 
JF 1 2 22.8 172.0 67 38.90 2.63 M 
MF 1 3 26.1 157.5 51.1 1.86 35.35 F 
MP 1 3 24.5 162.6 63 1.63 25.40 F 
NG 1 4 20.7 168.1 81.3 42.0 3.48 M 
PB 1 2 22.2 179.6 64.2 35.35 2.32 M 
PD 1 1 24.4 181.1 113.9 41.70 4.78 M 
VE 1 3 22.9 168.4 74.4 2.54 33.96 F 
YL 1 1 20 169.7 70.8 35.45 2.55 M 
AVG     22.1 169.1 70.9 25.5 14.0   
SEM     0.7 2.3 5.1 5.7 4.7   
CHO 
CF 2 1 19.4 178.6 81.34 47.70 3.90 M 
GM 2 2 20.2 157.5 67.5 28.60 1.97 F 
JQ 2 4 22.8 149.9 51.9 34.5 1.81 F 
KH 2 2 20.6 171.5 67.1 27.05 1.84 M 
LM 2 4 29.2 163.3 65.4 36.2 2.41 F 
MM 2 2 22.8 170.2 84 39.80 3.40 M 
NF 2 4 18.8 175.3 60.53 46.4 2.85 M 
RC 2 1 18.9 178.6 83.6 38.05 3.21 M 
RM 2 4 22.8 168.1 80.4 37.9 3.04 M 
SB 2 3 20.6 163.8 69.7 2.04 28.70 F 
TR 2 4 18.3 171.7 71.76 27.9 2.04 F 
AVG     21.3 168.0 71.2 33.3 5.0   
SEM     0.9 2.7 3.1 3.7 2.4   
PLA 
AR 3 3 21.4 150.1 58.2 1.70 28.90 F 
BM 3 3 19.4 169.7 70.31 2.50 34.65 F 
DT 3 2 22.1 180.3 99.1 33.30 3.30 M 
JH 3 4 20 175.8 73.8 52.3 3.85 M 
JL 3 3 28.5 165.1 61.3 1.91 30.65 F 
JM 3 2 26.3 180.3 97.9 36.20 3.57 M 
JO 3 1 24.9 164.6 75.6 30.77 2.35 F 
JW 3 4 22.8 177.3 66 38.0 2.59 M 
MN 3 1 18.8 158.2 64.4 35.85 2.34 F 
VR 3 3 21.3 166.4 65.4 2.11 31.70 F 
AVG     22.6 168.8 73.2 23.5 14.4   
SEM     1.0 3.1 4.5 6.1 4.7   





Study 4 Glucose (mmol/L) 
CM 

















CG 3.91 3.77 3.75   3.53 3.21 3.79 3.41 3.68 3.78 3.89 4.93 
DIT 3.99 4.33 4.05   4.30 5.23 3.91 4.42 3.48 3.82 3.74 3.19 
EV 3.49 3.82 3.83   3.83 3.55 3.84 4.19 3.65 4.52 3.85 4.67 
JF 4.65 4.12 4.67   4.58 4.26 4.19 3.60 4.32 4.13 4.57 4.22 
MF 4.24 4.44 4.20   4.22 4.79 4.24 4.72 4.22 4.58 4.24 4.70 
MP 4.29 3.68 4.39   4.10 4.14 3.88 4.06 4.20 4.00 4.50 3.55 
NG 4.52 4.36 4.32   4.30 4.59 4.49 4.78 4.82 4.61 4.74 5.08 
PB 4.27 3.69 4.01   3.65 3.68 4.63 3.29 3.97 3.34 3.82 3.52 
PD 4.61 4.57 4.47   4.71 5.37 4.56 5.00 4.54 5.00 4.46 5.41 
VE 4.31 4.66 3.80   4.14 4.75 3.68 3.78 4.02 4.15 4.30 3.93 
YL 5.22 4.97 4.75   5.23 4.36 4.67 4.37 4.86 4.54 4.79 4.53 
AVG 4.32 4.22 4.20   4.23 4.36 4.17 4.15 4.16 4.22 4.26 4.34 
SEM 0.14 0.13 0.10   0.15 0.21 0.11 0.17 0.14 0.14 0.12 0.22 
CHO 

















CF 4.27 3.92 4.09   4.08 5.51 3.86 4.91 4.35 5.21 3.97 6.52 
JQ 5.20 5.28 5.06   5.08 5.58 4.94 5.24 5.22 5.65 4.92 5.22 
KH 4.46 4.03 4.17   3.84 3.64 3.82 3.62 4.08 3.80 3.82 3.97 
LM 4.06 3.46 3.93   4.01 5.19 4.03 5.21 4.29 4.51 4.07 4.47 
MM 5.20 4.57 5.01   4.65 4.42 4.52 4.57 5.32 4.51 5.30 4.98 
NF 3.78 3.94 3.78   3.86 4.00 3.58 3.39 3.98 4.18 3.90 4.70 
RC 4.60 4.32 3.77   4.32 4.75 4.09 4.43 4.12 4.48 3.82 3.63 
RM 3.71 4.06 4.72   3.95 3.47 3.85 3.53 3.92 3.73 3.85 3.71 
SB 3.47 3.89 3.90   3.67 3.67 4.30 3.93 3.87 3.36 3.88 3.58 
TR 3.21 3.88 3.59   3.41 3.30 3.49 3.34 3.47 3.32 3.53 3.47 
AVG 4.20 4.13 4.20   4.09 4.35 4.05 4.22 4.26 4.27 4.11 4.42 
SEM 0.22 0.16 0.17   0.15 0.27 0.14 0.24 0.18 0.24 0.18 0.31 
PLA 

















AR 4.09 4.17 4.82   4.36 3.23 4.23 3.49 4.22 3.84 4.38 3.65 
BM 4.88 4.61 4.54   4.37 3.60 4.58 3.75 4.40 3.65 4.50 4.03 
JH 4.85 4.58 4.57   4.15 4.04 4.65 4.23 4.96 4.33 5.00 5.14 
JL 4.61 4.53 5.09   4.37 5.93 4.44 5.40 5.12 5.46 4.49 5.62 
JM 4.33 4.39 4.54   4.16 3.98 4.38 3.96 4.35 3.95 4.47 5.08 
JO 4.96 4.35 4.39   4.16 5.00 3.91 5.13 4.37 5.14 4.12 5.05 
JW 4.03 3.68 3.88   4.05 4.00 3.91 4.01 4.25 4.53 4.20 4.12 
MN 4.50 5.02 5.87   5.65 5.08 5.26 5.03 4.81 5.45 5.22 4.93 
VR 4.69 4.24 4.27   4.22 3.62 4.31 4.19 4.02 3.81 4.61 4.14 
AVG 4.55 4.40 4.66   4.39 4.28 4.41 4.35 4.50 4.46 4.55 4.64 
SEM 0.11 0.12 0.19   0.16 0.29 0.14 0.22 0.12 0.24 0.12 0.22 
 300 
 
Study 4 Insulin (pmol/L) 
CM 
Subject Base Mid End 
CG 151.26 166.75 121.40 
DIT 127.27 87.33 112.55 
EV 106.40 127.65 133.41 
JF 126.19 106.40 113.06 
MF 53.40 67.90 80.73 
MP 75.80 101.19 84.22 
NG 112.75 156.07 120.12 
PB 101.21 73.49 89.07 
PD 89.87 93.90 118.20 
VE 61.53 60.28 59.17 
YL 124.25 104.24 81.88 
AVE 102.72 104.11 101.26 
SE 9.10 10.33 6.98 
        
CHO 
Subject Base Mid End 
CF 69.24 71.46 69.66 
JQ 127.02 78.76 110.29 
KH 151.75 118.41 173.07 
LM 84.52 54.73 54.73 
MM 95.77 117.86 110.77 
NF 184.72 229.26 107.67 
RC 132.44 152.72 220.43 
RM 97.30 66.46 89.80 
SB 83.34 120.50 111.88 
TR 171.65 143.55 185.64 
AVE 119.78 115.37 123.39 
SE 12.63 16.51 16.73 
PLA 
Subject Base Mid End 
AR 205.35 247.88 353.97 
BM 110.77 148.13 101.42 
JH 97.34 70.55 101.80 
JL 86.92 89.63 121.33 
JM 127.58 116.05 80.08 
JO 114.45 72.78 136.89 
JW 83.55 63.62 64.31 
MN 165.08 98.76 110.56 
VR 158.69 102.65 95.42 
AVE 127.75 112.23 129.53 





Study 4 Glucose/Insulin Ratio 
CM Base Mid End 
CG 3.2 2.8 3.9 
DIT 3.9 6.2 4.5 
EV 4.1 3.7 3.6 
JF 4.6 4.8 5.2 
MF 9.9 8.2 6.5 
MP 7.1 4.5 6.5 
NG 5.0 3.5 4.5 
PB 5.3 6.3 5.6 
PD 6.4 6.1 4.7 
VE 8.8 9.7 8.0 
YL 5.3 6.0 7.3 
AVG 5.8 5.6 5.5 
SEM 0.6 0.6 0.4 
        
CHO Base Mid End 
CF 7.7 6.9 7.3 
JQ 5.1 8.4 5.7 
KH 3.7 4.3 3.0 
LM 6.0 7.9 9.0 
MM 6.8 4.9 5.7 
NF 2.6 2.1 4.4 
RC 4.3 3.5 2.1 
RM 4.8 7.6 6.6 
SB 5.2 4.0 4.4 
TR 2.3 3.4 2.4 
AVG 4.8 5.3 5.1 
SEM 0.5 0.7 0.7 
        
PLA Base Mid End 
AR 2.5 2.1 1.7 
BM 5.5 3.9 5.6 
JH 6.2 8.1 5.6 
JL 6.6 6.3 5.2 
JM 4.2 4.7 7.1 
JO 5.4 7.5 4.0 
JW 6.0 7.2 7.5 
MN 3.4 6.4 6.6 
VR 3.7 5.2 5.6 
AVG 4.8 5.7 5.4 





Study 4 Lactate (mmol/L) 
CM 
  TT1_pre TT1_post TT2_pre TT2_post TT3_pre TT3_post TT4_pre TT4_post 
CG 0.52 2.73 0.51 5.46 0.79 4.84 0.80 8.16 
DIT 1.05 6.47 0.83 2.87 1.06 2.05 1.07 2.19 
EV 0.86 8.24 0.77 9.68 0.99 6.74 0.86 6.26 
JF 0.96 7.42 1.09 4.25 0.68 1.69 1.42 2.26 
MF 0.52 5.85 0.79 5.09 0.66 5.71 0.79 6.97 
MP 1.07 10.29 1.06 8.22 1.10 7.00 1.24 6.06 
NG 0.68 9.87 0.67 9.89 0.66 7.60 0.75 10.18 
PB 0.80 6.27 1.00 3.92 0.71 4.05 0.70 3.43 
PD 0.78 5.11 0.88 5.00 0.72 4.94 0.72 5.97 
VE 0.54 4.09 0.68 1.84 0.55 3.16 0.95 1.63 
YL 0.67 5.27 1.37 4.64 0.66 3.76 0.65 3.54 
AVE 0.77 6.51 0.88 5.53 0.78 4.69 0.90 5.15 
SE 0.06 0.70 0.07 0.80 0.06 0.59 0.07 0.83 
  
CHO 
Subject TT1_pre TT1_post TT2_pre TT2_post TT3_pre TT3_post TT4_pre TT4_post 
CF 2.05 8.88 2.70 8.40 1.57 8.81 0.58 10.73 
JQ 0.64 9.51 0.86 7.49 0.84 6.46 0.77 6.75 
KH 0.64 2.80 0.84 4.20 0.80 3.33 0.72 4.78 
LM 1.21 5.53 0.84 6.90 0.99 4.22 0.78 6.39 
MM 0.63 4.26 0.67 5.97 0.69 3.53 0.77 6.59 
NF 1.60 7.60 0.80 3.66 0.82 4.77 0.72 5.88 
RC 0.91 4.69 1.26 3.93 0.69 3.58 0.69 2.41 
RM 0.57 4.28 0.80 3.02 0.51 2.83 0.99 9.78 
SB 0.98 5.75 0.58 0.52 0.71 5.58 0.84 6.92 
TR 0.56 3.40 0.63 3.50 0.64 3.46 0.99 3.46 
AVE 0.98 5.67 1.00 4.76 0.83 4.66 0.78 6.37 
SE 0.16 0.72 0.20 0.76 0.09 0.58 0.04 0.80 
PLA 
  TT1_pre TT1_post TT2_pre TT2_post TT3_pre TT3_post TT4_pre TT4_post 
AR 1.14 6.20 1.11 5.54 0.82 3.28 1.27 2.26 
BM 0.73 4.00 1.02 4.96 0.90 4.00 0.80 3.39 
JH 0.76 6.47 0.64 7.03 0.96 5.82 0.49 7.49 
JL 1.02 5.93 0.58 4.07 0.64 4.70 0.57 3.92 
JM 0.93 3.24 0.80 7.55 0.81 6.68 0.66 7.58 
JO 1.02 4.02 0.80 3.64 0.76 2.59 0.67 2.68 
JW 0.80 2.50 0.62 1.11 0.68 2.22 0.89 3.13 
MN 2.38 2.42 0.54 1.80 0.86 3.20 0.61 1.75 
VR 0.66 2.47 2.80 3.24 0.79 2.80 1.06 2.38 
AVE 1.05 4.14 0.99 4.33 0.80 3.92 0.78 3.84 





Study 4 Cortisol (pmol/L) 
CM 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CG 992.5 1104.8 942.8   1064.6 1088.9 707.2 1340.5 
DIT 1887.5 2554.5 2237.8   2170.3 2290.2 2514.3 2178.1 
EV 2259.2 2038.6 2156.5   2538.8 2579.4 2268.4 2361.8 
JF 756.6 847.5 658.7   340.2 320.2 855.9 460.7 
MF 824.2 570.2 615.6   634.6 986.8 633.9 1275.0 
MP 776.2 2613.1 1621.6   1732.8 2001.1 2712.5 2093.0 
NG 694.7 869.9 813.7   986.1 1312.2 915.6 1582.3 
PB 741.9 898.7 738.3   769.0 779.8 798.5 621.3 
PD 945.0 725.6 723.9   965.6 891.8 895.4 843.8 
VE 705.4 1001.3 766.0   703.1 900.7 569.4 723.8 
YL 940.3 681.3 631.5   608.6 1027.7 729.0 924.4 
AVE 1047.6 1264.1 1082.4   1137.6 1289.0 1236.4 1309.5 
SE 157.9 228.7 186.3   211.8 210.6 248.2 201.2 
CHO 
Subject Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CF 874.3 814.6 870.0   827.0 1009.9 799.1 1060.4 
JQ 1159.3 913.5 1158.8   838.0 1157.5 391.5 1207.6 
KH 1119.7 753.8 577.1   779.6 772.5 818.2 866.3 
LM 983.4 1074.2 1111.9   1026.9 997.1 1021.8 930.2 
MM 782.9 702.1 758.9   755.3 630.3 892.9 716.5 
NF 1268.2 1042.0 872.5   815.6 880.5 812.4 1127.2 
RC 792.8 901.1 648.6   805.8 908.6 778.3 585.9 
RM 639.9 584.5 606.6   657.3 470.1 598.8 640.7 
SB 1048.3 931.5 843.2   1162.8 802.6 863.0 1177.7 
TR 864.6 886.1 802.8   765.8 717.3 687.3 723.1 
AVE 953.3 860.3 825.0   843.4 834.7 766.4 903.6 
SE 62.0 47.5 61.8   46.0 63.4 54.9 73.2 
  
PLA 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
AR 855.1 904.4 652.6   708.2 641.6 765.2 455.5 
BM 592.2 650.8 796.9   689.8 782.9 828.8 617.9 
JH 866.7 810.9 1061.4   920.8 1213.3 1076.3 1033.6 
JL 548.5 1194.5 1111.7   1134.2 1520.0 1004.8 934.7 
JM 986.8 724.0 717.6   781.0 823.3 940.4 848.4 
JO 392.6 564.4 647.2   565.4 551.5 502.5 498.2 
JW 1107.9 994.5 740.8   944.1 530.6 818.7 918.3 
MN 757.4 772.0 833.8   763.8 768.2 805.3 785.8 
VR 1432.8 1573.0 1520.3   1343.8 1147.3 1766.1 1683.3 
AVE 837.8 909.8 898.0   872.3 886.5 945.3 864.0 
SE 105.3 103.9 95.3   81.0 112.0 116.2 122.2 
 304 
 
Study 4 IL-6 (pg/mL) 
CM 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CG 0 0 0   0 0 0 12 
DIT 2.455 0 0   0 0 0.24 7.795 
EV 0 0 0   0 0 0 9.335 
JF 0 0 0   0 0 0 0 
MF 6.525 10.615 9.65   14.695 19.035 5.385 19.41 
MP 1.115 0 1.725   0 0 0 3.305 
NG 18.305 19.625 19.83   20.02 45.15 27.405 32.685 
PB 0.28 0 0.15   0 1.49 0.28 0.815 
PD 0 0 0   0 0 0 0.495 
VE 0 0 0   0 0 0 0 
YL 8.23 7.44 7.85   7.24 8.725 7.235 8.965 
AVE 3.36 3.43 3.56   3.81 6.76 3.69 8.62 
SE 1.73 1.96 1.93   2.15 4.24 2.49 3.03 
  
CHO 
Subject Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CF 54.14 18.16 55.09   51.16 77.255 32.38 23.225 
JQ 0 0.15 0   0 11.2 0 7.995 
KH 3.9 3.09 1.785   1.79 3.8 2.26 4.385 
LM 0 0 0   0 0 0 1.57 
NF 3.58 0.28 0.655   0.56 0.875 0.775 3.165 
RC 6.875 0 10.065   8.86 24.87 13.81 17.065 
RM 2.06 1.485 3.745   0 0 0.74 2.81 
SB 3.5 3.635 5.35   4.05 9.29 8.7 6.315 
TR 0 0 0   0 1.3 2.03 3.305 
AVE 8.23 2.98 8.52   7.38 14.29 6.74 7.76 
SE 5.79 1.95 5.93   5.56 8.32 3.57 2.48 
  
PLA 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
AR 24.57 74.055 56.705   50.345 65.35 69.37 100.24 
BM 11.76 11.435 45.015   7.165 16.095 11 41.035 
JH 6.635 7.905 3.24   3.16 7.265 5.115 26.04 
JL 0.54 2.065 0.93   0.185 4.93 0 3.395 
JM 0 1.61 0.895   1.46 0 0 3.215 
JO 2.01 2.04 0.21   0.255 1.62 0.525 0.13 
JW 16.205 14.215 11.28   13.995 14.57 10.47 22.95 
MN 0 0 0   0 0 0 0 
VR 38.68 29.315 36.755   28.97 39.295 38.33 43.3 
AVE 11.16 15.85 17.23   11.73 16.57 14.98 26.70 




Study 4 IL-8 (pg/mL) 
CM 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CG 0.495 1.58 2.065   0.88 3.615 2.875 8.99 
DIT 2.18 1.7 1.185   1.5 2.985 1.785 2.305 
EV 4.465 3.165 1.98   0.58 5.245 3.495 5.26 
JF 7.925 0 0.765   0 0 1.675 0.905 
MF 8.23 10.56 8.755   13.24 13.825 8.56 16.51 
MP 5.755 9.385 8.12   2.335 6.06 2.385 6 
NG 19.43 17.065 17.865   7.56 21.11 18.955 30.82 
PB 4.455 5.435 5.975   2.98 4.465 4.59 4.89 
PD 2.935 2.33 2.765   2.015 3.375 3.595 4.13 
VE 9.275 4.345 3.37   4.365 5.045 4.39 4.875 
YL 2.955 2.71 2.75   2.495 1.635 1.525 2.945 
AVE 6.19 5.30 5.05   3.45 6.12 4.89 7.97 
SE 1.56 1.53 1.52   1.16 1.83 1.53 2.61 
  
CHO 
Subject Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CF 26.82 9.91 22.195   24.69 34.29 20.03 47.085 
JQ 0.645 0.955 1.77   0.62 1.845 0.815 1.935 
KH 2.76 2.56 1.65   3.47 4.6 2.64 3.8 
LM 2.675 0.86 0.54   1.6 1.92 0.97 1.965 
NF 2.485 3.445 1.66   1.765 2.135 2.11 3.155 
RC 6.665 3.305 24.08   11.53 21.525 17.885 27.615 
RM 11.53 7.1 5.26   3.965 5.695 7.605 12.745 
SB 85.595 60.32 59.31   70.395 95.3 55.12 72.155 
TR 2.4 2.515 4.06   2.85 5 6.175 11.415 
AVE 15.73 10.11 13.39   13.43 19.15 12.59 20.21 
SE 9.15 6.35 6.49   7.56 10.21 5.82 8.20 
  
PLA 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
AR 25.01 28.585 23.235   21.55 34.515 25.52 37.015 
BM 83.62 58.55 166.77   71.055 86.89 74 98.65 
JH 31.385 31.555 17.825   11.61 17.465 14.92 27.265 
JL 6.55 5.385 8.27   4.695 8.77 5.765 7.01 
JM 4.41 7.255 9.94   3.245 4.35 0.755 12.475 
JO 8.12 3.95 5.435   4.43 8.325 5.415 7.495 
JW 4.1 7.145 5.62   4.725 9.24 7.265 11.145 
MN 2.77 4.12 3.41   3.96 4.29 4.02 4.905 
VR 13.39 19.04 15.905   15.735 15.805 17.585 17.685 
AVE 19.93 18.40 28.49   15.67 21.07 17.25 24.85 
SE 8.63 6.15 17.42   7.24 8.79 7.56 9.87 
 
 306 
Study 4 IL-10 (pg/mL) 
CM 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CG 0 0 0   0 0 0 0 
DIT 4.68 1.415 1.74   1.605 7.22 1.415 5.76 
EV 6.5 0 0   0 4.75 0 22.22 
JF 0 0 0   0 0 0 0 
MF 0.805 0.86 0.805   1.355 6.59 0.805 8.13 
MP 0 0 0   0 1.05 0 5.685 
NG 23.805 35.875 34.625   41.435 58.415 42.505 46.015 
PB 3.73 4.105 2.985   2.315 7.825 1.79 4.215 
PD 1.27 1.18 2.19   3.275 8.455 3.88 7.79 
VE 0.501 0.92 1.835   0 0.51 0.825 0.19 
YL 8.065 6.965 7.665   5.9 7.035 4.13 9.655 
AVE 4.49 4.67 4.71   5.08 9.26 5.03 9.97 
SE 2.11 3.19 3.07   3.68 5.02 3.77 4.07 
  
CHO 
Subject Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CF 1.68 1.7 3.89   3.86 4.525 1.71 2.39 
JQ 0.47 1.02 0.995   1.33 5.525 0.86 0.32 
KH 2.735 1.1 0   2.42 2 0.965 0.74 
LM 2.855 2.615 2.09   2.785 14.835 2.395 21.645 
NF 1.125 0 0   0 0.055 0 0.48 
RC 12.58 8.2 9.96   11.8 10.7 10.43 8.705 
RM 15.335 0.015 3.66   0.245 0.98 1.05 1.37 
SB 2.725 1.385 1.495   1.1 5.025 1.675 4.56 
TR 0 0 0   0 0 0 0 
AVE 4.39 1.78 2.45   2.62 4.85 2.12 4.47 
SE 1.85 0.85 1.06   1.23 1.68 1.07 2.34 
  
PLA 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
AR 2.01 4.36 5.64   2.855 3.335 0.935 2.58 
BM 0.19 0 0.295   0 0.71 0 0.785 
JH 0 0 0   0 13.075 0.055 2.865 
JL 0 1.3 0.54   0.295 7.005 0.425 1.3 
JM 2.178 11.29 2.63   0.91 2.03 0 1.875 
JO 8.425 9.98 6.955   5.71 10.915 6.485 7.945 
JW 4.46 2.31 1.93   3.665 6.84 3.48 15.19 
MN 0 0 0   1.025 6.9 3.48 3.955 
VR 72.24 63.32 68.685   67.4 68.45 72.52 72.675 
AVE 9.94 10.28 9.63   9.10 13.25 9.71 12.13 





Study 4 IL-1Ra (pg/mL) 
CM 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CG 0 0 0   0 0 0 0 
DIT 1.15 0 1.315   0 0.375 0 0 
EV 0 58.2 0   0 50.815 0 34.335 
JF 0 0 0   0 0 0 0 
MF 0 0.44 1.26   3.69 1.75 0 2.135 
MP 0 0 0   0 0 0 0 
NG 7.285 18.84 23.345   19.06 48.01 32.335 35.02 
PB 0 0 0.13   0 0 0 0 
PD 0 0 0   0 0 0.78 13.81 
VE 0 0 2.855   0 0 0 1.135 
YL 6.145 3.86 6.72   5.575 1.355 3.285 8.14 
AVE 1.33 7.39 3.24   2.58 9.30 3.31 8.60 
SE 0.81 5.36 2.10   1.75 5.99 2.92 4.11 
  
CHO 
Subject Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CF 0.2 1.93 1.355   2.135 0.78 0 0.78 
JQ 0 0 0   0 0 0 0 
KH 0 0 0   1.825 0 6.21 0 
LM 3 0 0   0 0.2 0 0.2 
NF 2.91 0.13 0   0.13 1.65 0 0 
RC 5.005 0.78 11.265   0 2.505 0 14.38 
RM 0 0 0   0 0 0 0 
SB 0 1.26 1.65   0.815 6.46 2.325 1.56 
TR 4.46 12.99 0   0 0 0 0 
AVE 1.73 1.90 1.59   0.55 1.29 0.95 1.88 
SE 0.70 1.41 1.23   0.29 0.71 0.71 1.57 
  
PLA 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
AR 0 0 0   0 0 0 0 
BM 0 0 0   0 0 0 0 
JH 0 0 0   0 0.805 0 4.44 
JL 0 0 0   0 0 0 0 
JM 0 0 0   0 0 0 0 
JO 49.89 31.2 31.77   20.06 33.56 17.995 44.195 
JW 0 0 0   0 0 2.295 0 
MN 0 0 0   0 0 0 0 
VR 39.065 36.37 43.535   32.335 45.775 45.775 47.565 
AVE 9.88 7.51 8.37   5.82 8.90 7.34 10.69 
SE 6.60 4.98 5.62   3.98 5.90 5.19 6.67 
 
 308 
Study 4 IL-1(pg/mL) 
CM 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CG 0.00 0.00 0.00   0.00 0.00 0.00 17.62 
DIT 4.00 0.39 0.67   2.14 4.22 0.50 1.38 
EV 0.00 0.00 0.00   0.00 0.00 0.00 0.00 
JF 0.00 0.00 0.00   0.00 0.00 0.00 0.00 
MF 8.08 17.47 19.36   18.35 15.30 13.61 34.91 
MP 2.47 1.24 0.09   2.09 4.67 1.01 2.40 
NG 1.58 3.10 3.59   3.33 7.08 4.89 3.02 
PB 1.44 0.53 0.00   2.19 0.29 0.00 0.34 
PD 1.90 0.00 2.17   2.00 1.05 6.55 14.02 
VE 0.29 0.14 1.38   0.00 0.00 0.04 1.93 
YL 2.94 1.58 3.24   1.49 2.00 0.34 5.57 
AVE 2.06 2.22 2.77   2.87 3.15 2.45 7.38 
SE 0.72 1.55 1.71   1.59 1.41 1.30 3.27 
  
CHO 
Subject Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CF 7.49 11.32 7.65   7.70 11.51 8.48 10.88 
JQ 0.54 0.16 0.95   0.37 0.43 1.54 1.12 
KH 2.23 0.96 3.42   6.15 4.00 6.44 2.45 
LM 15.52 2.18 3.71   6.47 6.92 2.02 12.35 
NF 13.94 5.58 1.29   4.34 2.36 1.82 1.12 
RC 8.99 5.05 21.51   15.79 27.19 15.20 26.05 
RM 3.29 0.86 0.62   0.55 1.24 1.36 2.34 
SB 1.92 2.14 2.42   0.98 7.16 1.92 1.82 
TR 50.45 56.79 14.75   6.80 21.00 1.40 18.81 
AVE 11.60 9.45 6.26   5.46 9.09 4.46 8.55 
SE 5.17 6.03 2.42   1.61 3.10 1.59 3.03 
  
PLA 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
AR 21.87 11.67 17.06   7.12 11.13 7.97 7.96 
BM 1.46 0.29 1.82   3.13 5.26 2.50 4.01 
JH 1.92 1.02 0.65   0.85 5.01 2.09 3.97 
JL 1.93 0.29 0.83   0.51 3.29 1.38 1.71 
JM 0.88 0.53 0.00   1.78 1.84 0.05 1.13 
JO 7.76 6.30 7.92   5.04 4.31 2.16 6.82 
JW 9.74 14.80 24.85   19.62 14.80 27.54 26.67 
MN 0.00 3.93 0.25   0.00 0.00 0.00 3.05 
VR 9.44 7.78 9.44   9.36 10.78 10.36 10.24 
AVE 6.11 5.18 6.98   5.27 6.27 6.00 7.28 




Study 4 TNF(pg/mL) 
CM 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CG 0 0 0   0 0 0 2.895 
DIT 46.085 54.945 37.59   35.085 41.74 34.645 27.525 
EV 9.475 12.685 9.285   7.685 11.63 11.875 12.6 
JF 10.62 0 0.96   0 0.295 0.025 0.855 
MF 8.245 21.93 10.2   21.15 22.53 7.745 20.215 
MP 3.965 3.1 3.425   2.66 4.145 2.835 4.59 
NG 14.075 16.335 17.575   15.96 23.66 21.18 22.42 
PB 6.135 8.28 5.835   5.99 6.325 6.775 5 
PD 5.785 5.3 6.88   6.04 7.25 9.945 13.53 
VE 0.295 1.58 1.9   0.85 1.215 0.85 1.24 
YL 4.425 2.57 2.775   2.53 2.69 1.86 3.01 
AVE 9.92 11.52 8.77   8.90 11.04 8.89 10.35 
SE 3.83 4.85 3.26   3.31 3.96 3.22 2.86 
  
CHO 
Subject Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
CF 16.61 14.235 24.195   20.05 22.985 17.105 17.21 
JQ 1.005 1.72 2.42   1.98 2.625 2.3 2.86 
KH 6.77 6.605 7.77   9.59 8 10.48 7.49 
LM 5.115 2.61 2.525   2.695 2.975 1.86 4.39 
NF 6.585 4.09 2.78   4.87 5.1 2.765 2.935 
RC 14.72 13.89 14.87   16.075 16.885 16 21.49 
RM 4.29 6.19 6.215   3.965 4.115 6.06 7.455 
SB 12.315 15.355 18.565   13.44 17.965 19.345 19.3 
TR 8.42 10.71 5.935   5.425 6.2 5.385 6.105 
AVE 8.43 8.38 9.48   8.68 9.65 9.03 9.92 
SE 1.71 1.76 2.63   2.16 2.53 2.30 2.45 
  
PLA 
  Base Mid End   TT2_pre TT2_post TT4_pre TT4_post 
AR 5.535 2.86 6.725   4.2 3.07 4.02 3.16 
BM 7.685 11.35 32.77   12.485 41.235 12 27.94 
JH 11.16 10.435 6.925   19.62 8.22 7.03 20.11 
JL 4.245 3.255 4.65   3.035 3.52 3.955 4.89 
JM 6.905 16.365 12.45   5.1 6.97 4.86 7.21 
JO 61.765 24.695 49.655   29.61 62.175 29.045 56.055 
JW 8.395 8.31 12.16   10.63 9.215 14.835 15.86 
MN 3.52 6.515 4.495   5.38 3.525 6.26 7.73 
VR 15.925 13.395 12.895   13.5 13.665 16.005 14.465 
AVE 13.90 10.80 15.86   11.51 16.84 10.89 17.49 
SE 6.11 2.28 5.11   2.89 6.91 2.74 5.50 
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NG 1 81.3 81.8 81.5 68.4 68.1 68.9 55605 55711 56152 27.4 27.6 26.9 22297 22554 21926 
JF 1 67 67.6 67.7 80.9 81.8 82.5 54175 55325 55841 14.9 13.9 13.4 9997 9412 9050 
PB 1 64.2 63.8 64.2 69.2 71.8 73.3 44430 45835 47036 26.5 24 22.5 17008 15289 14451 
PD 1 113.9 114.6 113.8 66.5 67.3 67.9 75749 77112 77299 29 28.3 27.6 33066 32438 31448 
YL 1 70.8 70.5 71.1 75.7 75.5 76.3 53565 53197 54243 20.6 20.9 20.1 14610 14703 14267 
DIT 1 55.75 55.92 56.11 65.4 66.5 66.0 36470 37166 37032 30 29 29.4 16706 16220 16475 
MF 1 51.1 51.2 50.3 63.1 64.9 65.8 32221 33227 33109 32.7 31 30 16691 15844 15071 
VE 1 74.4 73.7 73.9 59.5 62.3 63.2 44299 45904 46741 36.3 33.6 32.7 27020 24771 24130 
CG 1 75.96 73.84 74.26 79.0 80.5 82.0 60004 59478 60902 16.9 15.1 13.7 12802 11170 10154 
EV 1 62.4 63 64.3 62.6 62.7 64.2 39034 39501 41275 33.1 32.8 31.5 20654 20690 20249 
CF 2 81.34 81.6 83.1 87.5 85.9 85.6 71184 70072 71115 8.1 9.7 10.1 6565 7902 8371 
GM 2 67.5 66.8 67.4 57.1 56.1 57.3 38555 37481 38610 39.2 40.1 39.1 26412 26778 26382 
KH 2 67.1 68.8 70.6 76.1 77.8 77.0 51087 53547 54352 20 18.5 19.4 13457 12766 13667 
MM 2 84 81.9 82.5 71.5 73.0 74.2 60099 59752 61181 24.4 23 21.7 20504 18823 17919 
RC 2 83.6 82.2 82.8 68.4 66.7 68.6 57173 54839 56794 27.2 28.5 26.8 22739 23456 22225 
RM 2 80.4 79 79.1 69.9 72.5 71.6 56165 57258 56646 25.9 23.3 24 20834 18398 19012 
TR 2 71.76 72.78 72.45 58.1 58.2 59.2 41702 42367 42865 37.9 37.8 36.9 27230 27480 26754 
JQ 2 51.9 51.3 51.5 63.3 64.7 65.5 32868 33194 33730 32.6 31.3 30.5 16937 16065 15704 
LM 2 65.4 63.4 63.4 60.0 59.9 61.4 39237 37977 38953 36.5 36.4 34.9 23835 23063 22105 
NF 2 60.53 61.15 61.39 76.3 75.6 75.5 46159 46219 46320 19.5 20.1 20.2 11797 12269 12414 
JM 3 97.9 98.1 96.6 66.0 67.1 66.3 64587 65777 64043 30.3 29.3 30 29707 28769 28980 
JO 3 75.6 74.9 74.9 61.4 61.6 63.1 46384 46164 47241 34.3 34 32.6 25,951 25442 24451 
MN 3 64.4 64.7 65.4 60.3 60.5 60.5 38861 39129 39552 35.6 35.3 35.4 22901 22828 23170 
AR 3 58.2 58.3 58.9 57.2 58.6 60.7 33298 34146 35774 38.9 37.7 35.8 22607 21976 21077 
BM 3 70.31 68.78 67.47 58.1 58.8 60.0 40824 40420 40456 37.6 36.8 35.6 26450 25334 23989 
JL 3 61.3 61 61.1 64.3 64.7 65.1 39390 39454 39760 32 31.6 31.3 19639 19263 19116 
VR 3 65.4 65.6 66 57.1 58.8 59.6 37338 38581 39303 38.9 37.3 36.5 25421 24450 24101 
JH 3 73.8 72.3 73.4 84.7 85.4 86.4 62495 61751 63445 11.4 10.6 9.6 8401 7633 7039 
JW 3 66 66.5 66.4 80.4 80.6 81.4 53071 53601 54025 15.1 15 14.4 9949 9994 9536 
DT 3 99.1 99.7 99.3 61.6 61.9 62.0 61055 61763 61546 34.7 34.2 34.1 34358 34082 33902 
CM   Avg 71.7 71.6 71.7 69.0 70.1 71.0 49555.2 50245.6 50963.0 26.7 25.6 24.8 19085.1 18309.1 17722.1 
  SE 5.5 5.6 5.5 2.3 2.2 2.3 4090.1 4063.2 4074.0 2.3 2.2 2.2 2183.3 2180.1 2153.1 
 CHO Avg 71.4 70.9 71.4 68.8 69.0 69.6 49422.9 49270.6 50056.6 27.1 26.9 26.4 19031.0 18700.0 18455.3 
  SE 3.4 3.3 3.4 3.0 3.0 2.8 3744.6 3708.3 3743.2 3.1 3.1 2.9 2126.9 2066.2 1910.5 
 PLA Avg 73.2 73.0 72.9 65.1 65.8 66.5 47730.3 48078.6 48514.5 30.9 30.2 29.5 22538.4 21977.1 21536.1 






















































CG 60004.0 59478.0 60902.0 898.0 12802.0 11170.0 10154.0 -2648.0 3546.0 
DIT 36470.0 37166.0 37032.0 562.0 16706.0 16220.0 16475.0 -231.0 793.0 
EV 39034.0 39501.0 41275.0 2241.0 20654.0 20690.0 20249.0 -405.0 2646.0 
JF 54175.0 55325.0 55841.0 1666.0 9997.0 9412.0 9050.0 -947.0 2613.0 
MF 32221.0 33227.0 33109.0 888.0 16691.0 15844.0 15071.0 -1620.0 2508.0 
NG 55605.0 55711.0 56152.0 547.0 22297.0 22554.0 21926.0 -371.0 918.0 
PB 44430.0 45835.0 47036.0 2606.0 17008.0 15289.0 14451.0 -2557.0 5163.0 
PD 75749.0 77112.0 77299.0 1550.0 33066.0 32438.0 31448.0 -1618.0 3168.0 
VE 44299.0 45904.0 46741.0 2442.0 27020.0 24771.0 24130.0 -2890.0 5332.0 
YL 53565.0 53197.0 54243.0 678.0 14610.0 14703.0 14267.0 -343.0 1021.0 
AVG 49555.2 50245.6 50963.0 1407.8 19085.1 18309.1 17722.1 -1363.0 2770.8 
SEM 4090.1 4063.2 4074.0 254.0 2183.3 2180.1 2153.1 332.3 511.6 
CHO 
CF 71184.0 70072.0 71115.0 -69.0 6565.0 7902.0 8371.0 1806.0 -1875.0 
GM 38555.0 37481.0 38610.0 55.0 26412.0 26778.0 26382.0 -30.0 85.0 
JQ 32868.0 33194.0 33730.0 862.0 16937.0 16065.0 15704.0 -1233.0 2095.0 
KH 51087.0 53547.0 54352.0 3265.0 13457.0 12766.0 13667.0 210.0 3055.0 
LM 39237.0 37977.0 38953.0 -284.0 23835.0 23063.0 22105.0 -1730.0 1446.0 
MM 60099.0 59752.0 61181.0 1082.0 20504.0 18823.0 17919.0 -2585.0 3667.0 
NF 46159.0 46219.0 46320.0 161.0 11797.0 12269.0 12414.0 617.0 -456.0 
RC 57173.0 54839.0 56794.0 -379.0 22739.0 23456.0 22225.0 -514.0 135.0 
RM 56165.0 57258.0 56646.0 481.0 20834.0 18398.0 19012.0 -1822.0 2303.0 
TR 41702.0 42367.0 42865.0 1163.0 27230.0 27480.0 26754.0 -476.0 1639.0 
AVG 49422.9 49270.6 50056.6 633.7 19031.0 18700.0 18455.3 -575.7 1209.4 

















AR 33298.0 34146.0 35774.0 2476.0 22607.0 21976.0 21077.0 -1530.0 4006.0 
BM 40824.0 40420.0 40456.0 -368.0 26450.0 25334.0 23989.0 -2461.0 2093.0 
DT 61055.0 61763.0 61546.0 491.0 34358.0 34082.0 33902.0 -456.0 947.0 
JH 62495.0 61751.0 63445.0 950.0 8401.0 7633.0 7039.0 -1362.0 2312.0 
JL 39390.0 39454.0 39760.0 370.0 19639.0 19263.0 19116.0 -523.0 893.0 
JM 64587.0 65777.0 64043.0 -544.0 29707.0 28769.0 28980.0 -727.0 183.0 
JO 46384.0 46164.0 47241.0 857.0 25951.0 25442.0 24451.0 -1500.0 2357.0 
JW 53071.0 53601.0 54025.0 954.0 9949.0 9994.0 9536.0 -413.0 1367.0 
MN 38861.0 39129.0 39552.0 691.0 22901.0 22828.0 23170.0 269.0 422.0 
VR 37338.0 38581.0 39303.0 1965.0 25421.0 24450.0 24101.0 -1320.0 3285.0 
AVG 47730.3 48078.6 48514.5 784.2 22538.4 21977.1 21536.1 -1002.3 1786.5 
SEM 3685.2 3680.4 3551.1 292.0 2567.4 2537.5 2565.4 246.1 394.1 
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CG 25959 24763 24945 -1014 4436 3838 3680 -756 21523 20925 21266 -257 499 
DIT 32281 32684 33571 1290 11137 11102 11177 40 21144 21582 22394 1250 1210 
EV 18759 19251 19702 943 6554 6230 6333 -221 12205 13021 13369 1164 1385 
JF 20302 20890 21129 827 3513 3312 3343 -170 16789 17579 17786 997 1167 
MF 18256 17812 17670 -586 6925 6568 6228 -697 11332 11243 11442 110 807 
NG 25032 25595 25052 20 5669 5862 5434 -235 19374 19733 19618 244 479 
PB 20805 21173 20413 -392 5609 5251 4998 -611 15195 15922 15415 220 831 
PD 35597 36499 35839 242 9976 10021 9645 -331 25620 26478 26194 574 905 
VE 26477 26790 26664 187 11106 10578 10390 -716 15371 16212 16274 903 1619 
YL 24599 23948 23451 -1148 4677 4634 4490 -187 19922 19314 18961 -961 -774 
AVG 24806.7 24940.5 24843.6 36.9 6960.2 6739.6 6571.8 -388.4 17847.5 18200.9 18271.9 424.4 812.8 
SEM 1802.2 1862.5 1867.0 261.6 887.3 897.0 896.3 89.1 1414.2 1397.3 1390.8 220.2 210.7 
CHO 
CF 27505 28431 28345 840 2763 3301 3461 698 24742 25130 24884 142 -556 
GM 24876 25395 25963 1087 10926 11616 11788 862 13950 13779 14176 226 -636 
JQ 17116 17476 17164 48 6004 5981 5763 -241 11112 11495 11402 290 531 
KH 24156 25243 26302 2146 6298 6354 6647 349 17858 18889 19655 1797 1448 
LM 22454 22147 22174 -280 9347 9122 8937 -410 13107 13025 13237 130 540 
MM 26922 26548 27155 233 6892 6569 6437 -455 20030 19979 20718 688 1143 
NF 18427 18994 18740 313 3514 3675 3604 90 14913 15319 15136 223 133 
RC 24597 26120 25886 1289 6084 6575 6181 97 18512 19546 19704 1192 1095 
RM 25289 26057 23986 -1303 6725 6576 5835 -890 18563 19480 18150 -413 477 
TR 22868 23537 23590 722 8877 9132 9301 424 13990 14405 14289 299 -125 
AVG 23421.0 23994.8 23930.5 509.5 6743.0 6890.1 6795.4 52.4 16677.7 17104.7 17135.1 457.4 405.0 
SEM 1066.7 1103.6 1151.8 298.3 790.9 795.6 813.8 174.7 1274.0 1321.2 1315.6 197.6 223.9 
PLA 
AR 21334 21301 21551 217 9104 9126 8967 -137 12230 12174 12584 354 491 
BM 24977 24243 23587 -1390 10419 9934 9484 -935 14558 14309 14103 -455 480 
 314 
DT 18601 19616 18653 52 6506 6651 6171 -335 12095 12965 12482 387 722 
JH 23829 23432 24156 327 3353 3096 3068 -285 20476 20336 21088 612 897 
JL 21128 20184 20892 -236 7841 7328 7607 -234 13287 12857 13286 -1 233 
JM 30323 31192 30773 450 8031 8196 8232 201 22929 22996 22541 -388 -589 
JO 28424 28671 28012 -412 10998 10818 10427 -571 17426 17852 17585 159 730 
JW 21143 21280 21261 118 3359 3291 3088 -271 17785 17988 18173 388 659 
MN 21767 23758 23253 1486 8276 8966 8656 380 13491 14791 14597 1106 726 
VR 21476 22221 22484 1008 9341 9454 9170 -171 12135 12767 13314 1179 1350 
AVG 23300.2 23589.8 23462.2 162.0 7722.8 7686.0 7487.0 -235.8 15641.2 15903.5 15975.3 334.1 569.9 









































CG 33568 32879 33001 -567 7052 6220 5428 -1624 26516 26658 27573 1057 2681 
DIT 46753 46574 45674 -1079 19312 19141 18849 -463 27442 27433 26826 -616 -153 
EV 30633 30502 31256 623 11455 11730 11228 -227 19178 18772 20028 850 1077 
JF 30593 30643 30972 379 5392 5081 4767 -625 25201 25562 26205 1004 1629 
MF 22462 23223 22557 95 8049 7676 7328 -721 14413 15547 15230 817 1538 
NG 39759 39523 40272 513 14407 14520 14322 -85 25352 25004 25951 599 684 
PB 28915 28389 29724 809 9293 8204 7785 -1508 19622 20185 21939 2317 3825 
PD 54976 54444 53667 -1309 20105 19431 18594 -1511 34870 35013 35074 204 1715 
VE 33299 32718 33216 -83 12826 11374 11112 -1714 20473 21344 22104 1631 3345 
YL 31833 32050 32808 975 8207 8217 8049 -158 23626 23833 24759 1133 1291 
AVG 35279.1 35094.5 35314.7 35.6 11609.8 11159.4 10746.2 -863.6 23669.3 23935.1 24568.9 899.6 1763.2 
SEM 2994.0 2929.6 2816.8 249.5 1598.2 1614.7 1606.1 207.7 1780.8 1666.4 1666.4 247.5 382.9 
CHO 
CF 35231 34403 36298 1067 3016 3721 4006 990 32216 30682 32292 76 -914 
GM 28345 27269 27364 -981 11695 11471 10876 -819 16650 15798 16488 -162 657 
JQ 24114 23285 23809 -305 8996 8233 8109 -887 15119 15052 15701 582 1469 
KH 28220 28325 28784 564 5742 5049 5571 -171 22477 23276 23213 736 907 
LM 30944 29489 29290 -1654 11936 11461 10703 -1233 19008 18029 18587 -421 812 
MM 38546 37756 37400 -1146 11356 10356 9549 -1807 27191 27400 27851 660 2467 
NF 28641 28592 28811 170 6930 7282 7400 470 21711 21310 21411 -300 -770 
RC 41232 38140 39130 -2102 14306 14530 13733 -573 26926 23610 25397 -1529 -956 
RM 37773 36054 37837 64 12307 10156 11519 -788 25466 25898 26319 853 1641 
TR 34515 34828 34625 110 15291 15411 14443 -848 19225 19417 20182 957 1805 
AVG 32756.1 31814.1 32334.8 -421.3 10157.5 9767.0 9590.9 -566.6 22598.9 22047.2 22744.1 145.2 711.8 
SEM 1747.0 1600.2 1682.4 320.6 1235.6 1193.3 1062.8 256.7 1689.6 1611.0 1672.1 244.6 385.6 
PLA 
AR 25669 25678 26378 709 11081 10380 9826 -1255 14588 15298 16552 1964 3219 
BM 32232 31709 30794 -1438 13155 12622 11672 -1483 19077 19087 19122 45 1528 
 316 
DT 25461 24575 25776 315 8212 7545 8333 121 17249 17030 17443 194 73 
JH 34301 33142 30346 -3955 4194 3748 3202 -992 30107 29394 30364 257 1249 
JL 27838 28506 28052 214 9229 9448 9011 -218 18609 19058 19041 432 650 
JM 47528 47433 46661 -867 18771 17735 17947 -824 28757 29699 28714 -43 781 
JO 31406 30550 31123 -283 11786 11526 10969 -817 19620 19024 20154 534 1351 
JW 30423 30777 30988 565 5532 5655 5457 -75 24891 25123 25531 640 715 
MN 30093 28222 29518 -575 12021 11182 11922 -99 18072 17040 17595 -477 -378 
VR 31316 30964 30814 -502 13068 12302 12087 -981 18247 18662 18727 480 1461 
AVG 31626.7 31155.6 31045.0 -581.7 10704.9 10214.3 10042.6 -662.3 20921.7 20941.5 21324.3 402.6 1064.9 



























PD 1 1 5.2 4.7 5.7 6.5 9.1 6.2 8.9 
YL 1 1 4.2 3.4 3.9 5.2 9.8 4.5 8.7 
PB 1 2 6.7 10.8 8.4 9.4 9 7.6 9.8 
JF 1 2 4.7 4.7 4.9 5.7 7.1 4.5 6.4 
NG 1 4 7.2 8.4 6.1 8.7 13.7 8.4 12.6 
DIT 1 3 5.8 4.2 5.1 6.7 15 6.1 14.8 
EV 1 4 5.6 5.2 2.2 6 11.5 6.7 12.1 
MF 1 3 4.5 3.7 4.4 4.8 9.2 3.7 7.8 
MP 1 3 7.5 5.7 5.4 6.2 11.2 5.6 7.8 
VE 1 3 4 5 5.9 5.4 9.3 6.2 11.2 
CG 1 4 6.1 7.5 7 6.3 9.9 8.2 12.3 
LM 2 4 5.7 5.1 6.8 5.7 8.6 5.8 10.1 
NF 2 4 8.1 7.5 5.6 7.4 10.5 8.3 12.7 
RM 2 4 7.8 5.5 6.2 6 7.5 6.6 10.5 
JQ 2 4 5.4 4.9 4.2 6 10.2 6.7 12.3 
TR 2 4 3.5 5.1 6.7 5.3   6.5 7.4 
SB 2 3 8.6 6 7.2 6.3   6.7 12.2 
KH 2 2 4.7 6.5 5.3 5.6   6.9 6.1 
MM 2 2 6.4 6.5 5.2 8.2 8.9 6.7 9 
RC 2 1 5.1 5.2 5.4 5.3 9.6 7.2 9.2 
CF 2 1 5.5 5.4 8.9 5.7 8.6 4.9 10 
JO 3 1 2.9 4.8 4.5   8.3   6.8 
MN 3 1 6.8 6.3 6.2 6 9.4 4.6 10.8 
DT 3 2 5.6   2.5   7.7     
JM 3 2 6.9 3.6 6.2 7.1 9.9 6.8 10.5 
AR 3 3 9 8.8 8.3 8.4 13.2 7.6 9.8 
BM 3 3 4.8 3.5 3.7 3.4 6.7   7.6 
JL 3 3 4.6 5.4 6.8 5.6 21.6 4.8 16.8 
VR 3 3 8.3 5 5.7 6.4 7.7 5.2 11.2 
JH 3 4 4.1 3.4 4.5 5.2 8.4 5.3 8.8 
JW 3 4 8.4 4.4 7.3 8.5 9.1 7.3 9.9 
    CM 5.59 5.75 5.36 6.45 10.44 6.15 10.22 
    SEM 0.36 0.68 0.49 0.43 0.69 0.46 0.77 
    CHO 6.08 5.77 6.15 6.15 9.13 6.63 9.95 
  SEM 0.52 0.26 0.42 0.30 0.33 0.28 0.68 
  PLA 6.14 5.02 5.57 6.33 10.20 5.94 10.24 




























PD 1 1 1.8 2 2.7 3.2 4.2 2.8 4.1 
YL 1 1 1.3 1 0.9 3.2 5.4 2.3 3.9 
PB 1 2 2.7 5 4 4.1 4.8 3.3 4.8 
JF 1 2 2.2 2.4 2.3 3 3.3 2 2.2 
NG 1 4 4.7 6.1 3.1 5.7 8.1 5.4 7.8 
DIT 1 3 2.7 0.6 1.8 2.5 9.2 2.8 7.8 
EV 1 4 2.7 3.1 1.2 3.4 6.7 3.8 8 
MF 1 3 2.5 2 2.2 3.1 5.4 1.4 2.5 
MP 1 3 3.8 2.1 1.7 3.3 7.3 2.3 4.8 
VE 1 3 0.9 2.2 2.5 2.1 2.9 2.2 3.9 
CG 1 4 2.6 4.4 3.2 2.9 4.8 4.4 5.8 
LM 2 4 2.2 2 3.3 2.6 3.6 2.8 4.9 
NF 2 4 2.1 3.7 2.1 3.7 5.4 3.2 4.8 
RM 2 4 4.1 2.6 3.5 3 4.3 3.1 4.1 
JQ 2 4 1.6 2.3 1.3 3.4 5.2 3.4 5.7 
TR 2 4 1.2 2.3 3.3 2.8   3.1 3.3 
SB 2 3 5.5 3.2 3.8 3.3   3.8 7.7 
KH 2 2 1.1 2.7 1.3 2   1.9 1.5 
MM 2 2 3 3.1 2.5 4.2 4.2 2.8 3.6 
RC 2 1 1.3 2.3 1.6 2.3 3.6 3.7 4 
CF 2 1 2.9 3 6.6 2.6 4 2.4 4.5 
JO 3 1 1.1 2.7 2   4.6   2.7 
MN 3 1 3.1 2.5 2.8 2.5 5 1.7 6.3 
DT 3 2 2.7   0.9   4.3     
JM 3 2 3.7 1.6 3 3.8 5.2 3.9 4.9 
AR 3 3 5.5 4.3 5.1 4.9 8.2 3.9 6.4 
BM 3 3 2.9 1.5 1.7 1.3 2.3   3.3 
JL 3 3 2.5 3 4.3 3.4 18.12 1.7 12.4 
VR 3 3 3 2.2 2.5 2.7 4.2 2.7 7.5 
JH 3 4 2 1.4 1.8 2.5 3.6 2.3 3.8 
JW 3 4 3.9 1.3 2.8 3.9 5 2.4 3 
    CM 2.54 2.81 2.33 3.32 5.65 2.97 5.05 
    SEM 0.32 0.51 0.28 0.28 0.60 0.35 0.62 
    CHO 2.50 2.72 2.93 2.99 4.33 3.02 4.41 
  SEM 0.45 0.17 0.50 0.21 0.23 0.18 0.51 
  PLA 3.04 2.28 2.69 3.13 6.05 2.66 5.59 




























PD 1 1 0.6 0.4 0.5 0.5 0.7 0.6 0.7 
YL 1 1 0.4 0.3 0.4 0.3 0.5 0.3 0.5 
PB 1 2 0.7 0.9 0.7 0.7 0.8 0.5 0.8 
JF 1 2 0.4 0.4 0.7 0.4 0.6 0.5 0.6 
NG 1 4 0.4 0.3 0.7 0.5 1 0.5 0.5 
DIT 1 3 0.4 0.4 0.3 0.4 0.5 0.4 0.7 
EV 1 4 0.5 0.2 0.2 0.4 0.7 0.5 0.2 
MF 1 3 0.2 0.1 0.3 0.2 0.4 0.2 0.5 
MP 1 3 0.6 0.6 0.7 0.4 0.6 0.5 0.5 
VE 1 3 0.3 0.4 0.4 0.3 0.5 0.4 0.9 
CG 1 4 0.6 0.3 0.4 0.6 0.9 0.7 0.7 
LM 2 4 0.3 0.3 0.5 0.5 0.8 0.4 0.7 
NF 2 4 0.8 0.5 0.8 0.7 0.8 0.8 1.3 
RM 2 4 0.5 0.4 0.6 0.5 0.6 0.5 0.9 
JQ 2 4 0.6 0.2 0.8 0.5 0.8 0.5 1.1 
TR 2 4 0.2 0.3 0.3 0.4   0.3 0.4 
SB 2 3 0.5 0.5 0.4 0.4   0.5 0.7 
KH 2 2 0.6 0.5 0.6 0.5   0.6 0.5 
MM 2 2 0.6 0.4 0.5 0.4 0.6 0.5 0.5 
RC 2 1 0.4 0.5 0.6 0.3 0.6 0.5 0.8 
CF 2 1 0.6 0.5 0.7 0.6 0.9 0.5 1.1 
JO 3 1 0.2 0.2 0.2   0.2   0.3 
MN 3 1 0.6 0.5 0.4 0.5 0.8 0.6 1.1 
DT 3 2 0.6   0.4   0.6     
JM 3 2 0.3 0.4 0.3 0.5 0.6 0.3 0.5 
AR 3 3 0.5 0.1 0.4 0.4 0.7 0.5 0.5 
BM 3 3 0.3 0.3 0.3 0.3 0.7   0.8 
JL 3 3 0.3 0.4 0.5 0.3 1.3 0.4 1 
VR 3 3 0.7 0.5 0.4 0.7 0.8 0.4 0.8 
JH 3 4 0.3 0.5 0.7 0.5 0.8 0.5 0.9 
JW 3 4 0.7 0.6 0.8 0.7 0.7 0.7 1.1 
    CM 0.46 0.39 0.48 0.43 0.65 0.46 0.60 
    SEM 0.05 0.06 0.06 0.04 0.06 0.04 0.06 
    CHO 0.51 0.41 0.58 0.48 0.73 0.51 0.80 
  SEM 0.05 0.03 0.05 0.04 0.04 0.04 0.09 
  PLA 0.45 0.39 0.44 0.49 0.72 0.49 0.78 
  SEM 0.06 0.05 0.06 0.05 0.09 0.04 0.09 
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Citrate synthase activity (mol/g/min) 
Subject Base Mid End 
CM 
PD 25.425 27.878 34.046 
PB 14.607 19.960 21.580 
YL 16.896 20.289 22.285 
JF 11.963 17.339 18.718 
DIT 20.4965 34.4895 42.269 
VE 17.777 25.5055 27.331 
MF 20.055 22.6605 30.5355 
MP 16.66 19.682 29.275 
CG 21.3555 27.827 21.94 
EV 21.51 20.31 28.8585 
NG 25 25.7955 31.2265 
AVG 19.25 23.79 28.01 
SEM 1.25 1.52 2.04 
CHO 
RC 23.197 29.096 28.777 
KH 11.493 16.423 13.071 
MM 12.112 18.870 17.657 
CF 23.673 24.839 27.420 
GM 9.311 17.518 18.435 
RM 15.6915 16.9185 23.7495 
TR 18.2195 25.7875 21.7835 
LM 24.666 30.978 37.831 
NF 30.76 36.5595 34.606 
JQ 21.7915 25.233 31.627 
AVG 19.09 24.22 25.50 
SEM 2.08 2.04 2.40 
PLA 
DT 14.642 17.899 20.605 
JM 16.987 17.142 20.458 
JO 16.537 17.922 27.216 
MN 17.314 20.468 24.730 
AR 14.98 24.877 24.5345 
BM 22.42 31.0105 31.186 
JL 15.87 22.085 24.0565 
VR 17.7045 21.8035 27.78 
JH 21.3045 24.3515 29.3 
JW 20.2025 24.917 25.388 
AVG 17.80 22.25 25.53 




Succinate dehydrogenase activity 
(mol/g/min) 
Subject Base Mid End 
CM 
PD 4.425 4.954 5.883 
PB 3.186 2.819 3.763 
YL 4.013 4.337 5.569 
JF 3.733 5.416 6.349 
DIT 4.81 6.216 7.477 
VE 4.262 6.262 5.269 
MF 5.309 6.135 6.748 
MP 5.032 3.755 6.108 
CG 4.283 4.616 4.982 
EV 4.449 5.959 5.454 
NG 6.057 6.827 7.709 
AVG 4.51 5.21 5.94 
SEM 0.24 0.37 0.34 
CHO 
RC 4.219 4.471 4.572 
KH 3.597 3.185 3.359 
MM 3.534 3.281 4.158 
CF 4.399 5.745 5.266 
GM 2.906 3.663 3.984 
RM 3.665 4.674 7.104 
TR 4.969 5.014 5.569 
LM 4.775 6.609 6.607 
NF 4.444 9.896 8.056 
JQ 5.684 6.665 7.139 
AVG 4.22 5.32 5.58 
SEM 0.25 0.61 0.48 
PLA 
DT 2.585 3.719 4.596 
JM 4.465 4.502 5.792 
JO 3.515 3.784 5.09 
MN 5.024 4.594 5.079 
AR 3.174 4.805 4.941 
BM 5.296 4.822 6.362 
JL 4.313 4.156 5.776 
VR 4.705 3.985 5.015 
JH 5.798 4.604 6.874 
JW 5.846 5.67 6.918 
AVG 4.47 4.46 5.64 





PGC-1, % of standard 
CM 
Subject Base End 
CG 84.7 139.2 
DIT 117.3 342.5 
EV 90.0 181.2 
JF 65.6 120.2 
MF 86.3 260.6 
MP 156.1 240.3 
NG 172.4 215.1 
PB 62.5 90.2 
PD 97.9 105.6 
VE 169.3 178.0 
YL 101.4 108.2 
AVE 109.40 180.10 
SE 11.92 23.70 
CHO 
Subject Base End 
CF 141.4 253.3 
GM 88.0 125.7 
JQ 111.6 183.2 
KH 68.7 91.7 
LM 217.4 229.8 
MM 80.0 105.2 
NF 120.5 203.2 
RC 115.6 165.7 
RM 122.5 142.5 
TR 172.7 260.5 
AVE 123.84 176.08 
SE 14.11 19.05 
PLA 
Subject Base End 
AR 71.6 138.9 
BM 178.5 219.5 
DT 105.3 183.8 
JH 134.9 184.8 
JL 103.4 201.8 
JM 63.5 87.1 
JO 95.1 107.2 
JW 117.2 161.7 
MN 36.9 249.8 
VR 109.7 142.9 
AVE 101.61 167.75 
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